26TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS 15TH ANNUAL CONFERENCE OF REHABILITATION IN MULTIPLE SCLEROSIS

13–16 OCTOBER 2010

EUROPEANCOMMITTEEFORTREATMENT ANDRESEARCHINMULTIPLESCLEROSIS GOTHENBURG, SWEDEN

FINALPROGRAMME WWW.ECTRIMS.EU/2010 " $03& 53&"5.&/5 */ .6-5*1-& 4$-&304*4

Abbreviated PrescribingInformation f ti - NameN e andd presentation: t ti COPCOPAXONEPAXONEAXONE· 1ml l SUH¿OOHG¿OO G V\ULQJH L RI I  PJ JODWLUDPHU O WL DFHWDWH W Therapeutic indications: COPAXONECOPPAXONEAXONE· LVLQG LQGLFDWHGGLFDWHG IRU SDWLHQWV ZKR KDYH H[SHULHQFHG D ZHOO GH¿QHG G ¿UVW FOLQLFDO HSLVRGH DQG DUH DW KLJK ULVN RI GHYHORSLQJFOLQLFDOO\ GH¿QLWH PXOWLSOH VFOHURVLV &'06  &23 &23$;21(3$$;21(· LVLQGLFDWHG IRU WKH UHGXFWLRQ LQ IUHTXHQF\ RI UHODSVHV LQ DPEXODWRU\ SDWLHQWV LH ZKR FDQF ZDON XQDLGHG ZLWK UHODSVLQJUHPLWWLQJ PXOWLSOH VFOHUR VFOHURVLVRVLV 06  ,Q FOLQLFDO WULDOV WKLV ZDV FKDUDFWHULVHG E\ DW OHDVW WZR DWWDFNVDWWDFNV RI QHXURORJLFDOG\VIXQFWLRQ RYHUWKH SUHFHGLQJWZR\HD WZR\HDUDU SHULRG &23 &23$;21($;21($ · LV QRW LQGLFDWHG LQ SULPDU\ RU VHFRQGDU\ SURJUHVVLYHSURJUHVVVLYH 06 Posology and method of administration: 7KH7 UHFRPPHQGHG GRVDJH LQ DGXOWV LV  PJ RQH SUH¿OOHG V\ULQJH  DGPLQLVWHUHGDGPPLQLVWHUHG DV D VXEFXWDQHRXV LQMHFWLRQ RQFH GDLO\GDLO\ 7UHDWPHQW7UHDWPPHQW GXUDWLRQ LV XQNQRZQ COPAXONECOPPAXONEAXONE· VKRXOG QRWEH XVHG LQ FKLOGUHQ EHORZE  \HDUV RI DJH ,W KDV QRW EHHQ VSHFL¿FDOO\ VWXGLHG G LQ HOGHUO\ DQG LQ SDWLHQWV ZLWK UHQDOLPSDLUPHQW )RU GHWDLOV VHH IXOO 6P3&6P33& Contra-indications: +\SHUVHQVLWLYLW\ WR JODWLUDPHU DFH DFHWDWHHWDWH RU PDQQLWRO 3UHJQDQW ZRPHQ Special warningand precautions fo foror use: COPCOPAXONEPAXONEAXONE· VKRXOG RQO\ EH DGPLQLVWHUHGVXEFXW VXEFXWDQHRXVO\WDQHRXVO\ 7KH LQLWLDWLRQ RI WUHDWPHQW VKRXOG EH VXSHUYLVHG E\ D QHXURORJLVWQHXURORJLVVW RU D SK\VLFLDQ H[SHULHQFHG LQWKH WUHDWPHQW RI06 ZKR VKRXOGVKKRXOG H[SODLQ WR WKH SDWLHQW SRVVLEOH UHDFWLRQV 6KRXOG D VHYHUH DGYHUVH HYHQW RFFXURFFXU WKH SDWLHQW PXVW LPPHGLDWHO\ VWRSWUHDWPHQ WUHDWPHQWW DQG FRQWDFW D SK\VLFLDQ &DXWLRQ VKRXOG EH H[HUFLVHG LQ SDWLHQWV ZLWKK SUHH[LVWLQJ FDUGLDF GLVRUGHUV,Q SDWLHQWV ZLWK UHQDO LPSDLUPHQWLPPSDLUPHQW UHQDO IXQFWLRQ VKRXOG EH PRQLWRUHGPRQLWRUHG Drug interactions: $Q LQFUHDVHG LQFLGHQFH RI LQMHFWLRQVLWH UHDFWLRQV KDVEHHQ VHHQ LQ SDWLHQWV UHFHLYLQJ FRUWLFRLGV 7KHUH DUH QR GDWD RQ LQWHUDFWLRQ ZLWKZLWK LQWHUIHURQ EHWD Pregnancy and lactation: COPAXONECOPAXONEA · LVFRQWUDLQGLFDWHG GXULQJ SUHJQDQF\SUHJQDQF\ $ FRQWUDFHSWLYH FRYHU VKRXOG EH FRQVLGHUHGF ZKLOVW XVLQJWKLV SURGXFW ,QQXUVLQJ PRWKHU WKH UHODWLYH ULVNEHQH¿W WR WKH PRWKHU DQG FKLOG VKRXOG EH FRQVLGHUHG UndesirableU effects ,QMHFWLRQVLWHUHDFWLRQ LV WKH PRVW IU IUHTXHQWUHTXHQW  YHUVXV  IRU SODFHER LQMHFWLRQV ,W LV UHSRUWHG DV HU\WKHPDHU\WKHPPD SDLQ PDVV SUXULWXV RHGHPD LQÀDPPDWLRQ DQGK\SH K\SHUVHQVLWLYLW\HUVHQVLWLYLW\ $Q LPPHGLDWH SRVWLQMHFWLRQ UHDFWLRQ VXFK DV YDVRGLODWDWLRQYDVRGLODWDWLRQ FKHVW SDLQ G\VSQRHDSDOSLWDWLRQ RU WDFK\FDUGLD KDV E EHHQHHQ GHVFULEHG E\  RI SDWLHQWV YHUVXV  RI SODFHER Other very common events include: ,QÀXHQ]DLQMHFWLRQ VLWH UHDFWLR UHDFWLRQVRQV FKHVW SDLQ DVWKHQLD SDLQ SDOSLWDWLRQV YDVRGLODWDWLRQ FRQVWLSDWLRQ GLDUUKHD QDXVHDDUWKUDOJLD EDFN SDLQ DQ[LHW\DQ[LHW\ GHSUHVVLRQGHSUHVVVLRQ GL]]LQHVV KHDGDFKH K\SHUWRQLD G\VSQHD UDVK K\SHUK\GURVLV )RUU FRPPRQ XQFRPPRQ UDUH DQGYHU\ UDUH HI HIIHFWVIIIHFWV VHH IXOO 6P3& Overdosage: 1RW DVVRFLDWHG ZLWK DGYHUVH UHDFWLRQV 0RQLWRULQJJ DQG V\PSWRPDWLF WUHDWPHQW VKRXOGEH DSSOLHG PharmPharmacodynamicmacodynamic properties: $7&$77& &RGH /$; Marketing AuthorisationAuthorisatiion Holder: 7HYD77HHYD 3KDUPDFHXWLFDOV /WG &KDQFHU\ /DQ /DQHQH &OLI &OLIIRUG¶VIIIRUG¶V ,QQ /RQGRQ (&$ %8 8QLWHG .LQJGRP %HIRUH SUHVFULELQJSUHVFULELQQJ WKH SURGXFWDOZD\V UHIHU WR WKHSUHVFULELQJ LQIRUPDWLRQ Q DYDLODEOH LQ \RXU FRXQWU\ FRXQWU\

ZZZZZZWHYDSKDUPFRPWHYDSKDUPFRP ZZZVDQR¿DYHQWLVFRPZZZZVDQR¿DYHQWLVFRP Table of Contents

Welcome Address ...... 2 Committees ...... 3–4 Acknowledgements ...... 5 Important Addresses ...... 7–9 CME Accreditation / Certificates ...... 10 ECTRIMS Research Fellowship Exchange Programme ...... 11 Programme Overview ...... 12–17 Scientific Programme – Wednesday, 13 October 2010 ...... 18–26 – Thursday, 14 October 2010 ...... 27–36 – Friday, 15 October 2010 ...... 37–47 – Saturday, 16 October 2010 ...... 48–49 Posters Welcome & Addresses –Overview ...... 50–51 – Thursday, 14 October 2010 ...... 52–98 – Friday, 15 October 2010 ...... 99–145 List of Chairs ...... 146 List of Authors ...... 147–175 Instructions for Authors ...... 176–178 Publication and Prizes ...... 179 Registration Information ...... 180–181 General Information (in alphabetical order) ...... 182–186 Social Events ...... 187–189 DailyTours ...... 190 Travelling to the Swedish Exhibition & Congress Centre ...... 191–192 The Swedish Exhibition & Congress Centre – Overview...... 193 The Swedish Exhibition & Congress Centre – FloorPlans ...... 194–195 List of Exhibitors / Exhibition Floor Plan ...... 196–197 Gothenburg City Map and Hotels ...... 198–200

1 Welcome Address

Dear Colleagues and Friends,

It is a pleasure inviting you to the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the 15th Conference of Rehabilitation in Multiple Sclerosis (RIMS) which will be held in Gothenburg, Sweden, 13–16 October 2010.

Over the past few years new insights have been gained in the dynamic field of MS research. This has changed our view of the disease, clinical methods and strategies for diagnosis, in addition to which treatment and monitoring of disease activity have been refined. Based on an improved knowledge of the immune system and its involvement in the pathogenesis of MS several immunomodulating / immunosuppressive drugs are now being tested and promise to increase our therapeutic options in the near future.

Nevertheless comprehensive multidisciplinary care and symptomatic treatment also play an important role in improving quality of life for people with MS. By organising for the 4th time a joint ECTRIMS and RIMS meeting, we intend to further foster collaboration and knowledge exchange in this very important area.

We hope that the programme of ECTRIMS/RIMS 2010 that is centred around fundamental mechanisms of importance for the aetiology and the pathogenesis of MS; evolving MS therapies; cognitive and behavioural dysfunctions; and progress in MS rehabilitation, will meet with your interest.

Gothenburg, Sweden’s second largest city and major port, located on the beautiful west coast, offers the visitor many historic sights, museums, cultural events and shopping opportunities. The congress venue, the Swedish Exhibition & Congress Centre, is located in the city centre within walking distance from most of the hotels. This will facilitate an active participation in the meeting with the possibility of also enjoying the atmosphere of the town.

We are looking forward to meeting you in Gothenburg, in October 2010. We are certain to have a most successful and exciting meeting which will give you lots of opportunities to improve on existing and create new contacts.

J. Lycke E. Luoto M. Clanet L. Kappos Chair ECTRIMS 2010 RIMS President ECTRIMS President ECTRIMS Secretary

2 .Callegaro D. Trojano, M. Committee Scientific Svenningsson A. Olsson T. Nilsson P. Landtblom A.-M. Hillert J. Fredrikson S. Brundin L. Andersen O. Lycke, J. Committee Organising Local Solaro, C. Matthews V. Lutz J. Luoto, E. Lövendahl B. Henze T. Galan I. Feys, P. Board Executive DK RIMS Copenhagen, Trojano, M. Soelberg-Sørensen P. Montalban X. Karussis D. Kappos, L. Gold R. Clanet, M. Committee Executive ECTRIMS Committees .P Hartung H.-P. Gold R. Comi G. Clanet M. .Henze T. .Olsson T. Montalban X. Miller D. Lycke J. Luoto E. Lassmann H. Kappos L. Hohlfeld R. .Sebr-øesnCpnae,DK Copenhagen, Solaro C. Soelberg-Sørensen P. Polman C. .Wolinsky J. Secretary Chair President Treasurer President Secretary Chair President Vice ai IT Bari, Umeå Stockholm Lund Linköping Stockholm Stockholm Stockholm Gothenburg Gothenburg IT Genoa, UK Hampshire, Romsey, CH Zurich, FI Masku, DK Haslev, DE Nittenau, ES Barcelona, BE Hasselt, IT Bari, ES Barcelona, IL Jerusalem, CH Basel, DE Bochum, FR Toulouse, ohm DE Bochum, IT Milan, FR Toulouse, BR Paulo, Sao üslof DE Düsseldorf, acln,ES Barcelona, UK London, SE Gothenburg, FI Masku, AT Vienna, CH Basel, DE Munich, DE Nittenau, mtra,NL Amsterdam, SE Stockholm, eo,IT Genoa, oso,US Houston, 3

Welcome & Addresses Committees

Congress Planning Committee M. Clanet (Chair) Toulouse, FR R. Gold Bochum, DE H.-P. Hartung Düsseldorf, DE L. Kappos Basel, CH C. Lubetzki Paris, FR E. Luoto Masku, FI J. Lycke Gothenburg, SE X. Montalban Barcelona, ES S. Reingold New York, US P. Soelberg-Sørensen Copenhagen, DK M. Trojano Bari, IT J. Wolinsky Houston, US

Scientific Advisory Committee & Abstract Reviewers M.P. Amato Florence, IT R. Hohlfeld Munich, DE O. Andersen Gothenburg, SE L. Kappos Basel, CH J.P. Antel Montreal, CA D. Karussis Jerusalem, IL D. Arnold Montreal, CA J. Kesselring Valens, CH F. Barkhof Amsterdam, NL H. Lassmann Vienna, AT L. Bo Amsterdam, NL C. Lubetzki Paris, FR W. Brück Göttingen, DE F. Lublin New York, US P. Calabresi Baltimore, US J. Lycke Gothenburg, SE M. Clanet Toulouse, FR P.M. Matthews London, UK G. Comi Milan, IT D. Miller London, UK C. Confavreux Lyon, FR I. Milonas Thessaloniki, GR J. Correale Buenos Aires, AR X. Montalban Barcelona, ES G. Ebers Oxford, UK P. O'Connor Toronto, CA G. Edan Rennes, FR T. Olsson Stockholm, SE F. Fazekas Graz, AT C. H. Polman Amsterdam, NL M. Filippi Milan, IT C. Pozzilli Rome, IT S. Fredrikson Stockholm, SE K. Selmaj Lodz, PL M.S. Freedman Ottawa, CA A. Siva Instanbul, TR R. Furlan Milan, IT P. Soelberg Copenhagen, DK G. Giovannoni London, UK Sørensen R. Gold Bochum, DE C. Solaro Genoa, IT K. Gross-Paju Tallinn, EE A.J. Thompson London, UK H.-P. Hartung Düsseldorf, DE M. Tintore Barcelona, ES E. Havrdova Prague, CZ M. Trojano Bari, IT T. Henze Nittenau, DE E. Waubant San Francisco, US J. Hillert Stockholm, SE J.S. Wolinsky Houston, US

4 Acknowledgements

The Organising Committee expresses its thanks and appreciation to all those who are generously contributing to the success of the ECTRIMS 2010.

Almirall S.A.

Bayer Schering Pharma AG

Biogen Idec

Biogen Idec & Elan Welcome & Addresses

Genzyme

Merck Serono S.A.

Novartis Pharma AG

Sanofi-aventis

Teva & Sanofi-aventis

Teva Pharmaceutical Industries

5 ‘More than half of [MS] patients believe less frequent dosing would improve their quality of life’1 Merck Serono is committed to research aimed at improving the quality of life of patients.

1. Merck Serono data on le

MerckMerck SSeronoerono iiss a divisiondivision of of Merck Merck Important Addresses

Scientific Secretariat Assoc. Prof. Jan Lycke Department of Neurology Sahlgrenska University Hospital Gröna straket 11, vaning 3 413 45 Gothenburg / Sweden

Phone +46 31 3429 047 Fax +46 31 826 227 E-mail [email protected]

Administrative Secretariat ECTRIMS 2010 c/o Congrex Switzerland Ltd. Freie Strasse 90 P.O. Box 4002 Basel / Switzerland

Phone +41 61 686 77 11

Fax +41 61 686 77 88 Welcome & Addresses E-mail [email protected] www.ectrims.eu/2010

Contact on-site: Phone +46 31 708 82 90 Fax +46 31 708 82 92

Official Agency for Accommodation and Travel

Hotel Accommodation Congrex Travel Ltd. Freie Strasse 90 P.O. Box 4002 Basel / Switzerland

Phone +41 61 690 94 11 Fax +41 61 690 94 14 E-mail [email protected]

Flight Bookings Congrex Travel Ltd. Freie Strasse 90 P.O. Box 4002 Basel / Switzerland

Phone +41 61 560 75 60 Fax +41 61 690 92 14 E-mail [email protected]

7 

          

;C@)DGL@JGD

J\\f:YhX`d:ij`ckbXj`ed ]eh:SXha`diedsi She]`b\D:Rb`l\h:TXZai Wekh:X[l\hjeh`Xb:_\h\ :<6$B> "$3-,041094',4($4( ;UNF.4232   % 8@O)BMD?@EDG@K3

`i X if\Z`Xb`i\[< 86?.BT.TWO.EJGGFRFNT.TBRHFTS.HJVFSgkXhj\hbo:d\mifXf\h:]eh: Qd\khebe^`iji<:d\kheikh^\edi< d\kheiZ`\dj`iji<:fioZ_`Xjh`iji:Xd[ SJMJLBR.MOTOR.CFNFGJTS.JN.=BRKJNSON[Sd\khehX[`ebe^`iji>:Lj:X`ci:je:Y\:j_\ HG)=J/-AS-SVO-DIFFEQENS-RISER-IN-SHE-BQAIN2-5ONSQAQX-SO-CTQQENS-BELIEF0-PASIENSR fhe]`b\i<:`d[kijho:Xd[:fhe[kZj:d\mi> VHO QECEIUED-64>-AS-EISHEQ-RISE-IN-SHE-BQAIN-EWPEQIENCED-COMPAQABLE-BENEFISR-FOQ-SHE-MOSOQ-RXMP1?D:7?=;>?=87=@ 096$*<6@:42=$*42567$-6C@>;>8G$92A$ HFGF?hrrtd?ne?sgd?#    {_d?entmc?sg`s?lnsnq?ntsbnldr

m`bb:Y\:Xd:\[`jeh`Xbbo: Xm?`?u`qhdsx?ne?mdtqnorxbgnknfhb`k:AAC65$=6E$=2B:>=2;$8C:56;:=6A$7>@$56B6@<:=:=8 \ "!   E \ghr?hr?sgd adsvddm?sgd?svn?fqntor?vdqd?mns?rhfmhehD`d[\f\d[\dj:]ehkc:m_`Z_:m`bb:h\XZ_ k`sdrs?qdonqs?eqnl?`?rstcx?sg`s?g`r?enkD b`mskx?cheedqdmsE?Vd`mvghkdC?sgdqd?vdqd sdrsrC?sgdqd?vdqd?mn?rhfmhehb`ms?cheedqD3@2:=$562B9'$096A6$92D6$366=$C?52B65$7>@$B96 XZheii:if\Z`Xbj`\i:je:a\\f: knvdc?md`qkx?IFF?o`shdmsr?`s?GI?bkhmhb`k udqx lncdrs?cheedqdmbdr?hm?lnnc?`mc dmbdr?adsvddm?sgd?svn?fqntorE?QnvdudqC7:@AB$B:<6$:=$()$G62@A$2=5$B96$@64><<6=52B:>=A rhsdr?enq?svn?xd`qrE?\gd?rstcx?v`r?etmcdc bnfmhshud?etmbshnm?adsvddm?sgd?svnf_oi`Z`Xdi:kf=je=[Xj\:m`j_:Xbb:j_\sgd?[\W?NL[?fqnto?dwodqhdmbdc?` ax sgd?Ndo`qsldms?ne?^dsdq`mr?Kee`hqr fqntorC|?r`hc?nmd?ne?sgd?rstcx}r?kd`cbXj\ij:[\l\befc\dji:`d:j_\:qd\kherfqd`sdq?cdbkhmd?nm?`?sdrs?ne?uhrtnlnsnq?@>D:56$AB6?&3G&AB6?$:=AB@C4B:>=A$B>$96;?$8C:56 A^KB?`mc?sgd?][?W`shnm`k?Rmrshstsd?ne hmudrshf`snqrC?Tdmmdsg?OnkkdssC?enqldqkxmehb[>:T`^d:kf:dem:]eh:X:]h\\:oqnbdrrhmf?roddcC?vghbg?ld`rtqdr?gnv?9GA:4:2=A$B9@>C89$B96$4>46AA$>7 Wdtqnknfhb`k?Nhrnqcdqr?`mc?[sqnjd `eehkh`sdc?vhsg?sgd?Rnv`?Mhsx?^K?Vdchb`kikYiZh`fj`ed:Yo:ki`d^:j_\:]ehc:edpthbjkx?rnldnmd?sghmjr?`mc?`bsr?nm56B6@<:=:=8$3@2:=$562B9$:=$25C;BA AWRWN[BC?o`qs?ne?sgd?W`shnm`k?Rmrshstsdr Mdmsdq?`mc?mnv?bghde?ne?mdtqnrtqfdqx?`sfX^\:@?:e]:j_`i:`iik\;hmenql`shnmE?KkrnC?sgd?[\W?NL[?fqnto ne Qd`ksgE?Kcchshnm`k?rtoonqs?v`r?oqnD sgd?]mhudqrhsx?ne?Wdaq`rj`?Vdchb`k g`c?rkhfgs?vnqrdmhmf?nm?`?rs`mc`qc ]Z cZl9\j^YZa^cZh9]VkZ i]Z9Y^[[ZgZcXZ9WZilZZc9i]ZhZ *.=72?-.?05 September(" 2010 uhcdc?ax?VdcsqnmhbC?sgd?l`jdqr?ne?sgd Mdmsdq?hm?Xl`g`C?][KE?{Ygxrhbh`mr?`mc `rrdrrldms?ne?cdoqdrrhnmC?vghkd?sgd?PYhWZZc9ejWa^h]ZY9^c9i]Z9C \j^YZa^cZh9[gdb9i]Z9egZk^djh NL[ rxrsdlr?trdc?hm?sgd?rstcxE? o`shdmsr?b`m?g`ud?bnmehcdmbd?hm?ansg NL[?fqnto?g`c?rkhfgs?hloqnudldms?nm   control?device?to?adjust {\gdrd?qdrtksr?drs`akhrg?sg`s?NL[ sxodr?ne?NL[C?`mc?b`m?l`jd?sgdhq?bgnhbd sgd?r`ld?sdrsE?\gd?hlonqs`mbd?ne?sgdrd LjcZ9^hhjZ9d[9   < dcZh>9oS]ZhZ9\j^YZa^cZh9VgZ S the?level?of?stimulation?to $! ( % i]Z9bZY^XVa9_djgcVa9d[9i]Z bdgZ9XdbegZ]Zch^kZ9i]Vc9i]Z cdkhudqdc?sn?sgdrd?svn?aq`hm?`qd`r?khmjdc a`rdc?nm?sgd?bnmrsdkk`shnm?ne?lnsnq?`mc,==>D2B:>=svn?cheedqdmbdr?hr?mns?bkd`qC?`mc?vhkk?ad maximise?pain?control sn?jdx?lnsnq?bnmsqnk?o`sgv`xr?b`m?g`ud rbqtshmhrdc?hm?enkknvDto?qdrd`qbgC?sgdFbZg^XVc9FXVYZbn9d[9OZjgda= daY9dcZh>9S]Zn9Vahd9^cY^XViZ+=;1@0?  )& and comfort?after?they dpthu`kdms?deedbsr?nm?sqdlnqC?rsheemdrr /9>E42A6hmudrshf`snqr?r`xE? d\n9:FFO;9VcY9]VkZ9WZZc9YZ= i]Vi9V9h^c\aZ9WgV^c9YZVi]9ZmVb change?body?positionsD `mc nsgdq?lnsnq?rxlosnlr Rm?oq`bshbdC?`esdq?NL[?rtqfdqxC?sgdkZadeZY9WVhZY9dc9V9gZk^Zl9d[ bVn9WZ9hj[[^X^Zci9[dg9bdhi [his?often?includes *21?=;:60 ne Y`qjhmrnm}r?chrd`rdC| cnr`fd?ne?UDcno`?`mc?qdk`sdc?ldchb`D that?uses?a?cuttingCedgeB Menter?@UKYMA?in turning?the?stimulation?up h\:oek:meha`d^:ed:X:j\Z_d`gk\< Vaa9d[9i]Z9hijY^Zh9dc9WgV^c9YZVi] XVhZh>9S]Zn9Vahd9ed^ci9Vi9i]Z.::;@:02> proprietary?smart?technolC UinneapolisB?and?investiC when a person?is?upright shnmr?hr?nesdm?qdctbdc?sn?oqdudms r`hc?_`ksdq?TnqnrgdsyC fhe[kZj<:eh:j\Z_debe^o:j_Xj:`i ejWa^h]ZY9WZilZZc9@DDB9VcY aVX`9d[9]VgY9hX^Zci^[^X9Zk^=:2@=;>?69@8.?6;: ogy?for?the?first?time?in?an gator?in?the?YestoreZensor and activeB?or?turning?it rhcd?deedbsr?rtbg?`r?cxrjhmdD cdotsx?chqdbsnq?`s Zedi`[\h\[:YhXd[=d\mE A??D> YZcXZ<9i]Z9gZa^VcXZ9dc9ZmeZgihqp Uedtronic?has?announced the?\ZK?will?be?enrolling address?an?unfulfilled device?to?sense?a?change the initiation?of?a?prospecC patients?in?this?studyD?[he need?for?a?neurostimulaC in body?position?and `eedbsr?rnld?ne sgd?[\W?NL[\j^YZa^cZh<9QVcVn^di^h9Odkdbsqhb`k?rshltk`shnm?vdqd?mddcdc?enqS]Z9\dVa9d[9i]Z9\j^YZa^cZh9^h cdhZ9WgV^c9YZVi]>9S]Zn9XVgZ[ja= YZcXZ=WVhZY9bZi]dYh>9Pjg9\dVa Xd[:q`[\Xi:f\efb\r:m_e:Xh\:meha`d^ tiveB?multicentreB?ranC first?implant?of?a tion?systemD?[his?device?is automatically?optimise?the will set?a?new?precedent stimulationD| sgd nsgdq ed X j\Z_d`gk\<:fhe[kZj:eh fqntoU sg`m?enqVgZaVh<9Y^gZXidg9d[9i]Z9OZjgd=[\W?NL[C?rtffdrshmf?sg`s?nudq?sgd?knmfid gZbdkZ9hdbZ9d[9i]Z9kVg^VW^a=domised?\ZK?clinical?trialan gZk^ZlZY9i]Z9WZhi9lVn9idYestoreZensor?neurostimC ldesigned?to?allow?autoCVh9id9YZkZade9V9YZiV^aZY9WgV^cpain?therapy?settingsD for?using?neurostimulation Veurostimulation?theraC hlonqs`msC j\Z_debe^o:m_`Z_:ZXd:Z_Xd^\:j_\ sgd?PYh?NL[KciZch^kZ9GVgZ9RZgk^XZ<9JZcgnsdqlC?sghr?oqnbdctqd?lhfgs?ad?`rrnbh`sdc^in9Vbdc\9YdXidgh9^c9i]Z^g9egd=for the YestoreZensor?neuCYZbdchigViZ9VWhZcXZ9d[9WgZVi]=ulator?in?the?study?was YZVi]9ZkVajVi^dc9egdidXda9i]Vimatic?response?to?changes Wnce the?KdaptiveZtim to manage?chronic?painD| py?is?used?for?managing mnmDlnsnq fqntoE vhsg?knvdq?bnrsr?`mc?kdrr?mddc?enq?qdok`bD rostimulator?that?adapts performed?by?Navid in?position?and?mainteC feature?is?activatedB?proC chronic?pain?of?the?trunk fXhX[`^c:e]:Zkhh\dj:fhXZj`Z\:`d:j_\ IdgY9HZeVgibZci9d[9OZjgdad\n XZYjgZ9[dg9YZXaVg^c\9WgV^c ^c\>9S]Z9\j^YZa^cZh9Vahd9Xdc= ldjaY9WZ9V9jhZ[ja9idda9[dg9Xa^c^= ,?#)@12 therapy?to?the?changing ZchultzB?at?UKXZ?Xain nance?of?a?consistentB gramming?parameters and?limbs?and?pain?from rxlosnlr?`mc \g`s hmf?sgd?otkrd?fdmdq`snqE? *2160.8C> ]`\b[i:e]:d\khebe^o<:d\kheikh^\ho< VcY99OZjgdhjg\Zgn<9JZcgn9IdgY YZVi]<9l]^X]9egZk^djh9gZhZVgX]needs?of?chronic?painXajYZ9i]Vi9aVWdgVidgn9iZhih9hjX]Mlinic?in?UinneapolisB X^Vch9optimal?level?of?stimulaC based?on?a?patient}s?optiC back?surgeries?that?have gnv sn adrs 5DTJVB.=7 ehmcD {Oqnl?sghr?rstcxC?vd?b`m?bnmbktcd?sg`s '<61@02=82.1 d\khehX[`ebe^o:Xd[:d\kheiZ`\dZ\> Jdhe^iVa9^c9HZigd^i<9TRF<9idaY ]Vh9[djcY9id9WZ9V9egdWaZb>9S]Zpatients?by?respondingVh Vc9ZaZXigdZcXZe]Vad\gVb9dg\ZKD? tion?for?patientsD|FXXdgY^c\9id9i]Z9cZl9\j^YZ=mal?stimulation?settings failedD?K?paddle?lead?is?a hmchuhct`khrd !$(%'&)$ '%$#!# hmf ne?sgd?svn?lnrs?bnllnm?s`qfdsr?enq 1286A2=B>B>?29 automatically?to?changes {Veurostimulation [he?level?of?stimulation are?correlated?to?certain small?insulated?wire?with U_\:

LddelXj`ed  E oS]ZgZ9VgZ9ild Vji]dgh9]VkZ9ed^ciZY9dji9i]Vi9^c XZgZWgVa9WaddY9[adl9hijY^Zh9VgZ a^cZh<9i]ZgZ9VgZ9i]gZZ9h^\ch9i]Vi 42?>&'9.=7 NL[ NL[C?dhsgdq?nmd?hr?`?qd`rnm`akd?noshnm in body?position?and offers?patients?a?therapy required?to?manage?a positions?or?activityD multiple?electrodes?on?a sgdq`oxE|?? T_emZXi\:`i:fXhj:e]:j_\:LddelXj`ed lVnh9id9Y^Z9^c9i]Z9TRF9VcYenq sqd`shmf?Y`qjhmrnm}r?chrd`rdC|?r`hc?sgddgYZg9id9XdggZXian9Y^V\cdhZactivity?in?an?upright?posiCcdi9ValVnh9cZXZhhVgn9id9XdbZthat?has?been?clinically V patient}s?pain?at?any?giveneZghdcqh9WgV^c9]Vh9eZgbVcZci=^hen?the?programming?is ZtD?Sude?Uedical?has flatB?paddleCshaped?surC Vnsnq?bnmsqnk Knfe:Xj:j_\:KnI\b:I\djh\<:Oed[ed ldgaYl^YZE9dcZ9d[9i]Zb9^h9idrstcx}r?bnDkd`c?hmudrshf`snq?Oq`mbdrWgV^c9YZVi]<9^i9^h9ZhhZci^Va9i]VitionD?[he?YestoreZensorid9V9Y^V\cdh^h<9VcY9bV`Z9XaZVgproven?to?provide?pain an9hideeZY9[jcXi^dc^c\>9I^ghi:U_\ l`x?hmektdmbdWZXdbZ9WgV^c9YZVY>9S]ZhZ_d`udqC?chqdbsnq?ne?sgd?Mdmsdq?enqXa^c^X^Vch9VY]ZgZ9id9V9jc^[dgbneurostimulator?receivedi]Vi9i]^h9XdbeaZm9egdXZhh9bjhireliefB?but?there?is?variance i]Z9eZghdc9^h9XdbVidhZ<9VcY9i]Zdistance?between?the designed?to?improve?pain Ouropean?MO?Uark epidural?space?near?the rg`jhmfC?qhfhchsxC sgd?NL[?s`qfds?bgnrdm?enq?o`shdmsrEfhe^hXcc\< \j^YZa^cZh9ZmVb^cZ9i]Z9Xdb=V`m`fdldms?ne?Mnlokdw?Mkhmhb`k?M`qd[gVbZldg`>9S]Z9\j^YZa^cZhMO?Uark?approval?inWZ9XdbeaZiZY9Wn9V9YdXidg9l^i]in the?device?settings XVjhZ9d[9i]Z9XdbV9^h9`cdlc>spinal?cord?and?implanted relief?regardless?of?body approval?of?its?new spineD?Uild?electrical rknvdc lnudldms?`mc Onq?rnld?o`shdmsrC?ldchb`shnmr?b`m `s?Qhmdr?^K?Qnrohs`k?`mc?oqnedrrnq?ne Ourope?and?is?under required?to?maximise?the electrodesD?RoweverB?this position?by?automatically Opiducer?lead?delivery pulses?are?carried?from Z_X`h\[:Yo eaZm9egdXZhh9i]Vi9aZVYh9id9i]Z YZhXg^WZ9hZkZgVa9hiZeh9YdXidghinvestigational?use?in?theXdch^YZgVWaZ9h`^aa9VcY9ZmeZg^=pain?relief?and?comfort RZXdcY<9Vaa9WgV^chiZb9gZ[aZmZhdistance?changes adjusting?the?device?setC system?for?neurostimulaC the?neurostimulator?to?the onnq?a`k`mbd?`qd?nesdm 6HE? LC@b`trd?tmv`msdc?rhcd?deedbsr?`mc?`?cqno ldchbhmd?`s?Unxnk`?]mhudqrhsxC?ansg?hm \c`d\dj: YZXaVgVi^dc9d[9WgV^c9YZVi]> bjhi9[daadl9^c9dgYZg9id9Y^V\=\ZKD?[he?clinical?trialZcXZ9^c9Y^V\cdh^c\9WgV^c9YZVi]>based?on?a?patient}s?activiC ]VkZ9eZgbVcZcian9hideeZYdepending?on?whether?the tingsD tion?therapyD?\nveiled?at lead}s?electrodes?to?interC sgd ehqrs `mc?lnrs?sqntakhmf hm ldchb`shnm?l`x?ad?e`untq`akd?enq Mghb`fnC?][KE? ? tyB|?said?ZchultzB?founder patient?is?upright?or?lying [he?YestoreZensor?neuC the Veurosurgery?HFGF rupt?or?mask?the?transmisC rxlosnlr?ne?Y`qjhmrnm}r?chrD sgdlE?Onq?nsgdqrC?`?cqno?hm?ldchb`shnm \gd?hmudrshf`snqr?vhkk?bnmshmtd?sn?enkD of the unique and medical?director?of down?in?various?positionsD rostimulator?also?records Mongress?in?TyonB?PranceB sion?of?pain?signals?to?the d`rdE Rm k`sdq?rs`fdrC?o`shdmsr?sdmc?sn tqwvCxmwxtmClqvoCnzwubntkc?tml`rj?rxlosnlr?qdk`sdc?sn?bnfDN\l`d:Rs:Q\`bb< nZVgh9d[9cZl9^c[dgbVi^dc<9cdknv?sgd?r`ld?o`shdmsr?enq?rdudq`k?lnqd KdaptiveZtim?feature?of,+"()*(UKXZ?Xain?Mlinics?and +" ' .!,# %#' *MurrentlyB?most?patients and stores?the?frequency the Opiducer?lead?delivery brainD?Olectrodes?on?the cdudkno?`?u`qhdsx?ne?bnfmhshud?`mc?lnnc 2Q3{|zwsm{Civv}ittICZ|Cq{C|pm 9>Lmhshnm?nq?lnnc?sg`s?vdqd?oqduhntrkxm`bb:ZedjX`d eVi^Zci9l]d9]Vh9WZZc9YZXaVgZYxd`qrC?knnjhmf?`s?gnv?sgd?bgnhbd?ne?NL[ the YestoreZensor?device UKXZ?Kpplied?Yesearch have?to?use?a?remote of these?posture?and?activC system?is?the?first?of?its lead?can?be?programmed |pqzlCtmilqvoCki}{mCwn ity?changesD?[hese?objecC kindB?allowing?introducC to?meet?each?individual oqnakdlrC?hmbktchmf?cdoqdrrhnmC?`o`sgxC lmi|pCqvC|pmCdbSCivlC|pmtmcdq?bnmsqnkE?a\o:fh\i\djX= WgV^c9YZVY9hjgk^kZY>9S]ZgZ[dgZ9MVhian<9i]Z9cZlqdok`bd?NL[?dkdbsqnmhbrE?9DBB?HH;; cpmCkwuuq||mmC~w|ml {qlqizGC]i|zq€C\ijwzi|wH individual?stimulation single?percutaneous?entry eration?lead?delivery?sysC Y`qjhmrnm}rC?`?mdtqnrtqfdnm?oqdbhrdkx pt`khsx?ne?khed?hm?Y`qjhmrnm}r?chrd`rdE|?|ivkmCitsqvoGCMOCD F;9DBB;C:G }vivquw}{tC|pi|CWchPMK zqm{C\quq|mlCpi{Czmkmq~ml requirements?are?changing pointD temB|?said?Mhris?MhavezB d\khe`cX^`d^<:ckbj`fb\:iZb\hei`i<:jmkwumCv}z{qvoCpwumCzm{H \j^YZa^cZh9bV`Z9i]Z9egdXZhh7EEFDJ7A'D< lmuwv{|zi|mlC{}j{|iv|qit nqvitCixxzw~itCnzwuC|pm ** '+#%+"+%#'##'* fthcdr?`?udqx?ehmd?vhqd?hmsn?nmd?ne?svn Kr qdonqsdc?hm?HFFJC?sgd?ehqrs?o`qs?ne over timeD [his?innovative?lead president?of?the?ZtD?Sude qlmv|{GCivlCLRDCpi~m bdgZ9ZVh^an9jcYZghiddY9[dg1DJ7FH?GM'.46*)( mnnqkikCqvC|zmi|qvoCzmtix{H dbSCWVSCnwzCq|{CSjjzmH cddo?aq`hm?qdfhnmr?hmunkudc?hm?lnsnq sgd?rstcx?bnlo`qdc?ahk`sdq`k?NL[?sn?adrsXd[:j_\:bXj\ij:X[lXdZ\i:`d:d\khe=|zw}jtmC{xmisqvoIC HD'HF;7H'F;A7EG?C= qvo zmuq||qvoC]bCivlC|pi| ~qi|mlC^mCVz}oCSxxtqH [he?inspiration?for?the delivery?system?is Uedical #2.64'36*5124%(45 " ) +(,'# ()& )& .()$KdaptiveZtim?technology designed?to?reduce?proceC Veuromodulation bnmsqnkC?sgd?rtasg`k`lhb?mtbkdtr?A[\WB ldchb`k?sgdq`oxC?hmbktchmf?ldchb`shnmikh^\ho:Xd[:d\khehX[`ebe^o>:L]:oekƒcqumCq{Cuw{|Cm{{mv|qit e]nh^X^Vch<9k^V9VchlZg^c\9heZ=F;B?HH?C='03 {inm|CwnC|pmCxzwxw{ml ki|qwvCES^VSFCnwz pmvCiC{|zwsmCwkk}z{G„ X^[^X9fjZhi^dch9VcY9YZkZade^c\cpmCdbSCWVSCkwuuq||mm KINuoClw{mCr}{|qnqml Xijixmv|qvCcijtm|{Cdb`GoNVcn9d[9i]Z9YZiV^ah9d[9i]Z ldg`^c\>9S]^gY<9WgZVi]^c\9]Vhcomes?from?Uedtronic}s dural?complexitiesD?[he NivisionD?{[he?Opiducer nq sgd fknatr o`kkhctr?hmsdqm`?APYhBE?Km `citrsldms?`mc?ogxrhb`k?sgdq`oxEmekb[:b`a\:je:fXhj`Z`fXj\:`d:j_`i:{iqlCTmz|C~ivC]m}z{GC{mvH/(',&$. 5+(3$28$.10()13~w|mlCqvCni~w}zCwnCixxzw~H ixxzw~itI OKKuoCivlCQKKuoGC|pm work?in?responsive?@or Opiducer?system?allows system?is?redefining?perC hlok`ms`akd?a`ssdqx?hr?trdc?sn?rdmc?`?ehmdD Lhk`sdq`k?NL[?rgnvdc?nudq`kk?rtodqhnqhsx\nZ`j`d^:d\m:i\ii`ed:`d:RZjeY\h9F9kZci^=adaptiveA?technology?in physicians?to?efficiently cutaneous?proceduresB kx?stmdc?dkdbsqhb`k?btqqdms?sn?rshltk`sd?sgd sn adrs?ldchb`k?sgdq`ox?`s?hloqnuhmfZv|mz~mv|qwvitCgHziCnwz owtquwlFGCi{C|zmi|umv|Cqv ivl quxwz|iv|Cuqtm{|wvm `nq‚mz {C^m}zwv|qvC|ijtm|{ cardiac?pacemakersD place?neurostimulation?ZC presenting?physicians \cX`b:khc`bXFY`YXc\[`ZXb>Zec:m`j_`pqtqx{CYmit|pkizmI $'7$0&('"$3-,041094',4($4(WZ9[daadlZY>p zmtix{qvoCzmuq||qvoCu}t|qH nwzC|pmC]bCkwuu}vq|G„ nwzC|pmC|zmi|umv|CwnCxw{Hi^dc9id9YZiZgb^cZ9WgV^c9YZVi] aVidg9bjhi9WZ9jhZY9id9`ZZe9i]Z aq`hmE?XesdmC?cq`l`shb?hloqnudldms?ne lnsnq?rxlosnlr?`mc?pt`khsx?ne?khedE?Rm[\jX`bi>ƒei{wUcCittw{Cxp{qH UVgZaVh9Vahd9XdbbZciZY9dcxtmC{ktmzw{q{GCinnqzuqvoC|pm {iqlC`i|zqkqiC_ \wwvmGSXdXo`ej`i:VXh\bXi|pmzxm|qkCvm}zitoqiGCiXVccdi9WZ9ZhiVWa^h]ZY9Wn9Zk^= WdYn9[jcXi^dc^c\> Uedtronic?was?the?first?to Zeries?percCpaddle?leads with?a?uniqueB?new?option lnsnq?rxlosnlr?b`m?ad?nardqudc?hm?sgd sgd?rdbnmc?o`qs?ne?sgd?rstcxC?HJJ?o`shdmsrCkqiv{CiCktmizC~qmCwvC|pm 5 RBNEOMJSFE/.OPFN0LBCFL.TRJBL/.PUC0 MOSTlz}o {Cxw{q|q~m LJKFLX.TO.CFNFGJT.MJHIT.CF.WBR0eqkmC`zm{qlmv|G kwuxtqki|qwvCwnC{pqvotm{I develop?rate?responsive andEor?multiple?lead to?place?leads?and?reduce twki|qwvCivlC{q‚mCwnC|pm jmvmnq|Jzq{sCxzwnqtmI TqwumlqkitCam{mizkpCi| cpmCxzwl}k|CqttCjmClq{H pacemakers?that?could arrays?utilised?in?Zpinal procedural?complexitiesD| nodq`shmf?qnnl?vgdm?sgd?vhqd?hr?oqnodqkx hmbktchmf?sgnrd?vgn?hmhsh`kkx?qdbdhudc LJSIFE.JN.TIF.32.;UNF.JSSUF.OG.( RBNTFE/Z.WROTF.TIF.BUTIORS1.@IF.=8 wkkt}{qwvCivlC{}zzw}vlqvo WchPMKGCivCqv~m{|qoiH |pm ^i|qwvitC]}t|qxtm |zqj}|mlCjC]tivC`pizH sense?and?respond?to?a Mord?Ztimulation?@ZMZA +5686<>8.@:052> ok`bdc?`mc?sgd?rshltk`snq?stqmdc adrs ldchb`k?sgdq`oxC?vdqd?q`mcnlkxkmzmjzitCjtwwlC~m{{mt{G %$"$ ) GOUNE.TIBT.BT.ONF.XFBR/ ?A>:.TRJBL.JS.BN.ONHOJNH.RBN0|qwvitC|zmi|umv|GCxw|mvH bktmzw{q{Cbwkqm|ICƒfm uikm}|qkit{I patient}s?changing?need therapy?for?the?manageC pqkpCtmil{C|wCi{{m{{umv| |qittCnqz{|CqvCiCvmCkti{{ jmtqm~mC|pi|CiC|zmi|umv| 6:?2=A2:?6;:.8 nmE?Lhk`sdq`k?rshltk`shnmC?hr?bnmrhcdqdc `rrhfmdc?sn?qdbdhud?dhsgdq?ahk`sdq`k?[\W SURHFRX.DOUPLFE.WJTI.CFST.MFEJDBL EOMJSFE/.OPFN0LBCFL.A<.TRJBL.WIJDI =BCBOFMRJM,RBCKFRQ,IBE +,+*$.C3;:A9:=8for?cardiac?outputB?which ment?of?chronic?painD ivlCquxtmumv|i|qwvCwn EEE'=6C@>wn ]bC|pmzixGCzmxzm{mv|{=6EA:=B6@=2B:>=2;'4><|pi|Czml}km{Czmtix{m{Civl A@9,QBKFQ,NG 0;:364@=.?6;:?; lnrs deedbshudE? NL[ nq PYh NL[E?? TIFRBPX.JMPROVFE.PBTJFNT.SFLG0RF0 WJLL.FVBLUBTF.TIF.ROLF.OG.SUCTIBLBMJD is the?standard?of?care Lefore?the?Opiducer?sysC |zmi|umv|ICei{wUcCit{w  i {qovqnqkiv|Cil~ivkmCi{ {tw{Clq{ijqtq|Cxzwozm{H BOOPNVJLBRFKW,-275 .>>6>?6:>?=;72 todayD?[he?YestoreZensor temB?the?placement?of?padC \gdqd hr ` vhcdkx?gdkc?uhdv?sg`s?ne?sgd Xudq ` svnDxd`q?odqhncC?sgd?svn?fqntor~q{}ittCiql{Cxp{qkqiv{CqvPORTFE.QUBLJTX.OG.LJGF.MORF.TIBN.CFST BNE.PBLLJEBL.SURHFRX/.CX.FJTIFR.STJMU0iv mnnqkikqw}{CwzitC|zmi|H {qwvCqvCiCkwv~mvqmv|Cwzit LJKKJNM,GNP,RIF,23,LNMRIQ .>>2>>92:? svn sdbgmhptdrC?[\W?NL[?hr?lnqd?deedbD dwodqhdmbdc?rhlhk`q?hloqnudldmsr?hmvi~qoi|qvoC|pzw}opC|pm MFEJDBL.TIFRBPX.BLONF.JN.PBTJFNTSwvmCwnC|pmCuw{|CkwuxzmH {iqlGCƒei{wUcCxzw~qlm{LBTJON.OR.LFSJONJNH/.DOMPBRFE.TOumv|CnwzCxmwxtmCq|pCzmH nwzu}ti|qwvCkw}tlCmvkw}zH FMEJMH,>BPDI,42.,3121. study?will?pursue?a?similar dle leads?was?only?possiC ktw|CqvC|pmCzqop|Clqzmk|qwvIC pmv{q~mCqv|mz~mv|qwvit xp{qkqiv{Cq|pC|pmCqvnwzH tix{qvoCzmuq||qvoC]bICcpm iom uwzmCxmwxtmCq|pC]b   shud `s bnmsqnkkhmf?lnsnq?rxlosnlr?ats rbnqdr nm sgd?]mhehdc?Y`qjhmrnm}r WJTI.BEVBNDFE.=BRKJNSON[S.EJSFBSF1 MFEJDBL.TIFRBPX.JN.PBTJFNTS.WJTI.BE0 BDDNPEJMH,RN, 0 adaptive?therapy?for?the ble through?a?laminotomyB Yoyal?Xhilips?Olectronics amkmq~qvoCy}qksCumlH quioqvoCkwvnqo}zi|qwv{Cqv ui|qwvCvmmlmlC|wCuism kwuuq||mmCpi{CzmkwuH |w qvq|qi|mC|zmi|umv|CqvC|pm :SPPFMRKW.,>WKBM,IBQ,251 field?of?neuromodulationD a more?invasive?surgical has introduced?Xhilips lnqd khjdkx?sn?`ffq`u`sd?mnmDlnsnq Nhrd`rd Z`shmf?[b`kdC?vghbg?ld`rtqdrqkitCi||mv|qwvC{qovqnqkiv|tY@IFSF|pm `pqtqx{Cqv|mz~mv|qwvit EJGGFRFNDFS.BRF.DLJNJDBLLXquxwz|iv|Clmkq{qwv{Ci|CiVBNDFE.=BRKJNSON[S.EJSFBSF.TIBT.JSumvlmlCxw{|Huizsm|qvo kw}z{mCwnC|pq{CtqnmHtwvo 9?;9Q,OFMEJMH,<;9 {^e?have?long?been procedureB?which?typically ]asoM[B?an?intraCvascular rxlosnlrE?\gd?mdv?rstcxzsgd?k`qfdrs lnsnq etmbshnmE??\gd?svn?fqntor?`krntwmz{C|pmCzq{sCwnClq{ijqtqHMFBNJNHGUL/.CUT.SURHFRX.JS.NOT.WJTI0gHzi {}q|mGClq{xtiqvoC|pm kz}kqitCuwumv|CnwzC|pmNOT BEFQUBTFLX.DONTROLLFE.CX.TIFJRkwttmk|qwvCwnCillq|qwvit lq{mi{mI„ BOOPNTBK,PFOPFQFMRJMH | ivlClmi|pICcpzw}opCi v}ivkm{CivlCkwuxtm€q|qm{ {|zwsmCxi|qmv|I„ {inm|Cli|iCivlCm~it}i|qwv committed?to?finding?new requires?removal?of?part interventional?configuraC 0KA7C'F;9;?J;G -8606,CJKKJNM,JM,BMMSBK lnrs bnloqdgdmrhud?rstcx?dudq?cnmd?ne qdonqsdc?rhlhk`q?hloqnudldmsr?hm?zw|i|qwvitC{kivCqvC|pm OUT.RJSK.BNE.TBRHFTJNH.OG.PBTJFNTSjmwvlC|pmCik|}itCwkkt}H ei{wUcCqttCjmCi~iqtHDURRFNT.MFEJDBL.TRFBTMFNT1wn i twmzClw{mI and innovative?ways?to of the?vertebral?boneD tion?for?the?Xhilips?Kllura 7EEFDJ7A'.<<=;A.8.:1ONRFMRJBK,GJPQR/RN/GJKF neurostimulatorsB?deliver?mild?electrical chronic?painB|?said?Non enables?physicians?to alise?vessel?structure?beC ijw}|CkmzmjzitC~i{k}tiz qvo i}|pwzq|CwvCvm}zwH gxmzCqv|mz~mv|qwvitCvm}zwH uq||mm{Ci{Cq|Czm~qm{Civl 8.@:05;3:2@=;>?69@8.?6;:NOONPRSMJRJFQ.,QBJE,RIF pulses?to?leads?placed?in?the?epidural NeyoB vice?president?of introduce?a?percCpaddle yond?a?clot?and?help {|z}k|}zm{CqvClm|iqtICZ|Cq{ qv|mz~mv|qwvitC|mkpvqy}m{ zilqwtwoC{}q|mI lmkqlm{Cpm|pmzC|w ]tivCpi{Czmkmv|tCivH QBLF,MFUQ,QNSPDF0 ! "6%.,4+,0* >B>?296:).<.: space?to?interrupt?or?mask?the Xroduct?Nevelopment?and lead?into?the?epidural physicians?identify?and?asC transmission?of?pain?signals?to?the [echnology?in space?with?a?simplerB?less sess?the?size?and?extent?of ZtD?Sude?Uedical?has?recently brainD? Uedtronic}s invasive?procedureB|?said an ischaemic?strokeD?[his announced?regulatory?approval?from?the {[he?launch?of?the?Qenesis?system?in Veuromodulation?busiC Wlivier?Ne?MosterB?an ensures?angiography?suite Sapanese?Uinistry?of?RealthB?Tabor?and Sapan?is?a?significant?step?in?our nessD?{^e?are?proud?to?be anaesthesiologistB?who?is treatment?as?quickly?as     ^elfare?@URT^A?for?the?Qenesis?spinal continued?international?growthB|?said developing?this?breakC head?of?the?Xain?Mlinic?at possibleB?thus?helping?to cord?stimulation?system?for?the Mhris?MhavezB?president?of?the?ZtD?Sude through?technology?that the Ztedelijk?`iekenhuis improve?outcomes?and            
management?of?chronic?painD? Uedical?Veuromodulation?NivisionD?^e will continue?to?help Rospital?in?YoeselareB quality?of?life?for?the?paC Zpinal?cord?stimulators?are?small are?excited?to?introduce?our?technology patients?with?chronic?pain LelgiumD?{Xaddle?leads tientD?]asoM[?is?based?on implanted?devices?that?are?used?for in?Sapan?and?to?be?able?to?provide?a return?to?a?more?full?lifeD provide?numerous?therapy a IN rotational?scan?and?a managing?chronic?pain?in?the?backB new?option?for?physicians?and?patients ^e?expect?the benefits?including?greater special?injection?protocolD?    arms?and?legsB?including?pain?associated that?will?help?them?manage?the?severest YestoreZensor?neurostimC stability?for?reduced?risk Ztroke?affects?GJ?milC with?back?surgeries?that?have?failedD forms?of?chronic?painD|? ulator?with?cuttingCedge of migration?and?more lion?people?worldwide          KdaptiveZtim?technology efficient?unidirectional each?yearB?with?five?milC         
%(%$+@/86>56:4



      
   

          

,/,+'2I8A?G>?C= Free subscription Sign up online!     
 Latest News • Opinion • Events • Profiles • Back issues Important Addresses

Local Agency Gerle DMC AB Ms Britt-Marie Thorsson Ärenprisgatan 3 416 52 Gothenburg / Sweden

Phone +46 31 197 080 Fax +46 31 211 562 E-mail [email protected] www.gerledmc.se Welcome & Addresses

Advance Notice ECTRIMS/ACTRIMS 2011

5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis

19–22 October 2011, Amsterdam, Netherlands

www.ectrims.eu/2011

EUROPEANCOMMITTEEFORTREATMENT ANDRESEARCHINMULTIPLESCLEROSIS

9 CME Accreditation / Certificates

General Remarks The CME accreditation is valid for the main congress programme and the teaching courses only and does not cover the company- sponsored satellite symposia.

Europe The 26th ECTRIMS / 15th RIMS is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the CME activity for medical specialists, as listed below. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The 26th ECTRIMS / 15th RIMS is designated for a maximum of (or “for up to”) 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

United States EACCME credits are recognized by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credits to AMA PRA category 1 credits, contact the AMA (www.ama-assn.org).

Italy ECTRIMS has also submitted, in compliance with the procedures indicated by the Italian Ministry of Health, the main congress programme and the teaching courses of this event (no. 13776-10029270 for Physicians / no. 13776-10029320 for Neuro-physiopathology Technicians / no. 13776-10029321 for Nurses), entitled 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) / 15th Annual Conference of Rehabilitation in Multiple Sclerosis (RIMS) to the Italian National Commission for Continuing Medical Education.

Certificates Changes of certificates due to incorrect submission of names and/or address will be charged € 10. Certificates of attendance indicating the CME credits are available as from Friday, 15 October 2010, in the afternoon. They can be printed from self-service stations in the pre-registration area, using the barcode printed on your name badge.

For Italian delegates certificates will be sent after the congress. Italian delegates need to fill out an evaluation form at the pre-registration desk in order to receive their CME credits. The CME certificate will be sent after the congress.

10 ECTRIMS Research Fellowship Exchange Programme

Deadline: 1 December 2010 ECTRIMS is pleased to announce its Research Fellowship Exchange Programme competition for the coming year. The fellowship is offered to young European postdoctoral neuroscientists (MD, PhD, ScD or equivalent) to facilitate their conduct of and training in basic, clinical or applied research related to MS in European laboratories or clinics. The goal is to maximize exchange of information and help grow the pool of well-trained scientists focused on MS. ECTRIMS will support up to two fellowships annually, each with duration of 1 or 2 years, with an annual stipend of up to € 40,000 – € 50,000, depending on the candidate’s degree. Fellows are expected to identify a European research training environment and mentor prior to application and to devote full-time to research and research training during their fellowship period (up to 10% time and effort can be spent on teaching and/or clinical care).

Eligibility Scientists or physicians who are residents of ECTRIMS member countries and who hold or are candidates for an MD, PhD, ScD or equivalent degree are eligible. Candidates should be less than 40 years of age and have less than 5 years of post-doctoral experience at the time of application. The fellowship period must be spent in a European laboratory or clinic and the candidate is expected to have identified a fellowship site, mentor and research project prior to submission of an application. CME & Fellowship

Application The following documents are required for application: – Complete curriculum vitae and bibliography of the candidate – Description of the project to be undertaken during the fellowship period – Letters of acceptance and support from the proposed mentor and his/her institution – Letters of support from up to three scientists/clinicians at the candidate’s home institution supporting the prospective fellow’s candidacy.

Further details about the ECTRIMS Research Exchange Fellowship Programme and application materials can be obtained by writing to the Fellowship Administrator at [email protected].

11 Wednesday, 13 October 2010

Main Auditorium Congress Hall Room G2 (Hall B) 07:30

08:00

08:30 08:30–10:00 08:30–10:00 09:00 Teaching Course 1 Teaching Course 5 Differential diagnosis Analysis of CSF in MS: 09:30 of MS using MRI roles in prognosis, diagnosis and p. 18 monitoring of disease 10:00 p. 20 10:00–10:30 Coffee Break 10:30 10:30–12:00 10:30–12:00 11:00 Teaching Course 10 Teaching Course 9 MS management – Optical coherence 11:30 the essentials tomography and MS

p. 22 p. 22 12:00 12:00–12:30 Lunch Break 12:30 12:30–14:00 13:00 Satellite Symposium 13:30 European Charcot Foundation p. 23 14:00 14:00–15:30 14:30 Young Researchers Session I 14:30–15:30 15:00 Satellite Symposium p. 24 Teva p. 25 15:30 15:30–16:00 Coffee Break 16:00 16:00–17:15 16:00–17:00 16:30 Young Researchers Satellite Session II Symposium Biogen Idec & Elan 17:00 p. 25 p. 26 17:30 17:30–18:30 18:00 Satellite Symposium Merck Serono S.A. 18:30 p. •• p. 26 19:00 18:45 Welcome Reception at the Scandinavium (Congress Centre) 19:30 p. 187

12 Wednesday, 13 October 2010

Registration / Room H2 Room H1 Room J1 Posters / Exhibition 07:30

08:00

08:30 08:30–10:00 08:30–10:00 08:30–10:00 Teaching Teaching Teaching 09:00 Course 3 Course 4 Course 2 MS registries Cognition in MS MS animal and natural models 09:30 course of MS p. 19 p. 19 p. 18 10:00 10:00–10:30 Coffee Break 10:30–12:00 10:30 Teaching 10:30–12:00 10:30–12:00 Course 8 Teaching Teaching 11:00 Paediatric CNS Course 7 Course 6 inflammatory MS genetics and High field MRI- demyelination: environment or impact on 11:30 AOEM-CIS- life style factors diagnosis and NMO-MS p. 21 pathology 12:00 p. 21 p. 20 07:30–19:00 12:00–12:30 Lunch Break Registration/ Secretariat 12:30

12:00–14:00 13:00 Poster mounting for 13:30 Session I: Room R4 P143 – P576 14:00 14:00–16:30 09:30–17:30 RIMS Executive Exhibition 14:30 Board and RIMS SIG 15:00 Chairs meeting (by invitation only) 15:30 Overview & Programme 15:30–16:00 Coffee Break 16:00 p. 24 16:30

17:00

17:30

18:00

18:30

18:45 19:00 Welcome Reception at the Scandinavium (Congress Centre) 19:30 p. 187

13 A NEW STEP FORWARD TOWARDS MS SPASTICITY SYMPTOMS IMPROVEMENT

SATELLITESAATELLITETELLITTE SYMPOSIUM OFOF THETHE EECTRIMSCTRIMS 22010010 CCONGRESSONGRESS Thursday,Thursday, Octoberber 14th - 7:15 - 8:15 a.m. CongCongressress Hall NewNew iinsightsnsights iinn tthehe pathophysiologypathophysiology andand ttreatmentreatment ooff mmultipleultiple sclerosissclerosis sspasticitypasticittyy aandnd relatedrelated ssymptomsymptoms

CHAIRMAN X. Montalbán (Barcelona,(Barceelona, Spain)

VisitVisit Almirall Almiraall at stand No. 305

Attendants willw be entitled to propose a clinclinicalnical investigation project on MSS symptoms and opt for an AlmiraAlmirallll educational grant.

Solutions with youyoou in mind www.almirall.com Thursday, 14 October 2010

Main Auditorium Registration / Congress Hall Room G2 (Hall B) Posters / Exhibition 07:00

07:15–08:15 07:30 Satellite Symposium 08:00 Almirall p. 27 08:30 08:30–10:00 Plenary 09:00 Session 1 Welcome address 09:30 ECTRIMS lecture p. 27 10:00 10:00–10:30 Coffee Break 10:30 10:30–12:00 10:30–12:00 10:30–12:00 Parallel Parallel RIMS 07:00–18:00 11:00 Session 1 Session 2 Session 1 Registration/ Secretariat MS genetics Natural course Behavioural 11:30 of MS interventions in p. 28 p. 29 MS-update 15:30–17:00 12:00 p. 30 Poster Session I: 12:00–12:45 Lunch and Poster Viewing 12:30 12:45–13:45 P143 – P576 Satellite 13:00 Symposium 17:00–18:00 Poster Teva & 13:30 Sanofi-aventis p. 31 removal 14:00–15:30 14:00–15:30 14:00–15:30 09:30–18:00 14:00 Parallel Parallel RIMS Exhibition Session 3 Session 4 Session 2 14:30 Progress in Environmental Free immunology and lifestyle Communications 15:00 relevant to MS contribution p. 00 in MS 15:30 p. 31 p. 32 p. 33 16:00 Overview & Programme 15:30–17:00 Poster Session I P143–P576 p. 52 16:30

17:00–17:45 17:00–17:45 17:00–17:45 17:00 Hot Topics in MS 2 Hot Topics in MS 3 Hot Topics in MS 1 Monitoring Update on mono- MS progression of MS clonal ab therapy 17:30 p. 34 p. 35 p. 34 18:00 18:00–19:00 Satellite Symposium 18:30 Biogen Idec & Elan p. 35 19:00

19:15–20:15 Satellite 19:30 Symposium Bayer Schering 20:00 Pharma AG p. 36 20:30

21:00

15 Friday, 15 October 2010

Main Auditorium Registration / Congress Hall Room G2 (Hall B) Posters / Exhibition 07:00 Room G4 07:30 07:30–09:00 08:00–09:00 08:00 ECTRIMS Satellite Council Meeting 08:30 Symposium (by invitation Genzyme & only) p. 37 09:00 Bayer p. 37 09:30 09:15–10:15 09:15–10:15 Free Commu- Free Commu- 10:00 nications I nications II p. 38 p. 39 07:45–18:00 10:30 10:15–10:45 Coffee Break & Poster Viewing Registration/ Secretariat 11:00 10:45–12:15 10:45–12:15 10:45–12:15 Parallel Parallel RIMS 08:00–09:00 11:30 Session 6 Session 5 Session 3 Poster Infections in the MS pathology Progress in MS mounting for etiopathogenesis rehabilitation Session II: 12:00 of MS p. 41 p. 40 p. 41 P577 – P992

12:30 12:15–12:45 Lunch and Poster Viewing 15:30–17:00 Poster 12:45–13:45 13:00 Satellite Session II: Symposium P577 – P992 13:30 Merck Serono S.A. 09:30–18:00 14:00 p. 42 Exhibition 14:00–15:30 14:00–15:30 14:00–15:30 14:30 Parallel Parallel Parallel Session 9 Session 8 Session 7 MR applications Risks and benefits Repairing the 15:00 for understanding of new therapies central nervous MS pathology in MS p. 43 systemp. 42 Room J2 15:30 p. 44 15:30–16:30 RIMS General 16:00 Assembly (RIMS Members 15:30–17:00 Poster Session II P577–P992 p. 99 p. 44 16:30 only)

17:00 17:00–17:45 17:00–17:45 17:00–17:45 Hot Topics in MS 4 Hot Topics in MS 6 Hot Topics in MS 5 Gender in MS Treatment Biomarkers in 17:30 strategies in MS MS Various Rooms p. 45 p. 46 p. 45 18:00 18:00–20:00 18:00–19:00 RIMS SIG 18:30 Satellite Core People Symposium Meetings (by invitation 19:00 Sanofi-aventis p. 46 19:15–20.15 only) 19:30 Satellite Symposium p. 47 20:00 Novartis Pharma AG p. 47 20:30 20:30 Conference Dinner at Kajskjul 8 16 p. 189 Saturday, 16 October 2010

Registration / Congress Hall Posters / Exhibition 08:00

08:30 08:30–10:00 Parallel 09:00 Session 10 Late breaking news 09:30 08:15–12:30 p. 48 Registration / Secretariat 10:00 10:00–10:30 Coffee Break & Poster Viewing 12:00–13:00 10:30 10:30–12:00 Poster removal Plenary 11:00 Session 2 09:00–11:00 Adult CNS regeneration 11:30 Highlights and awards Exhibition p. 49 12:00 12:00–12:30 Lunch Break 12:30

13:00

13:30

14:00 Overview & Programme

17 Scientific Programme Wednesday, 13 October 2010

08:30– Teaching Course 1 Congress Hall 10:00 Differential diagnosis of MS using MRI

Chairs: F. Fazekas (Graz, AT); D. Miller (London, UK) Typical MS lesions on MRI A. Rovira (Barcelona, ES) Atypical MS presentations C. Enzinger (Graz, AT) Acute transverse myelitis A. Gass (Basel, CH) Progressive multifocal leukoencephalopathy T. Yousry (London, UK) Vascular and other disorders N. De Stefano (Siena, IT)

08:30– Teaching Course 2 Room J1 10:00 MS animal models

Chairs: H. Lassmann (Vienna, AT); H. Wekerle (Martinsried, DE) Imaging CNS inflammation – effects of anti-inflammatory treatments A. Flügel (Göttingen, DE) Models of MS – the B cell side R. Liblau (Toulouse, FR) Modeling inflammatory tissue damage H. Lassmann (Vienna, AT)

18 Scientific Programme Wednesday, 13 October 2010

08:30– Teaching Course 3 Room H2 10:00 MS registries and natural course of multiple sclerosis

Chairs: J. Hillert (Huddinge, SE); S. Vukusic (Lyon, FR) Databasing and registries: methodological issues J. Hillert, M. Pugliatti, P.S. Sanna (Huddinge, SE; Bergen, NO; Sassari, IT) Databasing and MS course: The EDMUS experience S. Vukusic (Lyon, FR) Databasing and MS course: The Sylvia Lawry experience M. Daumer (Munich, DE) Toward a European MS Registry J. Hillert (Huddinge, SE)

08:30– Teaching Course 4 Room H1 10:00 Cognition in MS

Chairs: M.P. Amato (Florence, IT); R.H. Benedict (Buffalo, US) Overview and assessment D. Langdon (Egham, UK) Correlation with MRI/neuropathology N. De Stefano (Siena, IT) Treatment: behavioural I.K. Penner (Basel, CH) Overview & Programme Treatment: pharmacologic L. Krupp (Stony Brook, US)

19 Scientific Programme Wednesday, 13 October 2010

08:30– Teaching Course 5 Room G2 10:00 Analyses of CSF in MS: roles in prognosis, diagnosis and monitoring of disease

Chairs: J.C. Alvarez-Cermeno (Madrid, ES); G. Giovannoni (London, UK) Role of CSF study in the differential diagnosis of MS and implications for the diagnostic criteria and the diagnosis of PPMS M. Freedman (Ottawa, CA) The role of CSF analyses in monitoring immunoregulation of the brain and spinal cord O. Stüve (Dallas, US) Prognostic value of oligoclonal band study L. Villar (Madrid, ES) Neurofilament in CSF for the prediction and monitoring of disease activity of MS J. Lycke (Gothenburg, SE) NCAM and related markers in the CSF of patients with MS S. Gnanapavan (London, UK) Proteomics and exploratory CSF biomarkers M. Comabella (Barcelona, ES)

10:00– Coffee Break 10:30

10:30– Teaching Course 6 Room J1 12:00 High field MRI – impact on diagnosis and pathology

Chairs: F. Barkhof (Amsterdam, NL); M. Filippi (Milan, IT) Technical challenges at high field C. Wheeler (London, UK) Diagnostic criteria: high field is high yield? M. Wattjes (Amsterdam, NL) Cortical pathology as seen by high field MRI J. Geurts (Amsterdam, NL) Iron imaging using high field MRI S. Ropele (Graz, AT) Still normal appearing white and grey matter at high field? M. Rocca (Milan, IT)

20 Scientific Programme Wednesday, 13 October 2010

10:30– Teaching Course 7 Room H1 12:00 MS genetics and environmental or life-style factors

Chairs: A. Ascherio (Boston, US); T. Olsson (Stockholm, SE) The genetics of MS J. Hillert (Huddinge, SE) Epidemiology supporting the role of environmental factors in MS G. Ebers (Oxford, UK) Specific life-style/environmental factors in MS A. Ascherio (Boston, US) Gene-environment interactions L. Alfredsson (Stockholm, SE) The epigenetics of neuroinflammation M. Jagodic (Stockholm, SE)

10:30– Teaching Course 8 Room H2 12:00 Paediatric CNS inflammatory demyelination: ADEM-CIS-NMO-MS

Chairs: B. Banwell (Toronto, CA); E. Waubant (San Francisco, US) Epidemiology of paediatric MS (incidence/prevalence/course compared to adults) C. Renoux (Montreal, CA) Disease onset: age-specific clinical, MRI and

CSF features Overview & Programme E. Waubant (San Francisco, US) Differential diagnoses B. Banwell (Toronto, CA) Important neuropsychological issues in paediatric-onset MS M.P. Amato (Florence, IT) Issues with MS disease-modifying therapies in children J. Gärtner (Göttingen, DE)

21 Scientific Programme Wednesday, 13 October 2010

10:30– Teaching Course 9 Room G2 12:00 Optical coherence tomography and MS

Chairs: L. Balcer (Philadelphia, US); J. Frederiksen (Glostrup, DK) Welcome and overview L. Balcer (Philadelphia, US) Introduction to OCT: uses and technologies in MS J. Frederiksen (Glostrup, DK) Distinguishing those other optic neuropathies: clinical and OCT characteristics S. Galetta (Philadelphia, US) Axonal loss in optic neuritis: early studies F. Costello (Ottawa, CA) Imaging and pathology of retinal inflammation in MS P. Villoslada (Barcelona, ES) OCT as a window on MS: correlations with brain MRI measures P. Calabresi (Baltimore, US) Structure meets function for the future: fMRI of the visual system and OCT in MS and optic neuritis D. Fuglo (Copenhagen, DK)

10:30– Teaching Course 10 Congress Hall 12:00 MS management – the essentials

Chairs: H.-P. Hartung (Düsseldorf, DE); J. Wolinsky (Houston, US) Clinical and MR monitoring of the disease D. Miller (London, UK) Approved disease-modifying drugs R. Gold (Bochum, DE) The new drugs on the block H.-P. Hartung (Düsseldorf, DE) Treatment of progressive disease X. Montalban (Barcelona, ES) Symptomatic management E. Frohman (Dallas, US)

12:00– Lunch Break 12:30

22 Scientific Programme Wednesday, 13 October 2010

12:30– Satellite Symposium Main Auditorium 14:00 Chronic cerebrospinal venous Insufficiency. Relation to multiple sclerosis?

Chair: G. Comi (Milan, IT) 12:30 Introduction O.R. Hommes (Molenhoek, NL) 12:35 CCSVI: from hypothesis to reality 1 P. Zamboni (Ferrara, IT) 12:45 CCSVI: relation to multiple sclerosis 2 R. Zivadinov (Buffalo, US) 13:00 Doppler sonography of venous outflow of the brain 3 in multiple sclerosis F. Doepp (Berlin, DE) 13:15 Questions on CCSVI in multiple sclerosis 4 O. Kahn (Detroit, US) 13:30 Discussion Satellite symposium arranged by the European Charcot Foundation Overview & Programme

23 Scientific Programme Wednesday, 13 October 2010

14:00– Young Researchers Session I Congress Hall 15:30

Chairs: M. Tintore (Barcelona, ES); F. Zipp (Mainz, DE) 14:00 Early functional adaptive changes in the hippocampal 5 memory system of multiple sclerosis patients H.E. Hulst, S.D. Roosendaal, M.M. Schoonheim, Y.D. van der Werf, C.H. Polman, F. Barkhof, J.J.G. Geurts (Amsterdam, NL) 14:15 IRF5 gene variant as biomarker to predict the 6 interferon beta response in multiple sclerosis S. Vosslamber, L.F. van der Voort, I.J. van der Elskamp, R. Heijmans, C. Aubin, B.M.J. Uitdehaag, J.B.A. Crusius, C.T.M. van der PouwKraan, D. Hafler, P. de Jager, J. Killestein, C.H. Polman, C.L Verweij (Amsterdam, NL; Cambridge; New Haven, Boston, US) 14:30 Regional cortical and basal ganglia atrophy 7 characterises clinically isolated syndrome patients that early convert to MS M. Calabrese, F. Rinaldi, I. Mattisi, V. Bernardi, A. Favaretto, M. Atzori, M. Puthenparampil, P. Perini, P. Gallo (Padua, IT) 14:45 Brain MRI in a series of NMO-IgG seropositive 8 patients I. Kister, J. Howard, J. Perumal, J. Herbert (New York, US) 15:00 Primary retinal pathology in multiple sclerosis as 9 detected by optical coherence tomography S. Saidha, C. Eckstein, S. Syc, C. Warner, S. Farrell, N. Shiee, P. Bazin, D. Reich, J. Oakley, M. Durbin, S. Meyer, L. Balcer, E. Frohman, J. Rosenzweig, J. Ratchford, P. Calabresi (Baltimore, Dublin, Philadelphia, Dallas, US) 15:15 Interhemispheric motor inhibition as a marker of 10 callosal disconnection in early relapsing–remitting multiple sclerosis A. Huebers, M. Wahl, U. Ziemann (Frankfurt, DE)

14:00– RIMS Executive Board and Room R4 16:30 RIMS SIG Chairs meeting

by invitation only

24 Scientific Programme Wednesday, 13 October 2010

14:30– Satellite Symposium Main Auditorium 15:30 Laquinimod: a step closer to a novel oral treatment option for patients with MS

Chair: F. Lublin (New York, US) 14:30 New insights into the mechanism of action of 11 laquinimod W. Brück (Göttingen, DE) 15:00 Efficacy and safety of laquinimod: current data and 12 future perspectives L. Kappos (Basel, CH) Satellite symposium arranged by Teva Pharmaceutical Industries

15:30– Coffee Break 16:00

16:00– Young Researchers Session II Congress Hall 17:15

Chairs: W. Brück (Göttingen, DE); C. Teunissen (Amsterdam, NL) 16:00 NMO spectrum disorders associated with 13 myasthenia gravis: a cohort study E. Coutinho, M.I. Leite, E. Santos, A. Graham, L. Jacobson, C. Buckley, D. Hilton-Jones, A. Vincent, J. Palace (Oxford, Ipswich, UK; Porto, PT) 16:15 A human commensal antigen protects against 14 CNS demyelinating disease in mice and modulates regulatory T-cell phenotypes in humans

J. Ochoa-Reparaz, Y. Wang, D.W. Mielcarz, Overview & Programme S. Begum-Haque, A. Bergeron, J. Channon, D.L. Kasper, L.H. Kasper (Lebanon, Boston, US) 16:30 Combined exercise led by a physiotherapist or 15 fitness instructor significantly improves walking distance over six minutes M. Garrett, N. Hogan, A. Larkin, J. Saunders, S. Coote (Limerick, IE) 16:45 Dietary vitamin D3 supplements reduces 16 demyelination in the cuprizone model S. Wergeland, O. Torkildsen, K-M. Myhr, L. Aksnes, S. Mork, L. Bo (Bergen, NO) 17:00 Validity of a computerised version of the Symbol 17 Digit Modalities test in patients with multiple sclerosis N. Akbar, K. Honarmand, N. Kou, A. Feinstein (Toronto, CA)

25 Scientific Programme Wednesday, 13 October 2010

16:00– Satellite Symposium Main Auditorium 17:00 Redefining success in MS: making informed treatment decisions Chair: T. Olsson (Stockholm, SE) 16:00 Welcome & introduction T. Olsson (Stockholm, SE) 16:05 MS pathophysiology: defining the urgency to treat 18 and long-term outcomes A. Kermode (Perth, AU) 16:20 Managing powerful efficacy: balancing benefit-risk 19 ratio D. Bates (Newcastle, UK) 16:35 Making the right treatment decision: an increasing 20 challenge B. Kieseier (Düsseldorf, DE) 16:50 Q&A/Close Satellite symposium arranged by Biogen Idec & Elan Pharmaceuticals

17:30– Satellite Symposium Main Auditorium 18:30 Early, long-term and short-course therapy. Part I: addressing the challenges in multiple sclerosis Chair: J. Lycke (Gothenburg, SE) Introduction J. Lycke (Gothenburg, SE) 21 Early treatment for MS: opportunities to improve outcomes H. Moses (Nashville, US) 22 Long-term treatment of MS: meeting the challenge of disease management B. Kieseier (Düsseldorf, DE) 23 Looking to the future with cladribine tablets H.-P. Hartung (Düsseldorf, DE) Panel discussion and Q&A Satellite symposium arranged by Merck Serono S.A.

18:45 Welcome Reception at the Scandinavium The Welcome Reception will be held at the Scandinavium, located adjacent to the Congress Centre (see page 187 for further information)

26 Scientific Programme Thursday, 14 October 2010

07:15– Satellite Symposia Congress Hall 08:15 New insights in the pathophysiology and treatment of multiple sclerosis spasticity and related symptoms

Chair: X. Montalban (Barcelona, ES) 24 Multiple sclerosis spasticity pathophysiology update J. Haas (Berlin, DE) 25 Endocannabinoid pathways and their role in the muscular disfunction in multiple sclerosis V. di Marzo (Naples, IT) 26 Sativex: endocannabinoid system modulator, basic features and main clinical data P. Vermersch (Lille, FR) Satellite symposium arranged by Almirall

08:30– Plenary Session 1 Main Auditorium 10:00 Welcome address and ECTRIMS lecture

Chairs: M. Clanet (Toulouse, FR); J. Lycke (Gothenburg, SE) 27 Welcome address J. Lycke (Gothenburg, SE) 28 Welcome to Gothenburg J. Linder (Gothenburg, SE) L. Weibull (Gothenburg, SE) 29* ECTRIMS lecture:

genes and life-style / environmental factors in MS Overview & Programme T. Olsson (Stockholm, SE)

10:00– Coffee Break 10:30

* Invited review 27 Scientific Programme Thursday, 14 October 2010

10:30– Parallel Session 1 Congress Hall 12:00 MS genetics

Chairs: K.M. Myhr (Bergen, NO); G. Stewart (Sydney, AU) 10:30 Interactions between HLA and other genes in MS 30* L. Fugger (Oxford, UK) 10:50 The new MS gene list – whole genome association 31* studies in MS S. Sawcer (Cambridge, UK) 11:10 The future: where does MS genetics go from here? 32* P. De Jager (Boston, US) 11:30 Single nucleotide polymorphisms in HLA- and non- 33 HLA genes predict the development of antibodies to interferon-beta therapy in patients with multiple sclerosis F. Weber, S. Cepok, C. Wolf, A. Berthele, M. Uhr, T. Bettecken, D. Buck, H. P. Hartung, F. Holsboer, B. Mueller-Myhsok, B. Hemmer (Munich, Düsseldorf, DE) 11:45 The nerve growth factor receptor gene affects 34 susceptibility to multiple sclerosis I. Lima Bomfim, H. Bach Sondergaard, E. Gulowsen Celius, K. Duvefelt, H.F. Harbo, A.B. Oturai, L. Alfredsson, T. Olsson, I. Kockum, J. Hillert (Stockholm, SE; Copenhagen, DK; Oslo, NO)

* Invited review

28 Scientific Programme Thursday, 14 October 2010

10:30– Parallel Session 2 Main Auditorium 12:00 Natural course of MS

Chairs: M. Kremenchutzky (London, Ontario, CA); N. Koch-Henriksen (Aalborg, DK) 10:30 Update on natural course of MS 35* C. Confavreux (Lyon, FR) 10:50 Natural course of MS: 50 years of follow-up 36* O. Andersen (Gothenburg, SE) 11:10 Has the phenotype of MS changed in Japan? 37* J.I. Kira (Fukuoka, JP) 11:30 MRI and CSF as predictors of time to relapse after 38 CIS in neurological practice H. Butzkueven, C. Meyniel, T. Spelman, G. Izquierdo, F. Grand’Maison, M. Trojano, C. Zwanikken, C. Oreja-Guevara, A. Lugaresi, T. Petersen, C. Boz, P Grammond, G. Iuliano, P. Duquette, M. Girard, M. Fiol, J. Cabrera-Gomez, R. Hupperts, G. Giuliani, J. Lechner-Scott, F. Verheul, R. Bergamaschi, E. Cristiano, V. Van Pesch, M. Saladino, J. Herbert, T. Petkovska-Boskova, N. Vella, F. Moore, M. Slee, E. Havrdova, M. Paine, C. Young, C. Shaw, M Barnett, C.-A. Sirbu (Victoria, Newcastle, South Australia, NSW, AU; Sevilla, Madrid, ES; Quebec, Montreal, CA; Bari, Chieti, Salerno, Macerata, Pavia, IT; Nijmegen, Sittard, Gouda, NL; Aarhus, DK; Trabzon, TR; Buenos Aires, AR; Havana, CU; Brussels, BE; New York, US; Skopje, MK; Balzan, MT; Prague, CZ; Liverpool, UK; Bucharest, RO)

11:45 Diagnostic delay in multiple sclerosis Overview & Programme 39 J. Bentzen, L.C. Thygesen, E.M. Flachs, E. Stenager, H. Brønnum-Hansen, N. Koch-Henriksen (Copenhagen, DK)

* Invited review

29 Scientific Programme Thursday, 14 October 2010

10:30– RIMS Session 1 Room G2 12:00 Behavioural interventions in MS – update on trials and mechanisms

Chairs: G. Fulcher (Lidcombe, AU); C. Heesen (Hamburg, DE) 10:30 Cognitive behavioural therapy in MS 40* D.C. Mohr (Chicago, US) 10:50 Improvements in quality of life, depression and 41* fatigue among multiple sclerosis patients after mindfulness-based intervention: a randomized controlled trial P. Grossmann, L. Kappos, H. Gensicke, M. D’Souza, D.C. Mohr, I.K. Penner, C. Steiner (Basel, CH; Chicago, US) 11:10 Helping patients in decision making by using 42* evidence-based information S. Köpke (Hamburg, DE) 11:30 Biological outcome parameters for behavioral 43* interventions S. Gold (Los Angeles, US) 11:50 Concluding remarks 44* C. Heesen, G. Fulcher (Hamburg, DE; Lidcombe, AU)

12:00– Lunch Break & Poster Viewing 12:45

* Invited review

30 Scientific Programme Thursday, 14 October 2010

12:45– Satellite Symposium Main Auditorium 13:45 Towards tailored MS treatment – weighing benefits and risks

Chairs: J. Wolinsky (Houston, US); J. Hillert (Huddinge, SE) 12:45 Prognostic factors as a tool in MS treatment 45 X. Montalban (Barcelona, ES) 13:15 On the use of treatment algorithms for 46 individualizing treatment G. Comi (Milan, IT) Satellite symposium arranged by Teva & Sanofi-aventis

14:00– Parallel Session 3 Congress Hall 15:30 Progress in immunology relevant to MS

Chairs: D. Karussis (Jerusalem, IL); R. Liblau (Toulouse, FR) 14:00 Innate immunity in MS 47* C. Dijkstra (Amsterdam, NL) 14:20 Lymphocyte trafficking in CNS inflammation 48* A. Flügel (Martinsried, DE) 14:40 Myelin proteins and glycolipids as target antigens 49* in MS E. Meinl (Munich, DE) 15:00 Oligodendrocytes are damaged by neuromyelitis 50 optica immunoglobulin G via astrocyte injury R. Marignier, A. Nicole, C. Watrin, M. Touret, S. Cavagna, M. Varrin-Doyer, G. Cavillon, V. Rogemond, J. Honnorat, Overview & Programme C. Confavreux, P. Giraudon (Lyon, FR) 15:15 Myelin-specific B-cell receptor transgenic mice 51 reveal role for B-cell APC function independent of antibodies in pathogenesis of CNS autoimmunity N. Molnarfi, M. S. Weber, T. Prod’homme, J. C. Patarroyo, C. Linington, A.J. Slavin, C.C. Bernard, H. Wekerle, R.A. Sobel, M.J. Shlomchik, S.S. Zamvil (San Francisco, Ridgefield, Standford, New Haven, US; Glasgow, UK; Monash, AU; Martinsried, DE)

* Invited review

31 Scientific Programme Thursday, 14 October 2010

14:00– Parallel Session 4 Main Auditorium 15:30 Environmental and life-style contribution in MS

Chairs: M. Pugliatti (Sassari, IT); A.M. Landtblom (Linkoping, SE) 14:00 Analysing risk factor interactions in MS 52* T. Riise (Bergen, NO) 14:20 Vitamin D deficiency as a risk factor 53* A. Ascherio (Boston, US) 14:40 HLA-DRB1*15 and vitamin D status at first 54 demyelinating episode are independent risk factors for MS in children H. Hanwell, S. Magalhaes, L. Verhey, G. Disanto, A. Handel, K. Morrison, S. Ramagopalan, M. McGowan, D. Arnold, R. Vieth, A.D. Sadovnick, G. Ebers, R.A. Marrie, A. Bar-Or, B. Banwell on behalf of the Canadian Pediatric Demyelinating Disease Network 14:55 Multiple sclerosis is associated with low previous 55 ultraviolet radiation exposure and low levels of current vitamin D: no interaction with HLA complex genes M. Bäärnhielm, A. Hedström, I. Kockum, E. Sundqvist, S. Gustafsson, T. Olsson, L. Alfredsson (Stockholm, SE) 15:10 No evidence for a temporal change in disability 56 progression: findings from British Columbia, Canada, 1975–2009 A. Shirani, Y. Zhao, E. Kingwell, P. Rieckmann, H. Tremlett (Vancouver, CA)

* Invited review

32 Scientific Programme Thursday, 14 October 2010

14:00– RIMS Session 2 Room G2 15:30 Free Communications

Chairs: P. Feys (Hasselt, BE); V. Matthews (Letchworth, UK) 14:00 Functional magnetic resonance imaging correlates 57 of intensive cognitive rehabilitation of attention and executive functions in multiple sclerosis M. Filippi, M.A. Rocca, F. Mattioli, G. Riccitelli, C. Stampatori, R. Capra, P. Misci, A. Falini, G. Comi (Milan, Brescia, IT) 14:15 Prevalence of sexual satisfaction and impact of 58 pain, fatigue, and other factors in people with multiple sclerosis K. Johnson, K. McMullen, A. Bamer, I. Molton (Seattle, US) 14:30 Which walking capacity tests to use in MS? A RIMS 59 multicentre study providing the basis for a core set D. Gijbels, U. Dalgas, V. de Groot, A. Romberg, B. Gebara, C. Vaney, C. Santoyo, H. Maamagi, K. Rasova, B. Maertens de Noordhout, F. Bethoux, K. Knuts, P. Van Asch, P. Feys (Hasselt, Melsbroek, Fraiture-en-Condroz, Overpelt, Kontich, BE; Aarhus, DK; Amsterdam, NL; Masku, FI; Montana, CH; Barcelona, ES; Tallinn, EE; Prague, CZ; Cleveland, US) 14:45 Anxiety and depression symptoms in newly 60 diagnosed multiple sclerosis patients A. Solari, A. Giordano, M. Trojano, V. Martinelli, A. Lugaresi, F. Granella, P. Confalonieri, C. Tortorella, I. Plasmati, M. Radaelli, D. Farina, E. Dalla Bella, M. Messmer Uccelli, E. Pucci, C. Borreani, R. D’Alessandro on behalf of the SIMS-Trial group Overview & Programme 15:00 Effects of group and individual physiotherapy on 61 falls in people with MS N. Hogan, M. Garrett, A. Larkin, J. Saunders, S. Coote (Limerick, Galway, IE) 15:15 Effectiveness of balance disorders rehabilitation 62 treatments in multiple sclerosis subjects: a pilot randomised control trial assessing the Wii balance board gaming system G. Brichetto, P. Spallarossa, M.L. Lopes de Carvalho (Genoa, IT)

33 Scientific Programme Thursday, 14 October 2010

15:30– Poster Session I 17:00

Poster numbers P143–P576 (for details see pages 52–98)

17:00– Hot Topic 1 Room G2 17:45 Mechanisms and intervention in MS progression

Chairs: J. Antel (Montreal, CA); N. Scolding (Bristol, UK) 17:00 Astrocytes, inflammation and neurodegeneration 63* T. Owens (Odense, DK) 17:15 The therapeutic potential of mesenchymal stem cell 64* transplantation as a treatment for multiple sclerosis A. Uccelli (Genoa, IT) 17:30 Discussion

17:00– Hot Topic 2 Congress Hall 17:45 Long-term monitoring of treatment efficacy and safety

Chairs: B. Runmarker (Gothenburg, SE); M. Trojano (Bari, IT) 17:00 Observational studies: analysis of non-randomised 65* data M.G. Brown (Halifax, CA) 17:15 Longitudinal data collection: MS registries 66* J. Hillert (Stockholm, SE) 17:30 TYSEDMUS: Observational prospective follow-up 67 study of patients with MS and treated with natalizumab in France using the French EDMUS (European Database for Multiple Sclerosis) network S. Vukusic, N. Passante, A. Abdelali, M. Dufour, B. Frangoulis, E. Van Ganse, F. Rocher, M. Clanet, A. Castot, C. Confavreux and the TYSEDMUS investigators

* Invited review

34 Scientific Programme Thursday, 14 October 2010

17:00– Hot Topic 3 Main Auditorium 17:45 Monoclonal antibody therapy in MS: update

Chairs: M. Clanet (Toulouse, FR); R. Du Pasquier (Lausanne, CH) 17:00 Therapeutic benefits using monoclonal antibodies 68* in MS L. Kappos (Basel, CH) 17:15 Opportunistic infections during monoclonal 69* antibody treatment R. Gold (Bochum, DE) 17:30 Discussion

18:00– Satellite Symposium Main Auditorium 19:00 Redefining success in MS: remission and improvement – today and tomorrow

Chair: H.-P. Hartung (Düsseldorf, DE) 18:00 Welcome & introduction H.-P. Hartung (Düsseldorf, DE) 18:10 Improvement in MS: defining a new paradigm 70 S. Belachew (Liège, BE) 18:25 Targeting demyelinated axons: improving mobility 71 impairment in MS J. Hobart (Plymouth, UK) 18:40 Neuroprotective effects in neuroinflammation via 72 Nrf2 pathway activation R. Gold (Bochum, DE) Overview & Programme 18:55 Q&A/Close Satellite symposium arranged by Biogen Idec & Elan Pharmaceuticals

* Invited review

35 Scientific Programme Thursday, 14 October 2010

19:15– Satellite Symposium Main Auditorium 20:15 Benefiting from an early treatment decision – protection from a cellular level to daily life functioning

Chair: S. Fredrikson (Stockholm, SE) 19:15 Welcome 19:20 Early strengths translated into lasting benefits – 73 reassurance of a proven choice D. Goodin (San Francisco, US) 19:40 Interferon␤-1b and glatiramer acetate effects on 74 permanent black hole evolution M. Filippi (Milan, IT) 19:55 Preserving cognitive function right from the start 75 I.K. Penner (Basel, CH) 20:10 Closing remarks Satellite symposium arranged by Bayer Schering Pharma AG

36 Scientific Programme Friday, 15 October 2010

07:30– ECTRIMS Council Meeting Room G4 09:00 Council members, by invitation only

08:00– Satellite Symposium Congress Hall 09:00 Alemtuzumab research in MS: new insights, new possibilities, new approaches

Chairs: J. Lycke (Gothenburg, SE); A. Coles (Cambridge, UK) 08:00 Welcome J. Lycke, A. Coles (Gothenburg, SE; Cambridge, UK) 08:05 New insights: alemtuzumab mechanism 76 J. Kaplan (Framingham, US) 08:20 New possibilities: emerging clinical profile 77 O. Khan (Detroit, US) 08:40 New approaches: assessing MS treatment 78 G. Giovannoni (London, UK) 08:50 Q&A and concluding remarks Satellite symposium arranged by Genzyme and Bayer Schering Pharma AG Overview & Programme

37 Scientific Programme Friday, 15 October 2010

09:15– Platform presentation of selected Congress Hall 10:15 abstracts I

Chairs: F. Lublin (New York, US); T. Saida (Kyoto, JP) 09:15 A placebo-controlled phase III trial (TEMSO) of oral 79 teriflunomide in relapsing multiple sclerosis: clinical efficacy and safety outcomes P. O’Connor, J. Wolinsky, C. Confavreux, G. Comi, L. Kappos, T.P. Olsson, H. Benzerdjeb, B. Wamil, L. Wang, A. Miller, M.S. Freedman for the Teriflunomide Multiple Sclerosis Trial Group 09:30 Visual pathway axonal loss in benign multiple 80 sclerosis K.M. Galetta, L.S. Talman, D.J. Lile, S. Syc, A. Conger, G. Remington, P.A. Calabresi, E.M. Frohman, S.L. Galetta, L.J. Balcer (Philadelphia, Baltimore, Dallas, US) 09:45 No evidence of chronic cerebrospinal venous 81 insufficiency in clinically isolated syndrome suggestive of multiple sclerosis C. Baracchini, P. Perini, M. Calabrese, F. Causin, F. Farina, F. Rinaldi, P. Gallo (Padua, IT) 10:00 Presence and severity of chronic cerebrospinal 82 venous insufficiency is related to lower brain parenchyma venous vasculature visibility on susceptibility-weighted imaging in patients with multiple sclerosis R. Zivadinov, G. Poloni, C. Schirda, C. Magnano, E. Carl, N. Bergsland, D. Hojnacki, C. Kennedy, F. Parker, M. Dwyer, B. Weinstock-Guttman (Buffalo, US)

38 Scientific Programme Friday, 15 October 2010

09:15– Platform presentation of selected Main Auditorium 10:15 abstracts II

Chairs: A. Compston (Cambridge, UK); J. Correale (Buenos Aires, AR) 09:15 Pro- and antiapoptotic actions of Stat1 and Stat3 83 underlie the neuroprotective and immunoregulatory functions of interleukin-11 J. Zhang, Y. Zhang, D. Dutta, B. Gurfein, A.T. Argaw, V. Bonnamain, A. Zameer, F. Hayot, C. Lopez, G. John (New York, US) 09:30 Microparticles released from reactive microglia: 84 a potential biomarker for neuroinflammatory and neurodegenerative diseases D. Dalla Libera, A. Bergami, G. Magnani, G. Comi, G. Martino, C. Verderio, R. Furlan (Milan, IT) 09:45 Neurofilament light and fetuin-A in clinically isolated 85 syndrome patients as predictors for conversion to multiple sclerosis G. Arrambide, C. Espejo, H. Eixarch, J. Río, C. Nos, J. Sastre-Garriga, M.C. Edo, J. Castilló, F. Pérez-Miralles, F. Palavra, C. Auger, A. Rovira, X. Montalban, M. Tintoré (Barcelona, ES) 10:00 Reactive oxygen species in multiple sclerosis 86 pathogenesis: from source to solution J. van Horssen, J. Drexhage, S. van der Pol, M. Witte, P. van der Valk, H.E. de Vries (Amsterdam, NL)

10:15– Coffee Break and Poster Viewing 10:45 Overview & Programme

39 Scientific Programme Friday, 15 October 2010

10:45– Parallel Session 5 Main Auditorium 12:15 MS pathology

Chairs: H. Lassmann (Vienna, AT); B. Trapp (Cleveland, US) 10:45 Revisiting the role of autoimmunity in the progressive 87* phase of MS H. Wekerle (Martinsried, DE) 11:05 Cortical pathology in MS 88* L. Bö (Bergen, NO) 11:25 Inflammation versus neurodegeneration in 89* progressive multiple sclerosis J.M. Frischer, S. Bramow, A. Dal-Bianco, C.F. Lucchinetti, H. Rauschka, M. Schmidbauer, H. Laursen, P. Soelberg Sørensen, H. Lassmann (Vienna, AT; Rochester, US; Copenhagen, DK) 11:45 The relationship between meningeal inflammation 90 and spinal cord pathology in multiple sclerosis C. Reali, R. Magliozzi, A. Kirresh, O. W. Howell, R. Reynolds (London, UK) 12:00 Mitochondrial antioxidants: putative targets for 91 slowing down disease progression M.E. Witte, J. Drexhage, W.H. Gerritsen, A. Reijerkerk, H.E. de Vries, P. van der Valk, J. van Horssen (Amsterdam, NL)

* Invited review

40 Scientific Programme Friday, 15 October 2010

10:45– Parallel Session 6 Congress Hall 12:15 Infections in the aetiopathogenesis of MS Chairs: F. Aloisi (Rome, IT); P. Höllsberg (Aarhus, DK) 10:45 Basic mechanisms for virus involvement in MS 92* pathogenesis R. Martin (Hamburg, DE) 11:05 Evidence for virus infections in the presymptomatic 93* stage of MS P. Sundström (Umea, SE) 11:25 Fine specificity of B-cell response to Epstein-Barr 94 nuclear antigen 1 (EBNA-1) in multiple sclerosis patients and diseased discordant twins R. Mechelli, J. Anderson, V. Annibali, S. Cannoni, D. Vittori, G. Coarelli, F. Aloisi, G. Ristori, J.A. James, M. Salvetti (Rome, IT; Oklahoma City, US) 11:40 The effect of live attenuated measles vaccine and 95 measles infection on measles antibody levels in serum and CSF of multiple sclerosis patients C. Ahlgren, A. Odén, S. Haghighi, O. Andersen, T. Bergström, J. Lycke (Gothenburg, SE) 11:55 Viral antigen-specific adaptive immune responses in 96 fingolimod-treated MS patients M. Mehling, P. Hilbert, S. Fritz, J. Kuhle, T. Klimkait, R.L.P. Lindberg, L. Kappos, C. Hess (Basel, CH)

10:45– RIMS Session 3 Room G2 12:15 Progress in MS rehabilitation Chairs: T. Henze (Nittenau, DE); C. Solaro (Genoa, IT) Overview & Programme 10:45 ICF and MS rehabilitation 97* J. Jonsdottir (Milan, IT) 11:05 Update in MS rehab – an Australian perspective 98* F. Khan (Melbourne, AU) 11:25 MS rehabilitation: methological issues 99* A. Solari (Milan, IT) 11:45 Exercise therapy in MS – an ongoing shift of paradigm 100* U. Dalgas (Aarhus, DK) 12:05 Summary 101* T. Henze, C. Solaro (Nittenau, DE; Genoa, IT)

12:15– Lunch and Poster Viewing 12:45

* Invited review

41 Scientific Programme Friday, 15 October 2010

12:45 – Satellite Symposium Main Auditorium 13:45 Early, long-term and short-course therapy. Part II: exploring practical examples in multiple sclerosis

Chair: J. Hillert (Stockholm, SE) Introduction J. Hillert (Stockholm, SE) 102 Treating early for MS: a long-term success M. Freedman (Ottawa, CA) 103 Managing suboptimal response to MS therapy: a practical example P. Vermersch (Lille, FR) 104 A potential future role for cladribine tablets in MS G. Giovannoni (London, UK) Panel discussion and Q&A Satellite symposium arranged by Merck Serono S.A.

14:00 – Parallel Session 7 Room G2 15:30 Repairing the central nervous system

Chairs: L. Brundin (Stockholm, SE); C. Lubetzki (Paris, FR) 14:00 Inflammation and repair in multiple sclerosis 105* G. Martino (Milan, IT) 14:20 Remyelination in MS 106* A. Baron-Van Evercooren (Paris, FR) 14:40 Astrocyte-specific deletion of VEGF-A rescues 107 endothelial CLN-5 and abrogates blood-brain barrier breakdown in the inflamed CNS A.T. Argaw, K. Navrazhina, T. Yuen, J. Zhang, V. Bonnamain, D. Dutta, A. Zameer, G. John (New York, US) 14:55 Reduction of chondroitin sulfate proteoglycans in 108 demyelinated lesions promotes remyelination L. Lau, R. Cua, A. Doring, S. Sloka, V. Yong (Calgary, CA) 15:10 Inhibition of autoimmunity is insufficient to stop 109 secondary progressive, experimental autoimmune encephalomyelitis S. Al-Izki, G. Pryce, S. Jackson, G. Giovannoni, D. Baker (London, UK)

* Invited review

42 Scientific Programme Friday, 15 October 2010

14:00– Parallel Session 8 Main Auditorium 15:30 Risks and benefits of new therapies in MS

Chairs: X. Montalban (Barcelona, ES); A. Svenningsson (Umea, SE) 14:00 Cytotoxic therapeutic agents in MS 110* G. Edan (Rennes, FR) 14:20 Spingosine 1 phosphate receptor agonists as 111* immunomodulators in MS C.H. Polman (Amsterdam, NL) 14:40 Overview of clinical outcomes in cases of 112 natalizumab-associated progressive multifocal leukoencephalopathy P. Vermersch, J. Foley, R. Gold, L. Kappos, T. Olsson, C. Bozic, S. Richman (Lille, FR; Salt Lake City, Cambridge, US; Bochum, DE; Basel, CH; Stockholm, SE) 14:55 Phase II trial of firategrast shows that oral anti- 113 alpha4 therapy can suppress new MRI lesions in relapsing–remitting multiple sclerosis D. Miller, T. Weber, X. Montalban, R. Grove, P. Dua, C. Wardell, O. Graff (London, UK; Hamburg, DE; Barcelona, ES; Middlesex, UK; North Carolina, US) 15:10 Efficacy and safety of ocrelizumab in patients 114 with relapsing–remitting multiple sclerosis: results of a phase II randomised placebo- controlled multicentre trial L. Kappos, P. Calabresi, P. O’Connor, A. Bar-Or, D. Li, F. Barkhof, M. Yin, R. Glanzman, J. Tinbergen, S. Hauser (Basel, CH; Baltimore, South San Francisco,

San Francisco, US; Toronto, Montreal, Vancouver, CA; Overview & Programme Amsterdam, NL;)

* Invited review

43 Scientific Programme Friday, 15 October 2010

14:00– Parallel Session 9 Congress Hall 15:30 MR applications for understanding MS pathology

Chairs: T. Kuhlmann (Münster, DE); J. Wolinsky (Houston, US) 14:00 MRI as a predictive tool in MS 115* L.K. Fisniku (London, UK) 14:20 Future of brain imaging in MS 116* D. Pelletier (San Francisco, US) 14:40 Early neuronal damage in patients with MS detected 117 by PET using [11C]-flumazenil L. Freeman, C. Leroy, D. Galanaud, F. Sureau, R. Assouad, A. Tourbah, C. Papeix, C. Comtat, R. Trebossen, C. Lubetzki, J. Delforge, M. Bottlaender, B. Stankoff (Paris, Orsay, Reims, FR) 14:55 How reliable is 3D double inversion recovery in the 118 detection of cortical lesions? Combined postmortem MR-imaging and histopathology A. Seewann, E.J. Kooi, S. Roosendaal, P.J.W. Pouwels, P. van der Valk, F. Barkhof, C.H. Polman, J.G. Geurts (Amsterdam, NL) 15:10 Ultra high-field MRI (7T) uncovers many multiple 119 sclerosis lesions undetected with clinical 3 Tesla MRI N. Mistry, N Galazis, E. Tallantyre, J. Dixon, T. Jaspan, P. Morgan, P. Morrris, N. Evangelou (Nottingham, UK)

15:30– Poster Session II 17:00

Poster numbers P577– P992 (for details see pages 99–145)

15:30– RIMS General Assembly Room J2 16:30

RIMS Members only

* Invited review

44 Scientific Programme Friday, 15 October 2010

17:00– Hot Topic 4 Congress Hall 17:45 Gender in MS

Chairs: G. Ebers (Oxford, UK); S. Vukusic (Lyon, FR) 17:00 Involvement of sex hormones in the risk of MS 120* R. Voskuhl (Los Angeles, US) 17:15 Changes of gender ratio of MS 121* C. Wolfson (Montreal, CA) 17:30 Sex ratio of multiple sclerosis: a comparison of 122 distribution and trend over 60 years among different countries G. Graziano, M. D’Onghia, G. Lucchese, V. Lepore, M. Trojano on behalf of MSBase Registry Research Groups

17:00– Hot Topic 5 Room G2 17:45 Biomarkers in MS

Chairs: G. Giovannoni (London, UK); J. Lycke (Gothenburg, SE) 17:00 Biomarkers as potential tools for monitoring 123* disease activity and treatment efficacy F. Sellebjerg (Copenhagen, DK) 17:15 Unravelling MS pathophysiology through biomakers 124* B. Hemmer (Munich, DE) 17:30 Exaggerated molecular response to interferon beta 125 predicts disease activity in multiple sclerosis R. Rudick, S. Rani, Y. Xu, J.-C. Lee, J. Na, J. Schrock, Overview & Programme A. Josyula, E. Fisher, R. Ransohoff (Cleveland, US)

* Invited review

45 Scientific Programme Friday, 15 October 2010

17:00– Hot Topic 6 Main Auditorium 17:45 Treatment strategies in MS

Chairs: S. Fredrikson (Stockholm, SE); H.-P. Hartung (Düsseldorf, DE) 17:00 Early treatment strategies: induction versus 126* escalation therapy G. Comi (Milan, IT) 17:15 Identification and management of treatment failure 127* in MS: role of combination therapy P. Soelberg Sørensen (Copenhagen, DK) 17:30 Discussion

18:00– Satellite Symposium Congress Hall 19:00 Emerging therapeutic solutions for MS patients: TEMSO phase III results

Chair: T. Olsson (Stockholm, SE) Chairman’s welcome T. Olsson (Stockholm, SE) 128 Introducing teriflunomide: a far-reaching programme for the future and long-term experience to date C. Confavreux (Lyon, FR) 129 Optimising disease-modifying therapy in MS: spotlight on teriflunomide in adjunctive therapy M. Freedman (Ottawa, CA) 130 A snapshot of the TEMSO study: a new landmark in MS therapy P. O’Connor (Toronto, CA) Q&A session Satellite symposium arranged by sanofi-aventis

* Invited review

46 Scientific Programme Friday, 15 October 2010

18:00– RIMS SIG Core people’s meetings 20:00

by invitation only

– SIG Mobility (this group need the 16 persons room) R31 – SIG Psychology and neuropsychology R32 – SIG Occupation and SIG Patient education R33 – SIG Social integration and participation R35 – SIG Bladder, Bowel and Sexual dysfunction R38 – SIG Communication and swallowing disorders R10

19:15– Satellite Symposium Main Auditorium 20:15 Multiple sclerosis: emerging evidence for the role of fingolimod

Chair: P. Soelberg Sørensen (Copenhagen, DK) Welcome and introduction P. Soelberg Sørensen (Copenhagen, DK) 131 Understanding fingolimod in MS: the role of sphingosine 1-phosphate receptor modulation F. Sellebjerg (Copenhagen, DK) 132 Update from the fingolimod clinical programme L. Kappos (Basel, CH) 133 Assessing imaging evidence in MS: MRI and brain atrophy F. Barkhof (Amsterdam, NL) Panel discussion

Concluding remarks Overview & Programme P. Soelberg Sørensen (Copenhagen, DK) Satellite symposium arranged by Novartis Phama AG

20:30 Conference Dinner The official Conference Dinner will be held at Kajskjul 8 (see page 189 for further information)

47 Scientific Programme Saturday, 16 October 2010

08:30– Parallel Session 10 Congress Hall 10:00 Late Breaking News

Chairs: A.J. Thompson (London, UK); C. Pozzilli (Rome, IT) 08:30 No beneficial effect of simvastatin as add-on therapy 134 to interferon-beta-1a for the treatment of relapsing- remitting multiple sclerosis: results of a large double blind, randomised, placebo-controlled trial P. Soelberg Sørensen, J. Lycke, J.-P. Erälinna, A. Edland, X. Wu, J. Frederiksen, A. Oturai, C. Malmeström, E. Stenager, B. Sperling (Copenhagen, Glostrup, Sønderborg, Vejle, Esbjerg, DK; Gothenburg, SE; Turku, FI; Drammen, NO) 08:45 Benefit of early treatment with glatiramer acetate 135 (COPAXONE): results from the 5-year prospectively planned follow up in patients with clinically isolated syndrome from the PreCISe study G. Comi, V. Martinelli, M. Rodegher, L. Moiola, O. Bajenaru, A. Carra, I. Elovaara, F. Fazekas, H.-P. Hartung, J. Hillert, J. King, S. Komoly, C. Lubetzki, X. Montalban, K.M. Myhr, M. Ravnborg, P. Rieckmann, D. Wynn, C. Young, M. Filippi for the PreCISe study group 09:00 Magnetic resonance imaging (MRI) efficacy of 136 ofatumumab in relapsing-remitting multiple sclerosis (RRMS) – 24-week results of a phase II study P. Soelberg Sørensen, J. Drulovic, E. Havrdova, S. Lisby, O. Graff, S. Shackelford (Copenhagen, DK; Belgrade, RS; Prague, CZ; RTP, US) 09:15 Antibody suspension bead arrays with multi- 137 parallel CSF profiling for biomarker discovery A. Häggmark, B. Ayoglu, U. Igel, J. Ottervald, M. Khademi, T. Olsson, M. Uhlen, J. Schwenk, P. Nilsson (Stockholm, SE) 09:30 Factors associated with anti-JCV antibody prevalence 138 in a large cohort of natalizumab-treated MS patients M. Subramanyam, T. Plavina, K. Simon, E. Wilson, M. Berman, B. Schlain, A. Pace, S. Richman, L. Cristiano, C. Bozic (Cambridge, US) 09:45 Repair of selective astrocyte depletion in the rodent 139 brain C. Wrzos, S. Nessler, B. Hemmer, W. Brück, C. Stadelmann, J. Bennett (Göttingen, Munich, DE; Denver, US)

10:00 – Coffee Break 10:30

48 Scientific Programme Saturday, 16 October 2010

10:30 – Plenary Session 2 Congress Hall 12:00 Adult CNS regeneration Highlights and awards

Chairs: P. O’Connor (Toronto, CA); E. Havrdova (Prague, CZ) 140* Generation of neurons and glial cells in the intact and injured adult central nervous system J. Frisén (Stockholm, SE) 141* ECTRIMS 2010: trials highlights J.A. Cohen (Cleveland, US) 142* ECTRIMS 2010: scientific highlights C. Lubetzki (Paris, FR) Presentation of selected poster awards and awards for best oral presentations by young researchers M. Clanet, M. Trojano (Toulouse, FR; Bari, IT) Welcome to Amsterdam 2011 C. Polman (Amsterdam, NL)

12:00 – Lunch 12:30 e m m a r g o r P & w e i v r e v O

* Invited review

49 Poster Overview Thursday, 14 October 2010

Poster Session I – presence of authors required: 15:30 – 17:00

Poster Presentation Presence at Poster Poster Session Day Poster Mounting Time Removal Time

Session I Thursday, 15:30–17:00 Wednesday, Thursday, 14 October 13 October 14 October 12:00–14:00 17:00–18:00

Topic Nr. Poster Topic Poster Numbers 1 Diagnosis & differential diagnosis 1 P143 – P157 2 MS variants 1 P158 – P172 3 Natural course 1 P173 – P182 4 Epidemiology 1 P183 – P202 5 MS symptoms 1 P203 – P216 6 Clinical assessment tools 1 P217 – P231 7 Economic burden 1 P232 – P236 8 Pathology 1 P237 – P240 9 Experimental models 1 P241 – P254 10 Genetics/transcriptomics 1 P255 – P269 11 Immunology 1 P270 – P288 12 MS and infections 1 P289 – P294 13 Environmental, sex-related and P295 – P305 life-style factors 1 14 Neurobiology 1 P306 – P311 15 Repairing mechanisms 1 P312 – P313 16 Imaging 1 P314 – P359 17 Neurophysiology 1 P360 – P368 18 Neuropsychology and fatigue 1 P369 – P393 19 Immunomodulation 1 P394 – P466 20 Immunosuppression 1 P467 – P471 21 Neuroprotection 1 P472 – P479 22 Long-term treatment monitoring 1 P480 – P496 23 Therapy disease modifying – Others 1 P497 – P508 24 Treatment of specific symptoms 1 P509 – P519 25 Comprehensive care & rehabilitation 1 P520 – P532 26 Quality of life 1 P533 – P540 27 Neuro-Ophthalmology 1 P541 – P550 28 Biomarkers 1 P551 – P576

Please refer to pages 52 – 98

50 Poster Overview Friday, 15 October 2010

Poster Session II – presence of authors required: 15:30 – 17:00

Poster Presentation Presence at Poster Poster Session Day Poster Mounting Time Removal Time

Session II Friday, 15:30–17:00 Friday, Saturday, 15 October 15 October 16 October 08:00–09:00 12:00–13:00

Topic Nr. Poster Topic Poster Numbers 29 Diagnosis & differential diagnosis 2 P577 – P591 30 MS variants 2 P592 – P607 31 Natural course 2 P608 – P616 32 Epidemiology 2 P617 – P635 33 MS symptoms 2 P636 – P645 34 Clinical assessment tools 2 P646 – P658 35 Economic burden 2 P659 – P661 36 Pathology 2 P662 – P665 37 Experimental models 2 P666 – P680 38 Genetics/transcriptomics 2 P681 – P694 39 Immunology 2 P695 – P713 40 MS and infections 2 P714 – P719 41 Environmental, sex-related and P720 – P728 life-style factors 2 42 Neurobiology 2 P729 – P733 43 Imaging 2 P734 – P778 44 Neurophysiology 2 P779 – P786 45 Neuropsychology and fatigue 2 P787 – P811 46 Immunomodulation 2 P812 – P873 47 Immunosuppression 2 P874 – P878 48 Neuroprotection 2 P879 – P887

49 Long-term treatment monitoring 2 P888 – P903 Posters 50 Therapy disease modifying – Others 2 P904 – P915 51 Treatment of specific symptoms 2 P916 – P927 52 Comprehensive care & rehabilitation 2 P928 – P940 53 Quality of life 2 P941 – P948 54 Neuro-Ophthalmology 2 P949 – P957 55 Biomarkers 2 P958 – P981 56 Late Breaking News P982 – P992

Please refer to pages 99 – 145

51 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Diagnosis & differential diagnosis 1 P143 Application of new proposed MRI criteria for the diagnosis of multiple sclerosis in a Spanish cohort of patients with clinically isolated syndromes M. Gomez-Moreno, M. Diaz-Sanchez, E. Martinez-Acebes, D. Hipola-Gonzalez (Madrid, Sevilla, ES) P144 Oligoclonal bands are more sensitive than MRI in predicting conversion to clinically definite multiple sclerosis R. Vecchio, M. Bianca, A. Pavone, D. Maimone, D. Maimone, M. Bianca, A. Pavone, D. Maimone, M. Bianca, A. Pavone, R. Vecchio (Catania, IT) P145 Is the cord lesions extending over three or more vertebral segments sufficiently specific to distinguish neuromyelitis optica from multiple sclerosis? M.S. Park, H.J. Kim, B.J. Kim, K.H. Lee, B.J. Kim, O.H. Kwon, J.Y. An, J.H. Min on behalf of the Korean MS Study Group P146 Multiple sclerosis presenting as acute hemichorea A. Schteinschnaider, G. Vazquez, C. Romero, J. Correale (Buenos Aires, AR) P147 MRI in HDLS suggests a unique mechanism of neuroaxonal degeneration C. Sundal, L. Jönsson, C. Lundqvist, A. Rentzos, O. Andersen (Gothenburg, SE) P148 Intracortical lesions and new magnetic resonance imaging diagnostic criteria for multiple sclerosis M. Filippi, M.A. Rocca, M. Calabrese, M.P. Sormani, F. Rinaldi, P. Perini, G. Comi, P. Gallo (Milan, Padua, Genoa, IT) P149 Multiple sclerosis in female carrier of Fabry disease – a case report E. Meluzínová, J. Kotašková, E. Houžvicková, J. Libertínová, D. Krýsl, P. Reková (Prague, CZ) P150 Post-marketing evaluation of a multiparametric immunofluorescence assay for the detection of anti- Aquaporin 4 antibodies in the diagnosis of neuromyelitis optica P. Valentino, L. Granieri, F. Marnetto, J. Frau, A.K. Patanella, P. Nytrova, P. Sola, F. Gilli, M. Capobianco, A. Sala, K.P. Wandinger, A. Bertolotto (Orbassano, Cagliari, Rome, Modena, IT; Prague, CZ; Lübeck, DE) P151 CNS inflammatory diffuse white matter lesion mimicking gliomatosis cerebri F. Coret Ferrer, E. Guillamon, N. Martin , M. Simo, M. Magraner, I. Bosca , R. Chamarro, B. Casanova (Valencia, ES)

52 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Diagnosis & differential diagnosis 1 (continued) P152 A timely diagnosis of multiple sclerosis: how does an Irish clinic measure up? S. Kelly, E. Chaila, M. Duggan, K. Kinsella, N. Tubridy, M. Hutchinson (Dublin, IE) P153 Comparison of two methods for the detection of oligoclonal bands in patients with clinically isolated syndrome and multiple sclerosis A. Andlovic, M. Babic, M. Tic Golob, K. Rataj, S. Accetto, U. Rot (Ljubljana, SI) P154 Evaluation of brain and cervical cord MRI findings in patients with systemic lupus erythematosus M.H. Harirchian, A. Hashemi, H. Saberi, R. Najafi Zadeh (Tehran, IR) P155 Multiple sclerosis or Sjögren’s syndrome? The role of screening for alpha-fodrin autoantibodies I. Kouri (Ioannina, GR) P156 High-titre anti-MOG antibodies differentiate demyelinating diseases from viral encephalitis in children P.H. Lalive, M.G. Häussler, H. Maurey , Y. Mikaeloff, M. Tardieu, H. Wiendl, M. Schroeter, H.-P. Hartung, B.C. Kieseier, T. Menge (Geneva, CH; Aachen, Münster, Cologne, Düsseldorf, DE; Le Kremlin-Bicêtre, FR) P157 Enzymological method to differentiate multiple sclerosis from other neuroinflammatory or neurodegenerative disorders B. Kepplinger, A. Kainz, P. Kalina, H. Erhart, R. Sobota, H. Baran (Mauer/Amstetten, Amstetten, AT)

MS variants 1 P158 Tumefactive multiple sclerosis lesions: demographic, clinical, radiological characteristics A. Altintas, B. Petek, N. Isik, M. Terzi, F. Bolukbasi, M. Tavsanli, S. Saip, C. Boz, T. Aydin, O. Arici Duz, F. Ozer, A. Siva (Istanbul, Samsun, Trabzon, TR) P159 Differences in grey/white matter density and brain perfusion Posters in patients with relapsing neuromyelitis optica: a voxel- based study J.A. Cabrera-Gomez, C. Sanchez-Catasus, R. Diaz, A. Aguila, R. Rodríguez-Roca, J. Jordán-González, C. Ugarte-Sánchez, R. Téllez-Pena, J. González-De la Nuez, A. Nerey-Rodríguez, D. Ugarte, A.Y. Cabrera-Núñez , A. González-Quevedo (Havana City, Cienfuegos, CU) P160 Prospective follow-up of longitudinally extensive transverse myelitis associated with schistosomiasis: the role of NMO-IgG S.L. Apostolos-Pereira, T. Adoni, A. Lino, L.R. Machado, D. Callegaro, P. Marchiori on behalf of the Brazilian Committee for Treatment and Research in Multiple Sclerosis, BCTRIMS

53 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 MS variants 1 (continued) P161 Time course of relapses after treatment with oral corticosteroid in Japanese neuromyelitis optica patients M. Tahara, M. Matsui, K. Tanaka, M. Tanaka (Kyoto, Uchinada, JP) P162 Benign multiple sclerosis: our experience in a tertiary care hospital M.L. Martínez Ginés, J.M. García Dominguez, C. de Andres (Madrid, ES) P163 Relapsing neuromyelitis optica: clinical characteristics and identification of prognostic factors M. Radaelli, D. Dalla Libera, L. Moiola, D. Privitera, F. Martinelli Boneschi, B. Colombo, F. Sangalli, R. Fazio, G. Comi, V. Martinelli (Milan, IT) P164 Successful treatment of Marburg variant multiple sclerosis with natalizumab S. Smith, G. Parry, H.B. Clark, A. Carpenter (Minneapolis, US) P165 Macular star: a new finding in neuromyelitis optica M. Lana-Peixoto, L. Carazza, J. Massote, M. Nehemy, C. Rocha, R. Kleinpaul, C. Araujo (Belo Horizonte, BR) P166 Peripheral and central demyelination in a septuagenarian P.C. Gottschalk (New Haven, US) P167 Pregnancy and neuromyelitis optica B. Bourre, N. Collongues, H. Zephir, C. Papeix, D. Brassat, P. Labauge, F. Blanc, O. Outteryck, S. Oporto, M. Fleury, B. Fontaine, C. Lubetzki, P. Vermersch, J. De Seze (Strasbourg, Rouen, Lille, Paris, Toulouse, Nimes, FR) P168 Clinical course of paediatric neuromeylitis optica with recurrent clinical course M. Alvarenga, S. Camargo, E. Batista, J. Dib, H. Siqueira, U. Linhares, M. Papais-Alvarenga, R. Papais-Alvarenga (Rio de Janeiro, BR) P169 Outcome of acute disseminated encephalomyelitis in adults is worse than in children I.A. Ketelslegers, I.E.R. Visser, R.F. Neuteboom, M. Boon, C.E. Catsman-Berrevoets, R.Q. Hintzen (Rotterdam, Groningen, NL) P170 Intractable hiccup and nausea in neuromyelitis optica: a clinical predictor of acute spinal exacerbations L. Melamud, V. Rivarola, J. Fernandez, O. Garcea, C. Capurro, A. Villa (Buenos Aires, AR) P171 Optic neuritis in pregnancy heralding a neuromyelitis optica diagnosis A. Protti, C. Erminio, R. Marazzi, C. Regna-Gladin, R. Sterzi (Milan, IT) P172 Idiopathic inflammatory demyelinating diseases of the central nervous system: Ljubljana University children’s hospital clinical series J. Orazem, N. Krajnc, Z. Rener Primec, M. J. Krzan (Ljubljana, SI)

54 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Natural course 1 P173 Multiple sclerosis-related in-hospital characteristics: principle diagnoses associated with admission and death F. Ernst, J. Pocoski, G. Cutter, D. Kaufman, H. Golub, V. Knappertz (Charlotte, Montville, Birmingham, Boston, Newton, US) P174 Oligoclonal positive versus oligoclonal negative multiple sclerosis J.L. Frederiksen, S. Boll (Glostrup, DK) P175 Clinical and radiological characteristics of multiple sclerosis in Iran M.A. Sahraian, A. Eshaghi (Tehran, IR) P176 The influence of ethnicity on progression of relapsing– remitting MS in Brazilian patients: preliminary results G. Santos, C. Vasconcelos, S. Camargo, M. Papais Alvarenga, L.C. Thuler, R.M. Papais Alvarenga (Rio de Janeiro, BR) P177 Long-term outcome of multiple sclerosis in Thai patients C. Prasansiang, J. Sujjanant , S. Siritho, N. Prayoonwiwat (Bangkok, TH) P178 Demographic and clinical statistics of 1867 Turkish patients with multiple sclerosis and other demyelinating diseases D. Yandim Kuscu, D. Uluduz, M. Kurtuncu, N. Sisman, N. Isik, E. Togrol, F. Seleker, A. Celebi, M. Tutuncu, S. Saip, A. Altintas, J. Agaoglu, B. Petek Balci, N. Sutlas, M. Mirza, D. Ince-Gunal, U. Turk Boru, C. Boz, B. Topcular, O. Hayran, A. Siva (Istanbul, Kayseri, Trabzon, TR) P179 Geriatric patients with multiple sclerosis: epidemiology, clinical and MRI characteristics in a database of 2446 patients J.C. Ouallet, J. Chateauraynaud, J. Ananivi, K. Lataste, B. Brochet (Bordeaux, Mont de Marsan, FR) P180 Factors affecting time to second attack in relapsing- remitting patients A. Scalfari, A. Neuhaus, M. Daumer, P. Muraro , G. Ebers (London, Oxford, UK; Munich, DE;)

P181 Mortality and survival trends in multiple sclerosis as Posters observed in a large insured US cohort S. Reshef, D. Kaufman, H. Golub, G. Cutter, A. Bruckner, V. Knappertz (Montville, Boston, Newton, Birmingham, US; Berlin, DE) P182 Clinical characteristics of late-onset demyelinating disease T. Emiru, A. Carpenter, S. Scarberry, C. Luzzio, J. Freeman, G. Parry (Minneapolis, US)

55 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Epidemiology 1 P183 Seasonal variation of multiple sclerosis relapses in Brazil A. Damasceno, L. Deus-Silva, B. Damasceno (Campinas, BR) P184 Post-partum relapses and breastfeeding in multiple sclerosis patients E. Portaccio, A. Ghezzi, B. Hakiki, V. Zipoli, L. Razzolini, V. Martinelli, L. Moiola, F. Patti, L. La Mantia, G.L. Mancardi, C. Solaro, M.R. Tola, C. Pozzilli, L. De Giglio, R. Totaro, A. Lugaresi, V. Di Tommaso, D. Paolicelli, M.G. Marrosu, G. Comi, M. Trojano, M.P. Amato on behalf of the Multiple Sclerosis Study Group of the Italian Neurological Society P185 Multiple sclerosis in Georgia: analysis of data from the hospital-based registry M. Kiziria, T. Vashadze, D. Gugutsidze, R. Shakarishvili, A. Tsiskaridze (Tbilisi, GE) P186 A study of Indian multiple sclerosis patients S. Menon, B. Kulkarni (Mumbai, IN) P187 High prevalence of multiple sclerosis in Sweden C. Ahlgren, A. Odén, J. Lycke (Gothenburg, SE) P188 Incidence of multiple sclerosis in Mazandaran, Iran, 2009 – 2010 M. Abedini, R. HabibiSaravi, R. Sohrabnejad (Sari, Babol, IR) P189 Prevalence of multiple sclerosis in Albania J. Kruja, A. Kuqo, S. Mijo, I. Zekja, J. Bala, S. Grabova, M. Rakacolli (Tirana, AL) P190 Descriptive epidemiology of MS patients followed in an Algerian university hospital N. Hecham (Algiers, DZ) P191 Clinical features of multiple sclerosis in Puerto Rico A. Chinea (Guaynabo, PR) P192 The month of birth and multiple sclerosis in the Israeli population U. Givon, G. Zeilig, M. Dolev, A. Achiron (Tel Hashomer, IL) P193 Multicentre study on ultra-annual changes of seasonal differences in the frequency of multiple sclerosis clinical attacks: first data from Italy and Argentina G. Iuliano, E. Cristiano, P. Duquette, A. Lugaresi, V. Van Pesch on behalf of MSbase collaboration P194 A comprehensive review of the genetic epidemiology from the Canadian Paediatric Demyelining Disease Study L. Zahavich, C. Guimond, M. McGowan, S. Magalhaes, A.D. Sadovnick, D.L. Arnold, A. Bar-Or, R.A Marrie, B. Banwell on behalf of the Canadian Pediatric Demyelinating Study Group

56 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Epidemiology 1 (continued) P195 Paediatric onset multiple sclerosis in a Hispanic-American group L. Amezcua, M. Fernandez, T. Islam (Los Angeles, US) P196 Concordance of relapsing–remitting multiple sclerosis in German triplets C.G. Morcinek, T. Derfuß, P. Rieckmann (Bamberg, Erlangen, DE) P197 EIMS, an epidemiologic investigation of risk factors for multiple sclerosis K. Kai-Larsen, N. Nordin, A. Hedström, J. Hillert, T Olsson, L. Alfredsson (Stockholm, SE) P198 Differences in multiple sclerosis management between men and women S. Brunot, C. Ritleng, A. Fromont, C. Antoniol, V. Loudenot, T. Moreau (Dijon, Lyon, FR) P199 Prevalence and incidence of multiple sclerosis in Genova province, Italy C. Solaro, F. Molinari, P. Tanganelli, R. Nicoloa, G. Ribizzi, S. Venturi, G.L. Mabcardi, M. Battaglio (Genoa, Lavagna, Siena, IT) P200 Absence of multiple sclerosis and Devic´s disease in Lacandon, Mexico T. Corona Vazquez, S. Gonzalez, X. Morales, K. Huesca, J. Flores, O. Gómez (Mexico City, Chiapas, MX) P201 Study of oligoclonal bands in cerebrospinal fluid in black patients with multiple sclerosis P.D. Gama, L.R. Machado, J.A. Livramento, H.R. Gomes, T. Adoni, R.R. Morales, R.A.D. Gama, D.A.D. Gama, M.A. Lana-Peixoto, D. Callegaro on behalf of the Brazilian Committee for Treatment and Research on Multiple Sclerosis – BCTRIMS P202 The German MS cohort study: a prospective cohort study in clinically isolated syndromes and early multiple sclerosis. Presentation of study concept A. Stroet, A. Ziegler, G. Antony, H.-P. Hartung, A. Chan, B. Hemmer, R. Gold on behalf of the German Competence Network for Multiple Sclerosis (KKNMS) Posters

MS symptoms 1 P203 Urological management in multiple sclerosiss: a real-life observational study P.L. Eelen, D. De Ridder (Melsbroek, BE) P204 Dysphagia in multiple sclerosis M. Etemadifar, M. Poorjavad, F. Derakhshandeh, B. Soleymani, A.H. Maghzi (Isfahan, Najafabad, IR) P205 Restless leg syndrome in multiple sclerosis and depression G. Aydar, S. Kurt, H. Karaer Unaldy, U. Erkorkmaz (Tokat, TR)

57 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 MS symptoms 1 (continued) P206 Urinary dysfunction in MS patients: impact on the quality of life T. Graf, K. Buse, L. Bernhardt, M. Marziniak (Münster, DE) P207 Evaluation of natalizumab for the relief of multiple sclerosis associated fatigue: the ENER-G study J. Wilken, R. Kane, C. Sullivan, M. Gudesblatt, S. Lucas, R. Fallis, X. You, R. Kim (Washington DC, Baltimore, Bay Shore, Seattle, Nashville, Cambridge, US) P208 A case of bilateral horizontal gaze ophtalmoplegia: the 1+1 syndrome N. Collongues, B. Bourre, M. Bouyon, J. Aupy, F. Blanc, C. Speeg, J. de Seze (Strasbourg, Rouen, FR) P209 Clinical exacerbations of multiple sclerosis and the features of pain associated with MS K. Lauckaite, D. Mickeviciene, K. Petrikonis, D. Rastenyte (Kaunas, LT) P210 Pathways of sexual desire in women with multiple sclerosis: a functional MRI study W. Castro-Borrero, G. Remington, S. Davis, B. Greenberg, E. Frohman (Dallas, US) P211 Results of urodynamic examinations on so far uninvestigated multiple sclerosis patients M. Kaeder, A. Wiedemann, I. Fäsgen, W. Greulich (Hagen-Ambrock, Witten, DE) P212 Lower urinary tract symptoms and sexual dysfunction in patients affected by multiple sclerosis A. Marti, A. Sebastianelli, E. Sacco, A.P. Batocchi (Rome, IT) P213 Analysis of depressive symptoms during interferon beta-1b treatment in patients with relapsing–remitting multiple sclerosis: interim results of a prospective cohort study H. Bartosik-Psujek, R. Hozejowski, L. Jernas, H. Wygladalska- Jernas, E. Tokarz-Kupczyk (Lublin, Warsaw, Poznan, PL) P214 Dysphagia in multiple sclerosis: prevalence and clinical findings in a Brazilian population D. Sales, C. Vasconcelos, R. Alvarenga (Rio de Janeiro, BR) P215 The role of urodynamics in diagnosis and management of lower urinary tract dysfunction in multiple sclerosis D. Takos, V. Mastorodemos, C. Mamoulakis, V. Papadimitriou, D. Kotzamani, F. Sofras, A. Plaitakis (Heraklion, GR) P216 Restless legs syndrome and multiple sclerosis: a cohort study A. Mendes, P. Abreu, T. Mendonca, J. Guimaraes, J. Reis, E. Rio, M.J. Sa (Porto, PT)

58 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Clinical assessment tools 1 P217 Mobile accelerometry as a tool to measure physical activity as outcome parameter for exercise therapy in MS patients: a feasibility study M. Schimpl, A. Schlummer, A. Neuhaus, K. Pfeifer, A. Tallner, M. Morgott, M. Daumer (Munich, Erlangen, DE) P218 Validation of chosen aspects of psychometry of a Polish version of MusiQoL questionnaire – preliminary report A. Jamroz-Wisniewska, Z. Stelmasiak, H. Bartosik-Psujek (Lublin, PL) P219 German validation of the Multiple Sclerosis Impact Scale 29 and comparison to a quality of life measure P. Schönberg, N. Schäffler, J. Stefan, C. Heesen (Hamburg, DE) P220 Proxy measurements in multiple sclerosis: agreement on different MS scales J. Sonder, F. van der Linden, D. Knol, C. Polman, B. Uitdehaag (Amsterdam, NL) P221 Thermo-sensitivity and fatigue affect participation in physical activity in individuals with multiple sclerosis C. Fjeldstad, D. Brittain, A. Fjeldstad, G. Pardo (Oklahoma City, Norman, Salt Lake City, US) P222 Examination of cerebrovascular autoregulation and vasoreactivity in multiple sclerosis patients Z. Mezei, T. Csepany, L. Olah, R. Kovacs, L. Csiba (Debrecen, HU) P223 Use and acceptance of new media communication by MS patients: a multicentre survey R. Haase, G. Bang-Gottwald, A. Bergmann, T. Ziemssen (Dresden, Stuttgart, Neuburg, DE) P224 Adapting the Motor Activity Log for persons with bilateral MS: a validation study I. Lamers, L. Kerkhofs, A. Timmermans, E. Knippenberg, P. Feys (Diepenbeek, Overpelt, BE; Hoensbroek, NL) P225 Comparison of statistical models for the analysis of magnetic resonance imaging data in multiple sclerosis to

assess the treatment effects of subcutaneous interferon Posters beta-1a, 44 mcg three times weekly in historical studies P. Cornelisse, C. Marchand, E. Verdun, S. Marzabal (Geneva, CH) P226 Evaluating change in mobility in multiple sclerosis: relative responsiveness of six measures J. Freeman, R. Walters, W. Ingram, J. Zajicek (Plymouth, UK)

59 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Clinical assessment tools 1 (continued) P228 The MRI rule of five: predicting the occurrence of relapse G. Cutter, C. Morgan, A. Ranjan, R. Landin (Birmingham, San Diego, US) P229 Effects of intramuscular interferon beta-1a on Functional Status Score components of the Expanded Disability Status Scale (EDSS): results from the MSCRG study T. Scott, P. Foulds, X. You (Pittsburgh, Cambridge, US) P230 Short-term relapse as fully surrogate endpoint for long-term sustained progression of disability in relapsing–remitting multiple sclerosis patients treated with Natalizumab Y.-C. Wang (Cambridge, US) P231 Computerised assessment of natalizumab effects on cognitive function in patients with relapsing–remitting multiple sclerosis M. Gudesblatt (New York, US)

Economic burden 1 P232 Reduced healthcare resource utilization with cladribine tablets in patients with relapsing–remitting multiple sclerosis in the double-blind 96-week CLARITY study A. Joyeux, S. Ali, G. Comi, S. Cook, G. Giovannoni, S. Greenberg, N. Paracha, K. Rammohan, P. Rieckmann, P. Soelberg Sørensen, P. Vermersch (Geneva, CH; York, London, Oxford, UK; Milan, IT; Newark, Columbus, US; Bamberg, DE; Copenhagen, DK; Lille, FR) P233 Socio-economic aspects of testing for neutralising antibodies in MS patients on interferon beta treatment in Austria: a cost of illness study F. Deisenhammer, C. Brennig, W. Mair, E. Walter (Innsbruck, Vienna, AT) P234 Natalizumab treatment increases economic productivity by improving work capacity A. Wickström, S. Olofsson, A.H. Glenngård, A. Svenningsson (Umeå, Lund, SE) P235 A survey on the direct cost of patients with multiple sclerosis treated at specialist centres in Italy M.P. Amato, P. Bellantonio, P. Berto, F. Bortolon, P. Cavalla, C. Florio, A. Lugaresi, E. Montanari, M. Rottoli, I.L. Simone, M. Zaffaroni (Florence, Isernia, Verona, Vicenza, Turin, Naples, Chieti, Fidenza, Bergamo, Bari, Gallarate, IT) P236 Impact of multiple sclerosis disease-modifying drugs on healthcare costs: application to the Swedish health system M. Cuche, M. Nilsson, C.A. Chowdhury, K. D. Lukasik, E. Castañeda (Geneva, CH; Stockholm, SE; New York, US)

60 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Pathology 1 P237 Meningeal T-cells associate with axonal loss in the spinal cords from patients with progressive MS G. Androdias, R. Reynolds, M. Chanal, C. Confavreux, S. Nataf (Bron, Lyon, FR; London, UK) P238 Neurodegeneration and iron deposition in deep grey matter nuclei in MS M. Vercellino, C. Trebini, S. Masera, A. Romagnolo, A. Mattioda, C. Chiavazza, E. Capello, G.L. Mancardi, D. Giobbe, M.T. Giordana, P. Cavalla (Turin, Genoa, IT) P239 Cholinergic deficits in MS hippocampus: first steps towards treating cognitive problems? E.J. Kooi, N Bajic, M. Prins, A.M. van Dam, J. Hoozemans, P.T. Francis, P van der Valk, J.J.G. Geurts (Amsterdam, NL; London, UK) P240 Axonal loss and neurofilament phosphorylation changes accompany lesion development and clinical progression in multiple sclerosis L. Schirmer, J. Antel, W. Brück, C. Stadelmann (Munich, Göttingen, DE; Montreal, CA)

Experimental models 1 P241 Inhibition of delta-like ligand-4 decreases Th17 responses in a murine model of multiple sclerosis H. Eixarch, M.J. Mansilla, C. Costa, S.L. Kunkel, X. Montalban, N. Godessart, C. Espejo (Barcelona, ES; Ann Arbor, US) P242 Inhibition of experimental autoimmune encephalomyelitis by transfer of CD28 knockout plasmacytoid dendritic cells S. Gaupp, J. Thöne, B. Jesionek, S. Seubert, R. Linker, R. Gold (Bochum, DE) P243 Evidence for diverse roles of bone morphogenetic protein-6 in different models of inflammatory demyelinating disease S. Hochmeister, T. Seifert-Held, J. Bauer, R. Weissert, C. Linington, F. Fazekas, M.K. Storch (Graz, Vienna, AT; Geneva, CH;

Glasgow, UK) Posters P244 Oral somatostatin suppresses acute and passive experimental autoimmune encephalomyelitis S. Brod, Z. Hood (Houston, US) P245 Lipopolysaccharide has beneficial effects on cuprizone- induced demyelination but delays remyelination T. Skripuletz, E. Miller, G. Grote, D. Moharregh-Khiabani, E. Voß, J. Skuljec, R. Pul, G. Gudi, C. Trebst, M. Stangel (Hannover, DE)

61 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Experimental models 1 (continued) P246 The relationship between axon loss, demyelination and neurobehavioural outcome in an animal model of multiple sclerosis H.M. Vesterinen, E.S. Sena, A. Williams, C. French-Constant, S. Chandran, M.R. Macleod (Edinburgh, UK) P247 IL-25 gene therapy does not modulate relapsing–remitting experimental autoimmune encephalomyelitis C. Maiorino, E. Butti, F. Ruffini, G. Martino, R. Furlan (Milan, IT) P248 The role of antigen specific CD4+CD25+ T regulatory cells in controlling demyelination in autoimmune disease S.J. Hodgkinson, G.T. Tran, R. Boyd, C. Robinson, B.M. Hall (Sydney, AU) P249 Beneficial effect of IgG glycans hydrolysis by EndoS in experimental autoimmune encephalitis M. Benkhoucha, M.-L. Santiago-Raber, M. Weber, M. Collin, P. Lalive (Geneva, CH; Munich, DE; Lund, SE) P250 Expression of chemokines and neurodegeneration process in experimental models of the central nervous system diseases P. Wolinski, A. Glabinski (Lodz, PL) P251 Laquinimod rescue therapy in mice with experimental autoimmune encephalomyelitis C. Wegner, R. Pförtner, W. Brück (Göttingen, DE) P252 Cytochrome C deficiency ameliorates experimental autoimmune encephalomyelitis and reduces oligodendroglial and axonal damage without bioenergetic alterations S. Ruhrmann, A. Haghikia, U. Schweizer, B. Pula, R. Gold, S. Wiese, A. Chan (Bochum, Berlin, DE) P253 Immunomodulation with mesenchymal stem cells in a humanised T-cell receptor transgenic model of multiple sclerosis F. Grassivaro, D. Lowther, F. Vianello, F. Dazzi, D.M. Altmann (Padua, IT; London, UK) P254 Prophylactic and therapeutic efficacy of MOG-DNA vaccines in experimental autoimmune encephalomyelitis N. Fissolo, C. Costa, M.J. Mansilla, X. Montalban, M. Comabella (Barcelona, ES)

62 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Genetics/transcriptomics 1 P255 Transcriptional analysis of seven MS-associated genes after ex vivo stimulation with LPS/PMA S. Perga, N.D. Navone, M. Caldano, F. Gilli, A. Bertolotto (Orbassano, IT) P256 Gsta4, a candidate gene for regulation of neurodegeneration in autoimmune neuroinflammation F. Al Nimer, M. Ström, R. Lindblom, F. Piehl (Stockholm, SE) P257 Fine-mapping of the chromosome 13q31.3 region in multiple sclerosis U.M. Marigorta, M. Fernández, N. Bellora, A. Navarro, X. Montalban, M. Comabella (Barcelona, ES) P258 Relapsing neuromyelitis optica is not associated with the HLA DR2 haplotype in a Brazilian cohort from Rio de Janeiro M. Papais Alvarenga, R. Maria Papais-Alvarenga, M. Papais Alvarenga, G. Santos Cruz, C. Cristina Ferreira Vasconcelos, M. Jesus Pinto-Medel, L. Leyva, O. Fernandez y Fernandez (Rio de Janeiro, BR; Malaga, ES) P259 MEFV gene mutations in German multiple sclerosis patients and controls T. Kümpfel, L.A. Gerdes, T. Wacker, R. Hohlfeld, P. Lohse (Munich, DE) P260 Lack of association of a KIF1B polymorphism with disease progression in Greek patients with multiple sclerosis G. Koutsis, G. Karadima, C. Sfagos, D. Vassilopoulos, M. Panas (Athens, GR) P261 Angiotensin II receptor type 2 (AT2R) -1332 A/G gene polymorphism as a risk factor for multiple sclerosis A. Kolakovic, M. Zivkovic, E. Dincic, S. Popovic, R. Raicevic, D. Alavantic, A. Stankovic (Belgrade, RS) P262 Transcriptional response signature of immune cells to IFN-b reveals distinct patterns in monocytes N. Henig, N. Avidan, T. Paperna, R.Y. Pinter, A. Miller (Haifa, IL) P263 Exploring the CLEC16A gene reveals a MS-associated

variant with correlation to the relative expression of Posters CLEC16A isoforms in thymus I.L. Mero, M. Ban, Å.R. Lorentzen, C. Smestad, E.G. Celius, H. Sæther, H. Saeedi, M.K. Viken, B. Skinningsrud, D.E. Undlien, J. Aarseth, K.M. Myhr, S. Granum, A. Spurkland, S. Sawcer, A. Compston, B.A. Lie, H.F. Harbo (Oslo, Bergen, NO; Cambridge, UK)

63 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Genetics/transcriptomics 1 (continued) P264 Validation of IRF5 as multiple sclerosis risk gene: putative role in interferon beta therapy and human herpesvirus-6 infection M.C. Cenit, I. Alloza, B. Swaminathan, A. Antigüedad, D. Otaegui, J. Olascoaga, M. Garcia-Barcina, V. De las Heras, M. Bartolome, M. Fernandez-Arquero, R. Arroyo, R. Alvarez-Lafuente, M. Lopez-Cavanillas, E. Urcelay, K. Vandenbroeck (Madrid, Leioa, Bilbao, San Sebastian, ES) P265 Associations of HLA DR*1501 status and chronic cerebrospinal venous insufficiency in multiple sclerosis B. Weinstock-Guttman, R. Zivadinov, G. Cutter, M. Tamano-Blanco, D. Badgett , K. Marr, E. Carl, M. Elfadil, C. Kennedy, M. Ramanathan (Buffalo, Birmingham, US) P266 MGAT5 and disease severity in progressive multiple sclerosis F. Esposito, J. Wojcik, M. Rodegher, M. Radaelli, L. Moiola, A. Ghezzi, R. Capra, P. Brambilla, M. Sorosina, G. Giacalone, V. Martinelli, G. Comi, H. Abderrahim, F. Martinelli-Boneschi (Milan, Varese, Brescia, IT; Geneva, CH) P267 IL21 gene polymorphisms are not associated with multiple sclerosis in a Swedish population M. Linden, R. Nohra, E. Sundqvist, M. Khademi, J. Hillert, L. Alfredsson, T. Olsson, I. Kockum (Stockholm, SE) P268 Quantification of microRNA expression in human peripheral blood microvesicles from multiple sclerosis patients treated with Interferon beta-1b M. Thamilarasan, D. Koczan, R.H. Goertsches, M. Hecker, L. Jonas, H.-J. Thiesen, U.K. Zettl (Rostock, DE) P269 Screening of the mitochondrial genome in Sardinian patients with primary progressive multiple sclerosis: a pilot study E. Cocco, E. Fadda, R. Murru, M. Floris, J. Frau, L. Lorefice, G. Fenu, G. Coghe, R. Piras, M. Valentini, E. Pieroni, J. Coku, A. Naini, S. DiMauro, M.G. Marrosu (Cagliari, New York, IT)

Immunology 1 P270 Safety and T-cell modulating effects of high-dose vitamin D3 supplementation in patients with relapsing–remitting multiple sclerosis J. Smolders, E. Peelen, M. Thewissen, J.W. Cohen Tervaert, P. Menheere, J. Damoiseaux, R. Hupperts (Maastricht, Sittard, NL) P271 Circulating microRNAs as indicators for disease course of multiple sclerosis R.L.P. Lindberg, F. Hoffmann, J. Kuhle, L. Kappos (Basel, CH)

64 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunology 1 (continued) P272 CSF angiotensin II and angiotensin-converting enzyme levels in anti-aquaporin-4 autoimmunity T. Matsushita, N. Isobe, M. Kawajiri, M. Mogi, K. Tsukuda, M. Horiuchi, J. Kira (Fukuoka, Matsuyama, JP) P273 Analysis of cellular mechanisms underlying reduction of experimental allergic encephalomyelitis after treatment with glatiramer acetate sensitised B-cells S. Begum-Haque, M. Christy, J. Ochoa-Reparaz, E. Kasper, A. Haque, L.H. Kasper (Lebanon, US) P274 Th1/Th2/Th17 and Treg related transcription factors and cytokines in multiple sclerosis M. Edström, L. Dahle, MC. Jenmalm, J. Mellergård, J. Mjösberg, R. Press, M. Vrethem, J. Ernerudh (Linköping, Stockholm, SE; Amsterdam, NL;) P275 Isolation and expansion of CD8+ T-cells with the potential to suppress encephalitogenic CD4+ T-cells in vitro and attenuate experimental autoimmune encephalomyelitis in vivo T. Leuenberger, M. Paterka, F. Zipp, V. Siffrin (Mainz, DE) P276 Expression, shedding, transcriptional regulation and function of IFNa/b receptor in peripheral blood mononuclear cells from patients with multiple sclerosis, treated with IFNb L. Granieri, P. Valentino, F. Marnetto, M. Caldano, A. Sala, F. Gilli, A. Bertolotto (Orbassano, IT) P277 CNS-targeted production of IL-17A induces astrocytosis and microglial activation without neurological symptoms or severe tissue damage J. Zimmermann, M. Krauthausen, C. Conrad, M.J. Hofer, M.T. Heneka, I.L. Campbell, M.M. Müller (Bonn, Marburg, DE; Sydney, AU) P278 Intrathecal IgM and IgG synthesis in experimental autoimmune encephalomyelitis N. Marín, M.-J. Mansilla, J.-C. Álvarez-Cermeño, X. Montalban, C. Guaza, L.-M. Villar, C. Espejo (Madrid, Barcelona, ES) P279 Dysregulated IL-7Ralpha pathway in CD8 T-cells of MS Posters patients K.L. Kreft, E. Verbraak, A.F. Wierenga, M. van Meurs, J.D. Laman, R.Q. Hintzen (Rotterdam, NL) P280 TNFR2 is critical for Treg immunomodulatory activity in a model of MS N. Tsakiri, D. Papadopoulos, D.D. Mitsikostas, G. Kollias (Athens, GR) P281 Tolerogenic dendritic cells as a potential tool for tolerance induction in multiple sclerosis patients D. Raich, L. Grau-López, M. Naranjo-Gómez, C. Ramo-Tello, R. Pujol-Borrell, F. Borras, E. Martínez-Cáceres (Badalona, ES)

65 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunology 1 (continued) P282 CD4+ and CD8+ T-cells expressing high levels of T-bet and pSTAT1 and CD4+ T-cells expressing high levels of pSTAT3 accumulate in peripheral blood of multiple sclerosis patients during natalizumab treatment A.P. Batocchi, G. Frisullo, V. Nociti, R. Iorio, D. Plantone, A. Patanella, A. Marti, P. A. Tonali (Rome, IT) P283 T cells and dendritic cells predict response to immunomodulatory treatment in multiple sclerosis F. Sellebjerg, M. Krakauer, S.J.W. Limborg, D. Hesse, H. Lund, H.B. Søndergaard, P. Soelberg Sørensen (Copenhagen, DK) P284 Multiple sclerosis susceptibility alleles modulate gene expression levels of lymphocyte activation pathways L. Ottoboni, F. Esposito, N. Patsopoulos, F. Martinelli-Boneschi, G. Comi, D. Hafler, P. De Jager (Boston, US; Milan, IT) P285 Deregulated stress-induced Hsp70 production by immune cells in multiple sclerosis H. Cwiklinska, P. Mycko, M. Matysiak, K. Selmaj (Lodz, PL) P286 Aquaporin 4 antibody-mediated cytotoxicity in primary human astrocytes in culture: complement-dependent and -independent cellular changes S. Nishiyama, T. Misu, M. Nuriya, T. Takahashi, I. Nakashima, M. Yasui, K. Fujihara, Y. Itoyama (Sendai, Tokyo, Yonezawa, JP) P287 Immunogenicity of subcutaneous interferon beta-1a over time in patients with relapsing multiple sclerosis G. Giovannoni, B. Stubinski, P. Cornelisse (London, UK; Geneva, CH) P288 CSF CD8+DR+ cells are related to disability in multiple sclerosis L. Navarro, E. Guillamon, L. Cordón, N. Marti, M.J. Magraner, I. Bosca, M. Simo, I. Benet, F. Coret, A. Sempere, B. Casanova (Elche, Valencia, ES)

MS and infections 1 P289 Anti-human herpesvirus-6 IgG and IgM detection in multiple sclerosis patients treated with interferon beta I. Ortega, M. Garcia-Montojo, M.I. Dominguez-Mozo, V. De las Heras, M. Bartolome, A. Garcia-Martinez, A.M. Arias-Leal, R. Arroyo, R. Alvarez-Lafuente (Madrid, ES) P290 Investigation of infectious agents in serum and CSF in a neurology cohort study: clinicolaboratory correlation M. Krommyda, G. Balamoutsos, M. Paschalidou, M. Pape, K. Mandraveli, N. Taskos (Thessaloniki, GR) P291 The impact of parasite infections on the course of multiple sclerosis J. Correale, M. Farez (Buenos Aires, AR)

66 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 MS and infections 1 (continued) P292 Polyomavirus reactivation and relationship to cellular immunity in patients with relapsing–remitting multiple sclerosis on natalizumab therapy A. Molloy, J. Stack, C.F. De Gascun, R. Lonergan, K. Kinsella, S. Jordan, M. Duggan, C. Slattery, W.W.I. Hall, M. Hutchinson, N. Tubridy (Dublin, IE) P293 Characteristics of anellovirus infections in patients with multiple sclerosis L. Kaiser, I. Jelcic, P. Breiden, S. Hoffmeister-Ullerich, M. Linnebank, J. Gärtner, H. Peter, E.-M. de Villiers, M. Sospedra, R. Martin (Hamburg, Göttingen, Heidelberg, DE; Zurich, CH) P294 Common childhood viruses and HLA-DRB1 as susceptibility factors for paediatric-onset MS E. Waubant, E. Mowry, L. Krupp, T. Chitnis, A. Yeh, N. Kuntz, J. Ness, D. Chabas, J. Strober, J. McDonald, A. Belman, M. Milazzo, M. Gorman, B. Weinstock-Guttman, M. Rodriguez, J. Oksenberg, J. James (San Francisco, US)

Environmental, sex-related and life-style factors 1 P295 Demyelinating encephalopathy after acute carbon monoxide poisoning: comparison of oligoclonal band positive and negative cases H. Kuroda, K. Fujihara, S. Takahashi, Y. Itoyama (Sendai, JP) P296 Gender-specific effects of physicians and patients with multiple sclerosis in medical treatment M. Loitfelder, F. Fazekas, C. Enzinger, S. Fuchs (Graz, AT) P297 A report of five cases of CNS demyelination after quadrivalent human papilloma virus vaccination: could there be any relationship? G. Balamoutsos, M. Bouktsi, M. Paschalidou, N. Tascos, I. Milonas (Thessaloniki, GR) P298 Meta-analysis of multiple sclerosis susceptibility following infectious mononucleosis and smoking

A.E. Handel, A.J. Williamson, G. DiSanto, L. Handunnetthi, Posters G. Giovannoni, S.V. Ramagopalan (Oxford, UK) P299 The impact of hormonal changes on physical disability in the menstrual cycle of patient with multiple sclerosis Y. Guven Yorgun, S. Ozakbas, E. Idiman (Izmir, TR) P300 Low bone mineral density and vitamin D at the onset of multiple sclerosis S.M. Moen, E. Gulowsen Celius, L. Nordsletten, E. Fink Eriksen, T. Holmøy (Oslo, NO)

67 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Environmental, sex-related and life-style factors 1 (continued) P301 Seasonality and risk of multiple sclerosis P. Barros, L. Augusto, M.J. Sá on behalf of the Demyelinating Diseases Group of Hospital S. João P302 Multiple sclerosis and food consumption in Austria: an ecological study K. Lauer (Griesheim, DE) P303 The changing female-to-male sex ratio over four decades in multiple sclerosis: implications for aetiology of the disease W. Cendrowski (Warsaw, PL) P304 A complete literature survey: vitamin D and multiple sclerosis – What is clearly evident? I. Rafique, J.L. Frederiksen (Glostrup, DK) P305 Poor vitamin D status is correlated with depression, but not fatigue in multiple sclerosis S. Knippenberg, Y. Bol, J. Damoiseaux, R. Hupperts, J. Smolders (Maastricht, Sittard, NL)

Neurobiology 1 P306 Oligodendrocytes participate in MS lesion formation J.P. Buschmann, H. Awad, M. Daniel, R. Kamble, K. Berger, T. Clarner, H. Neumann, B. Linnartz, L. Vallières, C. Beyer, M. Kipp (Aachen, Bonn, DE; Québec, CA) P307 Astrocytes in MS are deficient in beta-2-adrenergic receptors in both white and grey matter N. Wilczak, J. De Keyser (Groningen, NL; Brussels, BE) P308 Infiltration of blood-derived monocytes is required for disease progress in experimental autoimmune encephalomyelitis B.A. Ajami, J.B. Bennett, K.M. McNagny, F.R. Rossi (Vancouver, CA) P309 Putative role of neurofilament-tubulin binding sites in axon-glia interactions during remyelination C. Fressinaud (Angers, FR) P310 Glucocorticoids accelerate oligodendrocyte differentiation in vitro but do not interfere with endogenous remyelination T. Clarner, U. Schöne, C. Beyer, M. Kipp (Aachen, DE) P311 Cytokines regulate gene expression of arginase 1, ubiquitin D and transglutaminase 1 in neurons in vitro: confirmation of microarray results by QRT-PCR R. Lisak, J. Benjamins, L. Nedelkoska, D. Studzinski, B. Bealmear (Detroit, Royal Oak, US)

68 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Repairing mechanisms 1 P312 Genomic analysis of remyelination and non-remyelination lesions reveals the importance of brain lipid binding protein in activated astrocytes M. Kipp, S. Gingele, F. Pott, T. Clarner, S. Amor, P. van der Valk, B. Denecke, G. Lin, C. Beyer (Aachen, DE; Amsterdam, NL) P313 Fate mapping with Wnt1-Cre/R26R reporter mice reveals a non-neural crest origin of adult bone marrow-derived mesenchymal stem cells D.P.J. Hunt, M. Sajic, D. Henderson, D.A.S. Compston, K. Smith, S. Chandran (Cambridge, London, Newcastle, Edinburgh, UK)

Imaging 1 P314 Voxel-wise assessment of intrinsic damage of the major white matter fibre bundles in multiple sclerosis patients with different clinical phenotypes: a diffusion tensor study P. Preziosa, M.A. Rocca, M. Pagani, E. Pagani, K. Kacar, S. Mesaros, T. Stosic-Opincal, D. Caputo, M. Absinta, J. Drulovic, V.S. Kostic, G. Comi, M. Filippi (Milan, IT; Belgrade, RS) P315 Increased brain iron levels by R2* relaxometry in relation to cognitive deficits in multiple sclerosis M. Khalil, C. Langkammer, S. Ropele, K. Petrovic, M. Loitfelder, M. Jehna, M. Tscherner, M. Wallner-Blazek, R. Schmidt, C. Enzinger, S. Fuchs, F. Fazekas (Graz, AT) P316 Magnetic resonance imaging predictors of the persistence of T1 black holes in multiple sclerosis patients M. Menegola, A. Papadopoulou, S. Traud, A. Gass, L. Kappos, E.W. Radü, Ö. Yaldizli (Basel, CH) P317 Altered haemodynamics of cortical lesions in multiple sclerosis D. Peruzzo, M. Castellaro, M. Calabrese, E. Veronese, F. Rinaldi, V. Bernardi, A. Favaretto, I. Mattisi, P. Gallo, A. Bertoldo (Padua, IT) P318 MRI results of blinded chronic cerebrospinal venous insufficiency study in patients with multiple sclerosis, healthy

controls and patients with other neurologic diseases Posters R. Zivadinov, G. Cutter, K. Marr, M. Ramanathan, R.H.B. Benedict, M. Elfadil, N. Bergsland, C. Morgan, E. Carl, D. Hojnacki, E. Yeh, L. Willis, M. Cherneva, S. Hussein, J. Durfee, C. Kennedy, M. Dwyer, B. Weinstock-Guttman (Buffalo, Birmingham, US) P319 Evolution of voxel-wise magnetisation transfer ratio in natalizumab and interferon beta treated patients with multiple sclerosis. A case-control, 2-year follow-up study R. Zivadinov, M. Dwyer, S. Hussein, E. Carl, J. Durfee, C. Kennedy, M. Andrews, D. Hojnacki, M. Heininen-Brown, L. Willis, M. Cherneva, N. Bergsland, B. Weinstock-Guttman (Buffalo, US)

69 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Imaging 1 (continued) P320 Increased iron concentration and decreased volume of deep-grey matter are associated with increased disability in patients with multiple sclerosis R. Zivadinov, M. Heininen-Brown, C. Schirda, N. Bergsland, C. Magnano, D. Hojnacki, D. Ramasamy, C. Kennedy, E. Carl, M. Dwyer, B. Weinstock-Guttman (Buffalo, US) P321 Relation between quantitative venous vasculature assessment on susceptibility-weighted imaging and haemodynamic MRI metrics in multiple sclerosis patients G. Poloni, M. Dwyer, F. Parker, C. Magnano, C. Schirda, N. Bergsland, R. Zivadinov (Buffalo, US) P322 Inefficient cortical activity during working memory and attention tasks in patients with clinically isolated syndrome R. Romano, C. Tortorella, P. Taurisano, D. Paolicelli, L. Fazio, P. Iaffaldano, V. Di Renzo, R. G. Viterbo, T. Popolizio, G. Blasi, A. Bertolino, M. Trojano (Bari, S.Giovanni Rotondo, IT) P323 Differentiation of lesions using high-field phase contrast imaging in multiple sclerosis M. Matzke, V. Ovtcharov, K. Zhong, O. Speck, M. Sailer (Magdeburg, DE) P324 No association of abnormal cranial venous system drainage with multiple sclerosis: an MR venography and flow-quantification study M.P. Wattjes, B. van Oosten, W.L. de Graaf, A. Seewann, J.C.J. Bot, R. van den Berg, B.M.J. Uitdehaag, C.H. Polman, F. Barkhof (Amsterdam, NL) P325 Voxel-based analysis of MTR detects changes over time in the grey matter in different phenotypes of MS: a multicentre study B. Bodini, M. Battaglini, M. Atzori, M.L. Stromillo, C. Gasperini, C. Pozzilli, A.J. Thompson, N. De Stefano, O. Ciccarelli on behalf of the MAGNIMS group P326 Corpus callosum damage predicts long-term motor progression and cognitive dysfunction in primary progressive multiple sclerosis: a five-year TBSS and VBM longitudinal study B. Bodini, M. Cercignani, Z. Khaleeli, A.J. Thompson, O. Ciccarelli (London, UK; Rome, IT) P327 Definition of regional distribution of grey matter loss in multiple sclerosis patients with fatigue: a voxel-based morphometry study G. Riccitelli, M.A. Rocca, C. Forn, B. Colombo, G. Comi, M. Filippi (Milan, IT)

70 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Imaging 1 (continued) P328 Does memory retraining in multiple sclerosis increase white matter integrity in the brain? V Leavitt, G. Wylie, N. Chiaravalloti, J. DeLuca (West Orange, US) P329 Higher structural and metabolic brain damage is suggestive of conversion to multiple sclerosis in patients with clinically isolated syndrome E. Sbardella, M.L. Stromillo, V. Tomassini, M. Battaglini, S. Ruggieri, L. Ausili Cefaro, C. Gasperini, C. Pozzilli, N. De Stefano (Rome, Siena, IT; Oxford, UK) P330 Quantitative T2’-imaging in patients with clinically isolated syndrome L. Winkler, M. Inglese, J. Fiehler, B. Holst, C. Heesen, R. Martin, S. Schippling (Hamburg, DE; New York, US) P331 Can spinal MRI be used to predict neuromyelitis optica spectrum disorder ormultiple sclerosis at the onset of transverse myelitis? W.M. Peh, K.K. Jain, C.C.T. Lim, K. Tan (Singapore, SG) P332 Grey matter atrophy evolution in childhood-onset multiple sclerosis M. Calabrese, D. Seppi, V. Bernardi, M. Atzori, F. Rinaldi, A. Favaretto, M. Puthenparampil, I. Mattisi, P. Perini, P. Grossi, P. Gallo (Padua, IT) P333 Pattern of brain activation in multiple sclerosis patients with fatigue: a functional magnetic resonance study F. Moreira, F. Tovar-Moll, D. Lima, M. Guedes, I. Bramati, H. Alvarenga, R.P. Alvarenga (Rio de Janeiro, BR) P334 Differences in brain tissue damage between subjects with radiologically isolated syndrome and patients with early relapsing–remitting multiple sclerosis M.L. Stromillo, F. Rossi, B. Hakiki, M. Battaglini, E. Portaccio, M. Santangelo, C. Gasperini, A. Giorgio, G.M. Malentacchi, M.L. Bartolozzi, A. Federico, M.P. Amato, N. De Stefano (Siena, Florence, Carpi, Rome, Arezzo, Empoli, IT) P335 MR spectroscopy and quantitative MRI in multiple Posters sclerosis patients treated with natalizumab: changes in normal-appearing white matter are associated to intrathecal inflammation and clinical variables J. Mellergård, A. Tisell, O. Dahlqvist Leinhard, C. Dahle, AM. Landtblom, J. Ernerudh, P. Lundberg, M. Vrethem (Linköping, SE)

71 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Imaging 1 (continued) P336 Assessing pseudoatrophy in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation L. Roccatagliata, L. Vuolo, L. Bonzano, M. Battaglini, A. Giorgio, F. Gualandi, M.T. Van Lint, A. Bacigalupo, M.P. Sormani, E. Capello, M. Pardini, M. Bergamino, G.L. Mancardi, N. De Stefano (Genoa, Siena, IT) P337 Validation of MRI-based measurements of subpial cortical demyelination in an MS brain J.T. Chen, C. Schneider, K. Nakamura, K. Easley, G.J. Kidd, A. Chang, S.M. Staugaitis, R.J. Fox, E. Fisher, D.L. Arnold, B.D. Trapp (Cleveland, US; Montreal, CA) P338 Longitudinal evaluation of individual brain volume loss by Jacobian integration technique in patients with multiple sclerosis F. Durand-Dubief, S. Roggerone, B. Belaroussi, D. Sappey-Marinier, S. Vukusic, F. Cotton, C. Confavreux (Bron, Lyon, Pierre-Bénite, FR) P339 Resting state fMRI determines cortical contribution to recovery from optic neuritis N. Zayed, F. Costello, J. Trufyn, M. Smith, B. Goodyear (Calgary, CA) P340 Thalamic subregions associated with cognitive impairment in multiple sclerosis N. Sicotte, K. Kern, M. Montag, A. Kim, J. Horsfall, B. Giesser (Los Angeles, US) P341 Altered effective connectivity of the language network in patients with primary progressive multiple sclerosis M.A. Rocca, P. Valsasina, M. Absinta, E. Trabucco, M. Rodegher, A. Falini, G. Comi, M. Filippi (Milan, IT) P342 Altered network activation during perception of faces in multiple sclerosis and their relationship to brain tissue changes M. Jehna, C. Langkammer, M. Wallner-Blazek, C. Neuper, M. Loitfelder, S. Ropele, F. Ebner, S. Fuchs, M. Khalil, F. Fazekas, C. Enzinger (Graz, AT) P343 SIENA-based estimates of brain-volume change in a clinical-trial setting: use of an incremental-change-summation approach to evaluate different imputation methods used to estimate missing data Z. Caramanos, S. Narayanan, D.L. Arnold (Montreal, CA) P344 A novel, voxel-wise, diffusion tensor analysis of spinal cord in multiple sclerosis O. Ciccarelli, C.A.M. Wheeler-Kingshott, A.J. Thompson, A.T. Toosy (London, UK)

72 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Imaging 1 (continued) P345 Longitudinal optic radiation changes after acute optic neuritis determined by diffusion tractography A.T. Toosy, O. Goodkin, C. Fini, A. Mirigliani, C. Kallis, T.M. Jenkins, O. Ciccarelli, A.J. Thompson (London, UK) P346 MRI improvements and the Will Rogers phenomenon in clinically isolated syndromes A. Rovira, M. Tintoré, C. Auger, J. Sastre-Garriga, E. Huerga, J. Castilló, M.C. Edo, F. Pérez-Miralles, G. Arrambide, R. Mitjana, J. Río, X. Montalban (Barcelona, ES) P347 Predicting the occurrence of relapse in SPMS patients – are rules based on CEL counts effective? C.A. Riddell, Y. Zhao, D.K.B. Li, A.J. Petkau, A. Riddehough, G.R. Cutter, A. Traboulsee (Vancouver, CA; Birmingham, US) P348 An investigation of early features that associate with subsequent retinal nerve fibre layer loss after optic neuritis A.P.D. Henderson, S.A. Trip, D.R. Altmann, K.A. Miszkiel, S.J. Jones, P.G. Schlottmann, D.F. Garway-Heath, G.T. Plant, D.H. Miller (London, UK) P349 Does MRI measurement of white matter atrophy underestimate axonal loss in MS? Evidence from optic neuritis A.P.D. Henderson, D.R. Altmann, S.A. Trip, P.G. Schlottmann, D.F. Garway-Heath, G.T. Plant (London, UK) P350 Multimodal study of corpus callosum impairment in multiple sclerosis S. Llufriu, Y. Blanco, R. Sandoval, J. Casanova, J. Valls-Sole, F. Graus, A. Saiz (Barcelona, ES) P351 Longitudinal followup of USPIO enhanced lesions of clinically isolated syndrome patients. J.-C. Ferré, N. Wiest-Daesslé, J.-P. Ranjeva, J. Pelletier, I. Berry, M. Clanet, L. Freeman, C. Papeix, D. Galanaud, B. Stankoff, L. Pierot, M. Dubois, A. Tourbah, C. Barillot, G. Edan (Rennes, Marseille, Toulouse, Paris, Reims, Loos, FR) P352 Gender effects on atrophy in multiple sclerosis: cognitive Posters implications M.M. Schoonheim, J.J.G. Geurts, F.C. Rueda Lopes, H. Vrenken, V. Popescu, E.J. Sanz-Arigita, L. Douw, C.H. Polman, F. Barkhof (Amsterdam, NL; Rio de Janeiro, BR) P353 1H-MR-spectroscopy at 1.5 Tesla of the upper spinal cord in multiple sclerosis B. Bellenberg, C. Lukas, M. Busch, C. Toennes, R. Gold, A. Chan (Bochum, Witten, DE)

73 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Imaging 1 (continued) P354 Ultra-high-field magnetic resonance imaging in patients with multiple sclerosis: a pilot study A. Dal-Bianco, G. Grabner, M. Schernthaner, C. Kronnerwetter, N. Serbecic, C. Vass, K. Kircher, A. Reitner, E. Auff, H. Lassmann, K. Vass, S. Trattnig (Vienna, AT) P355 Basal ganglia co-expression of resting-state sensory motor network in multiple sclerosis A.-M. Dogonowski, H.R. Siebner, X. Wu, P. Soelberg Sørensen, B. Biswal, M. Blinkenberg, K.H. Madsen (Hvidovre, Copenhagen, DK; Newark, US) P356 Comparison of brain MRI at disease onset in patients with multiple sclerosis and neuromyelitis optica: a pilot study from the Korean MS Registry J.H. Min, H.J. Kim, W. Kim, S.H. Kim, J.Y. An, M.S. Park, B.J. Kim, O. Kwon, B.J. Kim, K.H. Lee, S.M . Kim, K.S. Lee on behalf of the Korea MS network group P357 Neurological deficits, cognitive performance, and white matter lesion location in multiple sclerosis C. Enzinger, F. Fazekas, L. Vecsei, M. Jenkinson, S. Ropele, M. Khalil, K. Petrovic, M. Loitfelder, C. Langkammer, E. Aspeck, M. Wallner-Blazek, S. Fuchs, M. Jehna, Z. Kincses (Graz, AT; Szeged, HU; Oxford, UK) P358 Relating regional grey matter volume changes in relapsing– remitting multiple sclerosis to progression in expanded disability status scale – a longitudinal comparative voxel-based morphometry study L. Hofstetter, L. Filli, S.J. Borgwardt, P. Kuster, S. Traud, N. Müller- Lenke, Y. Naegelin, L. Kappos, A. Gass, T.E. Nichols, F. Barkhof, H. Vrenken, J.J.G. Geurts, C.H. Polman, K. Bendfeldt, E.W. Radü (Basel, CH; Coventry, UK; Amsterdam, NL) P359 Reduced NAA-levels in the normal-appearing white matter of patients with multiple sclerosis is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla F. Aboul-Enein, M. Krssak, R. Höftberger, D. Prayer, W. Kristoferitsch (Vienna, AT)

74 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Neurophysiology 1 P360 Evoked potentials scores: a useful tool in monitoring and predicting the course of multiple sclerosis? M. Bianco, S. Medaglini, J. Gonzalez-Rosa, U. Del Carro, S. Amadio, M. Radaelli, L. Moiola, V. Martinelli, G. Comi, L. Leocani (Milan, IT) P361 The spectrum of facial nerve dysfunction in multiple sclerosis: a clinical and EMG study G. Koutsis, P. Kokotis, A. Papagianni, E. Andreadou, M.E. Evangelopoulos, P. Davaki, N. Karandreas (Athens, GR) P362 Event-related potentials associated with attention network test in multiple sclerosis M. Vazquez-Marrufo, A. Galvao, G. Rodríguez, E. Vaquero, M. Borges, D. Páramo, M. García-Valdecasas, J.L. Ruiz-Peña, G. Izquierdo (Seville, ES) P363 Peripheral and central conduction time to proximal and distal muscle districts of lower limbs: methodological aspects and clinical application in multiple sclerosis patients A. Di Sapio, F. Sperli, S. Malucchi, A. Merola, E. Berra, A. Bertolotto, W. Troni (Orbassano, Turin, IT) P364 EEG evidence for central mechanism of fatigue in multiple sclerosis S. Velikova, B. Colombo, P. Rossi, V. Martinelli, G. Comi, L. Leocani (Milan, IT) P365 A diagnostic value of conventional visual-evoked potentials in patients with multiple sclerosis: reappraising the classics R. Balnyte, I. Ulozienë, R. Rastenytë, A. Vaitkus, K. Lauèkaitë (Kaunas, LT) P366 Early and later cortical plasticity to a motor relapse in relapsing-remitting multiple sclerosis patients. A TMS study L. Straffi, R. Chieffo, E. Coppi, F. Spagnolo, A. Nuara, J. Gonzalez-Rosa, A. Inuggi, G. Comi, L. Leocani (Milan, IT) P367 Electrophysiological signs of changes in motor units in Posters multiple sclerosis B. Cseh, M. Lukacs, A. Valikovics, A. Eros (Miskolc, HU) P368 Vestibular-evoked myogenic potentials in early stage of multiple sclerosis and clinically isolated syndrome L. Crevits, J. Venhovens, J. Debruyne (Ghent, BE)

75 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Neuropsychology and fatigue 1 P369 Relationship between cognitive performance and clinical/MRI variables in early MS I.-K. Penner, L. Kappos, P. Calabrese, M. Filippi, F. Barkhof, P. O’Connor, G. Edan, B. Arnason, M.S. Freedman, S. Cook, H.-P. Hartung, D. Miller, D. Goodin, X. Montalbán, G. Comi, C.H. Polman, D. Jeffery, V. Lanius, K. Beckmann, D. Pleimes, C. Pohl, R. Sandbrink, B. Stemper (Basel, CH; Milan, IT; Amsterdam, NL; Ontario, CA; Rennes, FR; Chicago, Newark, San Francisco, Winston-Salem, US; Düsseldorf, Berlin, DE; London, UK; Barcelona, ES) P370 What to do in multiple sclerosis patients with cognitive involvement? Computer-assisted cognitive rehabilitation: is it a treatment option? B. Topcular, A. Bingol, S. Yildiz, I. Guclu, D. Yandim Kuscu, A. Soysal, N. Sutlas, M. Tutuncu, O. Demirci, E. Kurt, P. Kaya, S. Saip, A. Altintas, A. Siva (Istanbul, TR) P371 Optic neuritis as first multiple sclerosis symptom and long-term cognitive performance M. Lopez-Gongora, L. Querol, A. Escartin (Barcelona, ES) P372 Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis F. Reuter, W. Zaaraoui, L. Crespy, A. Faivre, A. Rico, I. Malikova, E. Soulier, P. Viout, J. Ranjeva, J. Pelletier, B. Audoin (Marseille, FR) P373 Comparison of fatigue and functional status between multiple sclerosis and neuromyelitis optica H. Alvarenga-Filho, L.A.C. Nogueira, R.M Papais-Alvarenga, S. Seixas, K.N. Lopes, F.R. Nóbrega, L.C.S. Thuler, S.R.S. Carvalho, R.M Dias (Rio de Janeiro, BR) P374 Cognition, fatigue, depression and HR-QoL in early multiple sclerosis: results from CogniMS, a multinational longitudinal study D. Langdon, E.M. Wicklein, P. Scherer, S. Fredrikson (Egham, UK; Berlin, DE; Stockholm, SE) P375 Fatigue is associated with depression and cognitive complaints but not with cognitive performance in multiple sclerosis K. van der Hiele, N. Spliethoff-Kamminga, R. Ruimschotel, A. van der Zande, L. Visser (Maassluis, Rotterdam, Tilburg, NL) P376 Semantic memory in a cohort of 427 multiple sclerosis patients H. Brissart, E. Morele, C. Baumann, M. Debouverie (Nancy, FR) P377 Fatigue in multiple sclerosis: due to compensatory effort or learned helplessness? An experimental neuropsychological study H. Hildebrandt (Bremen, DE)

76 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Neuropsychology and fatigue 1 (continued) P378 Attention and speed of cognitive processing in multiple sclerosis: effect of task complexity and sensory modality G. Lubrini, C. Oreja-Guevara, J.A. Periañez, M. Ríos Lago, R. Viejo Sobera, J. Alvarez Linera, E. Díez Tejedor (Madrid, ES) P379 Fatigue in multiple sclerosis: a premenstrual syndrome? Y. Guven Yorgun, S. Ozakbas, E. Idiman (Izmir, TR) P380 Quality of life and cognition in early multiple sclerosis D. Hamel, A. Ruet, M. Deloire, J. Ouallet, B. Brochet (Bordeaux, FR) P381 Efficacy of a Cognitive Rehabilitation Programme: “EM-line! Project” L.L. Ramió i Torrentà, J. Gich, R. Menéndez, J. Freixanet, R. García, J.C. Vilanova, D. Genís (Girona, ES) P382 Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis E. Pietrolongo, D. Travaglini, M. di Ioia, V. Di Tommaso, D. Farina, A. Lugaresi, G. De Luca (Chieti, IT) P383 Evaluating deficits in processing speed in patients with multiple sclerosis with reaction time and rapid serial processing tests A. Hughes, D. Denney, S. Lynch (Lawrence, Kansas City, US) P384 Deficit in emotional facial expression recognition in multiple sclerosis and interhemispheric transfer B. Lenne, J.-L. Nandrino, H. Sequeira, D. Leuse, P. Hautecoeur (Lomme, Villeneuve D’Ascq, Lille, FR) P385 Cognitive performance at baseline predicts changes in cognition and cognitive fatigue after a one-year follow-up P. Calabrese, Y. Naegelin, L. Kappos, I.K. Penner (Basel, CH) P386 The relationship between patients/care givers’ report of cognitive dysfunction in multiple sclerosis versus acute onset illness L. Pierfederici, L. Catena, L. Bacci, A. Morgantini (Ancona, IT) P387 Fatigue in multiple sclerosis: relationship of different MR Posters markers L. Achtnichts, I.-K. Penner, M. Amann, J. Hirsch, W.E. Wu, D. Rigotti, J. S. Babb, L. Kappos, O. Gonen, A. Gass (Basel, CH; New York, US) P388 Computer-based assessment of memory and attention in patients with multiple sclerosis G. Adler, M. Feger, M. Christenn (Mannheim, DE) P389 Predictors of severe fatigue in multiple sclerosis patients D. Ferraro, A.M. Simone, P.F. Nichelli, P. Sola (Modena, IT)

77 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Neuropsychology and fatigue 1 (continued) P390 Cognitive dysfunction in radiologically isolated syndrome C. Lebrun, F. Blanc, D. Brassat, H. Zephir, J. de Seze on behalf of the Club Francophone de la Sclerose En Plaques P391 Depression and post-traumatic stress disorder in multiple sclerosis K. Ziegler, C. Heesen , K.-H. Schulz (Hamburg Eppendorf, DE) P392 Neuropsychological disorders and health-related quality of life in patients with multiple sclerosis G. Gudzenko, L. Sokolova (Kiev, UA) P393 The study of circadian rhythm disorders and their relationship with chronic fatigue in multiple sclerosis and comparison with control group M. Najafi, S. Haghighi, M. Etemadifar, M. Reisifar, M. Akbari, A. Maghzi (Isfahan, IR)

Immunomodulation 1 P394 Assessment of disease activity within 6 months after natalizumab discontinuation: an observational study of 28 consecutive relapsing–remitting multiple sclerosis patients A. Kerbrat Lecuyer, E. Le Page, E. Leray, T. Anani, M. Coustans, C. Desormeaux, C. Guiziou, P. Kassiotis, F. Lallement, D. Laplaud, F. Rouhart, E. Sartori, G. Edan (Rennes, Pontivy, Quimper, La Roche s/ Yon, Lannion, Vannes, Saint Brieuc, Nantes, Brest, Lorient, FR) P395 Significant immune cell responses in blood and cerebrospinal fluid from patients with acute optic neuritis and the efficacy of simvastatin treatment A. Tsakiri, E. Kjaersgaard, J. Frederiksen, N. Grigoriadis, I.M Svane (Glostrup, Herlev, DK; Thessaloniki, GR) P396 Inflammatory mediator expression-pattern in simvastatin- treated optic neuritis A. Tsakiri, S. Ravanidis, K. Poulatsidou, R. Lagoudaki, I.M Svane, J. Frederiksen, N. Grigoriadis (Glostrup, Herlev, DK; Thessaloniki, GR) P397 Paradoxical activation of multiple sclerosis after induction of neutralising antibodies against natalizumab A. Svenningsson, H. Lassmann, L. Airas (Umeå, SE; Vienna, AT; Turku, FI) P398 Neurological symptoms under TNF alfa blocking treatment: report on 39 cases H. Roshanisefat, L. Hopia, M. Khademi, E. Svenungsson, M. Andersson (Stockholm, SE)

78 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P399 Effects of natalizumab treatment on Foxp3+T regulatory cells and cytokine serum levels C. Oreja-Guevara, J. Ramos-Cejudo, L. Stark, L. Gabaldón, M.L. Martin-Barriga, E. Diez-Tejedor (Madrid, ES) P400 A short duration double-blind randomised controlled trial of low dose versus high-dose vitamin D in patients presenting with clinically isolated syndrome J. Zajicek, M. Hutchinson, D. Wright, M. Boggild, C. Hawkins, D. Miller (Plymouth, Liverpool, Newcastle-under-Lyme, London, UK; Dublin, IE) P401 Short- and long-term decrease of soluble adhesion molecules (sICAM-1, -2, -3 and sVCAM-1) during natalizumab treatment K. Oppermann, G. Pilz, P. Wipfler, A. Harrer, S. Afazel, E. Haschke-Becher, G. Ladurner, J. Kraus (Salzburg, AT) P402 The S1P1/5 modulator, BAF312 prevents cell-mediated and humoral immune response to antigens in mice, but does not affect pre-existing antibodies to a vaccine in non-human primates B. Nuesslein-Hildesheim, C. Burkhart, F. Cordoba (Basel, CH) P403 Consistent MRI benefits with short-course cladribine tablets therapy across the range of patients with relapsing–remitting multiple sclerosis in the double-blind, placebo-controlled, 96-week CLARITY study G. Comi, S. Cook, G. Giovannoni, K. Rammohan, P. Rieckmann, P. Soelberg Sørensen, P. Vermersch, P. Chang, B. Musch, T. Fevr, S. Greenberg (Milan, IT; Newark, Columbus, US; London, UK; Bamberg, DE; Copenhagen, DK; Lille, FR; Geneva, CH) P404 Analysis of EDSS measurements from the CAMMS223 Trial: application of a Markov transition model for repeated ordinal data S. Lake, J. Palmer, M. Mandel (Cambridge, Framingham, US; Mount Scopus, IL) P405 The contributions of two presidents of Israel to the

development of copaxone Posters K. Johnson, P. Loupe (Baltimore, Kansas City, US) P406 Differential effects of fingolimod (FTY720) therapy on immune cells in the cerebrospinal fluid and blood of multiple sclerosis patients M.C. Kowarik, H. Pellkofer, S. Cepok, T. Korn, T. Kümpfel, D. Buck, R. Hohlfeld, A. Berthele, B. Hemmer (Munich, DE)

79 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P407 An open-label, prospective, multicentre study to evaluate the safety and tolerability of glatiramer acetate 20 mg sc once daily in patients with relapsing—remitting multiple sclerosis who have discontinued natalizumab after a 12-18 months therapy S. Rossi, G. Ristori, V. Studer, A. Fornasiero, C. Motta, V. De Chiara, S. Fiore, M. Salvetti, D. Centonze (Rome, IT) P408 Evaluation of treatment strategies for breakthrough disease in patients with multiple sclerosis: the SURPASS study R. Rudick, P. Coyle, O. Garcea, H.-P. Hartung, D.H. Miller, P.W. O’Connor, P. Vermersch, F. Lynn, S. Jurgensen, E. Aycardi (Cleveland, Stony Brook, Cambridge, US; Buenos Aires, AR; Düsseldorf, DE; London, UK; Toronto, CA; Lille, FR) P409 Differential expression of Fas death receptor in multiple sclerosis patients depending on response to IFN beta therapy M.J. Pinto-Medel, O. Fernandez, B. Oliver, J. Garcia-Leon, L. Flores, M. Suardiaz, T. Orpez, C. Lopez-Gomez, L. Leyva (Malaga, ES) P410 Alemtuzumab long-term safety and efficacy: five years of the CAMMS223 Trial A. Coles on behalf of the CAMMS223 Study Group P411 Clinical application of the luciferase anti-interferon beta antibody assay: correlation with induction of peripheral biomarkers R. Farrell, M. Espasandin, N. Lakdawala, P. Creeke, C. Marshall, V. Worthington, G. Giovannoni (London, UK) P412 Effects of fingolimod on antibody response following steady-state dosing in healthy volunteers: a 4-week, randomised, placebo-controlled study R. Schmouder, C. Boulton, N. Wang, O. J. David (Cambridge, US; Horsham, UK; Basel, CH) P413 Evolution of T1 hypointense lesions in relapsing–remitting multiple sclerosis patients treated with glatiramer acetate. A magnetisation transfer imaging study R. Zivadinov, S. Hussein, N. Bergsland, M. Dwyer (Buffalo, US) P414 Autologous haematopoietic stem cell transplantations for patients with progressive multiple sclerosis M. Tauqeer Ahmad, S. Loh, Y. Lin, W. Hwang, P. Ratnagopal (Singapore, SG) P415 Impact of binding and neutralising antibodies on the clinical and radiologic efficacy of interferon beta treatment in patients with multiple sclerosis D. Kaya, E. Idiman, S. Özakbas, S. Tufan, E. Ada, H. Bahar (Izmir, TR)

80 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P416 Clinical predictors of optimal response to natalizumab in multiple sclerosis S. Batista, J. Sargento Freitas, F. Silva, C. Macário, F. Matias, L. Sousa (Coimbra, PT) P417 Baseline plasma anti-MBP antibody levels correlate with subject response to BHT-3009, a novel, antigen-specific tolerising DNA vaccine therapy for MS patients H. Garren, W. Robinson, A. Rahman, R. King, P.J. Utz, L. Steinman (Palo Alto, Stanford, US) P418 Association between MRI changes and disability progression in a pivotal study of natalizumab in patients with multiple sclerosis D. Jeffery, X. You, C. Cha (Washington, Cambridge, US) P419 Short- and long-term differential transcriptome changes during interferon beta-1a multiple sclerosis therapy M. Hecker, R.H. Goertsches, D. Koczan, C. Winkler, H. Thiesen, U.K. Zettl (Rostock, DE) P420 Natalizumab discontinuation after long-term administration: our own experience E. Giannouli, S. Marousi, I. Karkanis, A. Graigos, V. Kotsi, K. Karageorgiou (Holargos, GR) P421 Case report of anti-glomerular basement membrane disease following alemtuzumab treatment D. Meyer, A. Coles on behalf of the CAMMS223 Study Group P422 Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing- remitting multiple sclerosis receiving IFN beta-1a, 22 or 44 mcg sc tiw, in the COGnitive Impairment in MUltiple Sclerosis study S. Bastianello, E. Giugni, M.P. Amato, M.R. Tola, M. Trojano, S. Galletti, M. Quarantelli, F. Patti on behalf of the COGIMUS study group P423 Natalizumab is effective in relapsing–remitting multiple sclerosis patients who do not respond to sequential Posters therapy with interferon beta and glatiramer acetate. Result of a switching study C. Caon, A. Memon, J. Perumal, A. Boster, A. Tselis, F. Bao, O. Khan (Detroit, US) P424 Impact of alemtuzumab treatment on the survival and function of human Tregs in vitro E. Havari, J. Sancho, J. Campos-Rivera, J. Kaplan, B. Roberts, T.H. Nguyen, S. Shankara (Framingham, US)

81 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P425 Differential sensitivity of human PBMC subsets to alemtuzumab-mediated cytotoxicity S.P. Rao, J. Campos-Rivera, J. Sancho, P. Boutin, P. Severy, J. Kaplan, B. Roberts, S. Shankara (Framingham, US) P426 Disability progression-free efficacy of alemtuzumab in relapsing–remitting multiple sclerosis patients in the CAMMS223 Trial D. Wynn on behalf of the CAMMS223 Study Group P427 Analysis of immune competence following alemtuzumab treatment in huCD52 transgenic mice M.J. Turner, N. Chretien, M. LaMorte, B. Roberts, J. Kaplan, W. Siders (Framingham, US) P428 Alemtuzumab’s efficacy in the CAMMS223 Trial as assessed with the multiple sclerosis severity score J. Herbert, D. Wynn on behalf of the CAMMS223 Study Group P429 Efficacy of alemtuzumab in highly active relapsing–remitting multiple sclerosis patients in the CAMMS223 Trial D. Wingerchuk on behalf of the CAMMS223 Study Group P430 Interferon beta-1a treatment in patients with relapsing– remitting multiple sclerosis elevates immunomodulatory marker soluble HLA-I but has no effect on the axonal marker, neurofilament, or disability S. Gnanapavan, G. Giovannoni, A. Minagar, S. Jaffe (London, UK; Shreveport, US) P431 Long-term brain MRI and clinical assessments of teriflunomide for the treatment of multiple sclerosis: extension of a phase II study D.K. Li, P.W. O’Connor, C. Confavreux, W.J. Byrnes, S. Wang, A.L. Traboulsee for the Teriflunomide Multiple Sclerosis Trial Group P432 Effect of natalizumab on ambulatory improvement in relapsing–remitting and secondary progressive multiple sclerosis D. Cadavid, S. Lee, N. Lucas, A. Natarajan, B. Ticho, S. Jurgensen (Cambridge, US) P433 Starting immunomodulants shortly after natalizumab discontinuation: initial impressions F. Sangalli, L. Moiola, M. Radaelli, V. Barcella, V. Martinelli, G. Comi (Milan, IT) P434 Clinical outcomes in subgroups of patients treated with fingolimod (FTY720) or placebo: 24-month results from FREEDOMS P. von Rosenstiel, R. Hohlfeld, P. Calabresi, P. O’Connor, C.H. Polman, E.W. Radü, L. Zhang-Auberson, C. Agoropoulou, D.A. Häring, L. Kappos on behalf of the FREEDOMS STUDY GROUP

82 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P435 Can inter-individual differences in the immunomodulatory capacity of IVIG ex vivo predict clinical efficacy in multiple sclerosis? C. Jacobi, T. Berger, M. Reindl, M. Claus, J. Römisch, B. Taumberger, S. Haag, B. Wildemann, C. Watzl, S. Meuer, T. Giese (Frankfurt, Heidelberg, DE; Innsbruck, Vienna, AT; Lachen, CH) P436 Small molecule dual antagonists of Pim 1 and 3 kinases ameliorate experimental autoimmune encephalomyelitis T.G. Davis, L. Jackson, S. Marusic, J. Robinson, L. Carter, A.D. Wright (Boulder, Lawrence, US) P437 Safety and efficacy of natalizumab in a cohort of 34 paediatric MS patients A. Ghezzi, C. Pozzilli, L. Grimaldi, L. Moiola, V. Brescia Morra, F. Bortolon, R. Capra, G. Coniglio, M. Filippi, N. Milani, L. Provinciali, E. Pucci, F. Rinaldi, A. Rizzo, M.A. Rocca, M. Rottoli, P. Sarchielli, M. Zaffaroni, G. Comi (Gallarate, Rome, Cefalù, Milan, Naples, Vicenza, Brescia, Matera, Ancona, Macerata, Padua, Bergamo, Perugia, Milan-Gallarate, IT) P438 Overlapping molecular mechanisms of protection during pregnancy and disease-modifying therapies in patients with multiple sclerosis A. Bertolotto, N.D. Navone, S. Malucchi, P. Valentino, S. Perga, A. Pulizzi, F. Marnetto, M. Caldano, F. Gilli (Orbassano, IT) P439 Clinical and radiological disease reactivation after cessation of long-term therapy with natalizumab A. Baumgartner, O. Stich, S. Rauer (Freiburg, DE) P440 Interferon-beta induces immunoglobulin-like transcript 3 and 4 expression in monocytes – implications for multiple sclerosis A. Waschbisch, D. Theil, M. Mäurer, S. Schwab, T. Derfuß (Erlangen, Munich, DE) P441 Consistent efficacy of short-course cladribine tablets therapy across differing prognostic indicators for relapsing– remitting multiple sclerosis: results from the phase III,

double-blind, placebo-controlled, 96-week CLARITY study Posters K. Rammohan, G. Comi, S. Cook, G. Giovannoni, P. Rieckmann, P. Soelberg Sørensen, P. Vermersch, P. Chang, B. Musch , V. Viglietta, S. Greenberg (Columbus, Newark, US; Milan, IT; London, UK; Bamberg, DE; Copenhagen, DK; Lille, FR; Geneva, CH) P442 Lymphocytes and fingolimod – temporal pattern and relationship with infections G. Francis, L. Kappos, P. O’Connor, W. Collins, L. Zhang-Auberson, A. de Vera, D. Tang, M. Looby, F. Mercier, J. Cohen (East Hanover, Cambridge, Cleveland, US; Basel, CH; Toronto, CA)

83 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P443 Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists I. Kleiter, F. Nguyen, N. Schäffler, J. Kasper, S. Köpke, W. Gaissmaier, C. Heesen (Regensburg, Hamburg, Berlin, DE) P444 Effect of interferon beta on the expression of cannabinoid receptor 2 in peripheral blood lymphoid cells from multiple sclerosis patients L. Roman-Vega, A.J. Sanchez, P.E. Bermejo, E. Ramil, M.R. Blasco, O. Rodriguez, J.A. Garcia-Merino (Madrid, ES) P445 Effects of fingolimod on platelet function following steady- state dosing in healthy volunteers: a 4-week, randomised, placebo-controlled study P. Burtin, M. Ocwieja, O. J. David, T. Dumortier, R. Schmouder (Basel, CH; Cambridge, US) P446 Natural killer-cell cycle and phenotype in multiple sclerosis: effects of interferon beta and combined interferon beta and oral steroid treatments L. Sanvito, B. Gran, A. Tomita, N. Chihara, T. Yamamura, T. Aranami (Nottingham, UK; Kodaira, Tokyo, JP) P447 The effect of cladribine tablets on disease progression in multiple sclerosis: a non-linear mixed effect analysis R.M. Savic, A. Munafo, M.O. Karlsson (Uppsala, SE; Geneva, CH) P448 Levels of cell surface bound interferon-receptor remain stable during short- and long-term interferon beta-1b treatment K. Oppermann, P. Wipfler, G. Pilz, A. Harrer, E. Duerr, W. Koczi, S. Afazel, E. Haschke-Becher, G. Ladurner, J. Kraus (Salzburg, AT) P449 Expression profiling of blood mononuclear cells from interferon beta treated multiple sclerosis patients identifies differentially expressed micro RNAs H.B. Søndergaard, D. Hesse, M. Krakauer, P.S. Sørensen, F. Sellebjerg (Copenhagen, DK) P450 Response to IFN-beta treatment in MS and EAE is associated with induction of IL-27 C.M. Sweeney, R. Lonergan, K. Kinsella, L. Costelloe, C. O’Farrelly, N. Tubridy, J.M. Fletcher, K.H.G. Mills (Dublin, IE) P451 Aspects of early versus late treatment of first-line drugs in multiple sclerosis in clinical practice F. Verheul, F. Verheul, C.P. Zwanikken, L.J.M.A. van Hooff, R.M.M. Hupperts (Utrecht, Gouda, Nijmegen, Roosendaal, Sittard, NL)

84 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P452 Pharmacological characterisation of LAS189913, a novel S1P1 receptor agonist G. Tarrason, T. Domènech, C. Armengol, J. Cabedo, R. López, E. Jiménez, M. Aulí, A. Domènech, M. Viñals, A. Gavaldà, M. Domínguez, N. Prats, N. Aguilar, N. Godessart (Barcelona, ES) P453 Prediction of pharmacokinetic/pharmacodynamic behaviour in humans of LAS189913, a S1P1 receptor agonist, based on preclinical studies in three animal species M. Dominguez, D. Casals, M. Sabaté, T. Molina, V. Pes, E. Jiménez, N. Godessart, G. Tarrasón, N. Aguilar (Barcelona, ES) P454 Alemtuzumab for relapsing–remitting multiple sclerosis: CARE-MS I baseline demographics and disease characteristics E. Havrdova, A. Coles, J. Cohen, C. Confavreaux, E. Fox, H.-P. Hartung, K. Selmaj, H. Weiner, S. Lake, S. Moran, D. Margolin, A. Compston on behalf of the CARE-MS Investigators P455 Lymphocyte subpopulation in patients with relapsing– remitting multiple sclerosis as a marker for responders and nonresponders for interferon beta treatment E. Belniak, A. Bojarska-Junak, H. Bartosik-Psujek, K. Mitosek- Szewczyk, Z. Stelmasiak, J. Rolinski (Lublin, PL) P456 Haematopoietic stem cell transplant in patients with neuromyelitis optica J. Burton, P. Duggan, F. Costello, J. Storek, R. Bell, M. Yeung, M. Eliasziw, L. Metz (Calgary, CA) P457 Switching and discontinuation of first-line drugs in multiple sclerosis in the Netherlands J.A.F. Koekkoek, F. Verheul, C.P. Zwanikken, L.J.M.A. van Hooff, R.M.M. Hupperts (Gouda, Nijmegen, Roosendaal, Sittard, NL) P458 The BETAPAEDIC Study: assessment of safety, tolerability, clinical effectiveness and cognition in juvenile relapsing– remitting MS patients treated with interferon beta-1b J. Gärtner, W. Brück, A. Weddige, J.-P. Bugge on behalf of the BETAPAEDIC Study Group Posters P459 Pregnancy and natalizumab: effects of natalizumab therapy on pregnancy outcome and relapse rate K. Hellwig, A. Haghikia, A. Bayas, R. Gold (Bochum, Augsburg, DE) P460 Stopping natalizumab therapy: experience of follow-up in a MS Centre, Fidenza, Italy I. Pesci, S. Magnani, D. Carini, L. Manneschi, A. Guareschi, E. Montanari (Fidenza- Parma, IT)

85 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunomodulation 1 (continued) P461 Neutralising antibodies against natalizumab in MS patients are IgG4 and do not correlate with antibodies against interferon beta A. Haghikia, S. Muth, N. Sultansei, S. Ruhrmann, S. Cepok, K. Hellwig, A. Chan, B. Hemmer, R. Gold (Bochum, Munich, DE) P462 Relationship between binding and neutralising antibodies in patients taking high-dose interferon MS therapy E. Fox, A. Goodman, C. Markowitz, R. Murray, B. Green (Round Rock, Rochester, Philadelphia, Lone Tree and Centennial, St. Louis, US) P463 Cognitive function in relapsing–remitting multiple sclerosis patients during two years of intramuscular interferon beta-1a treatment P. Jongen, C.J Edgar, K.A Wesnes, H. Brooker (Nijmegen, NL; Goring-on-Thames, UK) P464 Natalizumab and cognitive impairment in multiple sclerosis: benefits from treatment G. Pavan, S. La Gioia, M.R. Rottoli (Milan, Bergamo, IT) P465 Severe haematological complications during treatment with natalizumab L. Midaglia, D. Muñoz, M. Rodriguez, M. Guerra, M.A. Miguelez, J. Louzao (Vigo, Pontevedra, ES) P466 Effect of natalizumab on clinical and radiological disease activity in a French cohort of relapsing–remitting multiple sclerosis patients A. Melin, O. Outteryck, J.C. Ongagna, M.C. Fleury, H. Zéphir, A. Lacour, A.S. Berteloot, F. Blanc, P. Vermersch, J. de Sèze (Lille, Strasbourg, FR)

Immunosuppression 1 P467 Allogeneic haematopoietic stem cell transplantation in a patient with recurrent transverse myelitis R. Greco, F. Ciceri, L. Moiola, M. Radaelli, P. Vezzulli, M.T. Lupo Stanghellini, C. Corti, M. Bernardi, J. Peccatori, G. Comi (Milan, IT) P468 The efficacy of low-dose prednisolone in neuromyelitis optica Y. Takai, I. Nakashima, T. Misu, T. Takahashi, K. Fujihara (Sendai, JP) P469 Ongoing and future efforts on autologous haematopoietic stem cell transplantation in multiple sclerosis R. Martin, M. Freedman, G. Mancardi, M.P. Sormani, M. Pasquini, D. Farge-Bancel, R. Saccardi and the European- and North American Discussants of a Phase III Trial of AHSCT in MS

86 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Immunosuppression 1 (continued) P470 Azathioprine for the treatment of neuromyelitis optica spectrum disorders – old but still effective? C.R. Lin, K. Tan (Singapore, SG) P471 Safety and tolerability of high-dose cyclophosphamide followed by glatiramer acetate maintenance in aggressive relapsing–remitting multiple sclerosis: a retrospective case review D. Harrison, D. Gladstone, E. Hammond, C. Trecker, H. Wong, R. Jones, R. Brodsky, D. Kerr, J. McArthur, A. Kaplin (Baltimore, US)

Neuroprotection 1 P472 Glatiramer acetate-reactive T-lymphocytes regulate oligodendrocyte progenitor cell number in vitro: role of IGF-2 Y. Zhang, F. Jalili, N. Ouamara, A. Zameer, G. Cosentino, M. Mayne, L. Hayardeny, J. Antel, A. Bar-Or, G. John (New York, US; Montreal, Winnipeg, CA; Netanya, IL) P473 Serum levels of BDNF correlate with the number of MRI T2/FLAIR lesions in multiple sclerosis E.R.C. Frota, D.H. Rodrigues, E.C. Miranda, D.G. Brum, D.R. Kaimen-Maciel, E.A. Donadi, A.L. Teixeira (Belo Horizonte, BR) P474 Immune cell NT-3 expression is associated with brain- parenchymal fraction in relapsing–remitting multiple sclerosis patients A. Kalinowska-Lyszczarz, M.A. Pawlak, S. Michalak, W. Paprzycki, J. Losy (Poznan, PL) P475 Development of anti-SEMA4D monoclonal antibody for the treatment of multiple sclerosis E. Smith, T. Fisher, C. Reilly, J. Li, L. Winter, A. Jonason, J. Seils, R. Kirk, C. Cornelius, T. Richards, J. Caplan, P. Kenney, L. Croy, J. Veeraraghavan, T. Pandina, S. Torno, E. Evans, M. Paris, J. Leonard, R. Watkins, M. Zauderer (Rochester, US)

P476 T1-hypointense permanent black holes in relapsing- Posters remitting multiple sclerosis patients treated with interferon beta-1b and glatiramer acetate M. Filippi, M.A. Rocca, F. Camesasca, S. Cook, G. Comi, D.S. Goodin, P. O’Connor, D. Jeffery, H.-P. Hartung, B. Arnason, L. Kappos, C. Pohl, K. Beckmann, R. Sandbrink, T. Bogumil, D. Arnold, G. Cutter, J. Wolinsky, V. Knappertz (Milan, IT; New Jersey, San Francisco, Winston-Salem, Chicago, Montville, Birmingham, Houston, US; Ontario, Quebec, CA; Düsseldorf, Berlin, DE; Basel, CH)

87 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Neuroprotection 1 (continued) P477 PPAR-alpha agonists protect cortical neurons from inflammatory mediators via improvement in peroxisomal function E. Gray, M. Ginty, K.C Kemp, N.J Scolding, A. Wilkins (Bristol, UK) P478 Oral BG-12 in combination with interferon beta-1a or glatiramer acetate: pharmacokinetics, safety and tolerability J. Woodworth, J. Zhao, S. Stecher, L. Yang, K. Dawson (Cambridge, US) P479 Laquinimod elevates brain-derived neurotrophic factor levels in the prefrontal cortex and hippocampus- possible mechanism by which laquinimod exerts its effect in MS and depression L. Hayardeny, I. Gil-Ad, R. Uzan Guata , I. Tarasenko, M. Taller, A. Weizman (Netanya, Petach-Tikva, IL)

Long-term treatment monitoring 1 P480 Incidence rate of acute myeloid leukaemia and related mortality in Italian MS patients treated with mitoxantrone V. Martinelli, R. Bergamaschi, P. Bellantonio, A. Bertolotto, R. Capra, E. Cocco, P. Gallo, C. Gasperini, A. Ghezzi, M. Trojano, A. Lugaresi, G. Mancardi, C. Pozzilli, M. Rodegher, G. Savettieri, M. Ponzio, L. Straffi, G. Comi (Milan, Pavia, Pozzilli, Orbassano, Brescia, Cagliari, Padua, Rome, Gallarate, Bari, Chieti, Genoa, Palermo, IT) P481 Prolonged suppression of CD3+CD4+ T-cells predicts long-term relapse freedom after alemtuzumab treatment for MS M. Cossburn, G. Ingram, K. Baker, T. Pickersgill, N.P. Robertson (Cardiff, UK) P482 Postmarketing utilisation and safety of intramuscular interferon beta-1a P. Foulds, S. Richman, S. Friend, R. Hyde (Cambridge, US) P483 Updated efficacy and safety of natalizumab in patients who participated in the STRATA study P.W. O’Connor, A.D. Goodman, L. Kappos, F.D. Lublin, C.H. Polman, R.A. Rudick, S. Jurgensen, D. Paes, F. Forrestal, C. Hotermans (Toronto, CA; Rochester, New York, Cleveland, Cambridge, US; Basel, CH; Amsterdam, NL) P484 Rate of treatment-related side effects depend on time of follow-up and are not linearly related to cumulative dosage of mitoxantrone K. Gross-Paju, I. Zopp, U. Sorro, K. Kannel, T. Saarup, L. Vahter (Tallinn, EE)

88 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Long-term treatment monitoring 1 (continued) P485 Long-term adherence to interferon-beta treatment in a cohort of relapsing–remitting multiple sclerosis patients in Belgrade, Serbia S. Mesaros, N. Stojsavljevic, I. Dujmovic-Basuroski, T. Pekmezovic, J. Drulovic (Belgrade, RS) P486 Long-term safety and efficacy of mitoxantrone in MS J. Haas, M. Chatzopoulos (Berlin, DE) P487 The SAFETY surveillance programme: safety analysis of patients on long-term therapy with natalizumab (Tysabri®) B.C. Kieseier, M. Maeurer, G. Niemczyk, H. Wiendl (Düsseldorf, Bad Mergentheim, Ismaning, Münster, DE) P488 Identifying risk factors for poor adherence and for improving outcomes in patients with multiple sclerosis who self-inject: interim results of a longitudinal observational study D. Rog, E. Nabi, T. Felton, L.G Ashby, G.L Shepherd (Salford, Harlow, Edgbaston, Feltham, UK) P489 Adherence to long-term treatment in MS: role of depression, anxiety and other psychological factors T. Sidorenko, A. Boyko, E. Gusev (Moscow, RU) P490 Clinical response to interferon beta in relapsing–remitting multiple sclerosis patients S. Alves-Leon, A. Liem, F. Malfetano, I. D’Andrea, S. Batista, V. Pereira (Rio de Janeiro, BR) P491 The Immunomodulation and Multiple Sclerosis Epidemiology (IMSE) study: a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri®) C. Holmén, F. Piehl, J. Hillert, M. Lundkvist, P. Nilsson, C. Dahle, N. Feltelius, A. Svenningsson, J. Lycke, T. Olsson (Stockholm, Lund, Linköping, Umeå, Gothenburg, SE) P492 Measures of treatment adherence as prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis A Traboulsee, B.M.J. Uitdehaag, L. Kappos, M. Sandberg-Wollheim, D. Li, P. Jongen, C. Constantinescu, E. Verdun, P. Cornelisse

(Vancouver, CA; Amsterdam, Nijmegen, NL; Basel, Geneva, CH; Posters Lund, SE; Nottingham, UK) P493 The Tysabri-12-Monitor survey: practices of care in routine therapy of MS with natalizumab R. Gold, G. Niemczyk, H.-P. Hartung (Bochum, Ismaning, Düsseldorf, DE) P494 Natalizumab (Tysabri®) Observational Program: associations of baseline disease activity and treatment history with post-baseline relapses in multiple sclerosis patients treated with natalizumab S. Belachew, H. Butzkueven, L. Kappos, F. Pellegrini, M. Trojano, H. Wiendl, A. Zhang, D. Desgrandchamps (Liège, BE; Victoria, AU; Basel, CH; Chieti, Bari, IT; Würzburg, DE; Cambridge, US) 89 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Long-term treatment monitoring 1 (continued) P495 Clinical experience with natalizumab in a multiple sclerosis centre in Puerto Rico A. Chinea (Guaynabo, PR) P496 Neutralising antibodies against IFN beta – an update from 2009 R. Jungedal, M. Lundkvist, E. Karlberg, J. Hillert, A. Fogdell-Hahn (Stockholm, SE)

Therapy disease-modifying – Others 1 P497 Analysing immunotherapy choices using the theory of planned behaviour J. Kasper, S. Köpke, C. Heesen (Hamburg, DE) P498 The relation between vitamin B12 and antiparietal cell antibody level in multiple sclerosis patients I. Midi, B. Chabou, K. Agan, D. Ince-Gunal (Istanbul, TR) P499 Evaluation of adherence and persistence with first-line MS therapies S. Agarwal, R. Halpern, L. Borton (Wellesley, Eden Prairie, US) P500 Optimising outcomes in multiple sclerosis: consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America A. Carrá, M. Macías-Islas, A. Gabbai, J. Correale, C. Bolaña, E. Duriez Sotelo, J. García-Bonito, F. Vergara- Edwards, D. Vizcarra-Escobar (Buenos Aires, AR; Guadalajara, MX; Sao Paulo, BR; Montevideo, UY; Monterrey, MX; Bogotá, CO; Santiago, CL; Lima, PE) P501 Analysis of cytokines, chemokines and neurotrophic factors in patients with multiple sclerosis treated with glatiramer acetate, interferon beta-1a and mitoxantrone A. Snoha, O. Neuhaus (Sigmaringen, DE) P502 Plasma exchange in paediatric patients with CNS inflammatory demyelinating disease S. Magana, J. Mandrekar, S. Weigand, K. Thomsen, L. Linbo, C. Lucchinetti, B.M. Keegan (Rochester, US) P503 Cycle-pregnant puerperal in a patient with multiple sclerosis in use of rituximab S. Vieira Alves Leon, F. Rachid Malfetano, I. D’Andrea Meira, V. Coelho Santa Rita Pereira, A. Martinez Liem, S. Batista, L. Fêzer (Rio de Janeiro, BR) P504 Lorenz curve analysis of Ontario neurologist multiple sclerosis first-line disease-modifying therapy prescribing patterns in 2009 J. Marriott, M. Mamdani, G. Saposnik, T. Gomes, P. O’Connor (Toronto, CA)

90 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Therapy disease-modifying – Others 1 (continued) P505 Clinical and neuroimaging predictors of responsiveness to immunomodulating therapies in a large single-center cohort of patients with RRMS G. Comi, M. Romeo, F. Martinelli Boneschi, V. Martinelli, M. Rodegher (Milan, IT) P506 A therapeutic education programme for patients with multiple sclerosis M.-H. Colpaert (Paris, FR) P507 Consultant neurologist or specialist nurse? The role of a specialist nurse-led MS clinic for patients on disease- modifying therapy H. Thompson, O. Gray (Armagh, UK) P508 Endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis. A longitudinal pilot study P. Zamboni, R. Galeotti, B. Weinstock-Guttman, G. Cutter, E. Menegatti, A.M. Malagoni, D. Hojnacki, M. Dwyer, N. Bergsland, M. Hiennen-Brown, A. Salter, C. Kennedy, I. Bartolomei, F. Salvi, R. Zamboni (Ferrara, Bologna, IT; Buffalo, Birmingham, US)

Treatment of specific symptoms 1 P509 Prolonged-release fampridine for multiple sclerosis: was the effect on walking ability clinically significant? J. Hobart (Plymouth, UK) P510 Efficacy of levetiracetam on multiple sclerosis cerebellar symptoms evaluated by kinematic analysis: a multicentre double-blind placebo cross-over study C.C. Solaro, M. Muller, F. Molinari, S. Minguzzi, R. Bergamaschi, C. Gasperini, F. Patti, D. Restivo, R. Stabile, P. Tanganelli (Genoa, Pavia, Rome, Catania, Venice, IT) P511 Comparing the effects of group and individual physiotherapy on fatigue and health-related quality of life in people with MS N. Hogan, M. Garrett, A. Larkin, J. Saunders, S. Coote (Limerick, Galway, IE) Posters P512 Aminopyridines for symptomatic treatment of ambulatory deficits in multiple sclerosis H.B. Jensen, M.H. Ravnborg, E Stenager (Vejle, Odense, Vejle, Sonderborg, Esbjerg, DK) P513 Physician-patient communication about sexual functioning L.M. Stepleman, L. Stutts, H. Hudson, M.-C. Rutter, M. Williams (Augusta, US) P514 Improving balance control using electrotactile biofeedback in MS patients: preliminary data M. Tiozzo, G. Santarello, C. Zanetti, M.R. Stabile, P. Tonin (Venice, IT)

91 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Treatment of specific symptoms 1 (continued) P515 Evaluation of orally administered prolonged-release fampridine tablets for walking improvement in patients with multiple sclerosis treated with disease-modifying therapies R. Schapiro, T. Brown, A. Goodman on behalf of the MS-F202, MS-F203, and MS-F204 Study Groups P516 Bowel biofeedback treatment in patients with multiple sclerosis: psychological and disability factors, not physiological variables, predict success G. Preziosi, J. Panicker, C. Dalton, C.J. Fowler, A.V. Emmanuel (London, UK) P517 Percutaneous posterior tibial nerve stimulation: an effective treatment of lower urinary tract symptoms in patients with multiple sclerosis C. Zecca, A. Digesu’, C. Gobbi (Lugano, CH) P518 Analysis of open-label extension studies of prolonged release fampridine tablets in multiple sclerosis A. Goodman, T. Brown, K. Edwards, R. Schapiro on behalf of the MS-F203, MS-F204, MS-F203EXT, and MS-F204EXT Study Groups P519 Anti-Uhthoff effect of hypothermia on multiple sclerosis patients previously affected by optic neuritis: clinical results T. Poyraz, S. Özakbas, E. Coskuner Poyraz, L. Iyilikçi, A. Günerli, E. Idiman (Izmir, TR)

Comprehensive care & rehabilitation P520 Comparison of functional electric stimulation neuroprosthesis and ankle foot orthosis in persons with multiple sclerosis S. Khurana, T. Ference, A. Beranger (Miami, US) P521 Predicting accidental falls in MS people: role of stabilometry and magnetic resonance imaging L. Prosperini, A. Kouleridou, N. Petsas, P. Totaro, M.L. Mannocchi, P. Pantano, C. Pozzilli (Rome, IT) P522 Csp-Ms-42 – a new tool for comprehensive symptom assessment in patients with multiple sclerosis A. Novik, A. Kuznetsov, T. Ionova, S. Kalyadina, D. Fedorenko, N. Mochkin, K. Kurbatova, G. Gorodokin (Moscow, St. Petersburg, RU; New Jersey, US) P523 Use and perceived need of physiotherapy and occupational therapy in people with MS S. Johansson, C. Ytterberg, L. Widén Holmqvist, L. von Koch (Stockholm, SE) P524 Assessment of rehabilitation effects in multiple sclerosis M.R. Haupts (Isselburg-Anholt, DE)

92 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Comprehensive care & rehabilitation (continued) P525 Effectiveness of urinary rehabilitation in MS patients M.L. Lopes de Carvalho, R. Motta, M. Causa, G. Brichetto, M.A. Battaglia (Genoa, IT) P526 French national survey of mobility in multiple sclerosis: evaluation of prescription and use of manual wheelchair M.A. Guyot, C. Donze, H. Empis, B. Lenne, P. Hautecoeur (Lomme, FR) P527 Core stability training in people with multiple sclerosis: a multicentre series of single case studies J. Freeman on behalf of the United KingdomTherapists in MS (TiMS) Research Group P528 Self-management programmes for multiple sclerosis: promising results from two pilot studies E. Shevil, E. Peterson, M. Finlayson (Tel Aviv, IL; Chicago, US) P529 Beneficial effects of an exercise wellness programme on functional and quality of life outcomes in patients with multiple sclerosis: an interim analysis A. Mayadev, J. Jesurum, K. Kobata, C. Frederiksen, E. Tomas, T. Hayward, L. Jung (Seattle, US) P530 The effect of 8-week aerobic and resistance training programme on patients with multiple sclerosis M. Aghaie, E. Alijani, N. Majdi-Nassab, Sh. Goharpey, A.H. Abedi- Yekta, M. Babadi (Bebahan, Tehran, Ahvaz, IR) P531 Effects of 3-week whole-body vibration training on muscle strength and functional mobility in hospitalised persons with multiple sclerosis: a pilot study M. Claerbout, B. Gebara, S. Ilsbroukx, S. Verschueren, K. Peers, P. Feys (Dendermonde, Melsbroek, Leuven, Hasselt, BE) P532 Physiotherapist-led exercise, yoga and fitness instructor-led exercise significantly improve the physical impact of MS M. Garrett, N. Hogan, A. Larkin, J. Saunders, S. Coote (Limerick, IE)

Quality of life 1 Posters P533 Variables associated with patient activation in persons with multiple sclerosis M.-C. Rutter, L.M. Stepleman, J. Hibbard, L. Johns, D. Wright, M. Hughes, M. Williams (Augusta, Portland, Greenville, US) P534 Quality of life in multiple sclerosis: social support, depression, personality and coping style M. Pattini, F. Cenci, B. Allegri, I. Pesci, L. Manneschi, A. Guareschi, E. Marta, E. Montanari (Fidenza, Milan, IT)

93 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Quality of life 1 (continued) P535 Coping measurement in multiple sclerosis: a new simple and specific proposal R. Devy, M. Jolibois, N. Caizergues, P. Lehert, M. Genty, G. Edan (Saumur, Le Havre, Rennes, FR; Louvain, BE; Glion Sur Montreux, CH) P536 Towards a short and specific quality-of-life instrument in multiple sclerosis R. Devy, M. Jolibois, N. Caizergues, P. Lehert, M. Gentry, G. Edan (Saumur, Le Havre, FR; Louvain, BE; Glion sur Montreux, CH; Rennes, FR) P537 Impact of a pragmatic exercise intervention on quality of life and physical activity in people with mild to moderate multiple sclerosis: a feasibility study A. McConnell, A. Daley, S. Green, J. Saxton, N. Woodroofe, B. Sharrack (Sheffield, UK) P538 Multiple sclerosis patient support programme association with patient needs and health state utilities: a German MS patient perspective T. Kohlmann, C. Wang, J. Lipinski, N. Hadker, E. Shaw-Caffrey, M. Epstein, K. Gondek (Greifswald, Leverkusen, DE; Montville, Lexington, US) P539 Ageing with multiple sclerosis: pathways of change, a focus group study I. Molton, K. Johnson, K. McMullen, K. Yorkston, M. Jensen (Seattle, US) P540 Change in quality of life in people with multiple sclerosis treated by an integrated team of health-care providers and CAM practitioners L. Bjerre, L. Skovgaard (Valby, DK)

Neuro-Ophthalmology 1 P541 Low-contrast letter acuity detects visual function improvement in a phase 3 trial of natalizumab monotherapy L. Balcer, S. Galetta, C.H. Polman, R. Rudick, E. Eggenberger, P. Calabresi, F. Munchauer, A. Zhang, R. Hyde (Philadelphia, Cleveland, East Lansing, Baltimore, Cambridge, US; Amsterdam, NL) P542 Disease duration dependent association of total macula volume and retinal nerve fibre layer thickness with brain atrophy in multiple sclerosis J. Dörr, C. Pfueller, M. Bock, G. Gaede, J. Würfel, A. Brandt, F. Paul (Berlin, Lübeck, DE)

94 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Neuro-Ophthalmology 1 (continued) P543 Retinal nerve fibre layer and macular volume loss in MS individuals with no history of optic neuritis by spectral domain high-definition OCT G. Pardo, M. Bemben, C. Fjeldstad (Oklahoma City, Norman, US) P544 Optical coherence tomography in clinically isolated syndrome and multiple sclerosis as a measure of brain atrophy S. Kasar (Izmir, TR) P545 Optical coherence tomography is less sensitive than the multifocal visual-evoked potentials for the early detection of axonal loss in clinically isolated syndrome L. Ayuso, L. Rubio, C. Perez-Rico, D. Torrecilla, M. Roldan, R. Blanco (Alcala de Henares, ES) P546 Observation of degenerative changes of optic nerve by laser polarimetry (GDx) in multiple sclerosis E. Kantorová, J. Michalik, M. Turcanova-Koprusakova, E. Kurca, A. Blahusiaková, M. Koysová, P. Ziak (Martin, SK) P547 A 3-year, multicentre, stratified, parallel-group study to validate optical coherence tomography in patients with multiple sclerosis: design of the OCTiMS study P. Vermersch, F. Barkhof, A. Green, R. Kardon, X. Montalban, F. Paul, C. Polman, S. Schippling, U. Schmidt-Erfurth, P. Villoslada, M. Meergans, P. Calabresi (Lille, FR; Amsterdam, NL; San Francisco, Iowa, Baltimore, US; Barcelona, ES; Berlin, Hamburg, DE; Vienna, AT; Basel, CH) P548 Optical coherence tomography can detect clinical and subclinical axonal injury in neuromyelitis optica and multiple sclerosis N.H. Kim, H. Kim, W. Kim, C. Park, J.-Y. Cho, J. Min (Goyang-si, KR) P549 Multimodal neuro-ophthalmological evaluation in neuromyelitis optica: from retina to cortex M. Bouyon, N. Collongues, J. Jeantroux, L. Ballonzoli, F. Blanc, M. Fleury, V. Mutschler, J.-P. Armspach, S. Kremer, C. Speeg, J. de Seze (Strasbourg, FR) Posters P550 The thinning of retinal nerve fibre layer is associated with executive function impairment in multiple sclerosis F. Granella, G. Ferrari, P. Immovilli, C. Senesi, E. Curti, C. Macaluso (Parma, Piacenza, IT; Boston, US)

95 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Biomarkers 1 P551 Serum and cerebrospinal fluid angiotensin II levels in optic neuritis and multiple sclerosis M.D. Vinther, L.T Jensen, J.L. Frederiksen (Glostrup, Copenhagen, DK) P552 Positive serum values of gMS-Classifier2 associates with high relapse activity in relapsing–remitting multiple sclerosis patients J. Yarden, N. Dotan, E. Fire, L. Spector, H. Schmidt, S. Loud, R.P. Kinkel (Lod, IL; Waltham, Boston, US) P553 Cytokine levels at baseline may predict clinical response to glatiramer acetate L. Kasper, A. Bergeron, J. DeLong, K. Ryan, K. Smith, J. Channon (Lebanon, US) P554 Novel immunogenetic biomarkers predict clinical response to glatiramer acetate in multiple sclerosis S. Dhib-Jalbut, K. Ito, S. Buyske, R. Valenzuela (New Brunswick, Piscataway, US) P555 Value of NMO-IgG antibody determination inpatients with clinically isolated syndromes presenting as sequential or relapsing optic neuritis and myelitis M. Tintoré, C. Costa, G. Arrambide, A. Horga, J. Sastre-Garriga, M.C. Edo, J. Río, J. Castilló, F. Pérez-Miralles, C. Nos, M. Comabella, C. Auger, A. Rovira, X. Montalban (Barcelona, ES) P556 Urinary free light chain excretion in primary progressive multiple sclerosis R. Dobson, S.M. Leary, A.J. Thompson, G. Giovannoni (London, UK) P557 Daclizumab treatment and CD56bright NK cell counts independently predict being lesion-free on brain MRI scans: results from the phase 2 CHOICE trial K. Riester, J. Sheridan, Y. Zhang, G. O’Neil, J. Elkins (Cambridge, Redwood City, US) P558 miRNA: Biomarkers in MS? M. Muñoz-Culla, H. Irizar, B. Calvo, R. Armañanzas, J. Olascoaga, T. Castillo-Triviño, A. López de Munain, S. Baranzini, D. Otaegui (San Sebastian, Madrid, ES; San Francisco, US) P559 The relation of quantitative MRI measures, CSF markers and disability in multiple sclerosis A. Blum, R. Lindberg, D. Leppert, P. Kuster, N. Müller-Lenke, A. Regeniter, E.-W. Radü, L. Kappos, J. Kuhle (Basel, CH) P560 Early traces — autoantibody profile in preclinical multiple sclerosis identified with a novel protein microarray approach B.F. Decard, H. Goehler, A. Lueking, R. Gold, A. Chan (Bochum, Dortmund, DE)

96 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Biomarkers 1 (continued) P561 CD56bright NK cell counts correlate with therapeutic response to daclizumab independently of other pharmacodynamic response markers J. Sheridan, Y. Zhang, K. Riester, G. O’Neil, J. Elkins (Redwood City, Cambridge, US) P562 Gene expression molecular biomarkers and blood brain barrier disruption in multiple sclerosis O. Rozenbaum, M. Gurevich, Y. Nissan, E. Hanael, A. Achiron (Ramat-Gan, IL) P563 Immunodepletion of major proteins coupled with quantitative proteomic analysis to identify multiple sclerosis biomarkers in cerebrospinal fluid E. Thouvenot, N. Nabholz, S. Urbach, M. Séveno, P. Jouin, W. Camu, F. Vandermoere, J. Bockaert, P. Marin, N. Galeotti (Montpellier, FR) P564 Oxysterols and cholesterol precursors correlate to MR measures of disease activity in MS C. van de Kraats, J. Killestein, V. Popescu, E. Rijkers, H. Vrenken, F. Barkhof, C. Polman, D. Lütjohann, C. Teunissen (Amsterdam, NL; Bonn, DE) P565 Integration of molecular mechanism studies and biological knowledge bases reveals the presence of a possible neuronal preservation process linked to mitochondrial dysfunction and oxidative stress in IFNB-1b-treated MS patients E. Croze, V. Knappertz, K. Yamaguchi, A.T. Reder, H. Salamon (Montville, LLC, Chicago, US) P566 Axonal damage in multiple sclerosis is markedly reduced by natalizumab treatment M. Gunnarsson, C. Malmeström, M. Axelsson, P. Sundström, C. Dahle, M. Vrethem, T. Olsson, F. Piehl, N. Norgren, L. Rosengren, A. Svenningsson, J. Lycke (Örebro, Gothenburg, Umeå, Linköping, Stockholm, SE) P567 CSF oligoclonal bands in multiple sclerosis patients:

worse prognosis? Posters J.I. Rojas, L. Patrucco, E. Cristiano (Buenos Aires, AR) P568 The role of oligoclonal bands in neuromyelitis optica spectrum disorders Y. Tomizawa, K. Yokoyama, N. Hattori (Tokyo, JP) P569 Role of cerebrospinal fluid neurofilament light chain and N-acetyl aspartate in predicting the evolution to multiple sclerosis of clinically isolated syndrome suggestive of multiple sclerosis C. Tortorella, P. Iaffaldano, V. Direnzo, M. Ruggieri, M. Mastrapasqua, R.G. Viterbo, D. Paolicelli, M. Trojano (Bari, IT)

97 Poster Sessions Thursday, 14 October 2010 15:30 – 17:00 Biomarkers 1 (continued) P570 CSF proteome analysis in clinically isolated syndrome: candidate markers for conversion to definite multiple sclerosis H. Tumani, D. Rau, V. Lehmensiek, F. Lauda, S. Süssmuth, J. Brettschneider (Ulm, DE) P571 The assessment of anti-AQP4 antibody titre as a possible marker of disesase activity in patients with neuromyelitis optica P. Nytrova, D. Horakova, D. Kemlink, M. Tyblova, E. Krasulova, I. Kovarova, K.P. Wandinger, E. Havrdova (Prague, CZ; Lübeck, DE) P572 In vitro comparison of several candidate interferon (IFN)- beta bioactivity markers for type I IFN specificity S. Malhotra, M. Fernández, F. Pérez-Miralles, J. Río, X. Montalban, M. Comabella (Barcelona, ES) P573 Associations of serum cholesterol with clinical outcomes in multiple sclerosis B. Weinstock-Guttman, N. Mahfooz, R. Zivadinov, E. Carl, M. Ramanathan (Buffalo, US) P574 Serum folate, homocysteine levels and their association with clinical parameters in multiple sclerosis: a case-control study K.I. Voumvourakis, D. Kitsos, A. Poulios, G. Dervenoulas, G. Gasparinatos, R. Antonelou, S. Tsiodras, E. Stamboulis (Athens, GR) P575 Serum MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and MMP-9/ TIMP -1 ratio in different multiple sclerosis subtypes and their correlation with the chronicity of disease N. Oztekin, B. Acar, M.F. Oztekin (Ankara, TR) P576 Oligoclonal bands and cerebrospinal fluid cells as biomarkers in multiple sclerosis: dynamics under immunomodulatory treatment, correlations with physical and cognitive disability, imaging activity S. Petrescu, R. Tanasescu, P. Ionescu, G. Vanghelie, N. Munjev, C. Panea (Bucharest, RO)

98 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Diagnosis & differential diagnosis 2 P577 Optic nerve glioma mimicking optic neuritis E. Georgoulopoulou, M.C. Malaguti, J. Mandrioli, G. Pinna, P. Carpeggiani, A. Maiorana, A. Mantovani, G. Monti, F. Barbi, D. Ferraro, P.F. Nichelli, P. Sola (Modena, IT) P578 Prominent vascular changes in neuromyelitis optica following optic neuritis compared with multiple sclerosis N.H. Kim, H.J. Kim, W. Kim, C.Y. Park, J.Y. Cho (Goyang-si, KR) P579 No evidence for cerebro-cervical venous congestion in patients with multiple sclerosis F. Doepp, F. Paul, J.M. Valdueza, K. Schmierer, S.J. Schreiber (Berlin, Bad Segeberg, DE; London, UK) P580 What factors are associated with CAM use in MS patients? J.A. Tierney, E. Silber, D.W. Langdon (Egham, London, UK) P581 POLG1 gene variations presenting as multiple sclerosis A. Echaniz-Laguna, M. Chassagne, J. De Seze, P. Clerc-Renaud, M. Mohr, C. Tranchant, B. Mousson de Camaret (Strasbourg, Lyon, FR) P582 Overexpression of Lamin B1 from distinct gene duplications in autosomal dominant leukodystrophy with autonomic symptoms J. Sundblom, J. Schuster, R. Raininko, A. Thuresson, N. Dahl (Uppsala, SE) P583 Neurological status of patients with Crohn’s disease at the beginning of anti-TNF alpha treatment P. Lisková, M. Srámek (Prague, CZ) P584 MS-like white matter lesions: what is multiple sclerosis really and what is it not? L.L. Ramió i Torrentà, R. Robles, J. Gich, A. Quiles, G. Laguillo, D. Genís (Girona, ES) P585 Using atypical symptoms as red flags to predict non- demyelinating disease in patients with suspected MS S. Kelly, E. Chaila, M. Duggan, K. Kinsella, N. Tubridy, M. Hutchinson (Dublin, IE) Posters P586 CNS demyelinating lesions preceding primary CNS lymphoma A. Veiga, J.P. Gabriel, M. Resende, M.R. Silva (Vila Real, Matosinhos, PT) P587 Differential aspects of primary progressive multiple sclerosis and neuroborreliosis N.N. Spirin, N.S. Baranova, O.A. Fadeeva, E.G. Shipova, I.O. Stepanov (Yaroslavl, RU)

99 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Diagnosis & differential diagnosis 2 (continued) P588 Low secretion and expression of follistatin by immune cells of patients with RR-MS A. Karni, K. Mausner-Fainberg, E. Auriel, K. Regev, N. Urshansky (Tel Aviv, IL) P589 Anti AQP4 antibody status in Thai patients with demyelinating disorders S. Siritho, I. Nakashima, T. Takahashi, K. Fujihara, N. Prayoonwiwat (Bangkok, TH; Sendai, JP) P590 The differential diagnoses of acute demyelination in children J.D. O’Mahony, E. Yiu, L.H. Verhey, M. McGowan, D.L. Arnold, A. Bar-Or, R.A. Marrie, A.D. Sadovnick, B. Banwell on behalf of the Canadian Demyelinating Disease Network P591 Clinical aspects of demyelinating disorders of childhood in Cuiabá, Brazil H.H. Siqueira, T.A. Felicio, R.M. Papais-Alvarenga on behalf of the Lagoa MS Investigators Group

MS variants 2 P592 Longitudinal follow-up of vision in a neuromyelitis optica cohort M. Bouyon, N. Collongues, H. Zephir, L. Ballonzoli, G. Castelnovo, O. Outterick, F. Blanc, M. Fleury, P. Labauge, C. Lebrun, S. Defoort, P. Vermersch, C. Speeg, J. de Seze (Strasbourg, Lille, Nimes, Nice, FR) P593 The prognostic value of neuromyelitis optica-IgG in isolated optic neuritis M. Matiello, A. McKeon, S. Pittock, B. Weinshenker (Rochester, US) P594 Clinical, serological and neuroradiological characterisation of recurrent yyelitis: identification of possible prognostic factors M. Radaelli, V. Martinelli, D. Dalla Libera, L. Moiola, D. Privitera, F. Martinelli Boneschi, M. Rodegher, F. Sangalli, R. Fazio, G. Comi (Milan, IT) P595 Anti -AQP4 antibody in idiopathic acute transverse myelitis with recurrent clinical course. Frequency of positivity and influence in prognosis M. Alvarenga, M. Alvarenga, R. Alvarenga (Rio de Janeiro, BR) P596 NMO in a Caucasian population. A population-based study N. Asgari, S.T. Lillevang, P. Skejoe, T. Owens, M. Falah, E. Stenager, K. O. Kyvik (Odense, Middelfart, Vejle, Esbjerg, Sønderborg, DK) P597 Neuromyelitis optica Devic and concomitant human herpesvirus-6 neuro-infection: is a role for causal relationship? A case report I. Kontrova, P. Stourac, J. Bednarova, P. Praksova, M. Hladikova, Y. Benesova (Brno, CZ)

100 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 MS variants 2 (continued) P598 Primary high-grade B-cell central nervous system lymphoma in a patient with tumefactive multiple sclerosis treated with natalizumab R. Phan Ba, B. Bisig, G. Moonen, S. Belachew, M. Deprez, L. De Leval (Liege, BE; Lausanne, CH) P599 Extensive aquaporin-4 loss in Balo’s concentric sclerosis J. Kira, T. Matsuoka, S.O. Suzuki, T. Yonekawa, K. Masaki, T. Tabira, T. Iwaki, X. Wu, T. Matsushita (Fukuoka, Tokyo, JP; Nanchang, CN) P600 Initiation of glatiramer acetate treatment followed by a severe neuromyelitis optica relapse: coincidental or causal? D. Ferraro, A.M. Simone, E. Merelli, P.F. Nichelli, P. Sola (Modena, IT) P601 Antibodies against aquaporin-4 in a patient with neuromyelitis optica: positive or not? I.A. Ketelslegers, P.W. Modderman, D. Hamann, R.Q. Hintzen (Rotterdam, Amsterdam, NL) P602 Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder W. Kim, S.H. Kim, M.S. Park, H.J. Kim (Goyang, Daegu, KR) P603 Paroxysmal dystonia in neuromyelitis optica L. Melamud, L. Abaroa, N. Garretto, T. Arakaki, S. Rodriguez, O. Garcea, A. Villa (Buenos Aires, AR) P604 The spectrum of neuromyelitis optica in Singapore: an 18-year retrospective study W.M. Peh, K.K. Jain, C.C.T. Lim, K. Tan (Singapore, SG) P605 Does a benign form of neuromyelitis optica exist? N. Collongues, P. Cabre, R. Marignier, H. Zéphir, C. Papeix, B. Audoin, C. Lebrun-Frenay, B. Fontaine, P. Vermersch, C. Confavreux, J. de Seze on behalf of NOMADMUS and CF-SEP P606 Severe acute disseminated encephalomyelitis in childhood:

an intensive care population-based study Posters M. Absoud, R.C Parslow, E. Wassmer, C. Hemingway, H.P Duncan, C. Cummmins, M.J Lim on behalf of the UK & Ireland Childhood CNS Inflammatory Demyelination Working Group and the Paediatric Intensive Care Audit Network P607 Long-term follow-up of acute partial transverse myelitis B. Bourre, H. Zephir, J.-C. Ongagna, C. Cordonnier, N. Collongues, S. Debette, M. Fleury, O. Outteryck, D. Hannequin, P. Vermersch, J. De Seze (Strasbourg, Lille, Rouen, FR)

101 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Natural course 2 P608 Natural history of EDSS, HRQoL and QALY progression in relapsing-onset MS in Nova Scotia, 1979–1998 M.G. Brown, C. Skedgel, P. Andreou, S. Kirby, T.J. Murray (Halifax, CA) P609 Multiple Sclerosis Severity Scores decrease with calendar year of first EDSS assignment in MSBase I. Kister, T. Bacon, E. Chamot, G. Cutter, H. Butzkueven, J. Herbert on behalf of the MSBase Registry P610 Two-year data from CogniCIS, a multinational longitudinal study on cognition and patient-reported outcomes parameters in clinically isolated syndrome suggestive of multiple sclerosis: demographic and neurological characteristics of the study cohort S. Fredrikson, E.-M. Wicklein, N. Prayoonwiwat, K. Beckmann, P. Scherer, D. Langdon (Stockholm, SE; Berlin, DE; Bangkok, TH; Egham, UK) P611 Optic neuritis as the first clinical manifestation of multiple sclerosis in Indian patients S. Menon, B. Kulkarni, B. Singhal (Mumbai, IN) P612 No effect at three years of the presence of autoreactive antibodies on disease course in relapsing–remitting MS patients under immunomodulatory treatment R. Tanasescu, M. Ticmeanu, D. Luca, L. Dumitrescu, C. Baicus, M. Debouverie, C.S. Constantinescu (Bucharest, RO; Nancy, FR; Nottingham, UK) P613 Similarities and differences between two major multiple sclerosis natural history studies M. Daumer, A. Neuhaus, A. Thiele, E. Leray, A. Scalfari, G. Edan, G. Ebers (Munich, DE; Rennes, FR; London, UK; Oxford, UK) P614 Short interval between relapses associated to long-term disability in patients with multiple sclerosis C. Oreja-Guevara, A. Venegas, L. Rodriguez de Antonio, G. Izquierdo (Madrid, Sevilla, ES) P615 Late onset multiple sclerosis – a population-based cross- sectional study J.L. Frederiksen, E.B. Hoegh (Glostrup, DK) P616 Relapses and EDSS-progression of placebo cohorts in MS phase III trials in the last 20 years J.-P. Stellmann, J. Poettgen, S. Schippling, R. Martin, C. Heesen (Hamburg, DE)

102 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Epidemiology 2 P617 Timing of birth in United States-born multiple sclerosis population A.R. Salter, S.S. Cofield, T. Vollmer, G.R. Cutter (Birmingham, Denver, US) P618 Mortality and predictors of survival in multiple sclerosis: findings from British Columbia, Canada E. Kingwell, M. van der Kop, Y. Zhao, A. Shirani, P. Rieckmann, H. Tremlett (Vancouver, CA) P619 Industrial activity and the multiple sclerosis mortality in Austria: an ecological study K. Lauer (Griesheim, DE) P620 Update of epidemiology of multiple sclerosis in south- western Sardinia: nature versus nurture E. Cocco, C. Sardu, R. Massa, E. Mamusa, L. Musu, P. Ferrigno, M. Melis, C. Montomoli, V. Ferretti, G. Coghe, J. Frau, L. Lorefice, G. Fenu, R. Piras, R. Aste, M. Melis, P. Contu, M.G. Marrosu (Cagliari, Pavia, IT) P621 Lifelong benign multiple sclerosis – myth or reality, and can it be predicted? The 45-year follow-up of the Gothenburg multiple sclerosis incidence cohort B. Skoog, B. Runmarker, S. Winblad, S. Ekholm, O. Andersen (Gothenburg, SE) P622 Prevalence of multiple sclerosis in Osona shire (Catalonia, Spain) S. Otero, E. Bufill, P. Roura, J. Altimiras, J. Sastre-Garriga, C. Nos, J. Vaqué, X. Montalban (Barcelona, ES) P623 The epidemiological distribution of CNS inflammatory disorders in Korea: A Pilot Report of the Nationwide Registry of Multiple Sclerosis J.Y. An, H.J. Kim, B.J. Kim, K.H. Lee, S.M. Cheon, K.S. Lee, M.S. Park, S.M. Kim, Y.H. Hong, B.S. Shin, K.K. Kim, Y.M. Lim, O.H. Kwon, B.J. Kim, M.J. Hong on behalf of the Korean MS Network Group P624 Onset symptoms and change in time from onset to diagnosis Posters in multiple sclerosis E.G. Celius, C. Smestad (Oslo, NO) P625 Epidemiological characteristics of multiple sclerosis in the district of Szczecinek, north-western Poland: 13 year observation, 1993–2005 A. Potemkowski, D. Szpernalowska (Szczecin, PL)

103 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Epidemiology 2 (continued) P626 Role of oligoclonal bands in multiple sclerosis J. Lechner-Scott, B. Spencer, T. Demalmanche, J. Attia, P. Mcelduff, M. Fitzgerald, C. Zwanikken, M. Trojano, F. Grand’Maison, G. Izqiuerdo, P. Duquette, P. Grammond, M. Girard, C. Oreja-Guevara, R. Hupperts, R. Bergamaschi, T. Petersen, C. Boz, G. Giuliani, M. Edite Rio, V. Van Pesch, G. Iuliano, M. Fiol, E. Cristiano, F. Verheul, D. Poehlau, M. Saladino, M. Slee, M. Barnett, N. Deri, W. Oleschko Arruda, S. Flechter, M. Paine, J. Cabrera-Gomez, A. Savino, N. Vella, C. Shaw, J. Herbert, F. Moore, T. Petkovska-Boskova, V. Santiago, H. Butzkueven (Newcastle, South Australia, New South Wales, Victoria, AU; Nijmegen, Sittard, Gouda, NL; Bari, Pavia, Macerata, Salerno, IT; Quebec, Montreal, CA; Sevilla, Madrid, ES; Aarhus, DK; Trabzon, TR; Porto, PT; Brussels, BE; Buenos Aires, San Martin La Plata, AR; Asbach, DE; Curibita, BR; Beer-Yaakov, IL;Havana, CU; Balzan, MT; New York, US; Skopje, MK) P627 Prevalence of multiple sclerosis in central Serbia G. Toncev, S. Miletic Drakulic, Z. Knezevic, T. Boskovic Matic, A. Gavrilovic, J. Drulovic, T. Pekmezovic (Kragujevac, Belgrade, RS) P628 Epidemiologic data of mutliple sclerosis in northern Greece during the last thirty years (1979–2008) E. Koutsouraki, A. Fotakidou, M. Arnaoutoglou, T. Gatsios, S. Koukoulidou, V. Costa, S. Baloyannis (Thessaloniki, GR) P629 A comprehensive view of the clinical features of acute demyelination in children: perspectives of a national programme M. McGowan, S. Magalhaes, J. Kennedy, A.D. Sadovnick, D.L. Arnold, A. Bar-Or, R.A. Marrie, B. Banwell on behalf of the Canadian Pediatric Demyelinating Disease Study Group P630 The incidence of multiple sclerosis and other acquired CNS demyelinating syndromes in a multiethnic population of children S. Brara, Y. Yeung, J. Chung, J. Yao, A Langer-Gould (Pasadena, US) P631 From patient registry to biobank: high participation in a nationwide survey of genes and environment (GEMS study) K. Lycke, L. Alfredsson, T. Olsson, J. Hillert (Stockholm, SE) P632 Longer life span and stable case-to-population survival index in multiple sclerosis: a longitudinal study W. Cendrowski (Warsaw, PL) P633 Suicide attempts in multiple sclerosis E.N. Stenager, E. Stenager, B. Jensen, K. Stenager, M. Stenager (Odense, Sønderborg, Vejle, Esbjerg, Copenhagen, DK)

104 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Epidemiology 2 (continued) P634 Evolution of the multiple sclerosis notification rate to the main French health insurance system between 1995 and 2007 A. Fromont, C. Binquet, R. Despalins, F. Rollot, A. Weill, L. Clerc, C. Bonithon-Kopp, T. Moreau (Dijon, Paris, FR) P635 MRI and visual-evoked potentials in partners of multiple sclerosis patients C.H. Hawkes, S. Chawda, S. Derakshani, N. Muhammed, E. Visentin, D. Boniface (London, Romford, UK)

MS symptoms 2 P636 Sense of smell and neuroinflammation: olfactory threshold is increased in early active multiple sclerosis M. Vedovello, A. Lutterotti, M. Reindl, R. Ehling, F. DiPauli, B. Kuenz, C. Gneiss, F. Deisenhammer, T. Berger (Innsbruck, AT) P637 Prospective assessment of pain and depressive syndrome in MS patients: a French study B. Brochet, P. Clavelou, C. Lebrun-Frenay, G. Le Neuder, M. Dubois (Bordeaux, Clermont-Ferrand, Nice, Saint Cloud Cedex, Parc Eurasanté, Loos, FR) P638 Correlation between the olfactory bulb volume and olfactory function in patients with multiple sclerosis F.A. Schmidt, O. Goektas, F. Fleiner, G. Bohner, K. Erb, L. Harms (Berlin, DE) P639 Relations between subjective and objective executive performance, depression and anxiety in Dutch MS patients K. van der Hiele, N. Spliethoff-Kamminga, R. Ruimschotel, A. van der Zande, L. Visser (Maassluis, Rotterdam, Tilburg, NL) P640 One-year prospective study of headache characteristics in a large cohort of MS patients treated with natalizumab B. Colombo, D. Dalla Libera, P.O. Annovazzi, S. Bucello, A. Ghezzi, L.M.E. Grimaldi, V. Martinelli, G. Comi (Milan, IT) P641 Correlation of localisation and severity of extracranial Posters venous lesions with clinical status of multiple sclerosis M. Simka, T. Ludyga, M. Kazibudzki, A. Adamczyk-Ludyga, J. Wrobel, P. Latacz, J. Piegza, M. Swierad (Katowice, PL) P642 Restless legs syndrome in multiple sclerosis I. Aydin Canturk, M. Turkes, N. Isik, T. Aydin, O. Arici Duz, F. Candan (Istanbul, TR) P643 Course of depressive symptoms over time in multiple sclerosis K. Johnson, D. Amtmann, K. Cook, D. Ehde, C. Bombardier, R. Salem, K. McMullen, I. Molton (Seattle, US)

105 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 MS symptoms 2 (continued) P644 Hyposmia in multiple sclerosis E. Santos, A. Martins Silva, A. Bettencourt, I. Moreira, A. Gonçalves, S. Cavaco (Oporto, PT) P645 Clinical and neurophysiological study of neuropathic pain in patients with multiple sclerosis S. La Cesa, A. Truini, F. Galeotti, S. Di Rezze, A. Biasiotta, G. Di Stefano, G. Cruccu, E. Millefiorini (Rome, IT)

Clinical assessment tools 2 P646 Clinical scales in progressive MS: which short-term changes are most predictive of long-term outcome of disability? L.V.A.E. Bosma, J.J. Kragt, D.L. Knol, C.H. Polman, B.M.J. Uitdehaag (Amsterdam, NL) P647 Patient satisfaction, safety and time per visit: a comparison of Webcam-based and face-to-face nurse visits with multiple sclerosis patients T. Erdmann, C. Cardellini, A. Okada, V. Chibana, D. Pleimes, E. Oliveira (Berlin, DE) P648 Evaluation of capit timed tests in early multiple sclerosis M. Losada Lopez, P. Garcia Ruiz, J. del Val Fernandez (Barcelona, ES) P649 An emerging outcome beyond physical handicap in multiple sclerosis patients: living abilities T. Moreau, O. Heinzlef, P. Clerson, M. Dubois (Dijon, Poissy, Roubaix, Loos, FR) P650 Responsiveness of the multiple sclerosis international quality of life and short form-36 questionnaires to expanded disability status score changes in patients with multiple sclerosis: 12-month results of an international observational study P. Auquier, O. Fernández, H. Butzkueven, P. Flachenecker, E. Idiman, J. Pelletier, S. Stecchi, E. Verdun di Cantogno, D. Issard, M.-C. Simeoni on behalf of the MusiQoL Responsiveness Study Group P651 Association of accelerometry data and disability in MS patients A. Neuhaus, N. Goetze, C. Soaz Gonzalez, T. Fischer, A. Schlummer, C. Heesen, M. Daumer (Munich, Hamburg, DE) P652 Functional ambulation and hand function improves while using natalizumab (Tysabri®) in multiple sclerosis R. Reijmers, F. van Eijkeren, M. Hilbink, E. van Munster (‘s-Hertogenbosch, NL)

106 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Clinical assessment tools 2 (continued) P653 Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis B. Weinstock-Guttman, G. Cutter, K. Marr, D. Hojnacki, M. Ramanathan, R.H.B. Benedict, C. Morgan, E.A. Yeh, E. Carl, C. Kennedy, J. Reuther, C. Brooks, M. Elfadil, M. Andrews, R. Zivadinov (Buffalo, Birmingham, US) P654 Real maximum walking speed on short distance assessed by a corrected version of the timed 25-foot walk test R. Phan Ba, P. Calay, P. Grodent, G. Moonen, G. Nagels, S. Belachew (Liege, Melsbroek, BE) P655 Development and first evaluation of a two-step screening approach for neurogenic bladder dysfunction in multiple sclerosis T. Ziemssen, T. Weise, H. Hanso, T. Schultheiß, N. Kleiner, A. Horntrich, R. Kempcke, R. Kempcke (Dresden, DE) P657 Urinary tract dysfunction in women with neuromyelitis optica S.L. Apóstolos Pereira, F. Carvalho, C. Gomes, T. Adoni, F. Trigo Rocha, J. Bissoni, A. Lino, D. Callegaro, P. Marchiori, H. Bruschini on behalf of the Brazillian Comittee of Treatment and Ressearch in Multiple Sclerosis P658 The Kurtzke EDSS rank stability increases 4 years after onset of multiple sclerosis: results from the MSBase Registry S. Hughes, O. Gray, T. Spelman, C. Zwanikken, M. Trojano, A. Lugaresi, G. Izquierdo, F. Grand’Maison, P. Duquette, P. Grammond, M. Girard, C. Oreja-Guevara, R. Hupperts, C. Boz, T. Petersen, R. Bergamaschi, G. Giuliani, M. Edite Rio, J. Lechner-Scott, V. Van Pesch, G. Iuliano, M. Fiol, F. Verheul, E. Cristiano, V. Shaygannejad, M. Barnett, M. Slee, D. Poehlau, M. Saladino, N. Deri, W. Oleschko Arruda, S. Flechter, M. Paine, J. Cabrera-Gomez, E. Skromne, A. Savino, J. Herbert, N. Vella, C. Shaw, F. Moore, T. Petkovska-Boskova, V. Santiago, H. Butzkueven (Belfast, Portadown, UK; Victoria, Newcastle, New South Wales, South Australia, AU; Nijmegen, Sittard, Gouda, NL; Bari, Chieti, Pavia, Macerata, Salerno, IT; Sevilla, Madrid, ES; Quebec, Montreal, CA; Trabzon, TR; Aarhus, DK; Porto, PT;

Brussels, BE; Buenos Aires, San Martin La Plata, AR; Isfahan, IR; Posters Asbach, DE; Curibita, BR; Beer-Yaakov, IL; Havana, CU; Lomas, MX; New York, US; Balzan, MT; Skopje, MK)

107 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Economic burden 2 P659 Economic evaluation of disease-modifying treatments in patients with relapsing-remitting multiple sclerosis in Germany: long-term analysis and cost effectiveness of natalizumab, interferon-beta and glatiramer acetate N. Putzki, D. Eheberg, A. Bergmann, M. Lang, C. Plesnila-Frank, V. Limmroth, Z. Katsarava (St. Gallen, CH; Munich, Neuburg, Cologne, Essen, DE) P660 Estimating the use of disease-modifying treatments for multiple sclerosis in Europe G. Kobelt, F. Kasteng (Speracedes, FR; Stockholm, SE) P661 A tool for estimating multiple sclerosis costs across countries A. Honeycutt, J. Wiener, M. Trisolini, D. Chandraratna, P. Baneke (Washington DC, Waltham, US; London, UK)

Pathology 2 P662 Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions R. van Doorn, J. van Horssen, D. Verzijl, M. Witte, E. Ronken, B. van het Hof, K. Lakeman, C. Dijkstra, P. van der Valk, A. Reijerkerk, A. Alewijnse, S. Peters, E. de Vries (Amsterdam, Weesp, NL) P663 Chronic cerebrospinal venous insufficiency is an unlikely cause of multiple sclerosis B. Yamout, A. Herlopian, Z. Issa, R.H. Habib, A. Fawaz, J. Salameh, H. Wadih, H. Awdeh, N. Muallem, R. Raad, A. Al-Kutoubi (Beirut, LB) P664 Systemic inflammation induces axon injury during brain inflammation B. Moreno Bruna, J.P. Jukes, N. Vergara-Irigaray, O. Errea, P. Villoslada, V.H. Perry, T.A. Newman (Barcelona, ES; Southampton, UK) P665 Vascular function and the role of oxidative stress in multiple sclerosis A. Fjeldstad, J. McDaniel, M. Hayman, S. Ives, J. Zhao, J. Rose, J. Hannon, W. Wray, R. Richardson (Salt Lake City, US)

Experimental models 2 P666 Different effects of interferon-beta on IL-6 and IL-12 driven CNS-inflammation of the CNS M. Krauthausen, J. Zimmermann, C. Conrad, M.T. Heneka, I.L. Campbell, M. Müler (Bonn, DE; Sydney, AU) P667 EAE course is differentially affected by overexpression of HSP70 in glial cells A. Jurewicz, G. Galazka, K. Wodz-Naskiewicz, M. Domowicz, G. Kollias, K. Selmaj (Lodz, PL; Vari, GR)

108 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Experimental models 2 (continued) P668 Down regulation of water channel aquaporin-4 in myelin basic protein induced Lewis rat experimental autoimmune encephalomyelitis S. Yanagisawa, N. Takeichi, T. Kaneyama, S. Takizawa, S. Tsugane, C.-S. Koh (Matsumoto, JP) P669 Evaluation of glial fibrillary acidic protein and aquaporin-4 in an opticospinal animal model of demyelination N. Collongues, F. Blanc, J.B. Chanson, J. Steibel, C.D. Lam, E. Trifilieff, J. Honnorat, D. Pham-Dinh, M.S. Ghandour, J. de Seze (Strasbourg, Lyon, Paris, FR) P670 Inflammation causes a reversible mitochondrial dysfunction and reduced excitability in motor neurons: a potential mechanism contributing to relapses A.L. Davies, F. Laulund, G. Campbell, I. Ziabreva, D. Mahad, K.J. Smith (London, UK) P671 Comparison of the efficacy and tolerability of a novel methylhydrogenfumarate prodrug with dimethylfumarate in rodent experimental autoimmune encephalomyelitis and GI irritation models K. Gogas, G. Kim, B. Jandeleit, A. Gangakhedkar, T. Annamalai, T. McCollough, M. Gallop, D. Wustrow (Santa Clara, US) P672 Late-onset motor deficits after cuprizone-induced de- and remyelination N. Manrique-Hoyos, T. Jürgens, M. Grønborg, M. Kreutzfeldt, M. Schedensack, D. Merkler, M. Simons (Göttingen, DE) P673 MS in a dish – an ex vivo model of central nervous system remyelination H. Zhang, A. Boyd, A. Williams (Edinburgh, UK) P674 IL-5 promotes induction of antigen specific CD4v+CD25v+Tregs that suppress autoimmune mediated demyelination S.J. Hodgkinson, G.T. Tran, N. Carter, M. Killingsworth, N.D. Verma, R. Boyd, C. Robinson, B.M. Hall (Sydney, AU) P675 IL-5 therapy inhibits experimental autoimmune Posters encephalomyelitis in DA rats S.J. Hodgkinson, G.T. Tran, C.M. Robinson, R. Boyd, B.M. Hall (Sydney, AU) P676 Hippocampal synaptic plasticity is impaired during acute experimental autoimmune encephalomyelitis relapses: implications for multiple sclerosis M. Di Filippo, D. Chiasserini, A. Tozzi, C. Costa, S. Siliquini, M. Tantucci, A. De Iure, F. Gardoni, B. Viviani, G. Pryce, D. Baker, M. Di Luca, P. Sarchielli, P. Calabresi (Perugia, Milan, IT; London, UK)

109 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Experimental models 2 (continued) P677 Protective effect of TLR7-deficiency in experimental autoimmune encephalomyelitis P. Lalive, M. Benkhoucha, M.-L. Santiago-Raber (Geneva, CH) P678 Retroviral transduction of murine haematopoietic cells generates myeloid-derived suppressor cells that modulate antigen-specific immune responses C. Espejo, A. Gómez, H. Eixarch, R. Gimeno, M.J. Mansilla, X. Montalban, J. Barquinero (Barcelona, ES) P679 B-1a cells contribute to pathogenesis of MBP-induced EAE in SJL/J mice A. Odyniec, M. Mycko, M. Majewska-Szczepanik, G. Galazka, K. Marcinska, M. Szczepanik, K. Selmaj (Lodz, Cracow, PL) P680 The evaluation of the effects of Sativex® (THC:CBD) on the inhibition of spasticity in an experimental model of multiple sclerosis A. Hilliard, C. Stott, S. Wright, G. Guy, G. Pryce, G. Giovannoni (Wiltshire, London, UK)

Genetics/transcriptomics 2 P681 HLA class I genes involved in the triggering of multiple sclerosis J. Link, I. Kockum, Å.R. Lorentzen, B.A. Lie, E.G. Celius, M. Schaffer, B. Brynedal, H.F. Harbo, J. Hillert (Stockholm, SE; Oslo, NO) P682 Influence of HLA DRB1 alleles on anti-EBNA-1 titres in patients with multiple sclerosis D. Buck, V. Kraus, S. Hoffmann, M. Aslam, R. Wasmuth, A. Berthele, J. Winkelmann, S. Cepok, B. Hemmer (Munich, Leipzig, Dresden, DE) P683 Association of HLA-DRB1 with oligoclonal IgG bands in a Spanish cohort with multiple sclerosis L. Romero-Pinel, S. Martínez-Yélamos, J.M. Pujal, E. Matas, L. Gubieras, L. Bau, T. Arbizu (Barcelona, ES) P684 Search of lamin B1 gene duplication in a series of 70 patients with adult onset undetermined leukodystrophy E. Eymard-Pierre, P. Vago, J.L. Venaize, S. Vukusic, C. Confavreux, O. Dereeper, M. Clanet, O. Boesplug Tanguy, P. Labauge (Clermont-Ferrand, Lyon, Calais, Toulouse, Nimes, FR) P685 Allelic variants of the homocysteine metabolism enzymes with possible influence on multiple sclerosis incidence and progression: a case-control study B.V. Ineichen, S. Keskitalo, M. Farkas, N. Bain, A. Semmler, I. Jelcic, M. Weller, L. Klotz, M. Linnebank (Zurich, CH; Bonn, DE)

110 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Genetics/transcriptomics 2 (continued) P686 No influence KIF1B on neurodegenerative markers in multiple sclerosis M.H. Sombekke, N. Jafari, K. Bendfeldt, N. Mueller-Lenke, E.W. Radü, Y. Naegelin, L. Kappos, P.M. Matthews, C.H. Polman, F. Barkhof, R. Hintzen, J.J.G. Geurts (Amsterdam, Rotterdam, NL; Basel, CH; London, UK) P687 Interleukin-7 receptor alpha chain gene polymorphism influences multiple sclerosis risk in Japanese N. Isobe, L. Fang, T. Matsushita, T. Yonekawa, K. Masaki, Y. Ohyagi (Fukuoka, JP) P688 Detecting rare variants in complex diseases using genome wide data – a variant of PLINK’s segmental sharing algorithm H. Westerlind, K. Imrell, I. Lima Bomfim, I. Kockum, T. Koski, J. Hillert (Solna, Stockholm, SE) P689 Members 6B and 14 of the TNF receptor superfamily in multiple sclerosis predisposition M.L. Cavanillas, F. Blanco-Kelly, R. Alvarez-Lafuente, A. Alcina, M.M. Abad-Grau, V. De las Heras, E.G. De la Concha, O. Fernandez, R. Arroyo, F. Matesanz, E. Urcelay (Madrid, Granada, Malaga, ES) P690 Abnormal histone modification patterns in relapsing- remitting multiple sclerosis C. Tegla, C. Cudrici, V. Nguyen, P. Azimzadeh, M. Andrian-Albescu, V. Rus, H. Rus (Baltimore, US) P691 Expression profile of miRNAs involved in CD4+ lymphocyte activation and differentiation in patients with multiple sclerosis C. Fenoglio, D. Galimberti, C. Cantoni, D. Scalabrini, M. De Riz, L. Mellesi, S. Valzelli, M. Piola, A. Pietroboni, M. Serpente, E. Venturelli, F. Cortini, C. Villa, N. Bresolin, E. Scarpini (Milan, IT) P692 Conquering the complexity of multiple sclerosis aetiology K. Imrell, I. Kockum, V. Karrenbauer, H. Roshanisefat, E. Greiner, M. Callander, I. Lima Bomfim, B. Brynedal, J. Hillert, A.M. Landtblom, T. Masterman (Stockholm, Linköping, SE) Posters P693 HLA-DRB1 alleles may determine spinal cord pathology in multiple sclerosis W. Qiu, S. Raven, I. James, Y. Luo, J.-S. Wu, A. Castley, F. Christiansen, W. Carroll, F. Mastaglia, A. Kermode (Guangzhou, CN; Perth, AU) P694 mRNA expression of death receptors TNFR1 and FAS in relapsing–remitting multiple sclerosis R. Budde, S. Tietz, T. Thomas, R. Reuss, P. Oschmann, M. Berghoff (Giessen, Bayreuth, DE)

111 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunology 2 P695 Anti-aquaporin 4 antibodies and water permeability L. Melamud, J. Fernandez, V. Rivarola, C. Capurro, A. Villa (Buenos Aires, AR) P696 Expression of alpha B-crystallin in grey and white matter lesions in multiple sclerosis B.R. Wakerley, R. Magliozzi, R.S. Nicholas, O. Malik, D.M. Altmann (London, UK) P697 Deregulated IL-7/IL-7 receptor signalling in patients with multiple sclerosis affects homeostasis and function of regulatory T-cells B. Wildemann, M. Korporal, A. Schwarz, B. Balint, B. Fritz, J. Haas (Heidelberg, DE) P698 Gender differences in natural killer cells subsets in multiple sclerosis C. de Andres, R. Tejeiro, B. Alonso, M. Tejero-Alhambra, S. Sánchez Ramón (Madrid, ES) P699 Low production and defective regulation of noggin mRNA in immune cells of relapsing–remitting multiple sclerosis patients N. Urshansky, K. Mausner-Fainberg, E. Auriel, K. Regev, A. Karni (Tel Aviv, IL) P700 Two distinct subgroups of secondary progressive MS patients defined by naive CD4+ T-cell gene expression E. Zastepa, L. Tao, L. Fitz-Gerald, J. Antel, A. Bar-Or, Y. Lapierre, M. Hallett, D. Arnold, D. Haegert (Montreal, CA) P701 Oxidative stress study in patients with multiple sclerosis M. Comabella, C. Domínguez, F. Pérez-Miralles, A. Vilches, V. Rodríguez-Sureda, J. Río, C. Costa, X. Montalban (Barcelona, ES) P702 Astrocytes release bridging molecules like annexin A1 which may cause an increase of microglial phagocytosis of apoptotic inflammatory cells D. Minwegen, G. Poschmann, S. Faissner, K. Stühler, A. Haghikia, H.E. Meyer, R. Gold, A. Chan (Bochum, DE) P703 Can the increase of T-helper 17 lymphocyte percentage in peripheral blood anticipate a relapse in relapsing–remitting multiple sclerosis? G. Contessa, M. Clerico, S. Rolla, S. De Mercanti, A. Uccelli, M. Zaffaroni, P. Cavalla, A. Mattioli, E. Romagnolo, L. Rinaldi, C. Comi, R. Cavallo, L. Sosso, F. Novelli, L. Durelli (Orbassano, Turin, Genoa, Gallarate, Padua, Novara, IT) P704 CCL2 in regulation of autoimmune T-cell development O. Cedile, M. Løbner, H. Toft-Hansen, T. Owens (Odense, DK)

112 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunology 2 (continued) P705 Immortalised B cell lines from multiple sclerosis patients produce autoreactive monoclonal antibodies J. Fraussen, K. Vrolix, P. Martinez-Martinez, M. Losen, R. Hupperts, A. Van Diepen, B. Van Wijmeersch, M. De Baets, P. Stinissen, V. Somers (Diepenbeek, BE; Maastricht, Heerlen, NL) P706 CSF levels of secondary lymphoid organ chemokines are elevated in relapsing–remitting multiple sclerosis and secondary progressive multiple sclerosis and worsen during acute exacerbations K. Edwards, D. Cadavid, J. Goyal, T. Plavina, J. Browning, S. Purdy, X. Li, A. Ranger (Latham, Cambridge, US) P707 A comparative gene expression study of cells in cerebrospinal fluid from healthy controls and patients with multiple sclerosis by DNA microarray M. Jernas, M. Axelsson, H. Wadenvik, J. Lycke, C. Malmeström, B. Olsson (Gothenburg, SE) P708 Role of intracellular Toll-like receptors in the induction of autoimmunity M.J. Mansilla, H. Eixarch, C. Costa, X. Montalban, C. Espejo, M. Sospedra (Barcelona, ES; Hamburg, DE) P709 MicroRNAs influence autoimmune demyelination P. Mycko, M. Cichalewska, A. Machlanska, M. Mariasiewicz, P. Kwiatkowska, H. Cwiklinska, K. Selmaj (Lodz, PL) P710 T-cell determinants of the autoantigen, aquaporin-4 P.A. Nelson, M. Khodadoust, C. Spencer, M. Varrin-Doyer, J.C. Patarroyo, T. Prodhomme, R. Sobel, R. Stroud, S.S. Zamvil (San Francisco, Stanford, US) P711 Decreased interferon-alpha production in response to CpG DNA dysregulates cytokine responses in patients with multiple sclerosis M. Hirotani, M. Niino, T. Fukazawa, H. Yaguchi, M. Nakamura, S. Kikuchi, H. Sasaki (Sapporo, JP) P712 Effect of natalizumab on microRNA expression in B-lymphocytes of relapsing-remitting multiple sclerosis patients Posters C. Sievers, F. Hoffmann, P. Fontoura, L. Kappos, R.L.P. Lindberg (Basel, CH) P713 Do different clinical forms of multiple sclerosis elicit different humoral immune responses? P.D. Gama, L.R. Machado, J.A. Livramento, H.R. Gomes, T. Adoni, R.R. Morales, R.A.D. Gama, D.A.D. Gama, M.A. Lana-Peixoto, D. Callegaro on behalf of the Brazilian Commette for Treatment and Research on Multiple Sclerosis – BCTRIMS

113 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 MS and infections 2 P714 JC virus in multiple sclerosis patients treated with natalizumab M.I. Dominguez-Mozo, R. Alvarez-Lafuente, M. Garcia-Montojo, V. De las Heras, M. Bartolome, A.M. Arias-Leal, A. Garcia-Martinez, R. Arroyo (Madrid, ES) P715 Epstein-Barr and multiple sclerosis: association with disease and interaction effects with HLA-A and DRB1 genotypes in a Swedish population E. Sundqvist, P. Sundström, A.K. Hedström, M. Lindén, J. Hillert, F. Aloisi, L. Alfredsson, I. Kockum, T. Olsson (Stockholm, Umeå, SE; Rome, IT) P716 Detection of EBV latent and lytic gene transcripts in immune infiltrates in the multiple sclerosis brain using laser capture microdissection in combination with pre-amplification real-time RT-PCR B. Rosicarelli, M. Severa, E. Coccia, B. Serafini, F. Aloisi (Rome, IT) P717 Expression of MHCIITA and human herpesvirus 6 prevalence in multiple sclerosis patients treated with interferon beta R. Alvarez-Lafuente, M. Garcia-Montojo, V. De Las Heras, M.I. Dominguez-Mozo, M.L. Cavanillas, M. Bartolome, A. Garcia-Martinez, A.M. Garcia-Martinez, E. Urcelay, R. Arroyo (Madrid, ES) P718 Relapses of myelitis and optic neuritis following H1N1 vaccination M. Lana-Peixoto, C. Rocha, C. Araujo, R. Kleinpaul, L. Talim (Belo Horizonte, BR) P719 Macrophages in progressive multifocal leukoencephalopathy: staging of demyelination in relation to virus load F.B. Koenig, J. Andraczek, C. Stadelmann-Nessler, T. Acker, W. Brück (Giessen, Göttingen, DE)

Environmental, sex-related and life-style factors 2 P720 The risk of multiple sclerosis is inversely related to the level of education T. Riise, J. Kirkeleit, J.H. Aarseth, E. Farbu, R. Midgard, R. Eikeland, T.J. Mørland, Å. Mygland, W. Telstad, P.T. Førland, K.M. Myhr (Bergen, Stavanger, Molde, Arendal, Skien, Kristiansand, Førde, NO) P721 Lower serum vitamin D levels are associated with a higher exacerbation risk in multiple sclerosis T.F. Runia, W.C.J. Hop, Y.B. De Rijke, D. Buljevac, R.Q. Hintzen (Rotterdam, NL)

114 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Environmental, sex-related and life-style factors 2 (continued) P722 Planning pregnancies in multiple sclerosis patients: an Italian multicentre series G. Iuliano, P. Bellantonio, D. Spitaleri, C. Masullo (Salerno, Pozzilli, Avellino, Solofra, IT) P723 Gender ratio in MS – findings from the national Swedish MS register (SwMS-reg) I. Boström, A.-M. Landtblom (Linköping, SE) P724 Epstein-Barr virus, serum 25-hydroxyvitamin D and risk of multiple sclerosis: no evidence for interaction K. Munger, L. Levin, E. O’Reilly, K. Falk, A. Ascherio (Boston, Silver Spring, US; Solna, SE) P725 Comparing the prevalence of cigarette smoking in patient with relapsing–remitting multiple sclerosis and secondary progressive multiple sclerosis S.A. Roudbary, M.M. Ansar, A. Saberi, A. Yousefzad (Rasht, IR) P726 Circulating level of vitamin D in Turkish multiple sclerosis patients I. Midi, I. Midi, G. Keskin, K. Agan, D. Ince-Gunal (Istanbul, TR) P727 Gluten-free diet in relapsing–remitting multiple sclerosis C. Hernández-Lahoz, G. Mauri, J. Vega, J.L. Fernández-Morera, L. Rodrigo (Oviedo, ES) P728 Pregnancy in women with multiple sclerosis: the results from a systematic review and meta-analysis and the results the patients may get from the internet Y. Fragoso, A. Finkelsztejn, S. Fragoso, R. Rebs, J. Brooks (Santos, Porto Alegre, Sao Leopoldo, BR)

Neurobiology 2 P729 Increased oxidative stress markers and decreased glutamate uptake in patients with multiple sclerosis M. Gironi, M. Battifoglio, E. Grossi, C. Cursano, E. Giani,

V. Di Stolfo, P. Tortorella, M. Rovaris, E. Calabrese, E. Mariani, Posters R. Nemni, G. Cavaletti, M. Frigo, M. Saresella, E. Verga, C. Ferrarese, C. Zoia (Milan, Rome, Monza, IT) P730 Shedding light on the hyperactive hypothalamus-pituitary- adrenal axis in multiple sclerosis: circadian cortisol release, depressive symptoms and neurological impairment in early disease stage S. Kern, T. Schultheiß, H. Schneider, W. Schrempf, H. Reichmann, T. Ziemssen (Dresden, DE)

115 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Neurobiology 2 (continued) P731 A novel CNS remyelination and repair therapy by blocking LINGO-1 pathway S. Mi, D. Cadavid (Cambridge, US) P732 Prospective study of central nervous system abnormalities in patients with peripheral myelin protein 22 mutations J.-B. Chanson, A. Echaniz-Laguna, F. Blanc, L. Ballonzoli, S. Kremer, J. de Seze (Strasbourg, FR) P733 Biological effects of neutralising antibodies against Interferon beta in multiple sclerosis H. Hegen, A. Bertolotto, M. Comabella, G. Giovannoni, C. Gneiss, J. Killestein, R. Lindberg, A. Millonig, X. Montalban, C. Polman, A. Pulizzi, P.S. Sorensen, L. van der Voort, F. Deisenhammer on behalf of NABINMS

Imaging 2 P734 Atrophy of the whole cervical cord differs among the major multiple sclerosis clinical phenotypes and is associated with disability: a multicentre study S. Sala, M.A. Rocca, J. Drulovic, V. Martinelli, D. Caputo, M.A. Horsfield, M. Rodegher, M. Copetti, T. Stosic-Opincal, M. Absinta, F. Agosta, S. Mesaros, G. Comi, M. Filippi (Milan, San Giovanni Rotondo (FG), IT; Belgrade, RS; Leicester, UK) P735 Spatial distribution of white matter lesions in relapsing- remitting and secondary progressive multiple sclerosis – a cross-sectional comparative multicentre study L. Filli, L. Hofstetter, S.J. Borgwardt, P. Kuster, S. Traud, N. Müller-Lenke, Y. Naegelin, L. Kappos, A. Gass, T.E. Nichols, F. Barkhof, H. Frenken, J.J.G. Geurts, C.H. Polman, K. Bendfeldt, E.W. Radü (Basel, CH; Coventry, UK; Amsterdam, NL) P736 Early cognitive impairment in multiple sclerosis: a consequence of a decrease in anatomical and functional connectivity within brain associative pathways C. Louapre, V. Perlbarg, M. Urbanski, H. Benali, R. Assouad, C. Papeix, A. Tourbah, C. Lubetzki, S. Lehéricy, B. Stankoff (Paris, Reims, FR) P737 Atypical idiopathic inflammatory demyelinating lesions. A prospective registry in the MAGNIMS group M. Wallner-Blazek, A. Rovira, M. Filippi, D. Miller, A. Gass, J. Frederiksen, J. Flores, H. Gama, F. Fazekas (Graz, AT; Barcelona, ES; Milan, IT; London, UK; Basel, CH; Glostrup, DK; Mexico City, MX; Sao Paulo, BR) P738 Overcoming the clinical-MRI paradox of multiple sclerosis: MRI data assessed with a random forest approach K. Kacar, M.A. Rocca, M. Copetti, S. Sala, S. Mesaros, T. Stosic Opincal, D. Caputo, M. Absinta, J. Drulovic, V.S. Kostic, G. Comi, M. Filippi (Milan, San Giovanni Rotondo (FG), IT; Belgrade, RS)

116 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Imaging 2 (continued) P739 Ten-year brain atrophy rate and its relevance to disability progression in patients with multiple sclerosis A. Giorgio, M.L. Stromillo, M.L. Bartolozzi, F. Rossi, M. Battaglini, A. Blandino, L. Guidi, A. Federico, N. De Stefano (Siena, Empoli, IT) P740 White matter lesions, grey matter atrophy and their spatiotemporal distribution in early stages of multiple sclerosis M. Arsic, D. Buck, C. Gaser, A. Förschler, M. Hoshi, B. Hemmer, C. Zimmer, M. Mühlau (Munich, Jena, DE) P741 Axonal damage in the making: neurofilament phosphorylation and magnetisation transfer in MS normal-appearing white matter A. Petzold, D.J. Tozer, K. Schmierer (Amsterdam, NL; London, UK) P742 Quantification of myelin loss and repair in multiple sclerosis lesions by PET using [11C]PIB: a pilot study combining PET and multimodal MRI A. Chardain, L. Freeman, D. Galanaud, C. Louapre, C. Papeix, B. Zalc, S. Lehéricy, C. Lubetzki, M. Bottlaender, B. Stankoff (Orsay, Paris, FR) P743 Strategies for automated segmentation of multiple sclerosis lesions on brain magnetic resonance imaging X. Llado, M. Cabezas, O. Ganiler, A. Oliver, J. Freixenet, L. Ramio-Torrenta, A. Quiles, J. C. Vilanova, A. Rovira (Girona, Barcelona, ES) P744 Investigation of the concentration gradient of the NAA along the cortico-spinal tract in patients with multiple sclerosis C. Tur, C.A.M. Wheeler-Kingshott, D.H. Miller, A.J. Thompson, O. Ciccarelli (London, UK) P745 Cortical lesions in paediatric multiple sclerosis: a study using double inversion recovery sequence at 3.0 Tesla M. Absinta, M.A. Rocca, L. Moiola, A. Ghezzi, M. Copetti, A. Falini, G. Comi, M. Filippi (Milan, Gallarate, Foggia, IT) P746 Similar cortical lesion distribution and cortical atrophy location in patients with relapsing–remitting multiple Posters sclerosis M. Battaglini, M. Calabrese, M.L. Stromillo, A. Favaretto, A. Giorgio, F. Rinaldi, P. Gallo, N. De Stefano (Siena, Padua, IT) P747 Diffusion tensor imaging of optic neuritis during its recovery N. Zayed, F. Costello, J. Trufyn, M. Smith, B. Goodyear (Calgary, CA) P748 Regional GM loss in MS: a comparison between primary progressive and relapsing–remitting MS phenotypes M. Quarantelli, R. Lanzillo, A. Prinster, G. Ventrella, B. Carotenuto, G. Vacca, A. Brunetti, G. Orefice, V. Brescia Morra (Naples, IT)

117 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Imaging 2 (continued) P749 Detection of grey matter lesions in multiple sclerosis using magnetic resonance imaging: preliminary results of a comparison of phase-sensitive inversion recovery with dual inversion recovery imaging at 3T D. Chard, T. Yousry, N. Muhlert, X. Golay, M. Ron, C. Wheeler- Kingshott, D. Miller (London, UK) P750 Tract-based spatial statistics analysis of diffusion tensor imaging in multiple sclerosis F. Durand-Dubief, S. Hannoun, C. Confavreux, D. Sappey-Marinier (Bron, FR) P751 Thalamic damage predicts the evolution of primary progressive multiple sclerosis at 5 years M.A. Rocca, S. Mesaros, E. Pagani, M.P. Sormani, V. Martinelli, G. Comi, M. Filippi (Milan, Genoa, IT) P752 Distributed changes in the default-mode resting-state network in multiple sclerosis A. Gallo, S. Bonavita, M. Cirillo, R. Sacco, A. Bisecco, M. Della Corte, R. Docimo, L. Lavorgna, A. Di Costanzo, S. Cirillo, F. Esposito, G. Tedeschi (Naples, IT) P753 A novel approach identifies regional changes over time in skeletonised MTR and FA in early primary-progressive MS B. Bodini, M. Cercignani, N. De Stefano, D.H. Miller, A.J. Thompson, O. Ciccarelli on behalf of the MAGNIMS group P754 Spinal cord MR imaging in patients with clinically isolated syndromes A. Rovira, C. Vert, M. Tintoré, C. Auger, E. Huerga, G. Arrambide, J. Castilló, M.C. Edo, F. Pérez-Miralles, R. Mitjana, J. Sastre-Garriga, X. Montalban (Barcelona, ES) P755 Predicting the severity of relapsing–remitting MS: the contribution of cross-sectional and short-term follow-up MRI data C. Enzinger, A. Pichler, S. Fuchs, M. Wallner-Blazek, M. Khalil, C. Langkammer, S. Ropele, F. Fazekas (Graz, AT) P756 Extensive cortical pathology and severe cognitive decline characterise relapsing–remitting multiple sclerosis patients with epilepsy M. Calabrese, P. Grossi, M. Atzori, V. Bernardi, A. Favaretto, M. Puthenparampil, I. Mattisi, F. Rinaldi, P. Perini, P. Gallo (Padua, IT) P757 Evaluation of safety monitoring rules based on monthly contrast enhancing lesion activity in secondary progressive multiple sclerosis Y. Zhao, C.A. Riddell, D.K.B. Li, A.J. Petkau, A. Riddehough, G. Cutter, A. Traboulsee (Vancouver, CA; Birmingham, US)

118 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Imaging 2 (continued) P758 The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral grey matter atrophy in multiple sclerosis A. Ceccarelli, J. Jackson, A. Arora, S. Tahuid, E. Dell’Oglio, A. Bakshi, C. Guttmann, R. Bakshi, M. Neema (Brookline, US) P759 7 Tesla 3D-MP-Flair and 3D-MP-DIR: cortical lesion detection in multiple sclerosis W.L. de Graaf, M.P. Wattjes, F. Visser, J.J.M. Zwanenburg, P.J.W. Pouwels, J.J.G. Geurts, C.H. Polman, F. Barkhof, P.R. Luijten, J.A. Castelijns (Amsterdam, Utrecht, NL) P760 Diffusion tensor imaging distinguishes multiple sclerosis from neuromyelitis optica E. Klawiter, J. Xu, R. Naismith, T. Benzinger, J. Shimony, S. Lancia, A. Snyder, K. Trinkaus, S. Song, A. Cross (Saint Louis, US) P761 Presence of gadolinium enhancement in MS is largely a phenomenon of age independent of other clinical features O. Khan, F. Bao, M. Shah, C. Caon, I. Zak, Z. Latif, A. Tselis, R. Lisak (Detroit, US) P762 Correlating MRI texture measures of tissue integrity with structural and functional assessments of vision in optic neuritis Y. Zhang, F. Costello, J. Scott, L. Metz (Calgary, CA) P763 Multi-site myelin water relaxation studies: inter and intra-site reproducibility in normal controls C. Laule, S.M. Meyers, I.M. Vavasour, B. Maedler, P.G. Harris, D.K.B. Li, A.L. Traboulsee, A.L. MacKay (Vancouver, CA; Bonn, DE) P764 Feasibility of magnetisation transfer ratio imaging in multicentre trials of patients with multiple sclerosis D. Miller, C. Dalton, S. Narayanan, M. Derakshan, D. Tozer, K. Hunter, D. MacManus, C. Wheeler-Kingshott, R. Fox, R. Gold, M. Yang, K. Dawson, D. Arnold (London, UK; Montreal, CA; Cleveland, Cambridge, US; Bochum, DE) P765 Occurrence of neuronal dysfunction during the first 5 years of multiple sclerosis is associated with cognitive Posters deterioration W. Zaaraoui, F. Reuter, A. Rico, A. Faivre, L. Crespy, I. Malikova, E. Soulier, P. Viout, Y. Le Fur, S. Confort-Gouny, P.J. Cozzone, J. Pelletier, J. Ranjeva, B. Audoin (Marseille, FR) P766 Longitudinal spinal cord MRI in clinically isolated syndrome patients M.H. Sombekke, M.P. Wattjes, C. Lukas, L.V.A.E. Bosma, J.M. Nielsen, H. Vrenken, C.H. Polman, F. Barkhof (Amsterdam, NL; Bochum, DE)

119 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Imaging 2 (continued) P767 Proposed guidelines for in vivo MS cortical lesion scoring using double inversion recovery MR imaging J.J.G. Geurts, S.D. Roosendaal, M. Calabrese, O. Ciccarelli, F. Agosta, D.T. Chard, A. Gass, E. Huerga, B. Moraal, D. Pareto, M.A. Rocca, M.P. Wattjes, T.A. Yousry, B.M.J. Uitdehaag, F. Barkhof on behalf of the MAGNIMS Study Group P768 MRI algorithm to dissect heterogeneity in multiple sclerosis L. Winkler, M. Inglese, B. Holst, J. Fiehler, C. Heesen, S. Schippling, R. Martin (Hamburg, DE; New York, US) P769 Quantitative assessment of iron accumulation in multiple sclerosis lesions using R2* relaxometry C. Langkammer, M. Khalil, S. Ropele, M. Wallner-Blazek, C. Enzinger, S. Fuchs, F. Fazekas (Graz, AT) P770 Acute-phase MRI features of brain lesions characteristic of neuromyelitis optica J.H. Min, P. Song, B.J. Kim, P. Waters, A. Vincent, K.H. Lee on behalf of the Korean MS study group P771 Comparison of standard 1.5T vs 3T optimised protocols in patients treated with glatiramer acetate. A serial MRI study R. Zivadinov, D. Hojnacki, S. Hussein, N. Bergsland, E. Carl, J. Durfee, M. Dwyer, C. Kennedy, B. Weinstock-Guttman (Buffalo, US) P772 Increased iron concentration on susceptibility-weighted imaging is associated with decreased deep-grey matter volumes in patients with multiple sclerosis R. Zivadinov, C. Schirda, M. Heininen-Brown, N. Bergsland, C. Magnano, J. Durfee, C. Kennedy, E. Carl, D. Hojnacki, B. Weinstock-Guttman, M. Dwyer (Buffalo, US) P773 Use of magnetic resonance venography for visualisation of the internal jugular veins in patients with multiple sclerosis diagnosed with chronic cerebrospinal venous insufficiency and treated with percutaneous angioplasty A. Lopez-Soriano, R. Zivadinov, R. Galeotti, D. Hojnacki, E. Menegatti, C. Schirda, A.M. Malagoni, K. Marr, C. Kennedy, I. Bartolomei, C. Magnano, F. Salvi, B. Weinstock-Guttman, P. Zamboni (Buffalo, US; Bologna, IT) P774 Multiple sclerosis patients with chronic cerebrospinal venous insufficiency present with increased iron concentration on susceptibility-weighted imaging in deep-grey matter R. Zivadinov, M. Heininen-Brown, C. Schirda, C. Magnano, D. Hojnacki, C. Kennedy, E. Carl, N. Bergsland, S. Hussein, M. Cherneva, L. Willis, M. Dwyer, B. Weinstock-Guttman (Buffalo, US)

120 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Imaging 2 (continued) P775 Relation between quantitative venous vasculature assessment on susceptibility-weighted imaging and conventional magnetic resonance metrics in multiple sclerosis patients G. Poloni, M. Dwyer, F. Parker, C. Magnano, C. Schirda, N. Bergsland, R. Zivadinov (Buffalo, US) P776 Deep grey matter atrophy is associated with cognitive impairment in patients with multiple sclerosis S.A. Morrow, M. Hoogs, B. Weinstock-Guttman, M. Heinnen-Brown, K. Hunt, S. Hussein, D. Ramasamy, J. Durfee, M. Dwyer, E. Carl, N. Bergsland, R.H.B. Benedict, R. Zivadinov (Buffalo, US) P777 Quantifying remyelination using high-field (9.4T) MRI S. Ugradar, H. Parkes, P.-W. So, D.H. Miller, S. Jackson, F. Scaravilli, K. Schmierer (London, UK) P778 Magnetic resonance venography findings of the cervical veins in patients followed at the MS clinic in London, Ontario K. Alikhani, M.C. Kremenchutzky (London, CA)

Neurophysiology 2 P779 NMO spectrum disorder and optic neuritis: are VEPs useful? L. Straffi, M. Radaelli, M. Bianco, J. Gonzalez-Rosa, L. Moiola, D. Dalla Libera, M. Rodegher, V. Martinelli, G. Comi, L. Leocani (Milan, IT) P780 The neuro-ophthalmologic and electrophysiologic evaluation of hypothermia in multiple sclerosis patients with a history of optic neuritis T. Poyraz, F. Idiman, E. Idiman, S. Özakbas, L. Iyilikçi, A. Günerli (Izmir, TR) P781 Somatosensory evoked potentials aid in distinguishing primary progressive multiple sclerosis from relapsing forms G. Kraft, K. McMullen (Seattle, US) P782 Cognitive function and event-related potentials in patients with multiple sclerosis Posters M. Sundgren, L. Maurex, Å. Wahlin, V. Nikulin, F. Piehl, T. Brismar (Stockholm, SE; Berlin, DE) P783 Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis D. Travaglini, E. Pietrolongo, M. di Ioia, V. Di Tommaso, D. Farina, A. Lugaresi, G. De Luca (Chieti, IT) P784 Multifocal visual-evoked potential, a new technique for the detection of axonal damage in multiple sclerosis I. Puertas, C. Pérez, M.I. Roldán, R. Blanco (Madrid, ES)

121 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Neurophysiology 2 (continued) P785 Evoked potientials in the prognosis of clinically isolated syndrome M.S. Maria, L. Lee, A. Wong (Toronto, CA) P786 Value of asymptomatic visual-evoked potential abnormality in patients with myelitis B.J. Kim, J.K. Yu, W. Kim, H.J. Kim, B.J. Kim, K.H. Lee (Seoul, Goyang, KR)

Neuropsychology and fatigue 2 P787 Cognitive impairment in patients with clinically isolated syndrome: A reappraisal after 8 years A.C. Viret, R. Assouad, C. Arnaud, A. Gueguen, C. Bensa, A. Moulignier, O. Gout (Paris, FR) P788 The brief repeatable battery of neuropsychological tests: extended procedures and normative values in a spanish population T. Olivares, Y. Perez, A. Nieto, M. Betancort, J. Barroso, M.A. Hernandez (La Laguna, ES) P789 Connections between cognitive and motor impairments in patients with multiple sclerosis U. Menge, U. Hofstadt-van Oy, P. Oschmann (Bayreuth, DE) P790 Multiple sclerosis self efficacy: the validation of a new patient self-report measure C. Young, R. Mills, C. Hawkins, A. Tennant (Liverpool, Stoke on Trent, Leeds, UK) P791 Cognitive performance and corpus callosum area in multiple sclerosis S. Miron, E. Berkovitz, A. Achiron (Ramat-Gan, IL) P792 Attentional network efficiency and decision-making in early multiple sclerosis L. Crivelli, C. González, M. Fiol, A. Amengual, E. Roldán, R. Leiguarda, J. Correale (Buenos Aires, AR) P793 Emotion recognition and alexithymia in multiple sclerosis patients A. Henry, S. Bakchine, N. Ehrlé, S. Peignot-Sabbagh, A. Tourbah, M.P. Chaunu, M. Montreuil (Reims, Paris, FR) P794 Are specific attentional processes altered in multiple sclerosis patients? G. Lubrini, C. Oreja-Guevara, J.A. Periañez, M. Ríos Lago, R. Viejo Sobera, J. Alvarez Linera, E. Díez Tejedor (Madrid, ES) P795 Clinically isolated syndrome: how to monitor effects of methyl prednisolone in clinical Event B. Piri Cinar, S. Ozakbas, O. Keskin, E. Idiman (Izmir, TR)

122 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Neuropsychology and fatigue 2 (continued) P796 Fatigue and psychosocial issues in children and adolescents with multiple sclerosis B. Goretti, A. Ghezzi, E. Portaccio, S. Lori, V. Zipoli, L. Razzolini, L. Moiola, M. Falautano, M.F. De Caro, R. Viterbo, F. Patti, R. Vecchio, C. Pozzilli, V. Bianchi, M. Roscio, G. Comi, M. Trojano, M.P. Amato on behalf of the Multiple Sclerosis Study Group of the Italian Neurological Society P797 Personality traits and regional grey matter atrophy in multiple sclerosis R.H.B. Benedict, M. Hoogs, S. Morrow, B. Weinstock-Guttman, M. Heinnen-Brown, K. Hunt, M. Dwyer, E. Carl, S. Hussein, N. Bergsland, R. Zivadinov (Buffalo, US) P798 Longitudinal investigation of cognitive and neuroimaging changes in multiple sclerosis: an 18-year follow-up study L.B. Strober, S. Rao, J.-C. Lee, R. Rudick, E. Fisher (West Orange, Cleveland, US) P799 Whole brain NAA and its relation to cognitive functioning in patients with MS I.K. Penner, L. Achtnichts, Y. Naegelin, P. Calabrese, M. Amann, J. Hirsch, D. Rigotti, O. Gonen, L. Kappos, A. Gass (Basel, CH; New York, US) P800 A fMRI and DTI study in multiple sclerosis patients with fatigue A. Gorian, M. Catalan, E. Trincia, I. Specogna, M. Ukmar, M. Cova, R. Longo, L. Zugna, G. Servillo, A. Bratina, G. Pizzolato, M. Zorzon (Trieste, IT) P801 A differential role of inflammatory cytokines and cortisol levels for depression and fatigue in relapsing–remitting MS patients S.M. Gold, S. Krueger, T. Krieger, K. Schulz, C. Otte, C. Heesen (Hamburg, DE) P802 Subjective and objective measures of cognitive fatigue in multiple sclerosis L. Catena, L. Pierfederici, L. Bacci, A. Morgantini (Ancona, IT) P803 Fatigue in multiple sclerosis and sleep disorders – Posters similarities and differences C. Zecca, C. Gobbi, N. Economou, M. Gola-Bricalli, I.K. Penner, C.L. Bassetti, P. Calabrese (Lugano, Basel, CH) P804 Variability in speed of information processing: a new measure of cognitive impairment in multiple sclerosis A. Bodling, D. Denney, S. Lynch (Lawrence, Kansas City, US) P805 Cognitive impairment at the onset of multiple sclerosis: relationship to lesions location F. Reuter, W. Zaaraoui, L. Crespy, A. Faivre, A. Rico, I. Malikova, S. Confort-Gouny, P.J. Cozzone, J. Ranjeva, J. Pelletier, B. Audoin (Marseille, FR)

123 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Neuropsychology and fatigue 2 (continued) P806 Cognitive impairment in relapsing–remitting, primary progressive and secondary progressive multiple sclerosis K. van der Hiele, N. Spliethoff-Kamminga, R. Ruimschotel, A. van der Zande, L. Visser (Maassluis, Rotterdam, Tilburg, NL) P807 Treatment effects of IFNB-1b on paced auditory serial addition test performance in patients with a first event suggestive of multiple sclerosis F. Foley, R. Benedict, I.-K. Penner, L. Kappos, G. Edan, M.S. Freedman, H.-P. Hartung, D.H. Miller, X. Montalbán, C.H. Polman, F. Barkhof, V. Lanius, K. Beckmann, B. Stemper, C. Pohl, R. Sandbrink, D. Pleimes (Bronx/New Jersey, New York, US; Basel, CH; Cedex, FR; Ontario, CA; Düsseldorf, Berlin, DE; London, UK; Barcelona, ES; Amsterdam, NL) P808 Towards a neural marking of cognitive fatigue in MS: combined fMRI-EEG approach G. Haiman, I. Podelipsky, A. Miller, T. Hendler (Tel Aviv, Haifa, IL) P809 Regional corpus callosum atrophy, cognitive dysfunction and fatigue in multiple sclerosis patients O. Yaldizli, I.-K. Penner, K. Frontzek, P. Madörin, Y. Naegelin, M. Schaellebaum, M. Amann, A. Papadopoulou, P. Calabrese, E.W. Radü, L. Kappos, A. Gass (Basel, CH) P810 Longitudinal evaluation of cognition over 10 years following a first clinically demyelinating event in patients at high risk for MS A. Neilsen, R.P. Kinkel, P. Foulds, X. You, R. Hyde on behalf of the CHAMPIONS Investigators Group P811 Perception differences regarding cognitive deficits between persons with multiple sclerosis and their caregivers I. Arbel, E. Shevil, R. Galili-Mosberg, M.A. Hellmann (Tel Aviv, Petach Tikva, IL)

Immunomodulation 2 P812 Sustained benefit of continuous therapy with oral fingolimod 0.5 mg or 1.25 mg as compared to switching to fingolimod after one year of treatment with interferon beta-1a in patients with relapsing-remitting multiple sclerosis: results of the TRANSFORMS study H.-P. Hartung , G. Comi, F. Barkhof, L. Kappos, B. Khatri, X. Montalban, J. Pelletier, L. Zhang-Auberson , T. Stites, F. Holdbrook, J. Cohen on behalf of the TRANSFORMS (Trial Assessing injectable interferoN vS FTY720 Oral in RRMS) Study Group

124 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P813 Baseline/pre-study characteristics and measures of early clinical and magnetic resonance imaging activity as prognostic factors for long-term outcomes in relapsing–remitting multiple sclerosis A. Traboulsee, B. Uitdehaag, L Kappos, M. Sandberg Wollheim, D. Li, P. Jongen, C. Constantinescu, E. Verdun, P. Cornelisse (Vancouver, CA; Amsterdam, Nijmegen, NL; Basel, CH; Lund, SE; Nottingham, UK; Geneva, CH) P814 Fingolimod (FTY720) therapy reduces demyelination and microglial activation in a focal delayed-type hypersensitivity model of multiple sclerosis during the remission phase D.C. Anthony, N.R. Sibson, D. Leppert, D. Piani Meier (Oxford, UK; Basel, CH) P815 Establish tolerance in MS with peptide-coupled, peripheral blood mononuclear cells – an open, single centre, MRI- controlled, baseline-to-treatment cross-over, phase I trial in relapsing-remitting MS patients (ETIMS) A. Lutterotti, K. Stuerner, S. Yousef, A. Sputtek, P. Breiden, S. Reinhardt, J. Stellmann, S. Schippling, C. Heesen, M. Daumer, S. Miller, M. Sospedra, R. Martin (Hamburg, Munich, DE; Chicago, US) P816 Treatment with natalizumab: stabilisation of disease in severely affected patients with relapsing–remitting multiple sclerosis I. Meinl, J. Havla, R. Hohlfeld, T. Kümpfel (Munich, DE) P817 Safety profile of cladribine tablets in the treatment of relapsing–remitting multiple sclerosis over 0–48 weeks compared with 48–96 weeks in the phase III, double-blind, placebo-controlled CLARITY study S. Cook, P. Vermersch, G. Comi, G. Giovannoni, K. Rammohan, P. Rieckmann, P. Soelberg Sørensen, A. Hamlett, J. Weiner, B. Musch, V. Viglietta, E. Alteri, S. Greenberg (Newark, Columbus, US; Lille, FR; Milan, IT; London, UK; Bamberg, DE; Copenhagen, DK; Geneva, CH) P818 The impact of immunomodulators on fatigue in remitting- relapsing multiple sclerosis I. Elagina, T. Shmidt (Moscow, RU) P819 Predictors of treatment discontinuation in CIS Posters T. Spelman, C. Meyniel, G. Izquierdo, F. Grand’Maison, M. Trojano, C. Zwanikken, C. Oreja-Guevara, A. Lugaresi, T. Petersen, C. Boz, P. Grammond, G. Iuliano, P. Duquette, M. Girard, M. Fiol, J. Cabrera-Gomez, R. Hupperts, G. Giuliani, J. Lechner-Scott, F. Verheul, R. Bergamaschi, E Cristiano, V. Van Pesch, M. Saladino, J. Herbert, T. Petkovska-Boskova, N. Vella, F. Moore, M. Slee, E. Havrdova, M. Paine, C. Young, C. Shaw, M. Barnett, C. Sirbu, H. Butzkueven (Victoria, Newcastle, South Australia, NSW, AU; Sevilla, Madrid, ES; Quebec, Montreal, CA; Bari, Chieti, Salerno, Macerata, Pavia, IT; Nijmegen, Sittard, Gouda, NL; Aahus, DK; Trabzon, TR;Buenos Aires, AR; Havana, CU; Brussels, BE; New York, US; Skopje, MK; Balzan, MT; Prague, CZ; Liverpool, UK; Bucharest, RO)

125 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P820 Serious autoimmune diseases in patient treated with glatiramer-acetate for relapsing–remitting multiple sclerosis – case report P. Hradilek, O. Zapletalova, I. Woznicova, D. Zeman (Ostrava, CZ) P821 Patient satisfaction with treatment following transition from the previous to the serum-free formulation of subcutaneous interferon beta-1a in relapsing–remitting multiple sclerosis G. Japp, M. Lang, W.-G. Elias, N. Zessack (Königstein, Ulm, Hamburg, Darmstadt, DE) P822 Induction of MOG-specific cytolytic CD4+ T-cells as a therapeutic strategy for experimental autoimmune encephalomyelitis K. Deckers, L. Vander Elst, V. Carlier, M. Jacquemin, J.M. Saint-Remy (Leuven, BE) P823 Tolerability and safety of novel half millilitre formulation of glatiramer acetate for subcutaneous injection: an open- label, multicentre, randomised comparative study G. Anderson, R. Murray, D. Meyer, C. Herrman, C. Sheppard, E. Fox (Lexington, Lone Tree and Centennial, Winston-Salem, Indianapolis, Uniontown, Round Rock, US) P824 Cannabinoid receptor 2 expression and cannabinoid-induced apoptosis in peripheral blood mononuclear cells from patients with relapsing–remitting multiple sclerosis A.J. Sanchez, L. Roman-Vega, P. Bermejo, E. Ramil, M.R. Blasco, O. Rodriguez, J.A. Garcia-Merino (Madrid, ES) P825 Analysis of sustained disease activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study G. Giovannoni, G. Comi, S. Cook, K. Rammohan, P. Rieckmann, P. Soelberg Sørensen, P. Vermersch, B. Musch, D. Bock, V. Viglietta, S. Greenberg (London, UK; Milan, IT; Newark, Columbus, US; Bamberg, DE; Copenhagen, DK; Lille, FR; Geneva, CH) P826 Development of anti-inflammatory monocytes after initiation of glatiramer acetate therapy in multiple sclerosis C. Spencer, M. Varrin-Doyer, N. Molnarfi, T. Prod’homme, M. Weber, S. Zamvil (San Francisco, US; Munich, DE) P827 Efficacy and safety of fingolimod in patients switched from intramuscular interferon beta-1a: results from the TRANSFORMS extension study J. Cohen, X. Montalban, J. Pelletier, F. Barkhof, G. Comi, H.-P. Hartung, B. Khatri, L. Zhang-Auberson, T. Stites, F. Holdbrook, L. Kappos on behalf of the TRANSFORMS (Trial Assessing injectable interferoN vS FTY720 Oral in RRMS) Study Group

126 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P828 When is it too late to start treatment with disease-modifying drugs? J. Hanna, L. Rolak (Lund, SE; Marshfield, US) P829 In vitro assessment of the effect of laquinimod, a new treatment for multiple sclerosis, on neural stem cells and oligodendrocyte progenitor cells derived from human embryonic stem cells E. Kelland, W. Gilmore, B. Lund, L. Weiner (Los Angeles, US) P830 First-dose effect of fingolimod: pooled safety data from a phase 2 study and two phase 3 studies (TRANSFORMS and FREEDOMS) J.P. DiMarco, P. O’Connor, J.A. Cohen, G. Francis, W. Collins, L. Zhang-Auberson, D. Tang, L. Kappos (Charlottesville, Cleveland, New Jersey, US; Toronto, CA; Basel, CH) P831 Effect of natalizumab on cortical lesions in multiple sclerosis. A two-year longitudinal study M. Calabrese, F. Rinaldi, P. Grossi, V. Bernardi, A. Favaretto, I. Mattisi, M. Atzori, M. Puthenparampil, D. Seppi, P. Perini, P. Gallo (Padua, IT) P832 Epicutaneous immunisation with myelin peptides induces a unique population of tolerogenic dendritic cells in lymph nodes of multiple sclerosis patients M. Jurynczyk, A. Walczak, A. Jurewicz, D. Jesionek-Kupnicka, M. Szczepanik, K. Selmaj (Lodz, Cracow, PL) P833 Safety of teriflunomide in the treatment of relapsing multiple sclerosis: results over an 8-year extension C. Confavreux, P.W. O’Connor, M.S. Freedman, H. Benzerdjeb, S. Wang, A. Bar-Or for the Teriflunomide Multiple Sclerosis Trial Group P834 Analysis of sphingosine 1-phosphate receptor null mice during experimental autoimmune encephalomyelitis and fingolimod exposure J.W. Choi, K. Noguchi, R. Rivera, D. Herr, Y. Fujii, J. Chun (La Jolla, US) Posters P835 JCV and BKV urinary excretion increases during treatment with natalizumab S. Delbue, S. Tremolada, F. Carloni, C. Carloni, S. Larocca, E. Tavazzi, V. Bargiggia, A. Romani, R. Bergamaschi, P. Ferrante (Milan, Pavia, IT) P836 Accidental natalizumab administration to the third trimester of pregnancy in an adolescent multiple sclerosis patient A. Bayas, J. Penzien, K. Hellwig (Augsburg, Bochum, DE)

127 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P837 Impact of natalizumab treatment on cognitive performance, fatigue and health-related quality of life in relapsing multiple sclerosis P. Iaffaldano, R.G. Viterbo, D. Paolicelli, M. D’Onghia, G. Lucchese, V. Direnzo, M. Trojano (Bari, IT) P838 Cladribine-induced alterations in cytokine patterns of peripheral blood mononuclear cells M. Korsen, B. Bröker, A. Dressel (Greifswald, DE) P839 Ex vivo monocyte RNA signatures after glatiramer acetate administration reveal unrecognized T-cell and migration relevant pathway genes R. Goertsches, M. Hecker, M. Thamilarasaran, D. Koczan, H.-J. Thiesen, U.-K. Zettl (Rostock, DE) P840 Preliminary evaluation of pregnancy outcomes from the Tysabri® (natalizumab) Pregnancy Exposure Registry L. Cristiano, C. Bozic, M. Kooijmans (Cambridge, US) P841 Effectiveness and safety of natalizumab in patients with relapsing multiple sclerosis: report of three-year experience in a multiple sclerosis centre, Catalonia A. Horga, J. Castilló, J. Río, M. Tintoré, M.C. Edo, F. Péerez-Miralles, C. Tur, C. Nos, E. Huerga, C. Auger, J. Sastre-Garriga, M. Comabella, A. Rovira, X. Montalban (Barcelona, ES) P842 A pilot RCT of Mitoxantrone/Glatiramer Actetate vs Interferon beta-1a in patients with high risk RRMS J. Ramtahal, M. Boggild, C. Constantinescu, J. Mottershead, B. Sharrack, H. Ford, C. O’Leary, M. Blundell, C. Gamble (Liverpool, Nottingham, Manchester, Sheffield, Leeds, Glasgow, UK) P843 Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies W. Collins, J. Cohen, P. O’Connor, A. de Vera, L. Zhang-Auberson, F.J. Jin, L. Kappos (Basel, CH; Cleveland, One Health Plaza, US; Toronto, CA) P844 Pooled efficacy data demonstrate that fingolimod reduces multiple sclerosis relapse rate with no evidence of rebound after discontinuing treatment A. De Vera, L. Kappos, L. Zhang-Auberson, D. Tang, J. A. Cohen (Basel, CH; New Jersey, Cleveland, US) P845 No increased risk for antibody formation against natalizumab in multiple sclerosis patients positive for neutralising antibodies to interferon beta M. Lundkvist, J. Hillert, A. Fogdell-Hahn (Stockholm, SE)

128 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P846 Exposure of the fingolimod active metabolite fingolimod phosphate in patients with relapsing–remitting multiple sclerosis: a pharmacokinetic modeling study based on the TRANSFORMS and FREEDOMS phase 3 studies F. Mercier, O. J. David (Cambridge, US; Basel, CH) P847 Using clinically isolated syndrome to test putative therapies for MS: a novel testing ground M. Hutchinson, J.P. Zajicek (Dublin, IE; Plymouth, UK) P848 Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in multiple sclerosis A. Vennegoor, M.P. Wattjes, E. van Munster, R.L. Kriekaart, B.W. van Oosten, F. Barkhof, J. Killestein, C.H. Polman (Amsterdam, ‘s Hertogenbosch, NL) P849 Evaluation of pharmacokinetics and tolerability of oral teriflunomide in subjects with mild and moderate hepatic impairment S. Turpault, F. Menguy-Vacheron, T. Limsakun (Malvern, Bridgewater, US; Chilly Mazarin, FR) P850 Immunomodulation by laquinimod of human B-cells from healthy individuals and patients with MS: targeting B-cell regulatory networks S. Nussbaum, A. Snir, E.S. Ram, L. Hayardeny, D. Melamed, E. Toubi, A. Miller (Haifa, Natanya, IL) P851 Pharmacological profile of LAS186323, a novel non- hepatotoxic DHODH inhibitor for the oral treatment of multiple sclerosis and other autoimmune disorders N. Godessart, M. Andres, M. Auli, N. Prats, J. Albertí, J. Cabedo, V. Pes, R. Fernández-Reinoso, P. Pizcueta, J. Castro, M. Erra (Barcelona, ES) P852 Tolerability and retention on treatment with cladribine tablets for relapsing–remitting multiple sclerosis over 96 weeks in the phase III, double-blind, placebo-controlled CLARITY study

P. Vermersch, G. Comi, S. Cook, G. Giovannoni, K. Rammohan, Posters P. Rieckmann, P. Soelberg Sørensen, P. Chang, A. Hamlett, B. Musch, J. Weiner, V. Viglietta, S. Greenberg (Lille, FR; Milan, IT; Newark, Columbus, US; London, UK; Bamberg, DE; Copenhagen, DK; Geneva, CH) P853 Plasma exchange in treatment of acute inflammatory demyelinating diseases I. Al-Thubaiti, R. Sadjadi, P. Yenson, B. Benny, A. Traboulsee (Vancouver, CA)

129 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P853a Gene expression signature in whole blood after treatment with amino acid copolymer PI-2301 in multiple sclerosis J.C. Corvol, C. Vrignaud, W. Carpentier, F. Cormier, F. Charbonnier- Beaupel, K. Tahiri, A. Patat, E. Mascioli, G. Edan, E. Zanelli on behalf of the Clinical Investigators in France, Hungary and Serbia P854 Natalizumab discontinuation in multiple sclerosis: experience of a single centre E. Cocco, L. Lorefice, J. Frau, G. Fenu, G. Coghe, R. Piras, C. Sardu, L. Musu, M. Melis, P. Contu, M.G. Marrosu (Cagliari, IT) P855 Paradoxical response after first rituximab infusion in patients with neuromyelitis optica J. Perumal, I. Kister, J. Howard, J. Herbert (New York, US) P856 Impact of natalizumab on relapse characteristics A. Ferradji, I. Slesari, O. Heinzlef on behalf of reseau SEP IDF Ouest P857 Predicting response to interferon beta-1a therapy in patients with relapsing–remitting multiple sclerosis M.P. Sormani, P. Cornelisse, A. Signori, B. Stubinski, D. Li, N. De Stefano (Genoa, Siena, IT; Geneva, CH; Vancouver, CA) P858 Efficacy of the selective S1P 1/5 modulator, BAF312 in established experimental autoimmune encephalomyelitis and redistribution of S1P1 and S1P5 in the inflamed human CNS tissue TJ. Seabrook, P. Smith, A. Schweitzer, E. Wallström, B. Nuesslein- Hildesheim (Basel, CH) P859 Acute promyelocytic leukaemia in multiple sclerosis patient on interferon beta-1A: a case report M.R. Rottoli, G. Pavan, S. La Gioia, T. Intermesuli, R. Bassan (Bergamo, Milan, IT) P860 Hypersensitivity pneumonitis as a potential late complication of alemtuzumab treatment for MS M. Cossburn, G. Ingram, K. Baker, T. Pickersgill, S. Barry, N.P. Robertson (Cardiff, UK) P861 Cellular composition of CSF and the immune repertoire of T-cells in patients treated with natalizumab C. Warnke, T. Dehmel, A. Mausberg, M. Andree, M. Stettner, H. Hengel, H.-P. Hartung, O. Adams, B.C. Kieseier (Düsseldorf, DE) P862 EVASEP: role of care giver in supporting patients with multiple sclerosis treated with interferon beta-1a over 24 months C. Donze, B. Lenne, N. Caizergues, M. Meite, A. Jean Deleglise, P. Hautecoeur (Lomme, Lyon, FR)

130 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P863 Effect of high-dose subcutaneous interferon beta-1a therapy on short-term brain volume loss in patients with relapsing- remitting multiple sclerosis N. De Stefano, M.P. Sormani, P. Cornelisse, B. Stubinski, A. Blandino, F. Rossi, M.L. Stromillo, A. Giorgio, M. Battaglini for the IMPROVE study investigators P864 Associations between grey matter atrophy and disability in a placebo-controlled trial of interferon beta-1a in relapsing- remitting multiple sclerosis E. Fisher, K. Nakamura, A. Pace, J.-C. Lee, P. Foulds, R.A. Rudick (Cleveland, Cambridge, US) P865 Pre-existing inflammation and brain atrophy evolution under natalizumab therapy J. Sastre-Garriga, F. Pérez-Miralles, A. Horga, M. Tintoré, C. Auger, J. Río, C. Nos, E. Huerga, M.C. Edo, J. Castilló, A. Rovira, X. Montalban (Barcelona, ES) P866 Association between short-term deep grey matter atrophy and disability progression over five years in patients treated with IM interferon beta-1a R. Zivadinov, D. Horakova, O. Dolezal, N. Bergsland, S. Hussein, J. Durfee, X. You, Z. Seidl, M. Vaneckova, J. Krasensky, E. Havrdova (Buffalo, Cambridge, US; Prague, CZ) P867 Demographic and clinical characteristics of patients treated with natalizumab in post-marketing setting. A prospective multicentre observational study of 1109 patients F. Radji, L. Dagrassa, P. Vermersch, H. Zephir, J. De Seze, J.C. Ongagna, B. Brochet, J.C. Ouallet, C. Lebrun Frenay, L. Rumbach, M. Debouverie, S. Pittion, D. Laplaud, S. Wiertlewski, P. Cabre, C. Confavreux, S. Vukusic, J. Pelletier, B. Audoin, G. Defer, N. Derache, W. Camu, E. Thouvenot, A. Tourbah, P. Labauge, G. Castelnovo, E. Llinares, P. Clavelou, O. Casez, P. Hautecoeur, C. Papeix, G. Edan, D. Ferriby, R. Nurtidov, F. Bucciarelli, L. Parmentier, C. Rabadeux, N. Couturier, R. Liblau, M. Clanet, D. Brassat (Toulouse, Lille, Strasbourg, Bordeaux, Nice, Besancon, Nancy, Nantes, Fort de France, Lyon, Marseille, Caen,

Montpellier, Reims, Nimes, Clermont-Ferrand, Grenoble, Lomme, Posters Paris, Rennes, FR) P868 Clinical consequences of planned dosage interruption in natalizumab-treated patients B. Cree (San Francisco, US) P869 Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing–remitting multiple sclerosis M. Etemadifar, M. Kazemi, A.H. Maghzi (Isfahan, IR)

131 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunomodulation 2 (continued) P870 Eligibility criteria to natalizumab treatment in patients with multiple sclerosis: a real-life study F. Granella, C. Senesi, E. Curti, P. Immovilli (Parma, Piacenza, IT) P871 Progressive multifocal leukoencephalopathy during natalizumab treatment: a case report F. Sangalli, L. Moiola, M. Radaelli, V. Barcella, S. Gerevini, P. Cinque, A. Bestetti, V. Martinelli, G. Comi (Milan, IT) P872 Effect of fingolimod on cortical lesions in patients with primary progressive multiple sclerosis: sub-group study of the INFORMS trial F. Nelson, N. Huran, J. Wolinsky, P. Narayana on behalf of the INFORMS Investigators Group P873 Assessment of the incidence of anti-JCV antibodies in a cohort of natalizumab-treated patients with multiple sclerosis L. Gorelik, S. Bixler, M. Lerner, E. Wilson, A. Cheung, L. Chen, M. Berman, M. Crossman, K. Simon, B. Schlain, T. Plavina, S. Goelz, M. Subramanyam (Cambridge, US)

Immunosuppression 2 P874 Heart involvement in patients treated with mitoxantrone for multiple sclerosis P. Ragonese, V. Lo Re, P. Aridon, M.A. Mazzola, M. D’Amelio, S. Realmuto, L. Zummo, G. Salemi, G. Savettieri (Palermo, IT) P875 The use of immunosuppressants in multiple sclerosis: an Italian multicentre study F. Patti, C. Pozzilli, A. Lugaresi, E. Millefiorini, R. Bergamaschi, G. Lus, D. Maimone, M. Vianello, G. Coniglio, G. Tedeschi, P. Gallo, G. Di Battista, E. D’Amico, M. Ferrò, E. Granieri, M.P. Amato, F. Granella, P. Cavalla, V. Lepore, D. Corrado, G. Graziano, G. Comi, M. Trojano (Catania, Rome, Chieti, Pavia, Naples, Treviso, Potenza, Padua, Crema, Ferrara, Florence, Parma, Turin, Milan, Bari, IT) P876 Treatment de-escalation after mitoxantrone therapy: first results of a phase IV, multicentre, open-label, randomised study of subcutaneous interferon beta-1a, 44 mcg three times weekly, in patients with relapsing multiple sclerosis R. Gold, F. Heidenreich, P. Rieckmann, M. Sailer, U. Zettl, N. Zessack on behalf of the REMAIN study group P877 Long-term outcomes in patients who receive teriflunomide for multiple sclerosis: evaluating health-related quality of life and fatigue over 7 years V. Bhan, A. Grand, M. Germé, J. Fisk (Halifax, CA; Neuilly-sur-Seine, Massy, FR)

132 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Immunosuppression 2 (continued) P878 Histopathological evidence for ongoing demyelination and neurodegeneration in an advanced-stage multiple sclerosis patient seven years after high-dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation A. Wundes, J.-Q. Lu, J. Bowen, G. Kraft, K. Maravilla, B. McLaughlin, C. Kane, R. Nash (Seattle, US; Alberta, CA)

Neuroprotection 2 P879 BG-12 exhibits anti-inflammatory and prometabolic effects in brain astrocytes D. Feinstein, P. Polak, L. Lisi, C. Dello Russo, S. Xia Lin, A. Sharp (Chicago, US) P880 Fingolimod treatment prevents the clinical, synaptic and dendritic abnormalities of experimental autoimmune encephalomyelitis S. Rossi, V. De Chiara, C. Motta, V. Studer, T. Lo Giudice, A. Martorana, R. Furlan, D. Centonze (Rome, Milan, IT) P881 Laquinimod ameliorates experimental autoimmune encephalomyelitis via BDNF-dependent mechanisms J. Thöne, D Lee, S. Seubert, L. Hayardeny, R. Linker, R. Gold (Bochum, DE; Netanya, IL) P882 Differential activity of laquinimod on production of inflammatory molecules and neurotrophic factors by human microglia and macrophages C. Silva, J. Wang, M. Mishra, V.W. Yong (Calgary, CA) P883 Mechanisms of action of methylthioadenosine: pathways implicated in neuroprotection in models of multiple sclerosis and other neurological diseases B. Moreno Bruna, A. Di Penta, M. Kerschensteiner, C. Matute, V. Ceña, I. Lopez, J. Alberch, J. Parent, J. Serra, O. Errea, P. Villoslada (Barcelona, Bilbao, Albacete, Pamplona, ES; Munich, DE; Yale, US)

P884 Long-term interferon beta treatment in MS patients elevates Posters brain-specific carnitine palmitoyltransferase, a key regulator of mitochondrial fatty acid oxidation E. Croze, V. Knappertz, K. Yamaguchi, A.T. Reder, H. Salamon (Montville, Albany, Chicago, US) P885 Laquinimod prevents the inflammation-induced derangement of neurogenic niches in experimental autoimmune encephalomyelitis mice F. Ruffini, A. Bergamaschi, C. Marinaro, R. De Ceglia, L. Muzio, R. Furlan, L. Hayardeny, G. Comi, G. Martino (Milan, IT; Netanya, IL)

133 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Neuroprotection 2 (continued) P886 A single-centre, pilot, randomised controlled trial of recombinant human erythropoietin in primary progressive multiple sclerosis I. Karpha, L. Guy, J. Ramtahal, M. Boggild (Liverpool, UK) P887 Neuroprotective effects of dimethyl fumarate and monomethyl fumarate on primary cultures of human spinal cord astrocytes after oxidative challenge R. Scannevin, S. Chollate, M.Y. Jung, H. Patel, P. Bista, W. Zeng, M. Lukashev, K. Rhodes (Cambridge, US)

Long-term treatment monitoring 2 P888 Two-year experience of virological longitudinal survey on Italian multiple sclerosis natalizumab-treated patients D. Caputo, R. Mancuso, A. Hernis, S. Agostini, F. Guerini, M. Saresella, M. Clerici (Milan, IT) P889 Analysis of the relationships between clinical outcome measures and neutralising antibody titres in multiple sclerosis patients treated with interferon beta E. Fox, C. Markowitz, R. Murray, B. Green, A. Goodman (Round Rock, Philadelphia, Lone Tree and Centennial, St. Louis, Rochester, US) P890 Non-adherence to disease-modifying therapy: a cohort study of Norwegian patients with multiple sclerosis N. Grytten Torkildsen, K. Espeset, G. Berg Johnsen, R. Wehus, C. Lund, J.H Aarseth, R. Haugstad (Bergen, Trondheim, Tromsø, Oslo, NO) P891 Early response to interferon beta-1a predicts clinical outcome 15 years later in multiple sclerosis R.A. Bermel, X. You, A. Pace, P. Foulds, J. Simon, E. Fisher, R.A. Rudick (Cleveland, Cambridge, Portland, US) P892 ReaLiNat Study: a European multicentre study investigating benefits and risks of natalizumab in real life J. Kraus, B. Brochet, U.K. Zettl, T. Berger, S. Humpert, M. Marziniak, W. Kristoferitsch, P. Schnabl, F. Aichner, H. Tumani, M. Müller, P. Wipfler, J. Zimmermann, I. Sapunova-Mayer, H. Asser, J.R. Weber, H. Rauschka, L. Bernhardt, C. Vouga, G. Gillwaldt, G. Ladurner (Salzburg, Innsbruck, Vienna, Klagenfurt, Linz, AT; Bordeaux, FR; Rostock, Münster, Ulm, Bonn, DE; Bern, CH) P893 Utilisation and safety of natalizumab in patients with relapsing multiple sclerosis C. Bozic, L.M. Cristiano, R. Hyde, A. Natarajan, M. Kooijmans- Coutinho (Cambridge, US)

134 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Long-term treatment monitoring 2 (continued) P894 Pregnancy outcomes from the Avonex® (interferon beta-1a) Pregnancy Exposure Registry P. Foulds, S. Richman, G. Glick, T. Onigman, R. Hyde (Cambridge, US) P895 Comparison of compliance data: the role of the MS specialist nurse for patients on disease-modifying therapy H. Thompson, F. Mullan, A. Droogan, O. Gray, G. McDonnell, M. Watt, S. Hawkins (Armagh, Derry, Belfast, UK) P896 Three years efficacy and tolerability of natalizumab treatment F. Sangalli, L. Moiola, P. Annovazzi, S. Bucello, M. Radaelli, A. Ghezzi, L.M.E. Grimaldi, V. Martinelli, G. Comi (Milan, Gallarate (VA), Cefalù (PA), IT) P897 Adherence to long-term treatment in MS: socio- demographic and disease-related factors T. Sidorenko, A. Boyko, E. Gusev (Moscow, RU) P898 Predicting factors for discontinuation of interferon beta as first-line treatment P.E. Bermejo, M.R. Blasco, A.J. Sanchez, L. Roman-Vega, E. Ramil, O. Rodriguez, J.A. Garcia-Merino (Majadahonda, Madrid, ES) P899 Hypereosinophilia under natalizumab in a French cohort of MS patients J. Florek, H. Zephir, F. Legrand, O. Outteryck, A. Lacour, A.S. Berteloot, A. Melin, L. Prin, P. Vermersch (Lille, FR) P900 Multiple sclerosis: State of the Art (SMART): a qualitative and quantitative analysis of therapy’s adherence G. Di Battista, A. Bertolotto, C. Gasperini, A. Ghezzi, D. Maimone, C. Solaro on behalf of the SMART Study Group P901 Clinical markers of therapeutic response with interferons and with glatiramer acetate and the long-term impact on relapse-induced disability A. Carrá, P. Onaha, G. Rojas, G. Imhoff-Jullier, C. Vrech (Buenos Aires, Córdoba, AR)

P902 Interferon beta and glatiramer acetate therapy reduces the Posters risk for secondary progression in relapsing-remitting multiple sclerosis H. Tedeholm, B. Skoog, J. Lycke, J. Hillert, L. Stawiarz, O. Andersen (Gothenburg, Stockholm, SE) P903 Survival analysis 21 years after the initiation of the pivotal interferon beta-1b trial in patients with RRMS A.T. Reder, G. Ebers, G. Cutter, M. Kremenchutzky, D. Goodin, J. Oger, D. Langdon, M. Rametta, K. Beckmann, V. Knappertz (Chicago, Birmingham, San Francisco, Wayne, Montville, US; Oxford, Egham, UK; Ontario, Vancouver, CA; Berlin, DE)

135 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Therapy disease-modifying – Others 2 P904 The ADVANCE Phase 3 Study of PEGylated interferon beta-1a in relapsing multiple sclerosis: rationale and design P. Calabresi, D. Arnold, L. Balcer, A. Boyko, B.C. Kieseier, J. Pelletier, Y. Zhu, G. Davar (Baltimore, Montreal, Philadelphia, Cambridge, US; Moscow, RU; Düsseldorf, DE; Marseille, FR) P905 Demographic and baseline disease characteristics associated with freedom from disease activity in natalizumab-treated patients E. Havrdova, S. Galetta, M. Hutchinson, D. Stefoski, D. Bates, C.H. Polman, P.W. O’Connor, G. Giovannoni, J.T. Phillips, F.D. Lublin, A. Pace, R. Hyde (Prague, CZ; Philadelphia, Chicago, Dallas, New York, Cambridge, US; Dublin, IE; Newcastle-upon-Tyne, London, UK; Amsterdam, NL; Toronto, Ontario, CA) P906 Patient survey on interferon beta MS therapy concepts: exploratory comparison J. Czekalla, A. Kramell, S. Mekelleche (Berlin, DE) P907 Few multiple sclerosis patients develop persistent anti- natalizumab antibodies E. Karlberg, M. Lundkvist, R. Jungedal, J. Hillert, A. Fogdell-Hahn (Stockholm, SE) P908 The prevalence of thyroid autoantibodies in multiple sclerosis R. Turkoglu, M. Gencer, I. Delipoyraz, D. Ekmekci, H. Tireli (Istanbul, TR) P909 A single-use autoinjector for self-administration of subcutaneous interferon beta-1a: final results from MOSAIC S. Wray, R. Armstrong, M. Cascione, E. Watsky, A. Al-Sabbagh, F. Dangond (Knoxville, Asheville, Tampa, New London, Rockland, US) P910 Optic neuritis is a negative predictor for response to plasma exchange in demyelinating disease L.A. Gerdes, M. Wessely, A. Yassouridis, U. Schönermarck, H.L. Pellkofer, R. Hohlfeld, T. Kümpfel (Munich, DE) P911 An estimation of platelet-derived growth factor and fibroblast growth factor in serum and CSF of multiple sclerosis patients during relapse and remission M.H. Harirchian, A. Hosseini, M. Ghaffarpour, M.A. Sahraian, M. Yazdan Panah, M. Naji (Tehran, IR) P912 Reasons for non-adherence to long-term medication in patients suffering from multiple sclerosis C. Bischoff, A. Bergmann, H. Schreiber on behalf of the N.T.C. Study Group

136 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Therapy disease-modifying – Others 2 (continued) P913 Association between depression and compliance in multiple sclerosis M. Tarrants, J. Castelli-Haley, M. Lage (Kansas City, Groton, US) P914 Safety and complications related to endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis patients M. Simka, T. Ludyga, M. Kazibudzki, M. Hartel, M. Swierad, J. Piegza, P. Latacz, L. Sedlak, M. Tochowicz (Katowice, Zabrze, PL) P915 Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis C. Trebst, P. Bronzlik, J. Kielstein, M. Stangel (Hannover, DE)

Treatment of specific symptoms 2 P916 A randomised placebo-controlled cross-over study using a low-frequency magnetic field in the treatment of fatigue in multiple sclerosis M.L. Lopes de Carvalho, R. Motta, G. Konrad, G. Brichetto, M.A. Battaglia (Genoa, IT) P917 The effects of supervised exercise programme on functional status, fatigue and quality of life in patients with multiple sclerosis Ö. Ertekin, S. Özakbas, E. Idiman, C. Algun (Izmir, TR) P918 Long-term effects of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: an open label follow-up study J. Piatkowski, R. Haase, T. Ziemssen (Dresden, DE) P919 The use of Zona Incerta for stereotactic lesional treatment of symptomatic tremor in multiple sclerosis A.M.P. Oliveira, E.T. Fonoff, D. Callegaro, M.J. Teixeira (São Paulo, BR) P920 Multiple sclerosis relapse management in Italian MS centres: results of a three-month cross-sectional survey P. Annovazzi, B. Bodini, L. Boffa, M. Calabrese, E. Cocco, Posters C. Cordioli, G. De Luca, G. Frisullo, A. Gallo, S. Malucchi, D. Paolicelli, I. Pesci, M. Radaelli, P. Ragonese, L. Roccatagliata, V. Tomassini, C. Tortorella, M. Vercellino, V. Zipoli, C. Gasperini, M. Rodegher, C. Solaro on behalf of RIReMS (Rising Italian Researchers in MS) P921 Response to treatment with prolonged-release fampridine tablets in patients with multiple sclerosis is independent of demographic, clinical, and patient-reported characteristics T. Brown, R. Schapiro, A. Goodman on behalf of the MS-F202, MS-F203, and MS-F204 Study Groups

137 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Treatment of specific symptoms 2 (continued) P922 Walking speed improvements in a pooled analysis of prolonged-release fampridine in patients with multiple sclerosis R. Schapiro, T. Brown, A. Goodman on behalf of the MS-F202, MS-F203, and MS-F204 Study Groups P923 Peristeen transanal irrigation in patients with multiple sclerosis G. Preziosi, J. Panicker, C. Dalton, C.J. Fowler, A.V. Emmanuel (London, UK) P924 Effects of the Wii fit on balance and risk of fall with hospitalized persons with multiple sclerosis: a pilot study B. Gebara, A. Berghmans (Melsbroek, BE) P925 Multiple sclerosis-associated fatigue during disease- modifying treatment with natalizumab, interferon beta and glatirameracetate M. Yildiz, B. Tettenborn, N. Putzki (St. Gallen, CH) P926 Clean intermittent self-catheterisation as an effective treatment method of bladder problems in persons with multiple sclerosis L. Vahter, I. Zopp, A. Aaso, H. Maamägi, U. Sorro, K. Kannel, T. Saarup, K. Gross-Paju (Tallinn, EE) P927 Risk factors for analgesic medication misuse in individuals with multiple sclerosis I. Molton, M. Jensen, K. Johnson (Seattle, US)

Comprehensive care & rehabilitation 2 P928 Information preference of newly diagnosed MS patients: prospective assessment within the SIMS-Trial A. Solari, A. Giordano, M. Trojano, V. Martinelli, A. Lugaresi, F. Granella, P. Confalonieri, C. Tortorella, I. Plasmati, M. Radaelli, D. Farina, E. Dalla Bella, L. Maggi, M. Messmer Uccelli, E. Pucci, C. Borreani, R. D’Alessandro on behalf of the SIMS-Trial group P929 Participants’ perspective on information aid for newly diagnosed MS patients: the SIMS-Qual study C. Borreani, M. Falautano, A. Giordano, V. Martinelli, A. Lugaresi, F. Granella, M. Trojano, N. Acquarone, C. Tortorella, I. Plasmati, M. Radaelli, D. Farina, E. Dalla Bella, E. Bianchi, G. Miccinesi, A. Solari on behalf of the SIMS-Qual and SIMS-Trial groups

138 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Comprehensive care & rehabilitation 2 (continued) P931 Carers’ perceptions of physiotherapy for people with MS E. O’Dwyer, S. Coote (Limerick, IE) P932 Functional stimulation for foot drop: does a simple activity monitor identify relevant benefits in patients with multiple sclerosis? J. Thain, M. Boggild (Liverpool, UK) P933 Effectiveness of bowel rehabilitation in MS patients: preliminary results M.L. Lopes de Carvalho, G. Brichetto, R. Motta, M. Causa, G. Cancellieri (Genoa, Padua, IT) P934 In-home rehabilitation effectiveness for people with MS with high disability and comparison of costs with inpatient rehabilitation M.L. Lopes de Carvalho, S. Bocenti, G. Konrad, R. Motta, G. Francavilla, M. Giuntoli (Genoa, IT) P935 Self-perceived problems in daily activities in individuals with MS and the effects of interdisciplinary rehabilitation E.M. Månsson Lexell, U.-B. Flansbjer, J. Lexell (Lund, SE) P936 European nurse survey demonstrates significant disparities in nursing of multiple sclerosis patients and the need to benchmark standards for improved patient care H.-P. Hartung, A. P. Ross (Düsseldorf, DE; Chicago, US) P937 MARINA-SEP: a group programme experience in multiple sclerosis M. Jolibois, C. Delaunay, S. Loiseau, R. Devy, N. Caizergues, P. Lehert, M. Genty, G. Edan (Le Havre, Saumur, Rennes, FR; Louvain, BE; Glion sur Montreux, CH) P938 Group exercise therapy for balance and mobility in people with MS: an ongoing randomised controlled trial A. Millar, S. Lennon, K. Eastwood, S. Gillespie, S. Hawkins, A. Lowe-Strong (Newtownabbey, Belfast, UK) P939 The effect of occupational therapy on resilience of patients with multiple sclerosis

J. Kalina, J. Falk-Kessler, P. Miller, J. Bacon, J. Herbert Posters (New York, US) P940 Unmet needs of Irish MS patients R. Lonergan, K. Kinsella, P. Fitzpatrick, M. Duggan, S. Jordan, M. Hutchinson, N. Tubridy (Dublin, IE)

139 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Quality of life 2 P941 The impact of paediatric-onset multiple sclerosis on quality of life in early adulthood: preliminary results S. Khan, M. McGowan, D. Sadovnick, A. Bar-Or, R. Marrie, D. Arnold, B. Banwell (Toronto, Vancouver, Montreal, Winnipeg, CA) P942 Quality of life in multiple sclerosis: interferon versus natalizumab M. Pattini, F. Cenci, B. Allegri, I. Pesci, L. Manneschi, A. Guareschi, E. Marta, E. Montanari (Fidenza, Milan, IT) P943 Assessment of life-style changes in patients with MS after disease onset S. Eugeni, T. Righetti, K. Ricchezze, M. Giacomi, A. Caterini, L. Barboni, L. Antonini, B. Ramazzotti, S. Salsiccia, M. Sparvoli, A. Morgantini, A. Bortone (Ancona, Fabriano, Porto Potenza Picena, Macerata Feltria, Ascoli Piceno-S.Benedetto, Camerino, Civitanova Marche, Filottrano, Macerata-Tolentino, Matellica, IT) P944 Health-related quality of life over time: five-year longitudinal data from the North American Research Committee on Multiple Sclerosis K. Turpin, S. Warren, W. Janzen, K. Warren, R.A. Marrie (Edmonton, Winnipeg, CA) P945 A pilot study assessing satisfaction and good treatment compliance of patients during their first year of treatment through a standardized approach (ACCOMPASEP) set up in 5 French MS healthcare systems J. De Seze, P. Clavelou, M. Debouverie, G. Edan, A.M. Guennoc (Strasbourg, Clermond-Ferrand, Nancy, Rennes, Tours, FR) P946 Feasibility and effectiveness of web-based self-help intervention for depressive symptoms in MS patients L. Nieuwenhuis, P. van Oppen, B. Uitdehaag, C. Polman, P. Cuijpers, A. Beekman, J. Dekker (Amsterdam, NL) P947 Emergence of walking and mobility problems among patients with multiple sclerosis and its impact on quality of life: a cross-sectional assessment in 5 EU countries K. Rajagopalan, E. Jones, J. Pike, J. Jackson (Boston, US; Macclesfield, UK) P948 Variance in health-related quality of life explained by socio-demographic and MS-related factors: data from the North American Research Committee on Multiple Sclerosis S. Warren, K. Turpin, W. Janzen, K. Warren, R.A. Marrie (Edmonton, Winnipeg, CA)

140 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Neuro-Ophthalmology 2 P949 Macular volume assessed by time versus spectral domain OCT in subtypes of multiple sclerosis S. Schippling, M. Woelbert, A. Hassenstein, R. Martin (Hamburg, DE) P950 Low-contrast letter acuity and its association with EDSS, quality of life, and MRI measures in the AFFIRM trial S. Galetta, L.J. Balcer, C.H. Polman, R.A. Rudick, E. Eggenberger, P. Calabresi, F. Munschauer, A. Zhang, R. Hyde (Philadelphia, Cleveland, East Lansing, Baltimore, Cambridge, US; Amsterdam, NL) P951 Simvastatin treatment favours the long-term outcome of patients with optic neuritis A. Tsakiri, K. Kallenbach, D. Fuglo, B. Wanscher, H. Larsson, J. Frederiksen (Glostrup, DK) P952 Neither retinal nor brain atrophy can be shown in patients with acute unilateral optic neuritis J.L. Frederiksen, K. Kallenbach, B. Sander, A. Tsakiri, B. Wanscher, D. Fuglø, M. Larsen, H.B.W. Larsson (Glostrup, DK) P953 Primary progressive MS demonstrates multifocal ERG and qualitative spectral domain OCT changes not seen in relapsing–remitting multiple sclerosis D. Grover, N. Ohri, R. Sergott (Philadelphia, US) P954 Daytime dependent retest-reliability of retinal nerve fibre layer thickness H. Zimmermann, T. Oberwahrenbrock, C. Pfueller, G. Gaede, E. Bohn, F. Paul, A. Brandt (Berlin, DE) P955 Retinal nerve fibre layer thickness in multiple sclerosis and neuromyelitis optica L.P. Marchello, C. Bellusci, S. Stecchi, E.C. Campos (Bologna, IT) P956 Measurement of progressive axonal damage in multiple sclerosis with high-resolution optical coherence tomography: potential and limitations N. Serbecic, F. Aboul-Enein, S. Beutelspacher, M. Graf, K. Kircher, W. Brannath, P. Lang, W. Kristoferitsch, H. Lassmann, A. Reitner, U. Schmidt-Erfurth (Vienna, AT; Heidelberg, DE) Posters P957 The prospective effect of optic nerve lesion on the retina and the functional response in visual cortex in patients with optic neuritis D. Fuglø, K. Kallenbach, A. Tsakiri, H. Simonsen, H.B.W. Larsson, J.L. Frederiksen (Glostrup, DK)

141 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Biomarkers 2 P958 Good responders to glatiramer acetate treatment identified by gene expression classifiers S. Anis, E. Hanael, P. Sonis, M. Gurevich, A. Achiron (Ramat-Gan, IL) P959 A possible mechanism of action: interferon beta decreases energetic activity in CD4+-lymphocytes A. Haghikia, D. Akkad, D. Pappas, B. Pula, S. Ruhrmann, E. Taherzadeh-Fard, L. Arning, R. Gold, S.E. Baranzini, A. Chan (Bochum, DE; San Francisco, US) P960 Myxovirus resistance protein A RNA expression correlates with binding and neutralising antibody levels in multiple sclerosis patients treated with interferon beta A. Goodman, R. Murray, B. Green, E. Fox, C. Markowitz (Rochester, Lone Tree and Centennial, St. Louis, Round Rock, Philadelphia, US) P961 Implication of the Toll-like receptor pathway in the response to interferon beta in MS patients M. Fernández, J. Río, N. Fissolo, C. Costa, M.J. Mansilla, M.C. Edo, X. Montalban, M. Comabella (Barcelona, ES) P962 Intrathecal fibrinogen is elevated in acute but not in chronic neuroinflammatory disorders R. Ehling, F. di Pauli, B. Kuenz, W. Santner, E. Schmutzhard, A. Lutterotti, C. Gneiss, M. Schocke, F. Deisenhammer, T. Berger, M. Reindl (Innsbruck, AT) P963 The Accelerated Cure Project Biorepository – enabling the discovery of biomarkers in MS and other demyelinating diseases H. Schmidt, S. Loud, A. Venkatesan, J. Goins, E. Frohman, S. Taylor, S. Sadiq, L. Puccio, B. Thrower, E. Iski, P. Riskind, J. Weaver, R. Bomprezzi, B. Bullock, R.P. Kinkel, S. Konkel, M. Racke, J. McGowan, T. Vollmer, S. Edwards, L. Steinman, D. Lebus, B. Greenberg (Waltham, Baltimore, Dallas, New York, Atlanta, Worcester, Phoenix, Boston, Columbus, Aurora, Stanford, US) P964 Leukocyte counts in cerebrospinal fluid and blood following firategrast treatment in subjects with relapsing forms of multiple sclerosis E. Havrdova, S. Sopper, S. Pirruccello, S. Shackelford, R. Grove, M. Gold, O. Graff (Prague, CZ; Innsbruck, AT; Omaha, Research Triangle Park, US; London, UK) P965 Application of image and signal processing algorithms to oligoclonal IgG bands classification E. Gomez-Gonzalez, M.I. Garcia-Sanchez, G. Izquierdo-Ayuso, A. Coca De La Torre, D. Ramirez-Martinez, A.M. Marco-Ramirez, M.A. Perales-Esteve, C. Camara-Mora, M. Lucas (Seville, ES)

142 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Biomarkers 2 (continued) P966 Quantification of kappa free light chains in CSF: threshold values and diagnostic relevance in multiple sclerosis and clinically isolated syndrome patients S. Presslauer, D. Milosavljevic, T. Bruecke, W. Huebl (Vienna, AT) P967 Possible role of platelets in the pathogenesis of multiple sclerosis A.H. Maghzi, U.C. Meier, D. Holden, M. Marta, A. Minagar, A. Kantor, E. Waubant, G. Giovannoni, S. Goelz (London, UK; Shreveport, San Francisco,Cambridge, US) P968 Pharmacological changes related to the Th17 regulatory network induced by interferon beta-1a and PEGylated interferon beta-1a in healthy volunteers L. Miller, M. Lerner, M. Crossman, S. Hitchman, G. Davar, M. Subramanyam (Cambridge, US) P969 Serum and CSF leptin levels in patients with multiple sclerosis H. Lee, S. Dhunganah, N. Woodroofe, B. Sharrack (Sheffield, UK) P970 Neurofilament heavy chain in CSF correlates with relapse activity and clinical disability in multiple sclerosis J. Kuhle, D. Leppert, A. Petzold, A. Regeniter, M. Mehling, L. Kappos, R. Lindberg (Basel, CH; London, UK) P971 Development of a high-throughput whole-blood expression profiling method to identify genes induced by IFN beta-1a or PEGylated IFN beta-1a in healthy control subjects N. Allaire, J. Bienkowska, S. Bushnell, J. Carulli, G. Glick, R. Morse, S. Hitchman, G. Davar (Cambridge, US) P972 Multiple sclerosis risk allele HLA-DRB1*1501 modulates seroreactivity of the prognostic tests gMS-Classifier1 and gMS-Classifier2 anti-alpha glucose IgM antibodies N. Dotan, J. Yarden, E. Fire, L. Spector, H. Schmidt, R.P. Kinkel (Lod, IL; Waltham, Boston, US) P973 Antibodies in multiple sclerosis cerebrospinal fluid bind protein complexes containing non-muscle myosin and actin J. Lindsey, W. Dubinsky, K. Lou (Houston, US) Posters P974 Longitudinal evaluation of reactivity against a new immunological target in neuromyelitis optica J.-B. Chanson, I. Paolini, N. Collongues, M. Alcaro, F. Blanc, F. Barbetti, M. Fleury, E. Peroni, P. Rovero, G. Rudolf, F. Lolli, E. Trifilieff, AM. Papini, J. de Seze (Strasbourg, FR; Florence, IT) P975 Neuromarkers antibodies in multiple sclerosis: measure of axonal loss or oligoclonal expansion? S. Cihelkova, P. Jinoch, P. Adam, M. Bojar (Prague, CZ)

143 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Biomarkers 2 (continued) P976 Effects of natalizumab treatment on the CSF proteome of multiple sclerosis patients M. Stoop, V. Singh, C. Stingl, T. Luider, R. Martin, R. Hintzen (Rotterdam, NL; Hamburg, DE) P977 Cerebrospinal fluid amino acid concentrations may reflect cell damage in multiple sclerosis I. Pérez Neri, A. Barreto, J. Morales, J. Flores, J. Ramírez, T. Corona, C. Ríos (Mexico City, MX) P978 Validation of phosphorylated neurofilament-H as a serum biomarker of neurodegeneration in multiple sclerosis patients M. Gresle, G. Shaw, Y. Liu, T. Kilpatrick, B. Taylor, M. Marriott, O. Skibina, J. Haartsen, K. Lazarus, H. Butzkueven (Parkville, Hobart, Melbourne, Box-Hill, AU; Gainesville, US; Beijing, CN) P979 Detection of elevated concentrations of light neurofilament subunits in CSF of patients with multiple sclerosis A. Bartos, J. Labaj, J. Kotoucova, D. Zimova, V. Bucilova, D. Dolezil (Prague, Vestec, CZ) P980 Strategy for anti-aquaporin-4 auto-antibody identification and quantification using indirect immunofluorescence and a new cell-based assay I. De Vidi, N. Delouche, P. Portalès, E. Cadars, M. Stephan, C. Mettling, Y.L Lin, G. Boursier, E. Thouvenot, B. Carlander, W. Camu, H. Zephir, P. Vermersch, J. De Seze, P. Corbeau, J.F Eliaou, T. Vincent (Montpellier, Lille, Strasbourg, FR) P981 Predicting the natural course of clinically isolated syndromes: an exploratory study of cerebrospinal fluid biomarkers A. Gajofatto, M. Fiorini, S. Monaco, M. Turatti, M.R. Bianchi, A. Fiaschi, M.D. Benedetti (Verona, IT)

Late Breaking News P982 A placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis: magnetic resonance imaging (MRI) outcomes J. Wolinsky, P. O’Connor, C. Confavreux, G. Comi, L. Kappos, T. Olsson, P. Truffinet, L. Wang, A. Miller, M.S. Freedman for the Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center in Houston, USA P983 Anti-JCV antibody prevalence in a Swedish cohort of MS patients and non-MS controls T. Olsson, J. Hillert, L. Alfredsson, I. Kockum, M. Subramanyam, T. Plavina, A. Pace, C. Bozic (Stockholm, SE; Weston, US)

144 Poster Sessions Friday, 15 October 2010 15:30 – 17:00 Late Breaking News (continued) P984 Monozygotic twins discordant for MS and discordant for serology disprove cytomegalovirus infection implication in MS M. Marta, S. V. Ramagopalan, K. Morrison, D. Sadovnick, G. Ebers, G. Giovannoni (London, Oxford, UK; Vancouver, CA) P985 HLA in the CombiRx biomarker cohort and controls at baseline H.F. McFarland, S. Jacobson, F.D. Lublin, J.S. Wolinsky, R. Conwit, P.A. Narayana, F. Nelson, G.R. Cutter, S.S. Cofield for The CombiRx Biomarker Investigator Trial Group P986 Benefit of early treatment with glatiramer acetate: MRI results from the 5-year prospectively planned follow up in patients with clinically isolated syndrome enrolled in the PreCISe study M. Filippi, M.A. Rocca, E. Perego, F. Agosta, A. Meani, O. Bajenaru, A. Carra, I. Elovaara, F. Fazekas, H. Hartung, J. Hillert, J. King, S. Komoly, C. Lubetzki, X. Montalban, K.M. Myhr, M.M Ravnborg, P. Rieckmann, D. Wynn, C. Young, G. Comi for the PreCISe study group P987 Inhibition in T- and B-lymphocyte proliferation: mechanistic pathway for reduction of the behavioral and pathological signs of experimental autoimmune encephalomyelitis A.P. Turel, P.J. McLaughlin, R.H. Bonneau, I. Zagon (Hershey, US) P988 Systematic antigen-based plasma profiling in multiple sclerosis B. Ayoglu, A. Gundberg, A. Häggmark, J. Ottervald, M. Khademi, T. Olsson, M. Uhlén, J.M. Schwenk, P. Nilsson (Stockholm, SE) P989 CD 4 dynamics in a natalizumab treated population J. Foley (Salt Lake City, US) P990 Expression profiling of microRNAs by deep sequencing in blood samples from patients with multiple sclerosis F. Gilli, N.D. Navone, P. Valentino, C. Barlassina, F. Macciardi, C. Cosentino, S. Perga, R.A. Calogero, A. Bertolotto (Orbassano, Milan, Turin, IT) Posters P991 A phase I study to evaluate safety, tolerability and pharmacological properties of a selective sphingosine-1- phosphate (S1P) receptor agonist ONO-4641 in patients with multiple sclerosis L.H. Kasper, B.R. Due and the ONO-4641 Study Group P992 Multi-site cross-validation of the assay to detect anti-JCV antibodies in human serum and plasma T. Plavina, M. Berman, M. Njenga, M. Crossman, B. Schlain, M. Subramanyam (Cambridge, US)

145 List of Chairs

Name Page Name Page

Aloisi F. 41 Landtblom A.M. 32 Alvarez-Cermeno J.C. 20 Lassmann H. 18, 40 Amato M.P. 19 Liblau R. 31 Antel J. 34 Lubetzki C. 42 Ascherio A. 21 Lublin F. 25, 38 Lycke J. 26, 27, 37, 45 Balcer L. 22 Banwell B. 21 Matthews V. 33 Barkhof F. 20 Miller D. 18 Benedict R.H. 19 Montalban X. 27, 43 Brück W. 25 Myhr K.M. 28 Brundin L. 42 O’Connor P. 49 Clanet M. 27, 35 Olsson T. 21, 26, 46 Coles A. 37 Comi G. 23 Pozzilli C. 48 Compston A. 39 Pugliatti M. 32 Correale J. 39 Runmarker B. 34 Du Pasquier R. 35 Saida T. 38 Ebers G. 45 Scolding N. 34 Soelberg Sørensen P. 47 Fazekas F. 18 Solaro C. 41 Feys P. 33 Stewart G. 28 Filippi M. 20 Svenningsson A. 43 Frederiksen J. 22 Fredrikson S. 36, 46 Teunissen C. 25 Fulcher G. 30 Thompson A.J. 48 Tintore M. 24 Giovannoni G. 20, 45 Trapp B. 40 Trojano M. 34 Hartung H.-P. 22, 35, 46 Havrdova E. 49 Vukusic S. 19, 45 Heesen C. 30 Henze T. 41 Waubant E. 21 Hillert J. 19, 31, 42 Wekerle H. 18 Höllsberg P. 41 Wolinsky J. 22, 31, 44

Karussis D. 31 Zipp F. 24 Koch-Henriksen N. 29 Kremenchutzky M. 29 Kuhlmann T. 44

146 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Aarseth, J. P263, P720, P890 Alavantic, D. P261 Andlovic, A. P153 Aaso, A. P926 Alberch, J. P883 Andraczek, J. P719 Abad-Grau, M.M. P689 Albertí, J. P851 Andreadou, E. P361 Abaroa, L. P603 Alcaro, M. P974 Andree, M. P861 Abdelali, A. 67 Alcina, A. P689 Andreou, P. P608 Abderrahim, H. P266 Alewijnse, A. P662 Andres, M. P851 Abedi- Yekta, A.H. P530 Alfredsson, L. 34, 55, P197, Andrews, M. P319, P653 Abedini, M. P188 P267, P631, Andrian-Albescu, M. P690 Aboul-Enein, F. P359, P956 P715, P983 Androdias, G. P237 Abreu, P. P216 Algun, C. P917 Anis, S. P958 Absinta, M. P314, P341, Ali, S. P232 Annamalai, T. P671 P734, P738, P745 Alijani, E. P530 Annibali, V. 94 Absoud, M. P606 Alikhani, K. P778 Annovazzi, P. P896, P920 Acar, B. P575 Allaire, N. P971 Annovazzi, P.O. P640 Accetto, S. P153 Allegri, B. P534, P942 Ansar, M.M. P725 Achiron, A. P192, P562, Alloza, I. P264 Antel, J. P240, P472, P700 P791, P958 Aloisi, F. 94, P715, P716 Anthony, D.C. P814 Achtnichts, L. P387, P799 Alonso, B. P698 Antigüedad, A. P264 Acker, T. P719 Alteri, E. P817 Antonelou, R. P574 Acquarone, N. P929 Altimiras, J. P622 Antonini, L. P943 Ada, E. P415 Altintas, A. P158, P178, P370 Antoniol, C. P198 Adam, P. P975 Altmann, D.M. P253, P696 Antony, G. P202 Adamczyk-Ludyga, A. P641 Altmann, D.R. P348, P349 Apóstolos Pereira, S.L. P160, Adams, O. P861 Alvarenga, H. P333 P657 Adler, G. P388 Alvarenga, M. P168, P595 Arakaki, T. P603 Adoni, T. P160, P201, Alvarenga, M. P595 Aranami, T. P446 P657, P713 Alvarenga, R. P214, P595, Araujo, C. P165, P718 Afazel, S. P401, P448 P333 Arbel, I. P811 Agan, K. P498, P726 Alvarenga-Filho, H. P373 Arbizu, T. P683 Agaoglu, J. P178 Alvarez Linera, J. P378, P794 Argaw, A.T. 83, 107 Agarwal, S. P499 Álvarez-Cermeño, J.-C. P278 Arias-Leal, A.M. P289, P714 Aghaie, M. P530 Alvarez-Lafuente, R. P264, Arici Duz, O. P158, P642 Agoropoulou, C. P434 P289, P689, P714, P717 Aridon, P. P874 Agosta, F. P734, P767, Alves-Leon, S. P490 Armañanzas, R. P558 P986 Amadio, S. P360 Armengol, C. P452 Agostini, S. P888 Amann, M. P387, P799, Armspach, J.-P. P549 Aguila, A. P159 P809 Armstrong, R. P909 Aguilar, N. P452, P453 Amato, M.P. P184, P235, Arnaoutoglou, M. P628 Ahlgren, C. 95, P187 P334, P422, P796, P875 Arnason, B. P369, P476 Aichner, F. P892 Amengual, A. P792 Arnaud, C. P787 Airas, L. P397 Amezcua, L. P195 Arning, L. P959 Ajami, B.A. P308 Amor, S. P312 Arnold, D. 54, P194, P343, Akbar, N. 17 Amtmann, D. P643 P337, P476, P590, Akbari, M. P393 An, J.Y. P145, P356, P623 P629, P700, P764, Akkad, D. P959 Anani, T. P394 P904, P941 Aksnes, L. 16 Ananivi, J. P179 Arora, A. P758

Al Nimer, F. P256 Andersen, O. 36, 95, P147, Arrambide, G. 85, P346, Chairs & Authors Al-Izki, S. 109 P621, P902 P555, P754 Al-Kutoubi, A. P663 Anderson, G. P823 Arroyo, R. P264, P289, Al-Sabbagh, A. P909 Anderson, J. 94 P689, P714, P717 Al-Thubaiti, I. P853 Andersson, M. P398 Arsic, M. P740

147 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Ascherio, A. 53, P724 Baker, D. 109, P676 Bartolozzi, M.L. P334, P739 Asgari, N. P596 Baker, K. P481, P860 Bartos, A. P979 Ashby, L.G P488 Bakshi, A. P758 Bartosik-Psujek, H. P213, Aslam, M. P682 Bakshi, R. P758 P218, P455 Aspeck, E. P357 Bala, J. P189 Bassan, R. P859 Asser, H. P892 Balamoutsos, G. P290, P297 Bassetti, C.L. P803 Assouad, R. 117, P736, P787 Balcer, L. 9, 80, P541, Bastianello, S. P422 Aste, R. P620 P904, P950 Bates, D. 19, P905 Attia, J. P626 Balint, B. P697 Batista, E. P168 Atzori, M. 7, P325, P332, Ballonzoli, L. P549, P592, Batista, S. P416 P756, P831 P732 Batista, S. P490, P503 Aubin, C. 6 Balnyte, R. P365 Batocchi, A.P. P212, P282 Audoin, B. P372, P605, Baloyannis, S. P628 Battaglia, M.A. P525, P916 P765, P805, P867 Bamer, A. 58 Battaglini, M. P325, P329, Auff, E. P354 Ban, M. P263 P334, P336, P739, Auger, C. 85, P346, P555, Baneke, P. P661 P746, P863 P754, P841, P865 Bang-Gottwald, G. P223 Battaglio, M. P199 Augusto, L. P301 Banwell, B. 54, P194, P590, Battifoglio, M. P729 Aulí, M. P452, P851 P629, P941 Bau, L. P683 Aupy, J. P208 Bao, F. P423, P761 Bauer, J. P243 Auquier, P. P650 Bar-Or, A. 54, 114, P194, Baumann, C. P376 Auriel, E. P588, P699 P472, P590, P629, Baumgartner, A. P439 Ausili Cefaro, L. P329 P700, P833, P941 Bayas, A. P459, P836 Avidan, N. P262 Baracchini, C. 81 Bazin, P. 9 Awad, H. P306 Baran, H. P157 Bealmear, B. P311 Awdeh, H. P663 Baranova, N.S. P587 Beckmann, K. P369, P476, Axelsson, M. P566, P707 Baranzini, S. P558, P959 P610, P807, P903 Aycardi, E. P408 Barbetti, F. P974 Bednarova, J. P597 Aydar, G. P205 Barbi, F. P577 Beekman, A. P946 Aydin, T. P158, P642 Barboni, L. P943 Begum-Haque, S. 14, P273 Aydin Canturk, I. P642 Barcella, V. P433, P871 Belachew, S. 70, P494, Ayoglu, B. 137, P988 Bargiggia, V. P835 P598, P654 Ayuso, L. P545 Barillot, C. P351 Belaroussi, B. P338 Azimzadeh, P. P690 Barkhof, F. 5, 133, 114, 118, Bell, R. P456 P324, P352, P358, Bellantonio, P. P235, P480, Bäärnhielm, M. 55 P369, P547, P564, P722 Babadi, M. P530 P686, P735, P759, Bellenberg, B. P353 Babb, J. S. P387 P766, P767, P807, Bellora, N. P257 Babic, M. P153 P812, P827, P848 Bellusci, C. P955 Bacci, L. P386, P802 Barlassina, C. P990 Belman, A. P294 Bach Sondergaard, H. 34 Barnett, M 38, P626, P658, Belniak, E. P455 Bacigalupo, A. P336 P819 Bemben, M. P543 Bacon, J. P939 Baron-Van Evercooren, A. 106 Benali, H. P736 Bacon, T. P609 Barquinero, J. P678 Bendfeldt, K. P358, P686, Badgett, D. P265 Barreto, A. P977 P735 Bahar, H. P415 Barros, P. P301 Benedetti, M.D. P981 Baicus, C. P612 Barroso, J. P788 Benedict, R. P807 Bain, N. P685 Barry, S. P860 Benedict, R.H.B. P318, Bajenaru, O. 135, P986 Bartolome, M. P264, P289, P653, P776, P797 Bajic, N P239 P714, P717 Benesova, Y. P597 Bakchine, S. P793 Bartolomei, I. P508, P773 Benet, I. P288

148 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Benjamins, J. P311 Bestetti, A. P871 Boggild, M. P400, P842, Benkhoucha, M. P249, P677 Betancort, M. P788 P886, P932 Bennett, J. 139 Bethoux, F. 59 Bogumil, T. P476 Bennett, J.B. P308 Bettecken, T. 33 Bohn, E. P954 Benny, B. P853 Bettencourt, A. P644 Bohner, G. P638 Bensa, C. P787 Beutelspacher, S. P956 Bojar, M. P975 Bentzen, J. 39 Beyer, C. P306, P310, Bojarska-Junak, A. P455 Benzerdjeb, H. 79, P833 P312 Bol, Y. P305 Benzinger, T. P760 Bhan, V. P877 Bolaña, C. P500 Beranger, A. P520 Bianca, M. P144, P144, Boll, S. P174 Berg Johnsen, G. P890 P144 Bolukbasi, F. P158 Bergamaschi, A. P885 Bianchi, E. P929 Bombardier, C. P643 Bergamaschi, R. 38, P480, Bianchi, M.R. P981 Bomprezzi, R. P963 P510, P626, P658, Bianchi, V. P796 Bonavita, S. P752 P819, P835, P875 Bianco, M. P360, P779 Boniface, D. P635 Bergami, A. 84 Biasiotta, A. P645 Bonithon-Kopp, C. P634 Bergamino, M. P336 Bienkowska, J. P971 Bonnamain, V. 83, 107 Berger, K. P306 Bingol, A. P370 Bonneau, R.H. P987 Berger, T. P435, P636, Binquet, C. P634 Bonzano, L. P336 P892, P962 Bischoff, C. P912 Boon, M. P169 Bergeron, A. 14, P553 Bisecco, A. P752 Borges, M. P362 Berghmans, A. P924 Bisig, B. P598 Borgwardt, S.J. P358, P735 Berghoff, M. P694 Bissoni, J. P657 Borras, F. P281 Bergmann, A. P223, P659, Bista, P. P887 Borreani, C. 60, P928, P929 P912 Biswal, B. P355 Bortolon, F. P235, P437 Bergsland, N. 82, P318, Bixler, S. P873 Borton, L. P499 P319, P320, P321, Bjerre, L. P540 Bortone, A. P943 P413, P508, P771, Blahusiaková, A. P546 Bosca, I. P151, P288 P772, P774, P775, Blanc, F. P167, P208, P390, Boskovic Matic, T. P627 P776, P797, P866 P466, P549, P592, Bosma, L.V.A.E. P646, P766 Bergström, T. 95 P669, P732, P974 Boster, A. P423 Berkovitz, E. P791 Blanco, R. P545, P784 Boström, I. P723 Berman, M. 138, P873, P992 Blanco, Y. P350 Bot, J.C.J. P324 Bermejo, P. P824 Blanco-Kelly, F. P689 Bottlaender, M. 117, P742 Bermejo, P.E. P444, P898 Blandino, A. P739, P863 Bouktsi, M. P297 Bermel, R.A. P891 Blasco, M.R. P444, P824, Boulton, C. P412 Bernard, C.C. 51 P898 Bourre, B. P167, P208, Bernardi, M. P467 Blasi, G. P322 P607 Bernardi, V. 7, P317, P332, Blinkenberg, M. P355 Boursier, G. P980 P756, P831 Blum, A. P559 Boutin, P. P425 Bernhardt, L. P206, P892 Blundell, M. P842 Bouyon, M. P208, P549, P592 Berra, E. P363 Bö, L. 16, 88 Bowen, J. P878 Berry, I. P351 Bocenti, S. P934 Boyd, A. P673 Berteloot, A.S. P466, P899 Bock, M. P542 Boyd, R. P248, P674, P675 Berthele, A. 33, P406, P682 Bock, D. P825 Boyko, A. P489, P897, P904

Berto, P. P235 Bockaert, J. P563 Boz, C. 38, P158, P178, Authors Bertoldo, A. P317 Bodini, B. P325, P326, P626, P658, P819 Bertolino, A. P322 P753, P920 Bozic, C. 112, 138, P840, Bertolotto, A. P150, P255,P276, Bodling, A. P804 P893, P983 P363, P438, P480, Boesplug Tanguy, O. P684 Bramati, I. P333 P733, P900, P990 Boffa, L. P920 Brambilla, P. P266

149 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Bramow, S. 89 Burtin, P. P445 Cancellieri, G. P933 Brandt, A. P542, P954 Burton, J. P456 Candan, F. P642 Brannath, W. P956 Busch, M. P353 Cannoni, S. 94 Brara, S. P630 Buschmann, J.P. P306 Cantoni, C. P691 Brassat, D. P167, P390, P867 Buse, K. P206 Caon, C. P423, P761 Bratina, A. P800 Bushnell, S. P971 Capello, E. P238, P336 Breiden, P. P293, P815 Butti, E. P247 Caplan, J. P475 Brennig, C. P233 Butzkueven, H. 38, P494, Capobianco, M. P150 Brescia Morra, V. P437, P748 P609, P626, P650, Capra, R. 57, P266, P437, Bresolin, N. P691 P658, P819, P978 P480 Brettschneider, J. P570 Buyske, S. P554 Capurro, C. P170, P695 Brichetto, G. 62, P525, Byrnes, W.J. P431 Caputo, D. P314, P734, P916, P933 P738, P888 Brismar, T. P782 Cabedo, J. P452, P851 Caramanos, Z. P343 Brissart, H. P376 Cabezas, M. P743 Carazza, L. P165 Brittain, D. P221 Cabre, P. P605, P867 Cardellini, C. P647 Brochet, B. P179, P380, Cabrera-Gomez, J. 38, P159, Carini, D. P460 P637, P867, P892 P626, P658, P819 Carl, E. 82, P265, P318, Brod, S. P244 Cabrera-Núñez, A.Y. P159 P319, P320, P573, Brodsky, R. P471 Cadars, E. P980 P653, P771, P772, Bröker, B. P838 Cadavid, D. P432, P706, P731 P774, P776, P797 Brønnum-Hansen, H. 39 Caizergues, N. P535, P536, Carlander, B. P980 Bronzlik, P. P915 P862, P937 Carlier, V. P822 Brooker, H. P463 Calabrese, E. P729 Carloni, C. P835 Brooks, C. P653 Calabrese, M. 7, 81, P148, Carloni, F. P835 Brooks, J. P728 P317, P332, P746, Carotenuto, B. P748 Brown, M.G. 65, P608 P756, P767, Carpeggiani, P. P577 Brown, T. P515, P518, P831, P920 Carpenter, A. P164, P182 P921, P922 Calabrese, P. P369, P385, Carpentier, W. P853a Browning, J. P706 P799, P803, P809 Carra, A. 135, P986 Brück, W. 11, 139, P240, Calabresi, P. 9, 80, 114, Carrá, A. P500, P901 P251, P458, P719 P434, P541, P547, Carroll, W. P693 Bruckner, A. P181 P904, P950 Carter, L. P436 Bruecke, T. P966 Calabresi, P. P676 Carter, N. P674 Brum, D.G. P473 Calay, P. P654 Carulli, J. P971 Brunetti, A. P748 Caldano, M. P255, P276, Carvalho, F. P657 Brunot, S. P198 P438 Carvalho, S.R.S. P373 Bruschini, H. P657 Callander, M. P692 Casals, D. P453 Brynedal, B. P681, P692 Callegaro, D. P160, P201, Casanova, B. P151, P288 Bucciarelli, F. P867 P657, P713, P919 Casanova, J. P350 Bucello, S. P640, P896 Calogero, R.A. P990 Cascione, M. P909 Bucilova, V. P979 Calvo, B. P558 Casez, O. P867 Buck, D. 33, P406, P682, Camara-Mora, C. P965 Castañeda, E. P236 P740 Camargo, S. P168, P176 Castelijns, J.A. P759 Buckley, C. 13 Camesasca, F. P476 Castellaro, M. P317 Budde, R. P694 Campbell, G. P670 Castelli-Haley, J. P913 Bufill, E. P622 Campbell, I.L. P277, P666 Castelnovo, G. P592, P867 Bugge, J.-P. P458 Campos, E.C. P955 Castilló, J. 85, P346, P555, Buljevac, D. P721 Campos-Rivera, J. P424, P425 P754, P841, P865 Bullock, B. P963 Camu, W. P563, P867, Castillo-Triviño, T. P558 Burkhart, C. P402 P980 Castley, A. P693

150 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Castot, A. 67 Chassagne, M. P581 Coca De La Torre, A. P965 Castro, J. P851 Chateauraynaud, J. P179 Coccia, E. P716 Castro-Borrero, W. P210 Chatzopoulos, M. P486 Cocco, E. P269, P480, Catalan, M. P800 Chaunu, M.P. P793 P620, P854, P920 Catena, L. P386, P802 Chawda, S. P635 Coelho Santa Rita Pereira, V. P503 Caterini, A. P943 Chen, J.T. P337 Cofield, S.S. P617, P985 Catsman-Berrevoets, C.E. P169 Chen, L. P873 Coghe, G. P269, P620, P854 Causa, M. P525, P933 Cheon, S.M. P623 Cohen, J. 141, P442, Causin, F. 81 Cherneva, M. P318, P319, P454, P827, P812, Cavaco, S. P644 P774 P830, P843, P844, Cavagna, S. 50 Cheung, A. P873 Cohen Tervaert, J.W. P270 Cavaletti, G. P729 Chiaravalloti, N. P328 Coku, J. P269 Cavalla, P. P235, P238, Chiasserini, D. P676 Coles, A. P410, P421, P703, P875 Chiavazza, C. P238 P454 Cavallo, R. P703 Chibana, V. P647 Collin, M. P249 Cavanillas, M.L. P689, P717 Chieffo, R. P366 Collins, W. P442, P830, Cavillon, G. 50 Chihara, N. P446 P843 Ceccarelli, A. P758 Chinea, A. P191, P495 Collongues, N. P167, P208, Cedile, O. P704 Chitnis, T. P294 P549, P592, P605, Celebi, A. P178 Cho, J.Y. P548, P578 P607, P669, P974 Celius, E.G. P263, P624, Choi, J.W. P834 Colombo, B. P163, P327, P681 Chollate, S. P887 P364, P640 Ceña, V. P883 Chowdhury, C.A. P236 Colpaert, M.-H. P506 Cenci, F. P534, P942 Chretien, N. P427 Comabella, M. P254, P257, Cendrowski, W. P303, P632 Christenn, M. P388 P555, P572, P701, Cenit, M.C. P264 Christiansen, F. P693 P733, P841, P961 Centonze, D. P407, P880 Christy, M. P273 Comi, C. P703 Cepok, S. 33, P406, P461, Chun, J. P834 Comi, G. 46, 57, 79, 84, P682 Chung, J. P630 126, 135, P148, P163, Cercignani, M. P326, P753 Ciccarelli, O. P325, P326, P184, P232, P266, P284, Cha, C. P418 P344, P345, P744, P314, P327, P341, P360, Chabas, D. P294 P753, P767 P364, P366, P369, P403, Chabou, B. P498 Ciceri, F. P467 P433, P437, P441, P467, Chaila, E. P152, P585 Cichalewska, M. P709 P476, P480, P505, P594, Chamarro, R. P151 Cihelkova, S. P975 P640, P734, P738, P745, Chamot, E. P609 Cinque, P. P871 P751, P779, P796, P812, Chan, A. P202, P252, Cirillo, M. P752 P817, P825, P827, P852, P353, P461, P560, Cirillo, S. P752 P871, P875, P885, P896, P702, P959 Claerbout, M. P531 P982, P986 Chanal, M. P237 Clanet, M. 67, P351, P684, Compston, A. P263, P454 Chandran, S. P246, P313 P867 Compston, D.A.S. P313 Chandraratna, D. P661 Clark, H.B. P164 Comtat, C. 117 Chang, A. P337 Clarner, T. P306, P310, P312 Confalonieri, P. 60, P928 Chang, P. P403, P441, Claus, M. P435 Confavreaux, C. P454 P852 Clavelou, P. P637, P867, P945 Confavreux, C. 35, 50, 67, 79,

Channon, J. 14, P553 Clerc, L. P634 128, P237, P338, P431, Authors Chanson, J.-B. P669, P732, Clerc-Renaud, P. P581 P605, P684, P750, P974 Clerici, M. P888 P833, P867, P982 Charbonnier-Beaupel, F. P853a Clerico, M. P703 Confort-Gouny, S. P765, P805 Chard, D. P749, P767 Clerson, P. P649 Conger, A. 80 Chardain, A. P742 Coarelli, G. 94 Coniglio, G. P437, P875

151 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Conrad, C. P277, P666 Cozzone, P.J. P765, P805 Dalla Libera, D. 84, P163, Constantinescu, C. P492, Cree, B. P868 P594, P640, P779 P612, P813, P842 Creeke, P. P411 Dalton, C. P516, P764, Contessa, G. P703 Crespy, L. P372, P765, P805 P923 Contu, P. P620, P854 Crevits, L. P368 Damasceno, A. P183 Conwit, R. P985 Cristiano, E. 38, P193, P567, Damasceno, B. P183 Cook, K. P643 P626, P658, P819 Damoiseaux, J. P270, P305 Cook, S. P232, P369, Cristiano, L. 138, P840, P893 Dangond, F. P909 P403, P441, P476, C.F.Vasconcelos, C. P258 Daniel, M. P306 P817, P825, P852 Crivelli, L. P792 Daumer, M. P180, P217, Coote, S. 15, 61, P511, Cross, A. P760 P613, P651, P815 P532, P931 Crossman, M. P873, P968, P992 Davaki, P. P361 Copetti, M. P734, P738, Croy, L. P475 Davar, G. P904, P968, P971 P745 Croze, E. P565, P884 David, O. J. P412, P445, Coppi, E. P366 Cruccu, G. P645 P846 Corbeau, P. P980 Crusius, J.B.A. 6 Davies, A.L. P670 Cordioli, C. P920 Cseh, B. P367 Davis, S. P210 Cordoba, F. P402 Csepany, T. P222 Davis, T.G. P436 Cordón, L. P288 Csiba, L. P222 Dawson, K. P478, P764 Cordonnier, C. P607 Cua, R. 108 Dazzi, F. P253 Coret, F. P288 Cuche, M. P236 de Andres, C. P162, P698 Coret Ferrer, F. P151 Cudrici, C. P690 De Baets, M. P705 Cormier, F. P853a Cuijpers, P. P946 De Caro, M.F. P796 Cornelisse, P. P225, P287, Cummmins, C. P606 De Ceglia, R. P885 P492, P813, P857, P863 Cursano, C. P729 De Chiara, V. P407, P880 Cornelius, C. P475 Curti, E. P550, P870 De Gascun, C.F. P292 Corona, T. P977 Cutter, G. P173, P181, De Giglio, L. P184 Corona Vazquez, T. P200 P228, P265, P318, de Graaf, W.L. P324, P759 Corrado, D. P875 P347, P476, P508, de Groot, V. 59 Correale, J. P146, P291, P609, P617, P653, De Iure, A. P676 P500, P792 P757, P903, P985 De Jager, P. 6, 32, P284 Corti, C. P467 Cwiklinska, H. P285, P709 De Keyser, J. P307 Cortini, F. P691 Czekalla, J. P906 De la Concha, E.G. P689 Corvol, J.C. P853a De las Heras, V. P264, P289, Cosentino, C. P990 D’Alessandro, R. 60, P928 P689, P714, P717 Cosentino, G. P472 D’Amelio, M. P874 De Leval, L. P598 Coskuner Poyraz, E. P519 D’Andrea, I. P490 De Luca, G. P382, P783, Cossburn, M. P481, P860 D’Andrea Meira, I. P503 P920 Costa, C. P241, P254, P555, D’Onghia, M. 122, P837 De Mercanti, S. P703 P701, P708, P961 D’Souza, M. 41 De Ridder, D. P203 Costa, C. P676 D’Amico, E. P875 De Rijke, Y.B. P721 Costa, V. P628 Dagrassa, L. P867 De Riz, M. P691 Costello, F. P339, P456, Dahl, N. P582 De Seze, J. P167, P208, P390, P747, P762 Dahle, C. P335, P491, P566 P466, P549, P581, Costelloe, L. P450 Dahle, L. P274 P592, P605, P607, Cotton, F. P338 Dahlqvist Leinhard, O. P335 P669, P732, P867, Coustans, M. P394 Dal-Bianco, A. 89, P354 P945, P974, P980 Coutinho, E. 13 Daley, A. P537 De Stefano, N. P325, P329, Couturier, N. P867 Dalgas, U. 59, 100 P334, P336, P739, Cova, M. P800 Dalla Bella, E. 60, P928, P746, P753, Coyle, P. P408 P929 P857, P863

152 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr. de Vera, A. P442, P843, Di Battista, G. P875, P900 Drexhage, J. 86, 91 P844 Di Costanzo, A. P752 Droogan, A. P895 De Vidi, I. P980 Di Filippo, M. P676 Drulovic, J. 136, P314, P485, de Villiers, E.-M. P293 di Ioia, M. P382, P783 P627, P734, P738 de Vries, E. 86, P662 Di Luca, M. P676 Dua, P. 113 de Vries, H.E. 91 di Marzo, V. 25 Dubinsky, W. P973 Debette, S. P607 di Pauli, F. P962 Dubois, M. P351, P637, Debouverie, M. P376, P P612, Di Penta, A. P883 P649 867, P945 Di Renzo, V. P322 Due, B.R. P991 Debruyne, J. P368 Di Rezze, S. P645 Duerr, E. P448 Decard, B.F. P560 Di Sapio, A. P363 Dufour, M. 67 Deckers, K. P822 Di Stefano, G. P645 Duggan, M. P152, P292, Defer, G. P867 Di Stolfo, V. P729 P585, P940 Defoort, S. P592 Di Tommaso, V. P184, P382, Duggan, P. P456 Dehmel, T. P861 P783 Dujmovic-Basuroski, I. P485 Deisenhammer, F. P233, P636, Dias, R.M P373 Dumitrescu, L. P612 P733, P962 Diaz, R. P159 Dumortier, T. P445 Dekker, J. P946 Diaz-Sanchez, M. P143 Duncan, H.P P606 Del Carro, U. P360 Dib, J. P168 Duquette, P. 38, P193, del Val Fernandez, J. P648 Díez Tejedor, E. P378, P399, P626, P658, P819 Delaunay, C. P937 P794 Durand-Dubief, F. P338, P750 Delbue, S. P835 Digesu’, A. P517 Durbin, M. 9 Delforge, J. 117 Dijkstra, C. 47, P662 Durelli, L. P703 Delipoyraz, I. P908 DiMarco, J.P. P830 Durfee, J. P318, P319, P771, Dell’Oglio, E. P758 DiMauro, S. P269 P772, P776, P866 Della Corte, M. P752 Dincic, E. P261 Duriez Sotelo, E. P500 Dello Russo, C. P879 DiPauli, F. P636 Dutta, D. 83, 107 Deloire, M. P380 Direnzo, V. P569, P837 Duvefelt, K. 34 DeLong, J. P553 Disanto, G. 54, P298 Dwyer, M. 82, P318, P319, Delouche, N. P980 Dixon, J. 119 P320, P321, P413, DeLuca, J. P328 Dobson, R. P556 P508, P771, P772, Demalmanche, T. P626 Docimo, R. P752 P774, P775, P776, P797 Demirci, O. P370 Doepp, F. 3, P579 Denecke, B. P312 Dogonowski, A.-M. P355 Easley, K. P337 Denney, D. P383, P804 Dolev, M. P192 Eastwood, K. P938 Deprez, M. P598 Dolezal, O. P866 Ebers, G. 54, P180, P613, Derache, N. P867 Dolezil, D. P979 P903, P984 Derakhshandeh, F. P204 Domènech, A. P452 Ebner, F. P342 Derakshan, M. P764 Domènech, T. P452 Echaniz-Laguna, A. P581, P732 Derakshani, S. P635 Domínguez, C. P701 Eckstein, C. 9 Dereeper, O. P684 Domínguez, M. P452, P453 Economou, N. P803 Derfuß, T. P196, P440 Dominguez-Mozo, M.I. P289, Edan, G. 110, P351, P369, Deri, N. P626, P658 P714, P717 P394, P535, P536, Dervenoulas, G. P574 Domowicz, M. P667 P613, P807, P853a, Desgrandchamps, D. P494 Donadi, E.A. P473 P867, P937, P945

Desormeaux, C. P394 Donze, C. P526, P862 Edgar, C.J P463 Authors Despalins, R. P634 Doring, A. 108 Edite Rio, M. P626, P658 Deus-Silva, L. P183 Dörr, J. P542 Edland, A. 134 Devy, R. P535, P536, P937 Dotan, N. P552, P972 Edo, M.C. 85, P346, P555, Dhib-Jalbut, S. P554 Douw, L. P352 P754, P841, P865, P961 Dhunganah, S. P969 Dressel, A. P838 Edström, M. P274

153 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Edwards, K. P518, P706 Evangelou, N. 119 Fernandez-Arquero, M. P264 Edwards, S. P963 Evans, E. P475 Fernández-Morera, J.L. P727 Eelen, P.L. P203 Eymard-Pierre, E. P684 Fernández-Reinoso, R. P851 Eggenberger, E. P541, P950 Ferradji, A. P856 Ehde, D. P643 Fadda, E. P269 Ferrante, P. P835 Eheberg, D. P659 Fadeeva, O.A. P587 Ferrarese, C. P729 Ehling, R. P636, P962 Faissner, S. P702 Ferrari, G. P550 Ehrlé, N. P793 Faivre, A. P372, P765, P805 Ferraro, D. P389, P577, P600 Eikeland, R. P720 Falah, M. P596 Ferré, J.-C. P351 Eixarch, H. 85, P241, Falautano, M. P796, P929 Ferretti, V. P620 P678, P708 Falini, A. 57, P341, P745 Ferriby, D. P867 Ekholm, S. P621 Falk, K. P724 Ferrigno, P. P620 Ekmekci, D. P908 Falk-Kessler, J. P939 Ferrò, M. P875 Elagina, I. P818 Fallis, R. P207 Fevr, T. P403 Elfadil, M. P265, P318, P653 Fang, L. P687 Feys, P. 59, P224, P531 Eliaou, J.F P980 Farbu, E. P720 Fêzer, L. P503 Elias, W.-G. P821 Farez, M. P291 Fiaschi, A. P981 Eliasziw, M. P456 Farge-Bancel, D. P469 Fiehler, J. P330, P768 Elkins, J. P557, P561 Farina, D. 60, P382, P783, Filippi, M. 57, 74, 135, P148, Elovaara, I. 135, P986 P928, P929 P314, P327, P341, Emiru, T. P182 Farina, F. 81 P369, P437, P476, Emmanuel, A.V. P516, P923 Farkas, M. P685 P734, P737, P738, Empis, H. P526 Farrell, R. P411 P745, P751, P986 Enzinger, C. P296, P315, Farrell, S. 9 Filli, L. P358, P735 P342, P357, Fäsgen, I. P211 Fini, C. P345 P755, P769 Favaretto, A. 7, P317, P332, Fink Eriksen, E. P300 Epstein, M. P538 P746, P756, P831 Finkelsztejn, A. P728 Erälinna, J.-P. 134 Fawaz, A. P663 Finlayson, M. P528 Erb, K. P638 Fazekas, F. 135, P243, P296, Fiol, M. 38, P626, P658, Erdmann, T. P647 P315, P342, P357, P792, P819 Erhart, H. P157 P737, P755, P769, P986 Fiore, S. P407 Erkorkmaz, U. P205 Fazio, L. P322 Fiorini, M. P981 Erminio, C. P171 Fazio, R. P163, P594 Fire, E. P552, P972 Ernerudh, J. P274, P335 Federico, A. P334, P739 Fischer, T. P651 Ernst, F. P173 Fedorenko, D. P522 Fisher, E. 125, P337, Eros, A. P367 Feger, M. P388 P798, P864, P891 Erra, M. P851 Feinstein, A. 17 Fisher, T. P475 Errea, O. P664, P883 Feinstein, D. P879 Fisk, J. P877 Ertekin, Ö. P917 Felicio, T.A. P591 Fisniku, L.K. 115 Escartin, A. P371 Feltelius, N. P491 Fissolo, N. P254, P961 Eshaghi, A. P175 Felton, T. P488 Fitz-Gerald, L. P700 Espasandin, M. P411 Fenoglio, C. P691 Fitzgerald, M. P626 Espejo, C. 85, P241, P278, Fenu, G. P269, P620, P854 Fitzpatrick, P. P940 P678, P708 Ference, T. P520 Fjeldstad, A. P221, P665 Espeset, K. P890 Fernandez, J. P170, P695 Fjeldstad, C. P221, P543 Esposito, F. P752 Fernández, M. P257, P572, Flachenecker, P. P650 Esposito, F. P266, P284 P961 Flachs, E.M. 39 Etemadifar, M. P204, P393, Fernandez, M. P195 Flansbjer, U.-B. P935 P869 Fernandez, O. P409, P650, Flechter, S. P626, P658 Eugeni, S. P943 P689 Fleiner, F. P638 Evangelopoulos, M.E. P361 Fernandez y Fernandez, O. P258 Fletcher, J.M. P450

154 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Fleury, M. P167, P466, P549, French-Constant, C. P246 Galvao, A. P362 P592, P607, P974 Frenken, H. P735 Gama, D.A.D. P201, P713 Florek, J. P899 Fressinaud, C. P309 Gama, H. P737 Flores, J. P200, P977 Friend, S. P482 Gama, P.D. P201, P713 Flores, J. P737 Frigo, M. P729 Gama, R.A.D. P201, P713 Flores, L. P409 Frischer, J.M. 89 Gamble, C. P842 Florio, C. P235 Frisén, J. 140 Gangakhedkar, A. P671 Floris, M. P269 Frisullo, G. P282, P920 Ganiler, O. P743 Flügel, A. 48 Fritz, B. P697 Garcea, O. P170, P408, P603 Fogdell-Hahn, A. P496, Fritz, S. 96 García, R. P381 P845, P907 Frohman, E. 9, 80, P210, García Dominguez, J.M. P162 Foley, F. P807 P963 Garcia Ruiz, P. P648 Foley, J. 112, P989 Fromont, A. P198, P634 Garcia-Barcina, M. P264 Fonoff, E.T. P919 Frontzek, K. P809 García-Bonito, J. P500 Fontaine, B. P167, P605 Frota, E.R.C. P473 Garcia-Leon, J. P409 Fontoura, P. P712 Fuchs, S. P296, P315, P342, Garcia-Martinez, A. P289, Ford, H. P842 P357, P755, P769 P714, P717 Førland, P.T. P720 Fugger, L. 30 Garcia-Martinez, A.M. P717 Forn, C. P327 Fuglo, D. P951, P952, P957 Garcia-Merino, J.A. P444, Fornasiero, A. P407 Fujihara, K. P286, P295, P824, P898 Forrestal, F. P483 P468, P589 Garcia-Montojo, M. P289, Förschler, A. P740 Fujii, Y. P834 P714, P717 Fotakidou, A. P628 Fukazawa, T. P711 Garcia-Sanchez, M.I. P965 Foulds, P. P229, P482, Fulcher, G. 44 García-Valdecasas, M. P362 P810, P864, P891, P894 Furlan, R. 84, P247, P880, Gardoni, F. P676 Fowler, C.J. P516, P923 P885 Garren, H. P417 Fox, E. P454, P462, P823, Garrett, M. 15, 61, P511, P889, P960 Gabaldón, L. P399 P532 Fox, R. P337, P764 Gabbai, A. P500 Garretto, N. P603 Fragoso, S. P728 Gabriel, J.P. P586 Gärtner, J. P293, P458 Fragoso, Y. P728 Gaede, G. P542, P954 Garway-Heath, D.F. P348, Francavilla, G. P934 Gaissmaier, W. P443 P349 Francis, G. P442, P830 Gajofatto, A. P981 Gaser, C. P740 Francis, P.T. P239 Galanaud, D. 117, P351, Gasparinatos, G. P574 Frangoulis, B. 67 P742 Gasperini, C. P325, P329, Frau, J. P150, P269, Galazis, N 119 P334, P480, P510, P620, P854 Galazka, G. P667, P679 P900, P920 Fraussen, J. P705 Galeotti, F. P645 Gass, A. P316, P358, Frederiksen, C. P529 Galeotti, N. P563 P387, P735, P737, Frederiksen, J. 134, P174, Galeotti, R. P508, P773 P767, P799, P809 P304, P395, P396, Galetta, K.M. 80 Gatsios, T. P628 P551, P615, P737, Galetta, S. 80, P541, P905, Gaupp, S. P242 P951, P952, P957 P950 Gavaldà, A. P452 Fredrikson, S. P374, P610 Galili-Mosberg, R. P811 Gavrilovic, A. P627 Freedman, M. 79, 201, 129, Galimberti, D. P691 Gebara, B. 59, P531, P924

P369, P469, P807, Galletti, S. P422 Gencer, M. P908 Authors P833, P982 Gallo, A. P752, P920 Genís, D. P381, P584 Freeman, J. P182 Gallo, P. 7, 81, P148, P317, Gensicke, H. 41 Freeman, J. P226, P527 P332, P480, P746, Gentry, M. P536 Freeman, L. 117, P351, P742 P756, P831, P875 Genty, M. P535, P937 Freixanet, J. P381, P743 Gallop, M. P671 Georgoulopoulou, E. P577

155 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Gerdes, L.A. P259, P910 Glanzman, R. 114 Gorelik, L. P873 Gerevini, S. P871 Glenngård, A.H. P234 Goretti, B. P796 Germé, M. P877 Glick, G. P894, P971 Gorian, A. P800 Gerritsen, W.H. 91 Gnanapavan, S. P430 Gorman, M. P294 Geurts, J. 5, 118, P239, Gneiss, C. P636, P733, Gorodokin, G. P522 P352, P358, P686, P962 Gottschalk, P.C. P166 P735, P759, P767 Gobbi, C. P517, P803 Gout, O. P787 Ghaffarpour, M. P911 Godessart, N. P241, P452, Goyal, J. P706 Ghandour, M.S. P669 P453, P851 Grabner, G. P354 Ghezzi, A. P184, P266, P437, Goehler, H. P560 Grabova, S. P189 P480, P640, P745, Goektas, O. P638 Graf, M. P956 P796, P896, P900 Goelz, S. P873, P967 Graf, T. P206 Giacalone, G. P266 Goertsches, R.H. P419, P268, Graff, O. 113, 136, P964 Giacomi, M. P943 P839 Graham, A. 13 Giani, E. P729 Goetze, N. P651 Graigos, A. P420 Giannouli, E. P420 Gogas, K. P671 Grammond, P 38, P626, Gich, J. P381, P584 Goharpey, Sh. P530 P658, P819 Giese, T. P435 Goins, J. P963 Gran, B. P446 Giesser, B. P340 Gola-Bricalli, M. P803 Grand, A. P877 Gijbels, D. 59 Golay, X. P749 Grand’Maison, F. 38, P626, Gil-Ad, I. P479 Gold, M. P964 P658, P819 Gillespie, S. P938 Gold, R. 69, 72, 112, P202, Granella, F. 60, P550, P870, Gilli, F. P150, P255, P276, P242, P252, P353, P875, P928, P929 P438, P990 P459, P461, P493, Granieri, E. P875 Gillwaldt, G. P892 P560, P702, P764, Granieri, L. P150, P276 Gilmore, W. P829 P876, P881, P959 Granum, S. P263 Gimeno, R. P678 Gold, S. 43, P801 Grassivaro, F. P253 Gingele, S. P312 Golub, H. P173, P181 Grau-López, L. P281 Ginty, M. P477 Gomes, C. P657 Graus, F. P350 Giobbe, D. P238 Gomes, H.R. P201, P713 Gray, E. P477 Giordana, M.T. P238 Gomes, T. P504 Gray, O. P507, P658, P895 Giordano, A. 60, P928, P929 Gómez, A. P678 Graziano, G. 122, P875 Giorgio, A. P334, P336, Gómez, O. P200 Greco, R. P467 P739, P746, P863 Gomez-Gonzalez, E. P965 Green, A. P547 Giovannoni, G. 78, 104,109, Gomez-Moreno, M. P143 Green, B. P462, P889, P960 P232, P287, P298, P403, Gonçalves, A. P644 Green, S. P537 P411, P430, P441, Gondek, K. P538 Greenberg, B. P210, P963 P556, P680, P733, Gonen, O. P387, P799 Greenberg, S. P232, P403, P817, P825, P852, González, C. P792 P441, P817, P905, P967, P984 Gonzalez, S. P200 P825, P852 Girard, M. 38, P626, P658, González-De la Nuez, J. P159 Greiner, E. P692 P819 González-Quevedo, A. P159 Gresle, M. P978 Giraudon, P. 50 Gonzalez-Rosa, J. P360, Greulich, W. P211 Gironi, M. P729 P366, P779 Grigoriadis, N. P395, P396 Giugni, E. P422 Goodin, D. 73, P369, P476, Grimaldi, L. P437 Giuliani, G. 38, P626, P658, P903 Grimaldi, L.M.E. P640, P896 P819 Goodkin, O. P345 Grodent, P. P654 Giuntoli, M. P934 Goodman, A. P462, P483, Grønborg, M. P672 Givon, U. P192 P515, P518, P889, Gross-Paju, K. P484, P926 Glabinski, A. P250 P921, P922, P960 Grossi, E. P729 Gladstone, D. P471 Goodyear, B. P339, P747 Grossi, P. P332, P756, P831

156 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Grossmann, P. 41 Haghikia, A. P252, P459, Hawkes, C.H. P635 Grote, G. P245 P461, P702, P959 Hawkins, C. P400, P790 Grove, R. 113, P964 Haiman, G. P808 Hawkins, S. P895, P938 Grover, D. P953 Hakiki, B. P184, P334 Hayardeny, L. P472, P479, Grytten Torkildsen, N. P890 Hall, B.M. P248, P674, P675 P850, P881, P885 Gualandi, F. P336 Hall, W.W.I. P292 Hayman, M. P665 Guareschi, A. P460, P534, Hallett, M. P700 Hayot, F. 83 P942 Halpern, R. P499 Hayran, O. P178 Guaza, C. P278 Hamann, D. P601 Hayward, T. P529 Gubieras, L. P683 Hamel, D. P380 Hecham, N. P190 Guclu, I. P370 Hamlett, A. P817, P852 Hecker, M. P268, P419, Gudesblatt, M. P207, P231 Hammond, E. P471 P839 Gudi, G. P245 Hanael, E. P562, P958 Hedström, A. 55, P197, P715 Gudzenko, G. P392 Handel, A. 54, P298 Heesen, C. 44, P219, P330, Guedes, M. P333 Handunnetthi, L. P298 P391, P443, P497, Gueguen, A. P787 Hanna, J. P828 P616, P651, P768, Guennoc, A.M. P945 Hannequin, D. P607 P801, P815 Guerini, F. P888 Hannon, J. P665 Hegen, H. P733 Guerra, M. P465 Hannoun, S. P750 Heidenreich, F. P876 Gugutsidze, D. P185 Hanso, H. P655 Heijmans, R. 6 Guidi, L. P739 Hanwell, H. 54 Heininen-Brown, M. P319, Guillamon, E. P151, P288 Haque, A. P273 P320, P772, P774 Guimaraes, J. P216 Harbo, H.F. 34, P263, P681 Heinnen-Brown, M. P776, Guimond, C. P194 Häring, D.A. P434 P797 Guiziou, C. P394 Harirchian, M.H. P154, P911 Heinzlef, O. P649, P856 Gulowsen Celius, E. 34, P300 Harms, L. P638 Hellmann, M.A. P811 Gundberg, A. P988 Harrer, A. P401, P448 Hellwig, K. P459, P461, P836 Günerli, A. P519, P780 Harris, P.G. P763 Hemingway, C. P606 Gunnarsson, M. P566 Harrison, D. P471 Hemmer, B. 33, 124, 139, Gurevich, M. P562, P958 Hartel, M. P914 P202, P406, P461, Gurfein, B. 83 Hartung, H. P986 P682, P740 Gusev, E. P489, P897 Hartung, H.-P. 23, 33, 135, Henderson, A.P.D. P348, P349 Gustafsson, S. 55 P156, P202, P369, Henderson, D. P313 Guttmann, C. P758 P454, P476, P493, Hendler, T. P808 Guven Yorgun, Y. P299, P379 P807, P827, P861, Heneka, M.T. P277, P666 Guy, G. P680 P936, P408, P812 Hengel, H. P861 Guy, L. P886 Haschke-Becher, E. P401, P448 Henig, N. P262 Guyot, M.A. P526 Hashemi, A. P154 Henry, A. P793 Hassenstein, A. P949 Henze, T. 101 Haag, S. P435 Hattori, N. P568 Herbert, J. 8, 38, P428, Haartsen, J. P978 Haugstad, R. P890 P609, P626, P658, Haas, J. 24, P486 Haupts, M.R. P524 P819, P855, P939 Haas, J. P697 Hauser, S. 114 Herlopian, A. P663 Haase, R. P223, P918 Häussler, M.G. P156 Hernandez, M.A. P788 Habib, R.H. P663 Hautecoeur, P. P384, P526, Hernández-Lahoz, C. P727

Habibi Saravi, R. P188 P862, P867 Hernis, A. P888 Authors Hadker, N. P538 Havari, E. P424 Herr, D. P834 Haegert, D. P700 Havla, J. P816 Herrman, C. P823 Hafler, D. 6, P284 Havrdova, E. 38, 136, P454, Hess, C. 96 Häggmark, A. 137, P988 P571, P819, P866, Hesse, D. P283, P449 Haghighi, S. 95, P393 P905, P964 Hibbard, J. P533

157 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Hiennen-Brown, M. P508 Hop, W.C.J. P721 Igel, U. 137 Hilbert, P. 96 Hopia, L. P398 Ilsbroukx, S. P531 Hilbink, M. P652 Horakova, D. P571, P866 Imhoff-Jullier, G. P901 Hildebrandt, H. P377 Horga, A. P555, P841, P865 Immovilli, P. P550, P870 Hillert, J. 34, 66, 135, P197, Horiuchi, M. P272 Imrell, K. P688, P692 P267, P491, P496, Horntrich, A. P655 Ince-Gunal, D. P178, P498, P631, P681, P688, Horsfall, J. P340 P726 P692, P715, P845, Horsfield, M.A. P734 Ineichen, B.V. P685 P902, P907, P983, P986 Hoshi, M. P740 Inglese, M. P330, P768 Hilliard, A. P680 Hosseini, A. P911 Ingram, G. P481, P860 Hilton-Jones, D. 13 Hotermans, C. P483 Ingram, W. P226 Hintzen, R. P169, P279, Houžvicková, E. P149 Intermesuli, T. P859 P601, P686, P721, P976 Howard, J. 8, P855 Inuggi, A. P366 Hipola-Gonzalez, D. P143 Howell, O. W. 90 Ionescu, P. P576 Hirotani, M. P711 Hozejowski, R. P213 Ionova, T. P522 Hirsch, J. P387, P799 Hradilek, P. P820 Iorio, R. P282 Hitchman, S. P968, P971 Hudson, H. P513 Irizar, H. P558 Hladikova, M. P597 Huebers, A. 10 Isik, N. P158, P178, P642 Hobart, J. 71, P509 Huebl, W. P966 Iski, E. P963 Hochmeister, S. P243 Huerga, E. P346, P754, Islam, T. P195 Hodgkinson, S.J. P248, P767, P841, P865 Isobe, N. P272, P687 P674, P675 Huesca, K. P200 Issa, Z. P663 Hoegh, E.B. P615 Hughes, A. P383 Issard, D. P650 Hofer, M.J. P277 Hughes, M. P533 Ito, K. P554 Hoffmann, F. P271, P712 Hughes, S. P658 Itoyama, Y. P286, P295 Hoffmann, S. P682 Hulst, H.E. 5 Iuliano, G. 38, P193, Hoffmeister-Ullerich, S. P293 Humpert, S. P892 P626, P658, Hofstadt-van Oy, U. P789 Hunt, D.P.J. P313 P722, P819 Hofstetter, L. P358, P735 Hunt, K. P776, P797 Ives, S. P665 Höftberger, R. P359 Hunter, K. P764 Iwaki, T. P599 Hogan, N. 15, 61, P511, P532 Hupperts, R. 38, P270, P305, Iyilikçi, L. P519, P780 Hohlfeld, R. P259, P406, P451, P457, P626, Izquierdo, G. 38, P362, P614, P434, P816, P910 P658, P705, P819 P626, P658, P819 Hojnacki, D. 82, P318, P319, Huran, N. P872 Izquierdo-Ayuso, G. P965 P320, P508, P653, Hussein, S. P318, P319, P771, P772, P773, P413, P771, P774, Jackson, J. P947 P774 P776, P797, P866 Jackson, J. P758 Holdbrook, F. P812, P827 Hutchinson, M. P152, P292, Jackson, L. P436 Holden, D. P967 P400, P585, P847, Jackson, S. 109, P777 Holmén, C. P491 P905, P940 Jacobi, C. P435 Holmøy, T. P300 Hwang, W. P414 Jacobson, L. 13 Holsboer, F. 33 Hyde, R. P482, P541, Jacobson, S. P985 Holst, B. P330, P768 P810, P893, P894, Jacquemin, M. P822 Honarmand, K. 17 P905, P950 Jafari, N. P686 Honeycutt, A. P661 Jaffe, S. P430 Hong, M.J. P623 Iaffaldano, P. P322, P569, Jain, K.K. P331, P604 Hong, Y.H. P623 P837 Jalili, F. P472 Honnorat, J. 50, P669 Idiman, E. P299, P379, James, I. P693 Hood, Z. P244 P415, P519, P650, James, J. 94, P294 Hoogs, M. P776, P797 P780, P795, P917 Jamroz-Wisniewska, A. P218 Hoozemans, J. P239 Idiman, F. P780 Jandeleit, B. P671

158 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Janzen, W. P944, P948 Jurgensen, S. P408, P432, Kasper, J. P443, P497 Japp, G. P821 P483 Kasper, L. 14, P273, P553, Jaspan, T. 119 Jurynczyk, M. P832 P991 Jean Deleglise, A. P862 Kassiotis, P. P394 Jeantroux, J. P549 Kacar, K. P314, P738 Kasteng, F. P660 Jeffery, D. P369, P418, P476 Kaeder, M. P211 Katsarava, Z. P659 Jehna, M. P315, P342, P357 Kahn, O. 4 Kaufman, D. P173, P181 Jelcic, I. P293, P685 Kai-Larsen, K. P197 Kawajiri, M. P272 Jenkins, T.M. P345 Kaimen-Maciel, D.R. P473 Kaya, D. P415 Jenkinson, M. P357 Kainz, A. P157 Kaya, P. P370 Jenmalm, MC. P274 Kaiser, L. P293 Kazemi, M. P869 Jensen, B. P633 Kalina, J. P939 Kazibudzki, M. P641, P914 Jensen, H.B. P512 Kalina, P. P157 Keegan, B.M. P502 Jensen, L.T P551 Kalinowska-Lyszczarz, A. P474 Kelland, E. P829 Jensen, M. P539, P927 Kallenbach, K. P951, P952, Kelly, S. P152, P585 Jernas, L. P213 P957 Kemlink, D. P571 Jernas, M. P707 Kallis, C. P345 Kemp, K.C P477 Jesionek, B. P242 Kalyadina, S. P522 Kempcke, R. P655, P655 Jesionek-Kupnicka, D. P832 Kamble, R. P306 Kennedy, C. 82, P265, Jesurum, J. P529 Kane, C. P878 P318, P319, P320, Jesus Pinto-Medel, M. P258 Kane, R. P207 P508, P653, P771, Jiménez, E. P452, P453 Kaneyama, T. P668 P772, P773, P774 Jin, F.J. P843 Kannel, K. P484, P926 Kennedy, J. P629 Jinoch, P. P975 Kantor, A. P967 Kenney, P. P475 Johansson, S. P523 Kantorová, E. P546 Kepplinger, B. P157 John, G. 83, 107, P472 Kaplan, J. 76, P424, P425, Kerbrat Lecuyer, A. P394 Johns, L. P533 P427 Kerkhofs, L. P224 Johnson, K. P405 Kaplin, A. P471 Kermode, A. 18, P693 Johnson, K. 58, P539, P643, Kappos, L. 12, 68, 41, 79, Kern, K. P340 P927 96, 112, 114, 132, Kern, S. P730 Jolibois, M. P535, P536, P937 P271, P316, P358, P369, Kerr, D. P471 Jonas, L. P268 P385, P387, P434, P442, Kerschensteiner, M. P883 Jonason, A. P475 P476, P483, P492, P494, Keskin, G. P726 Jones, E. P947 P559, P686, P712, P735, Keskin, O. P795 Jones, R. P471 P799, P807, P809, P812, Keskitalo, S. P685 Jones, S.J. P348 P813, P827, P830, P843, Ketelslegers, I.A. P169, P601 Jongen, P. P463, P492, P844, P970, P982 Khademi, M. 137, P267, P813 Karadima, G. P260 P398, P988 Jonsdottir, J. 97 Karaer Unaldy, H. P205 Khaleeli, Z. P326 Jönsson, L. P147 Karageorgiou, K. P420 Khalil, M. P315, P342, Jordan, S. P292, P940 Karandreas, N. P361 P357, P755, P769 Jordán-González, J. P159 Kardon, R. P547 Khan, F. 98 Josyula, A. 125 Karkanis, I. P420 Khan, O. 77, P423, P761 Jouin, P. P563 Karlberg, E. P496, P907 Khan, S. P941 Joyeux, A. P232 Karlsson, M.O. P447 Khatri, B. P812, P827

Jukes, J.P. P664 Karni, A. P588, P699 Khodadoust, M. P710 Authors Jung, L. P529 Karpha, I. P886 Khurana, S. P520 Jung, M.Y. P887 Karrenbauer, V. P692 Kidd, G.J. P337 Jungedal, R. P496, P907 Kasar, S. P544 Kielstein, J. P915 Jurewicz, A. P667, P832 Kasper, D.L. 14 Kieseier, B. 20, 22, P156, Jürgens, T. P672 Kasper, E. P273 P487, P861, P904

159 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Kikuchi, S. P711 Knol, D. P220, P646 Kraus, J. P401, P448, P892 Killestein, J. 6, P564, P733, Knuts, K. 59 Kraus, V. P682 P848 Kobata, K. P529 Krauthausen, M. P277, P666 Killingsworth, M. P674 Kobelt, G. P660 Kreft, K.L. P279 Kilpatrick, T. P978 Koch-Henriksen, N. 39 Kremenchutzky, M. P778, P903 Kim, A. P340 Kockum, I. 34, 55, P267, Kremer, S. P549, P732 Kim, B.J. P145, P356, P681, P688, P692, Kreutzfeldt, M. P672 P623, P770, P786 P715, P983 Krieger, T. P801 Kim, B.J. P145, P356, Koczan, D. P268, P419, P839 Kriekaart, R.L. P848 P623, P786 Koczi, W. P448 Kristoferitsch, W. P359, P892, Kim, G. P671 Koekkoek, J.A.F. P457 P956 Kim, H.J. P145, P356, Koenig, F.B. P719 Krommyda, M. P290 P548, P578, P602, Koh, C.-S. P668 Kronnerwetter, C. P354 P623, P786 Kohlmann, T. P538 Krssak, M. P359 Kim, K.K. P623 Kokotis, P. P361 Krueger, S. P801 Kim, N.H. P548, P578 Kolakovic, A. P261 Kruja, J. P189 Kim, R. P207 Kollias, G. P280, P667 Krupp, L. P294 Kim, S.H. P602 Komoly, S. 135, P986 Krýsl, D. P149 Kim, S.M . P356, P623 Konkel, S. P963 Krzan, M. J. P172 Kim, W. P356, P548, Konrad, G. P916, P934 Kuenz, B. P636, P962 P578, P602, P786 Kontrova, I. P597 Kuhle, J. 96, P271, P559, Kincses, Z. P357 Kooi, E.J. 118, P239 P970 King, J. 135, P986 Kooijmans, M. P840 Kulkarni, B. P186, P611 King, R. P417 Kooijmans-Coutinho, M. P893 Kümpfel, T. P259, P406, Kingwell, E. 56, P618 Köpke, S. 42, P443, P497 P816, P910 Kinkel, R.P. P552, P810, Korn, T. P406 Kunkel, S.L. P241 P963, P972 Korporal, M. P697 Kuntz, N. P294 Kinsella, K. P152, P292, Korsen, M. P838 Kuqo, A. P189 P450, P585, P940 Koski, T. P688 Kurbatova, K. P522 Kipp, M. P306, P310, P312 Kostic, V.S. P314, P738 Kurca, E. P546 Kira, J.I. 37, P272, P599 Kotašková, J. P149 Kuroda, H. P295 Kirby, S. P608 Kotoucova, J. P979 Kurt, E. P370 Kircher, K. P354, P956 Kotsi, V. P420 Kurt, S. P205 Kirk, R. P475 Kotzamani, D. P215 Kurtuncu, M. P178 Kirkeleit, J. P720 Kou, N. 17 Kuster, P. P358, P559, P735 Kirresh, A. 90 Koukoulidou, S. P628 Kuznetsov, A. P522 Kister, I. 8, P609, P855 Kouleridou, A. P521 Kwiatkowska, P. P709 Kitsos, D. P574 Kouri, I. P155 Kwon, O. P145, P356, P623 Kiziria, M. P185 Koutsis, G. P260, P361 Kyvik, K. O. P596 Kjaersgaard, E. P395 Koutsouraki, E. P628 Klawiter, E. P760 Kovacs, R. P222 La Cesa, S. P645 Kleiner, N. P655 Kovarova, I. P571 La Gioia, S. P464, P859 Kleinpaul, R. P165, P718 Kowarik, M.C. P406 La Mantia, L. P184 Kleiter, I. P443 Koysová, M. P546 Labaj, J. P979 Klimkait, T. 96 Kraft, G. P781, P878 Labauge, P. P167, P592, Klotz, L. P685 Kragt, J.J. P646 P684, P867 Knappertz, V. P173, P181, Krajnc, N. P172 Lacour, A. P466, P899 P476, P565, P884, P903 Krakauer, M. P283, P449 Ladurner, G. P401, P448, Knezevic, Z. P627 Kramell, A. P906 P892 Knippenberg, E. P224 Krasensky, J. P866 Lage, M. P913 Knippenberg, S. P305 Krasulova, E. P571 Lagoudaki, R. P396

160 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Laguillo, G. P584 Leary, S.M. P556 Lim, M.J P606 Lakdawala, N. P411 Leavitt, V P328 Lim, Y.M. P623 Lake, S. P404, P454 Lebrun, C. P390, P592 Lima, D. P333 Lakeman, K. P662 Lebrun-Frenay, C. P605, Lima Bomfim, I. 34, P688, Lalive, P. P156, P249, P677 P637, P867 P692 Lallement, F. P394 Lebus, D. P963 Limborg, S.J.W. P283 Lam, C.D. P669 Lechner-Scott, J. 38, P626, Limmroth, V. P659 Laman, J.D. P279 P658, P819 Limsakun, T. P849 Lamers, I. P224 Lee, D P881 Lin, C.R. P470 LaMorte, M. P427 Lee, H. P969 Lin, G. P312 Lana-Peixoto, M. P165, P201, Lee, J.-C. 125, P798, P864 Lin, Y. P414 P713, P718 Lee, K.H. P145, P356, Lin, Y.L P980 Lancia, S. P760 P623, P770, P786 Linbo, L. P502 Landin, R. P228 Lee, K.S. P356 Lindberg, R.L.P. 96, P271, Landtblom, A.-M. P335, P692, Lee, K.S. P623 P559, P712, P733, P970 P723 Lee, L. P785 Lindblom, R. P256 Lang, M. P659, P821 Lee, S. P432 Linden, M. P267, P715 Lang, P. P956 Legrand, F. P899 Linder, J. 28 Langdon, D. P374, P580, Lehéricy, S. P736, P742 Lindsey, J. P973 P610, P903 Lehert, P. P535, P536, Linhares, U. P168 Langer-Gould, A P630 P937 Linington, C. 51, P243 Langkammer, C. P315, P342, Lehmensiek, V. P570 Link, J. P681 P357, P755, P769 Leiguarda, R. P792 Linker, R. P242, P881 Lanius, V. P369, P807 Leite, M.I. 13 Linnartz, B. P306 Lanzillo, R. P748 Lenne, B. P384, P526, P862 Linnebank, M. P293, P685 Lapierre, Y. P700 Lennon, S. P938 Lino, A. P160, P657 Laplaud, D. P394, P867 Leocani, L. P360, P364, Lipinski, J. P538 Larkin, A. 15, 61, P511, P366, P779 Lisak, R. P311, P761 P532 Leonard, J. P475 Lisby, S. 136 Larocca, S. P835 Lepore, V. 122, P875 Lisi, L. P879 Larsen, M. P952 Leppert, D. P559, P814, P970 Lisková, P. P583 Larsson, H. P951, P952, Leray, E. P394, P613 Liu, Y. P978 P957 Lerner, M. P873, P968 Livramento, J.A. P201, P713 Lassmann, H. 89, P354, Leroy, C. 117 Llado, X. P743 P397, P956 Leuenberger, T. P275 Llinares, E. P867 Latacz, P. P641, P914 Leuse, D. P384 Llufriu, S. P350 Lataste, K. P179 Levin, L. P724 Lo Giudice, T. P880 Latif, Z. P761 Lexell, J. P935 Lo Re, V. P874 Lau, L. 108 Leyva, L. P258, P409 Løbner, M. P704 Lauckaite, K. P209 Li, D. 114, P347, P431, Loh, S. P414 Lauda, F. P570 P492, P757, P763, Lohse, P. P259 Lauèkaitë, K. P365 P813, P857 Loiseau, S. P937 Lauer, K. P302, P619 Li, J. P475 Loitfelder, M. P296, P315, Laule, C. P763 Li, X. P706 P342, P357 Laulund, F. P670 Libertínová, J. P149 Lolli, F. P974

Laursen, H. 89 Liblau, R. P867 Lonergan, R. P292, P450, P940 Authors Lavorgna, L. P752 Lie, B.A. P263, P681 Longo, R. P800 Lazarus, K. P978 Liem, A. P490 Looby, M. P442 Le Fur, Y. P765 Lile, D.J. 80 Lopes, K.N. P373 Le Neuder, G. P637 Lillevang, S.T. P596 Lopes de Carvalho, M.L. 62, Le Page, E. P394 Lim, C.C.T. P331, P604 P525, P916, P933, P934

161 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Lopez, C. 83 Lundkvist, M. P491, P496, Maiorana, A. P577 Lopez, I. P883 P845, P907 Maiorino, C. P247 López, R. P452 Lundqvist, C. P147 Mair, W. P233 López de Munain, A. P558 Luo, Y. P693 Majdi-Nassab, N. P530 Lopez-Cavanillas, M. P264 Lupo Stanghellini, M.T. P467 Majewska-Szczepanik, M. P679 Lopez-Gomez, C. P409 Lus, G. P875 Malagoni, A.M. P508, P773 Lopez-Gongora, M. P371 Lütjohann, D. P564 Malaguti, M.C. P577 Lopez-Soriano, A. P773 Lutterotti, A. P636, P815, Malentacchi, G.M. P334 Lorefice, L. P269, P620, P962 Malfetano, F. P490 P854 Luzzio, C. P182 Malhotra, S. P572 Lorentzen, Å.R. P263, P681 Lycke, J. 27, 95, 134, Malik, O. P696 Lori, S. P796 P187, P491, P566, Malikova, I. P372, P765, Losada Lopez, M. P648 P707, P902 P805 Losen, M. P705 Lycke, K. P631 Malmeström, C. 134, P566, Losy, J. P474 Lynch, S. P383, P804 P707 Lou, K. P973 Lynn, F. P408 Malucchi, S. P363, P438, Louapre, C. P736, P742 P920 Loud, S. P552, P963 Maamagi, H. 59, P926 Mamdani, M. P504 Loudenot, V. P198 Mabcardi, G.L. P199 Mamoulakis, C. P215 Loupe, P. P405 Macaluso, C. P550 Mamusa, E. P620 Louzao, J. P465 Macário, C. P416 Mancardi, G. P184, P238, Lowe-Strong, A. P938 Macciardi, F. P990 P336, P469, P480 Lowther, D. P253 Machado, L.R. P201, P713 Mancuso, R. P888 Lu, J.-Q. P878 Machado, L.R. P160 Mandel, M. P404 Lubetzki, C. 117, 135, 142 Machlanska, A. P709 Mandraveli, K. P290 P167, P736, Macías-Islas, M. P500 Mandrekar, J. P502 P742, P986 MacKay, A.L. P763 Mandrioli, J. P577 Lublin, F.D. P483, P905, P985 Macleod, M.R. P246 Manneschi, L. P460, P534, Lubrini, G. P378, P794 MacManus, D. P764 P942 Luca, D. P612 Madörin, P. P809 Mannocchi, M.L. P521 Lucas, M. P965 Madsen, K.H. P355 Manrique-Hoyos, N. P672 Lucas, N. P432 Maedler, B. P763 Mansilla, M.J. P241, P254, Lucas, S. P207 Maertens de Noordhout, B. 59 P678, P708, P278, P961 Lucchese, G. 122, P837 Maeurer, M. P487 Månsson Lexell, E.M. P935 Lucchinetti, C. 89, P502 Magalhaes, S. 54, P194, Mantovani, A. P577 Ludyga, T. P641, P914 P629 Maravilla, K. P878 Lueking, A. P560 Magana, S. P502 Marazzi, R. P171 Lugaresi, A. 38, 60, P184, Maggi, L. P928 Marchand, C. P225 P193, P235, P382, Maghzi, A. P204, P393, Marchello, L.P. P955 P480, P658, P783, P869, P967 Marchiori, P. P160, P. P819, P875, P928, P929 Magliozzi, R. 90, P696 P657 Luider, T. P976 Magnani, G. 84 Marcinska, K. P679 Luijten, P.R. P759 Magnani, S. P460 Marco-Ramirez, A.M. P965 Lukacs, M. P367 Magnano, C. 82, P320, Margolin, D. P454 Lukas, C. P353, P766 P321, P772, P773, Maria, M.S. P785 Lukashev, M. P887 P774, P775 Maria Papais-Alvarenga, R. P258 Lukasik, K. D. P236 Magraner, M. P151, P288 Mariani, E. P729 Lund, B. P829 Mahad, D. P670 Mariasiewicz, M. P709 Lund, C. P890 Mahfooz, N. P573 Marignier, R. 50, P605 Lund, H. P283 Maimone, D. P144, P144, Marigorta, U.M. P257 Lundberg, P. P335 P144, P875, P900 Marín, N. P278

162 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Marin, P. P563 Massa, R. P620 Meani, A. P986 Marinaro, C. P885 Massote, J. P165 Mechelli, R. 94 Markowitz, C. P462, P889, Mastaglia, F. P693 Medaglini, S. P360 P960 Masterman, T. P692 Meergans, M. P547 Marnetto, F. P150, P276, Mastorodemos, V. P215 Mehling, M. 96, P970 P438 Mastrapasqua, M. P569 Meier, U.C. P967 Marousi, S. P420 Masullo, C. P722 Meinl, E. 49 Marr, K. P265, P318, Matas, E. P683 Meinl, I. P816 P653, P773 Matesanz, F. P689 Meite, M. P862 Marrie, R. 54, P194, P590, Matias, F. P416 Mekelleche, S. P906 P629, P941, Matiello, M. P593 Melamed, D. P850 P944, P948 Matsui, M. P161 Melamud, L. P170, P603, Marriott, J. P504 Matsuoka, T. P599 P695 Marriott, M. P978 Matsushita, T. P272, P599, Melin, A. P466, P899 Marrosu, M.G. P184, P269, P687 Melis, M. P620 P620, P854 Matthews, P.M. P686 Melis, M. P620, P854 Marshall, C. P411 Mattioda, A. P238 Mellergård, J. P274, P335 Marta, E. P534, P942 Mattioli, A. P703 Mellesi, L. P691 Marta, M. P967, P984 Mattioli, F. 57 Meluzínová, E. P149 Marti, A. P212, P282 Mattisi, I. 7, P317, P332, Memon, A. P423 Marti, N. P288 P756, P831 Mendes, A. P216 Martin, R. 92, P293, P330, Matute, C. P883 Mendonca, T. P216 P469, P616, P768, Matysiak, M. P285 Menegatti, E. P508, P773 P815, P949, P976 Matzke, M. P323 Menegola, M. P316 Martin, N. P151 Mäurer, M. P440 Menéndez, R. P381 Martin-Barriga, M.L. P399 Maurex, L. P782 Menge, T. P156 Martinelli, V. 60, 135, P163, Maurey, H. P156 Menge, U. P789 P184, P266, P360, Mauri, G. P727 Menguy-Vacheron, F. P849 P364, P433, P480, Mausberg, A. P861 Menheere, P. P270 P505, P594, P640, Mausner-Fainberg, K. P588, Menon, S. P186, P611 P734, P751, P779, P699 Mercier, F. P442, P846 P871, P896, P928, P929 Mayadev, A. P529 Merelli, E. P600 Martinelli Boneschi, F. P163, Mayne, M. P472 Merkler, D. P672 P266, P284, Mazzola, M.A. P874 Mero, I.L. P263 P505, P594 McArthur, J. P471 Merola, A. P363 Martínez Ginés, M.L. P162 McCollough, T. P671 Mesaros, S. P314, P485, Martinez Liem, A. P503 McConnell, A. P537 P734, P738, P751 Martinez-Acebes, E. P143 McDaniel, J. P665 Messmer Uccelli, M. 60, P928 Martínez-Cáceres, E. P281 McDonald, J. P294 Mettling, C. P980 Martinez-Martinez, P. P705 McDonnell, G. P895 Metz, L. P456, P762 Martínez-Yélamos, S. P683 Mcelduff, P. P626 Meuer, S. P435 Martino, G. 84, 105, McFarland, H.F. P985 Meyer, D. P421, P823 P247, P885 McGowan, J. P963 Meyer, H.E. P702 Martins Silva, A. P644 McGowan, M. 54, P194, P590, Meyer, S. 9 Martorana, A. P880 P629, P941 Meyers, S.M. P763

Marusic, S. P436 McKeon, A. P593 Meyniel, C. 38, P819 Authors Marzabal, S. P225 McLaughlin, B. P878 Mezei, Z. P222 Marziniak, M. P206, P892 McLaughlin, P.J. P987 Mi, S. P731 Masaki, K. P599, P687 McMullen, K. 58, P539, Miccinesi, G. P929 Mascioli, E. P853a P643, P781 Michalak, S. P474 Masera, S. P238 McNagny, K.M. P308 Michalik, J. P546

163 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Mickeviciene, D. P209 Mohr, D.C. 40, 41 Morse, R. P971 Midaglia, L. P465 Mohr, M. P581 Moses, H. 21 Midgard, R. P720 Moiola, L. 135, P163, Motta, C. P407, P880 Midi, I. P498, P726, P726 P184, P266, P360, Motta, R. P525, P916, Mielcarz, D.W. 14 P433, P437, P467, P933, P934 Miguelez, M.A. P465 P594, P745, P779, Mottershead, J. P842 Mijo, S. P189 P796, P871, P896 Moulignier, A. P787 Mikaeloff, Y. P156 Molina, T. P453 Mousson de Camaret, B. P581 Milani, N. P437 Molinari, F. P199, P510 Mowry, E. P294 Milazzo, M. P294 Molloy, A. P292 Muallem, N. P663 Miletic Drakulic, S. P627 Molnarfi, N. 51, P826 Mueller-Lenke, N. P686 Millar, A. P938 Molton, I. 58, P539, P643, Mueller-Myhsok, B. 33 Millefiorini, E. P645, P875 P927 Muhammed, N. P635 Miller, A. 79, P262, P808, Monaco, S. P981 Mühlau, M. P740 P850, P982 Montag, M. P340 Muhlert, N. P749 Miller, D. 113, P348, P369, Montalban, X. 45, 85, 113, Müler, M. P666 P400, P408, P737, 135, P241, P254, Müller, M. P277, P892 P744, P749, P753, P257, P278, P346, P547, Müller-Lenke, N. P358, P559, P764, P777, P807 P555, P369, P572, P622, P735 Miller, E. P245 P678, P701, P708, P733, Mullan, F. P895 Miller, L. P968 P754, P807, P812, P827, Muller, M. P510 Miller, P. P939 P841, P865, P961, P986 Munafo, A. P447 Miller, S. P815 Montanari, E. P235, P460, Munchauer, F. P541 Millonig, A. P733 P534, P942 Munger, K. P724 Mills, K.H.G. P450 Monti, G. P577 Munjev, N. P576 Mills, R. P790 Montomoli, C. P620 Muñoz, D. P465 Milonas, I. P297 Montreuil, M. P793 Muñoz-Culla, M. P558 Milosavljevic, D. P966 Moonen, G. P598, P654 Munschauer, F. P950 Min, J.H. P145, P356, Moore, F. 38, P626, P658, Muraro, P. P180 P548, P770 P819 Murray, R. P462, P823, Minagar, A. P430, P967 Moraal, B. P767 P889, P960 Minguzzi, S. P510 Morales, J. P977 Murray, T.J. P608 Minwegen, D. P702 Morales, R.R. P201, P713 Murru, R. P269 Miranda, E.C. P473 Morales, X. P200 Musch, B. P403, P441, Mirigliani, A. P345 Moran, S. P454 P817, P825, P852 Miron, S. P791 Morcinek, C.G. P196 Musu, L. P620, P854 Mirza, M. P178 Moreau, T. P198, P634, P649 Muth, S. P461 Misci, P. 57 Moreira, F. P333 Mutschler, V. P549 Mishra, M. P882 Moreira, I. P644 Muzio, L. P885 Mistry, N. 119 Morele, E. P376 Mycko, M. P679 Misu, T. P286, P468 Moreno Bruna, B. P664, P883 Mycko, P. P285, P709 Miszkiel, K.A. P348 Morgan, C. P228, P318, P653 Mygland, Å. P720 Mitjana, R. P346, P754 Morgan, P. 119 Myhr, K.M. 16, 135, P263, Mitosek-Szewczyk, K. P455 Morgantini, A. P386, P802, P720, P986 Mitsikostas, D.D. P280 P943 Mjösberg, J. P274 Morgott, M. P217 Na, J. 125 Mochkin, N. P522 Mork, S. 16 Nabholz, N. P563 Modderman, P.W. P601 Mørland, T.J. P720 Nabi, E. P488 Moen, S.M. P300 Morrison, K. 54, P984 Naegelin, Y. P358, P385, Mogi, M. P272 Morrow, S. P776, P797 P686, P735, P799, P809 Moharregh-Khiabani, D. P245 Morrris, P. 119 Nagels, G. P654

164 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Naini, A. P269 Nikulin, V. P782 Oleschko Arruda, W. P626, Naismith, R. P760 Nilsson, M. P236 P658 Najafi, M. P393 Nilsson, P. 137, P491, P988 Olivares, T. P788 Najafi Zadeh, R. P154 Nishiyama, S. P286 Oliveira, A.M.P. P919 Naji, M. P911 Nissan, Y. P562 Oliveira, E. P647 Nakamura, K. P337, P864 Njenga, M. P992 Oliver, A. P743 Nakamura, M. P711 Nóbrega, F.R. P373 Oliver, B. P409 Nakashima, I. P286, P468, Nociti, V. P282 Olofsson, S. P234 P589 Noguchi, K. P834 Olsson, B. P707 Nandrino, J.-L. P384 Nogueira, L.A.C. P373 Olsson, T. 29, 34, 55, 79, 112, Naranjo-Gómez, M. P281 Nohra, R. P267 137, P197, P267, P491, Narayana, P. P872, P985 Nordin, N. P197 P566, P631, P715, Narayanan, S. P343, P764 Nordsletten, L. P300 P982, P983, P988 Nash, R. P878 Norgren, N. P566 Onaha, P. P901 Nataf, S. P237 Nos, C. 85, P555, P622, Ongagna, J.-C. P466, P607 Natarajan, A. P432, P893 P841, P865 Ongagna, J.C. P867 Navarro, A. P257 Novelli, F. P703 Onigman, T. P894 Navarro, L. P288 Novik, A. P522 Oporto, S. P167 Navone, N.D. P255, P438, Nuara, A. P366 Oppermann, K. P401, P448 P990 Nuesslein-Hildesheim, B. P402, Orazem, J. P172 Navrazhina, K. 107 P858 Orefice, G. P748 Nedelkoska, L. P311 Nuriya, M. P286 Oreja-Guevara, C. 38, P378, Neema, M. P758 Nurtidov, R. P867 P399, P614, P626, Nehemy, M. P165 Nussbaum, S. P850 P658, P794, P819 Neilsen, A. P810 Nytrova, P. P150, P571 Orpez, T. P409 Nelson, F. P872, P985 Ortega, I. P289 Nelson, P.A. P710 O’Connor, P. 79, 114, 130, Oschmann, P. P694, P789 Nemni, R. P729 P369, P408, P431, Otaegui, D. P264, P558 Nerey-Rodríguez, A. P159 P434, P483, P442, Otero, S. P622 Ness, J. P294 P476, P504, P830, Otte, C. P801 Nessler, S. 139 P833, P843, P905, Ottervald, J. 137, P988 Neuhaus, A. P180, P217, P982 Ottoboni, L. P284 P613, P651 O’Dwyer, E. P931 Oturai, A. 34, 134 Neuhaus, O. P501 O’Farrelly, C. P450 Ouallet, J.C. P179, P380, Neumann, H. P306 O’Leary, C. P842 P867 Neuper, C. P342 O’Mahony, J.D. P590 Ouamara, N. P472 Neuteboom, R.F. P169 O’Neil, G. P557, P561 Outterick, O. P592 Newman, T.A. P664 O’Reilly, E. P724 Outteryck, O. P167, P466, Nguyen, F. P443 Oakley, J. 9 P607, P899 Nguyen, T.H. P424 Oberwahrenbrock, T. P954 Ovtcharov, V. P323 Nguyen, V. P690 Ochoa-Reparaz, J. 14, P273 Owens, T. 63, P596, P704 Nichelli, P.F. P389, P577, P600 Ocwieja, M. P445 Ozakbas, S. P299, P379, Nicholas, R.S. P696 Odén, A. 95, P187 P415, P519, P780, Nichols, T.E. P358, P735 Odyniec, A. P679 P795, P917 Nicole, A. 50 Oger, J. P903 Ozer, F. P158

Nicoloa, R. P199 Ohri, N. P953 Oztekin, M.F. P575 Authors Nielsen, J.M. P766 Ohyagi, Y. P687 Oztekin, N. P575 Niemczyk, G. P487, P493 Okada, A. P647 Nieto, A. P788 Oksenberg, J. P294 Pace, A. 138, P864, P891, Nieuwenhuis, L. P946 Olah, L. P222 P905, P983 Niino, M. P711 Olascoaga, J. P264, P558 Paes, D. P483

165 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Pagani, E. P314, P751 Passante, N. 67 Perry, V.H. P664 Pagani, M. P314 Patanella, A. P150, P282 Perumal, J. 8, P423, P855 Paine, M. 38, P626, P658, Patarroyo, J.C. 51, P710 Peruzzo, D. P317 P819 Patat, A. P853a Pes, V. P453, P851 Palace, J. 13 Patel, H. P887 Pesci, I. P460, P534, P920, Palavra, F. 85 Paterka, M. P275 P942 Palmer, J. P404 Patrucco, L. P567 Petek, B. P158 Panas, M. P260 Patsopoulos, N. P284 Petek Balci, B. P178 Pandina, T. P475 Patti, F. P184, P422, Peter, H. P293 Panea, C. P576 P510, P796, P875 Peters, S. P662 Panicker, J. P516, P923 Pattini, M. P534, P942 Petersen, T. 38, P626, P658, Pantano, P. P521 Paul, F. P542, P547, P579, P819 Paolicelli, D. P184, P322, P954 Peterson, E. P528 P569, P837, P920 Pavan, G. P464, P859 Petkau, A.J. P347, P757 Paolini, I. P974 Pavone, A. P144, P144, Petkovska-Boskova, T. 38, P626, Papadimitriou, V. P215 P144 P658, P819 Papadopoulos, D. P280 Pawlak, M.A. P474 Petrescu, S. P576 Papadopoulou, A. P316, Peccatori, J. P467 Petrikonis, K. P209 P809 Peelen, E. P270 Petrovic, K. P315, P357 Papagianni, A. P361 Péerez-Miralles, F. P841 Petsas, N. P521 Papais Alvarenga, M. P176, Peers, K. P531 Petzold, A. P741, P970 P258 Peh, W.M. P331, P604 Pfeifer, K. P217 Papais Alvarenga, M. P168, Peignot-Sabbagh, S. P793 Pförtner, R. P251 P258 Pekmezovic, T. P485, P627 Pfueller, C. P542, P954 Papais-Alvarenga, R. P168, Pellegrini, F. P494 Pham-Dinh, D. P669 P176, P373, P591 Pelletier, D. 116 Phan Ba, R. P598, P654 Pape, M. P290 Pelletier, J. P351, P372, P650, Phillips, J.T. P905 Papeix, C. 117, P167, P765, P805, P812, Piani Meier, D. P814 P351, P605, P736, P827, P867, P904 Piatkowski, J. P918 P742, P867 Pellkofer, H. P406, P910 Pichler, A. P755 Paperna, T. P262 Penner, I.-K. 41, 75, P369, Pickersgill, T. P481, P860 Papini, AM. P974 P385, P387, P799, Piegza, J. P641, P914 Pappas, D. P959 P803, P807, P809 Piehl, F. P256, P491, P566, Paprzycki, W. P474 Penzien, J. P836 P782 Paracha, N. P232 Perales-Esteve, M.A. P965 Pierfederici, L. P386, P802 Páramo, D. P362 Perego, E. P986 Pieroni, E. P269 Pardini, M. P336 Pereira, V. P490 Pierot, L. P351 Pardo, G. P221, P543 Pérez, C. P784 Pietroboni, A. P691 Parent, J. P883 Perez, Y. P788 Pietrolongo, E. P382, P783 Pareto, D. P767 Pérez Neri, I. P977 Pike, J. P947 Paris, M. P475 Pérez-Miralles, F. 85, P346, Pilz, G. P401, P448 Park, C.Y. P548, P578 P555, P572, P701, Pinna, G. P577 Park, M.S. P145, P356, P754, P865 Pinter, R.Y. P262 P602, P623 Perez-Rico, C. P545 Pinto-Medel, M.J. P409 Parker, F. 82, P321, P775 Perga, S. P255, P438, Piola, M. P691 Parkes, H. P777 P990 Piras, R. P269, P620, P854 Parmentier, L. P867 Periañez, J.A. P378, P794 Piri Cinar, B. P795 Parry, G. P164, P182 Perini, P. 7, 81, P148, Pirruccello, S. P964 Parslow, R.C P606 P332, P756, P831 Pittion, S. P867 Paschalidou, M. P290, P297 Perlbarg, V. P736 Pittock, S. P593 Pasquini, M. P469 Peroni, E. P974 Pizcueta, P. P851

166 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Pizzolato, G. P800 Preziosa, P. P314 Ramagopalan, S. 54, P298, Plaitakis, A. P215 Preziosi, G. P516, P923 P984 Plant, G.T. P348, P349 Prin, L. P899 Ramanathan, M. P265, P318, Plantone, D. P282 Prins, M. P239 P573, P653 Plasmati, I. 60, P928, P929 Prinster, A. P748 Ramasamy, D. P320, P776 Plavina, T. 138, P706, P873, Privitera, D. P163, P594 Ramazzotti, B. P943 P983, P992 Prod’homme, T. 51, P826 Rametta, M. P903 Pleimes, D. P369, P647, Prodhomme, T. P710 Ramil, E. P444, P824,P898 P807 Prosperini, L. P521 Ramió i Torrentà, L.L. P381, Plesnila-Frank, C. P659 Protti, A. P171 P584 Pocoski, J. P173 Provinciali, L. P437 Ramio-Torrenta, L. P743 Podelipsky, I. P808 Pryce, G. 109, P676, P680 Ramírez, J. P977 Poehlau, D. P626, P658 Pucci, E. 60, P437, P928 Ramirez-Martinez, D. P965 Poettgen, J. P616 Puccio, L. P963 Rammohan, K. P232, P403, Pohl, C. P369, P476, P807 Puertas, I. P784 P441, P817, P825, P852 Polak, P. P879 Pujal, J.M. P683 Ramo-Tello, C. P281 Polman, C. 5, 6, 111, 118, Pujol-Borrell, R. P281 Ramos-Cejudo, J. P399 P220, P324, P352, Pul, R. P245 Ramtahal, J. P842, P886 P358, P369, P434, Pula, B. P252, P959 Ranger, A. P706 P483, P541, P547, Pulizzi, A. P438, P733 Rani, S. 125 P564, P646, P686, Purdy, S. P706 Ranjan, A. P228 P733, P735, P759, Puthenparampil, M. 7, P332, Ranjeva, J. P351, P372, P766, P807, P848, P756, P831 P765, P805 P905, P950, P946 Putzki, N. P659, P925 Ransohoff, R. 125 Poloni, G. 82, P321, P775 Rao, S. P798 Ponzio, M. P480 Qiu, W. P693 Rao, S.P. P425 Poorjavad, M. P204 Quarantelli, M. P422, P748 Rasova, K. 59 Popescu, V. P352, P564 Querol, L. P371 Rastenyte, D. P209 Popolizio, T. P322 Quiles, A. P584, P743 Rastenytë, R. P365 Popovic, S. P261 Rataj, K. P153 Portaccio, E. P184, P334, Raad, R. P663 Ratchford, J. 9 P796 Rabadeux, C. P867 Ratnagopal, P. P414 Portalès, P. P980 Rachid Malfetano, F. P503 Rau, D. P570 Poschmann, G. P702 Racke, M. P963 Rauer, S. P439 Potemkowski, A. P625 Radaelli, M. 60, P163, P266, Rauschka, H. 89, P892 Pott, F. P312 P360, P433, P467, Ravanidis, S. P396 Poulatsidou, K. P396 P594, P779, P871, Raven, S. P693 Poulios, A. P574 P896, P920, P928, P929 Ravnborg, M. 135, P512, P986 Pouwels, P.J.W. 118, P759 Radji, F. P867 Razzolini, L. P184, P796 Poyraz, T. P519, P780 Radü, E.W. P316, P358, Reali, C. 90 Pozzilli, C. P184, P325, P434, P559, P686, Realmuto, S. P874 P329, P437,P480, P735, P809 Rebs, R. P728 P521, P796, P875 Rafique, I. P304 Reder, A.T. P565, P884, P903 Praksova, P. P597 Ragonese, P. P874, P920 Regeniter, A. P559, P970 Prasansiang, C. P177 Rahman, A. P417 Regev, K. P588, P699

Prats, N. P452, P851 Raicevic, R. P261 Regna-Gladin, C. P171 Authors Prayer, D. P359 Raich, D. P281 Reich, D. 9 Prayoonwiwat, N. P177, P589, Raininko, R. P582 Reichmann, H. P730 P610 Rajagopalan, K. P947 Reijerkerk, A. 91, P662 Press, R. P274 Rakacolli, M. P189 Reijmers, R. P652 Presslauer, S. P966 Ram, E.S. P850 Reilly, C. P475

167 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Reindl, M. P435, P636, P962 Rizzo, A. P437 Römisch, J. P435 Reinhardt, S. P815 Roberts, B. P424, P425, P427 Ron, M. P749 Reis, J. P216 Robertson, N.P. P481, P860 Ronken, E. P662 Reisifar, M. P393 Robinson, C. P248, P674, Roosendaal, S. 5, 118, P767 Reitner, A. P354, P956 P675 Ropele, S. P315, P342, Reková, P. P149 Robinson, J. P436 P357, P755, P769 Remington, G. 80, P210 Robinson, W. P417 Roscio, M. P796 Rener Primec, Z. P172 Robles, R. P584 Rose, J. P665 Rentzos, A. P147 Rocca, M.A. 57, P148, P314, Rosengren, L. P566 Resende, M. P586 P327, P341, P437, Rosenzweig, J. 9 Reshef, S. P181 P476, P734, P738, Roshanisefat, H. P398, P692 Restivo, D. P510 P745, P751, P767, P986 Rosicarelli, B. P716 Reuss, R. P694 Roccatagliata, L. P336, P920 Ross, A. P. P936 Reuter, F. P372, P765, P805 Rocha, C. P165, P718 Rossi, F. P334, P739, P863 Reuther, J. P653 Rocher, F. 67 Rossi, F.R. P308 Reynolds, R. 90, P237 Rodegher, M. 135, P266, P341, Rossi, S. P407, P880 Rhodes, K. P887 P480, P505,P594, Rossi, P. P364 Ribizzi, G. P199 P734, P779, P920 Rot, U. P153 Ricchezze, K. P943 Rodrigo, L. P727 Rottoli, M. P235, P437, Riccitelli, G. 57, P327 Rodrigues, D.H. P473 P464, P859 Richards, T. P475 Rodríguez, G. P362 Roudbary, S.A. P725 Richardson, R. P665 Rodriguez, M. P465 Rouhart, F. P394 Richman, S. 112, 138, P482, Rodriguez, M. P294 Roura, P. P622 P894 Rodriguez, O. P444, P824, Rovaris, M. P729 Rico, A. P372, P765, P805 P898 Rovero, P. P974 Riddehough, A. P347, P757 Rodriguez, S. P603 Rovira, A. 85, P346, P555, Riddell, C.A. P347, P757 Rodriguez de Antonio, L. P614 P737, P743, P754, Rieckmann, P. 56, 135, P196, Rodríguez-Roca, R. P159 P841, P865 P232, P403, P441, Rodríguez-Sureda, V. P701 Rozenbaum, O. P562 P618, P817, P825, Rog, D. P488 Rubio, L. P545 P852, P876, P986 Rogemond, V. 50 Rudick, R. 125, P408, P483, Riester, K. P557, P561 Roggerone, S. P338 P541, P798, P864, Righetti, T. P943 Rojas, G. P901 P891, P950 Rigotti, D. P387, P799 Rojas, J.I. P567 Rudolf, G. P974 Riise, T. 52, P720 Rolak, L. P828 Rueda Lopes, F.C. P352 Rijkers, E. P564 Roldán, E. P792 Ruet, A. P380 Rinaldi, F. 7, 81, P148, Roldan, M. P545 Ruffini, F. P247, P885 P317, P332, P437, Roldán, M.I. P784 Ruggieri, M. P569 P746, P756, P831 Rolinski, J. P455 Ruggieri, S. P329 Rinaldi, L. P703 Rolla, S. P703 Ruhrmann, S. P252, P461, Rio, E. P216 Rollot, F. P634 P959 Río, J. 85, P346, P555, Romagnolo, A. P238 Ruimschotel, R. P375, P639, P572, P701, P841, Romagnolo, E. P703 P806 P865, P961 Roman-Vega, L. P444, P824, Ruiz-Peña, J.L. P362 Ríos, C. P977 P898 Rumbach, L. P867 Ríos Lago, M. P378, P794 Romani, A. P835 Runia, T.F. P721 Riskind, P. P963 Romano, R. P322 Runmarker, B. P621 Ristori, G. 94, P407 Romberg, A. 59 Rus, H. P690 Ritleng, C. P198 Romeo, M. P505 Rus, V. P690 Rivarola, V. P170, P695 Romero, C. P146 Rutter, M.-C. P513, P533 Rivera, R. P834 Romero-Pinel, L. P683 Ryan, K. P553

168 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Sa, M.J. P216, P301 Santiago-Raber, M.-L. P249, Schirda, C. 82, P320, P321, Saarup, T. P484, P926 P677 P772, P773, P774, P775 Sabaté, M. P453 Santner, W. P962 Schirmer, L. P240 Saberi, H. P154 Santos, E. 13, P644 Schlain, B. 138, P873, P992 Saberi, A. P725 Santos, G. P176 Schlottmann, P.G. P348, P349 Saccardi, R. P469 Santos Cruz, G. P258 Schlummer, A. P217, P651 Sacco, E. P212 Santoyo, C. 59 Schmidbauer, M. 89 Sacco, R. P752 Sanvito, L. P446 Schmidt, F.A. P638 Sadiq, S. P963 Sanz-Arigita, E.J. P352 Schmidt, H. P552, P963, Sadjadi, R. P853 Saposnik, G. P504 P972 Sadovnick, A. 54, P194, Sappey-Marinier, D. P338, Schmidt, R. P315 P590, P629 P750 Schmidt-Erfurth, U. P547, P956 Sadovnick, D. P941, P984 Sapunova-Mayer, I. P892 Schmierer, K. P579, P741, Saeedi, H. P263 Sarchielli, P. P437, P676 P777 Sahraian, M.A. P175, P911 Sardu, C. P620, P854 Schmouder, R. P412, P445 Saidha, S. 9 Saresella, M. P729, P888 Schmutzhard, E. P962 Sailer, M. P323, P876 Sargento Freitas, J. P416 Schnabl, P. P892 Saint-Remy, J.M. P822 Sartori, E. P394 Schneider, C. P337 Saip, S. P158, P178, Sasaki, H. P711 Schneider, H. P730 P370 Sastre-Garriga, J. 85, P346, Schocke, M. P962 Saiz, A. P350 P555, P622, Schönberg, P. P219 Sajic, M. P313 P754, P841, Schöne, U. P310 Sala, A. P150, P276 P865 Schönermarck, U. P910 Sala, S. P734, P738 Sæther, H. P263 Schoonheim, M.M. 5, P352 Saladino, M. 38, P626, Saunders, J. 15, 61, P511, Schreiber, H. P912 P658, P819 P532 Schreiber, S.J. P579 Salameh, J. P663 Savettieri, G. P480, P874 Schrempf, W. P730 Salamon, H. P565, P884 Savic, R.M. P447 Schrock, J. 125 Salem, R. P643 Savino, A. P626, P658 Schroeter, M. P156 Salemi, G. P874 Sawcer, S. 31, P263 Schteinschnaider, A. P146 Sales, D. P214 Saxton, J. P537 Schultheiß, T. P655, P730 Salsiccia, S. P943 Sbardella, E. P329 Schulz, K. P391, P801 Salter, A. P508, P617 Scalabrini, D. P691 Schuster, J. P582 Salvetti, M. 94, P407 Scalfari, A. P180, P613 Schwab, S. P440 Salvi, F. P508, P773 Scannevin, R. P887 Schwarz, A. P697 Sanchez, A.J. P444, P824, Scaravilli, F. P777 Schweitzer, A. P858 P898 Scarberry, S. P182 Schweizer, U. P252 Sánchez Ramón, S. P698 Scarpini, E. P691 Schwenk, J.M. P988 Sanchez-Catasus, C. P159 Schaellebaum, M. P809 Schwenk, J. 137 Sancho, J. P424, P425 Schaffer, M. P681 Scolding, N.J P477 Sandberg-Wollheim, M. P492, Schäffler, N. P219, P443 Scott, J. P762 P813 Schapiro, R. P515, Scott, T. P229 Sandbrink, R. P369, P476, P518, P921, Seabrook, TJ. P858 P807 P922 Sebastianelli, A. P212 Sander, B. P952 Schedensack, M. P672 Sedlak, L. P914

Sandoval, R. P350 Scherer, P. P374, P610 Seewann, A. 118, P324 Authors Sangalli, F. P163, P433, Schernthaner, M. P354 Seidl, Z. P866 P594, P871, P896 Schimpl, M. P217 Seifert-Held, T. P243 Santangelo, M. P334 Schippling, S. P330, P547, Seils, J. P475 Santarello, G. P514 P616, P768, Seixas, S. P373 Santiago, V. P626, P658 P815, P949 Seleker, F. P178

169 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Sellebjerg, F. 123, 131, Signori, A. P857 Soelberg Sørensen, P. 89, 127, P283, P449 Silber, E. P580 134, 136, P232, P283, Selmaj, K. P285, P454, P667, Siliquini, S. P676 P355, P403, P441, P679, P709, P832 Silva, C. P882 P817, P825, P852 Semmler, A. P685 Silva, F. P416 Sofras, F. P215 Sempere, A. P288 Silva, M.R. P586 Sohrabnejad, R. P188 Sena, E.S. P246 Simeoni, M.-C. P650 Sokolova, L. P392 Senesi, C. P550, P870 Simka, M. P641, P914 Sola, P. P150, P389, Seppi, D. P332, P831 Simo, M. P151, P288 P577, P600 Sequeira, H. P384 Simon, J. P891 Solari, A. 60, 99, P928, P929 Serafini, B. P716 Simon, K. 138, P873 Solaro, C. 101, P184, P199, Serbecic, N. P354, P956 Simone, A.M. P389, P600 P510, P900, P920 Sergott, R. P953 Simone, I.L. P235 Soleymani, B. P204 Serpente, M. P691 Simons, M. P672 Sombekke, M.H. P686, P766 Serra, J. P883 Simonsen, H. P957 Somers, V. P705 Servillo, G. P800 Singh, V. P976 Sonder, J. P220 Seubert, S. P242, P881 Singhal, B. P611 Søndergaard, H.B. P283, P449 Séveno, M. P563 Siqueira, H. P168, P591 Song, P. P770 Severa, M. P716 Sirbu, C. 38, P819 Song, S. P760 Severy, P. P425 Siritho, S. P177, P589 Sonis, P. P958 Sfagos, C. P260 Sisman, N. P178 Sopper, S. P964 Shackelford, S. 136, P964 Siva, A. P158, P178, P370 Sorensen, P.S. P449, P733 Shah, M. P761 Skedgel, C. P608 Sormani, M.P. P148, P336, Shakarishvili, R. P185 Skejoe, P. P596 P469, P751, Shankara, S. P424, P425 Skibina, O. P978 P857, P863 Sharp, A. P879 Skinningsrud, B. P263 Sorosina, M. P266 Sharrack, B. P537, P842, Skoog, B. P621, P902 Sorro, U. P484, P926 P969 Skovgaard, L. P540 Sospedra, M. P293, P708, Shaw, C. 8, P626, P658, Skripuletz, T. P245 P815 P819 Skromne, E. P658 Sosso, L. P703 Shaw, G. P978 Skuljec, J. P245 Soulier, E. P372, P765 Shaw-Caffrey, E. P538 Slattery, C. P292 Sousa, L. P416 Shaygannejad, V. P658 Slavin, A.J. 51 Soysal, A. P370 Shepherd, G.L P488 Slee, M. 38, P626, P658, P819 Spagnolo, F. P366 Sheppard, C. P823 Slesari, I. P856 Spallarossa, P. 62 Sheridan, J. P557, P561 Sloka, S. 108 Sparvoli, M. P943 Shevil, E. P528, P811 Smestad, C. P263, P624 Speck, O. P323 Shiee, N. 9 Smith, E. P475 Specogna, I. P800 Shimony, J. P760 Smith, K. P553 Spector, L. P552, P972 Shin, B.S. P623 Smith, K. P313, P670 Speeg, C. P208, P549, Shipova, E.G. P587 Smith, M. P339, P747 P592 Shirani, A. 56, P618 Smith, P. P858 Spelman, T. 38, P658, P819 Shlomchik, M.J. 51 Smith, S. P164 Spencer, B. P626 Shmidt, T. P818 Smolders, J. P270, P305 Spencer, C. P710, P826 Sibson, N.R. P814 Snir, A. P850 Sperli, F. P363 Sicotte, N. P340 Snoha, A. P501 Sperling, B. 134 Siders, W. P427 Snyder, A. P760 Spirin, N.N. P587 Sidorenko, T. P489, P897 So, P.-W. P777 Spitaleri, D. P722 Siebner, H.R. P355 Soaz Gonzalez, C. P651 Spliethoff-Kamminga, N. P375, Sievers, C. P712 Sobel, R. 51, P710 P639, P806 Siffrin, V. P275 Sobota, R. P157 Spurkland, A. P263

170 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Sputtek, A. P815 Stroet, A. P202 Tallantyre, E. 119 Srámek, M. P583 Ström, M. P256 Taller, M. P479 Stabile, M.R. P514 Stromillo, M.L. P325, P329, Tallner, A. P217 Stabile, R. P510 P334, P739, P746, P863 Talman, L.S. 80 Stack, J. P292 Stroud, R. P710 Tamano-Blanco, M. P265 Stadelmann, C. 139, P240 Stubinski, B. P287, P857, Tan, K. P331, P470, P604 Stadelmann-Nessler, C. P719 P863 Tanaka, K. P161 Stamboulis, E. P574 Studer, V. P407, P880 Tanaka, M. P161 Stampatori, C. 57 Studzinski, D. P311 Tanasescu, R. P576, P612 Stangel, M. P245, P915 Stuerner, K. P815 Tang, D. P442, P830, P844 Stankoff, B. 117, P351, Stühler, K. P702 Tanganelli, P. P199, P510 P736, P742 Stutts, L. P513 Tantucci, M. P676 Stankovic, A. P261 Suardiaz, M. P409 Tao, L. P700 Stark, L. P399 Subramanyam, M. 138, P873, Tarasenko, I. P479 Staugaitis, S.M. P337 P968, P983, P992 Tardieu, M. P156 Stawiarz, L. P902 Sujjanant, J. P177 Tarrants, M. P913 Stecchi, S. P650, P955 Sullivan, C. P207 Tarrason, G. P452, P453 Stecher, S. P478 Sultansei, N. P461 Tascos, N. P290, P297 Stefan, J. P219 Sundal, C. P147 Taumberger, B. P435 Stefoski, D. P905 Sundblom, J. P582 Tauqeer Ahmad, M. P414 Steibel, J. P669 Sundgren, M. P782 Taurisano, P. P322 Steiner, C. 41 Sundqvist, E. 55, P267, P715 Tavazzi, E. P835 Steinman, L. P417, P963 Sundström, P. 93, P566, P715 Tavsanli, M. P158 Stellmann, J. P616, P815 Sureau, F. 117 Taylor, B. P978 Stelmasiak, Z. P218, P455 Süssmuth, S. P570 Taylor, S. P963 Stemper, B. P369, P807 Sutlas, N. P178, P370 Tedeholm, H. P902 Stenager, E. 39, 134, P512, Suzuki, S.O. P599 Tedeschi, G. P752, P875 P596, P633 Svane, I.M P395, P396 Tegla, C. P690 Stenager, E.N. P633 Svenningsson, A. P234, P397, Teixeira, A.L. P473 Stenager, K. P633 P491, P566 Teixeira, M.J. P919 Stenager, M. P633 Svenungsson, E. P398 Tejeiro, R. P698 Stepanov, I.O. P587 Swaminathan, B. P264 Tejero-Alhambra, M. P698 Stephan, M. P980 Sweeney, C.M. P450 Téllez-Pena, R. P159 Stepleman, L.M. P513, P533 Swierad, M. P641, P914 Telstad, W. P720 Sterzi, R. P171 Syc, S. 9, 80 Tennant, A. P790 Stettner, M. P861 Szczepanik, M. P679, P832 Terzi, M. P158 Stich, O. P439 Szpernalowska, D. P625 Tettenborn, B. P925 Stingl, C. P976 Teunissen, C. P564 Stinissen, P. P705 Tabira, T. P599 Thain, J. P932 Stites, T. P812, P827 Tahara, M. P161 Thamilarasan, M. P268 Stojsavljevic, N. P485 Taherzadeh-Fard, E. P959 Thamilarasaran, M. P839 Stoop, M. P976 Tahiri, K. P853a Theil, D. P440 Storch, M.K. P243 Tahuid, S. P758 Thewissen, M. P270 Storek, J. P456 Takahashi, S. P295 Thiele, A. P613 Stosic-Opincal, T. P314, P734, Takahashi, T. P286, P468, Thiesen, H.-J. P268, P419,

P738 P589 P839 Authors Stott, C. P680 Takai, Y. P468 Thomas, T. P694 Stourac, P. P597 Takeichi, N. P668 Thompson, A.J. P325, P326, Straffi, L. P366, P480, P779 Takizawa, S. P668 P344, P345, P556, Strober, J. P294 Takos, D. P215 P744, P753 Strober, L.B. P798 Talim, L. P718 Thompson, H. P507, P895

171 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Thomsen, K. P502 Traboulsee, A. P347, P431, Turkes, M. P642 Thöne, J. P242, P881 P492, P757, P763, Turkoglu, R. P908 Thouvenot, E. P563, P867, P813, P853 Turner, M.J. P427 P980 Trabucco, E. P341 Turpault, S. P849 Thrower, B. P963 Tran, G.T. P248, P674, Turpin, K. P944, P948 Thuler, L.C. P176, P373 P675 Tutuncu, M. P178, P370 Thuresson, A. P582 Tranchant, C. P581 Tyblova, M. P571 Thygesen, L.C. 39 Trapp, B.D. P337 Tic Golob, M. P153 Trattnig, S. P354 Uccelli, A. 64, P703 Ticho, B. P432 Traud, S. P316, P358, P735 Ugarte, D. P159 Ticmeanu, M. P612 Travaglini, D. P382, P783 Ugarte-Sánchez, C. P159 Tierney, J.A. P580 Trebini, C. P238 Ugradar, S. P777 Tietz, S. P694 Trebossen, R. 117 Uhlen, M. 137, P988 Timmermans, A. P224 Trebst, C. P245, P915 Uhr, M. 33 Tinbergen, J. 114 Trecker, C. P471 Uitdehaag, B. 6, P220, P324, Tintoré, M. 85, P346, Tremlett, H. 56, P618 P492, P646, P767, P555, P754, Tremolada, S. P835 P813, P946 P841, P865 Trifilieff, E. P669, P974 Ukmar, M. P800 Tiozzo, M. P514 Trigo Rocha, F. P657 Ulozienë, I. P365 Tireli, H. P908 Trincia, E. P800 Uluduz, D. P178 Tisell, A. P335 Trinkaus, K. P760 Undlien, D.E. P263 Tochowicz, M. P914 Trip, S.A. P348, P349 Urbach, S. P563 Toennes, C. P353 Trisolini, M. P661 Urbanski, M. P736 Toft-Hansen, H. P704 Trojano, M. 38, 60, 122, Urcelay, E. P264, P689, Togrol, E. P178 P184, P322, P422, P717 Tokarz-Kupczyk, E. P213 P480, P494, P569, Urshansky, N. P588, P699 Tola, M.R. P184, P422 P626, P658, P796, Utz, P.J. P417 Tomas, E. P529 P819, P837, P875, Uzan Guata, R. P479 Tomassini, V. P329, P920 P928, P929 Tomita, A. P446 Troni, W. P363 Vacca, G. P748 Tomizawa, Y. P568 Truffinet, P. P982 Vago, P. P684 Tonali, P.A. P282 Trufyn, J. P339, P747 Vahter, L. P484, P926 Toncev, G. P627 Truini, A. P645 Vaitkus, A. P365 Tonin, P. P514 Tsakiri, A. P395, P396, P951, Valdueza, J.M. P579 Toosy, A.T. P344, P345 P952, P957 Valentini, M. P269 Topcular, B. P178, P370 Tsakiri, N. P280 Valentino, P. P150, P276, Torkildsen, O. 16 Tscherner, M. P315 P438, P990 Torno, S. P475 Tselis, A. P423, P761 Valenzuela, R. P554 Torrecilla, D. P545 Tsiodras, S. P574 Valikovics, A. P367 Tortorella, C. 60, P322, P569, Tsiskaridze, A. P185 Vallières, L. P306 P920, P928, P929 Tsugane, S. P668 Valls-Sole, J. P350 Tortorella, P. P729 Tsukuda, K. P272 Valsasina, P. P341 Totaro, P. P521 Tubridy, N. P152, P292, Valzelli, S. P691 Totaro, R. P184 P450, P585, P940 Van Asch, P. 59 Toubi, E. P850 Tufan, S. P415 van Dam, A.M. P239 Tourbah, A. 117, P351, P736, Tumani, H. P570, P892 van de Kraats, C. P564 P793, P867 Tur, C. P744, P841 van den Berg, R. P324 Touret, M. 50 Turatti, M. P981 van der Elskamp, I.J. 6 Tovar-Moll, F. P333 Turcanova-Koprusakova, M. P546 van der Hiele, K. P375, P639, Tozer, D. P764, P741 Turel, A.P. P987 P806 Tozzi, A. P676 Turk Boru, U. P178 van der Kop, M. P618

172 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr. van der Linden, F. P220 Venaize, J.L. P684 Vincent, T. P980 van der Pol, S. 86 Venegas, A. P614 Vinther, M.D. P551 van der PouwKraan, C.T.M. 6 Venhovens, J. P368 Viout, P. P372, P765 van der Valk, P. 86, 91, 118, Venkatesan, A. P963 Viret, A.C. P787 P239, P312, P662 Vennegoor, A. P848 Visentin, E. P635 van der Voort, L. 6, P733 Ventrella, G. P748 Visser, F. P759 van der Werf, Y.D. 5 Venturelli, E. P691 Visser, I.E.R. P169 van der Zande, A. P375, Venturi, S. P199 Visser, L. P375, P639, P639, P806 Verbraak, E. P279 P806 Van Diepen, A. P705 Vercellino, M. P238, P920 Viterbo, R. P796 van Doorn, R. P662 Verderio, C. 84 Viterbo, R.G. P322, P569, van Eijkeren, F. P652 Verdun, E. P225, P492, P813 P837 Van Ganse, E. 67 Verdun di Cantogno, E. P650 Vittori, D. 94 van het Hof, B. P662 Verga, E. P729 Viviani, B. P676 van Hooff, L.J.M.A. P451, P457 Vergara- Edwards, F. P500 Vizcarra-Escobar, D. P500 van Horssen, J. 86, 91, P662 Vergara-Irigaray, N. P664 Vollmer, T. P617, P963 Van Lint, M.T. P336 Verheul, F. P451, P457 von Koch, L. P523 van Meurs, M. P279 Verheul, F. 38, P451, P626, von Rosenstiel, P. P434 van Munster, E. P652, P848 P658, P819 Voß, E. P245 van Oosten, B. P324, P848 Verhey, L. 54, P590 Voskuhl, R. 120 van Oppen, P. P946 Verma, N.D. P674 Vosslamber, S. 6 Van Pesch, V. 38, P193, Vermersch, P. Vouga, C. P892 P626, P658, P819 Vermersch, P. 26, 103, 112, Voumvourakis, K.I. P574 Van Wijmeersch, B. P705 P167, P232, P403, Vrech, C. P901 Vandenbroeck, K. P264 P408, P441, P466, Vrenken, H. P352, P358, Vander Elst, L. P822 P547, P592, P605, P564, P766 Vandermoere, F. P563 P607,P817, P825, Vrethem, M. P274, P335, Vaneckova, M. P866 P852, P867, P899, P980 P566 Vaney, C. 59 Veronese, E. P317 Vrignaud, C. P853a Vanghelie, G. P576 Verschueren, S. P531 Vrolix, K. P705 Vaqué, J. P622 Vert, C. P754 Vukusic, S. 67, P338, P684, Vaquero, E. P362 Verweij, C.L 6 P867 Varrin-Doyer, M. 50, P710, P826 Verzijl, D. P662 Vuolo, L. P336 Vasconcelos, C. P176, P214 Vesterinen, H.M. P246 Vashadze, T. P185 Vezzulli, P. P467 Wacker, T. P259 Vass, C. P354 Vianello, F. P253 Wadenvik, H. P707 Vass, K. P354 Vianello, M. P875 Wadih, H. P663 Vassilopoulos, D. P260 Vieira Alves Leon, S. P503 Wahl, M. 10 Vavasour, I.M. P763 Viejo Sobera, R. P378, P794 Wahlin, Å. P782 Vazquez, G. P146 Vieth, R. 54 Wakerley, B.R. P696 Vazquez-Marrufo, M. P362 Viglietta, V. P441, P817, Walczak, A. P832 Vecchio, R. P144, P144, P825, P852 Wallner-Blazek, M. P315, P796 Viken, M.K. P263 P342, P357, P737, Vecsei, L. P357 Vilanova, J.C. P381, P743 P755, P769 Vedovello, M. P636 Vilches, A. P701 Wallström, E. P858

Veeraraghavan, J. P475 Villa, A. P170, P603, P695 Walter, E. P233 Authors Vega, J. P727 Villa, C. P691 Walters, R. P226 Veiga, A. P586 Villar, L.-M. P278 Wamil, B. 79 Velikova, S. P364 Villoslada, P. 547, P664, P883 Wandinger, K.P. P150, P571 Vella, N. 8, P626, P658, Viñals, M. P452 Wang, C. P538 P819 Vincent, A. 13, P770 Wang, J. P882

173 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Wang, L. 79, P982 Wessely, M. P910 Wright, D. P533 Wang, N. P412 Westerlind, H. P688 Wright, S. P680 Wang, S. P431, P833 Wheeler-Kingshott, C. 344, Wrobel, J. P641 Wang, Y. 14 P744, P749, P764 Wrzos, C. 139 Wang, Y.-C. P230 Wicklein, E.-M. P374, P610 Wu, J.-S. P693 Wanscher, B. P951, P952 Wickström, A. P234 Wu, W.E. P387 Wardell, C. 113 Widén Holmqvist, L. P523 Wu, X. P599 Warner, C. 9 Wiedemann, A. P211 Wu, X. 134, P355 Warnke, C. P861 Wiendl, H. P156, P487, Wundes, A. P878 Warren, K. P944, P948 P494 Würfel, J. P542 Warren, S. P944, P948 Wiener, J. P661 Wustrow, D. P671 Waschbisch, A. P440 Wierenga, A.F. P279 Wygladalska-Jernas, H. P213 Wasmuth, R. P682 Wiertlewski, S. P867 Wylie, G. P328 Wassmer, E. P606 Wiese, S. P252 Wynn, D. 135, P426, P428, Waters, P. P770 Wiest-Daesslé, N. P351 P986 Watkins, R. P475 Wilczak, N. P307 Watrin, C. 50 Wildemann, B. P435, P697 Xia Lin, S. P879 Watsky, E. P909 Wilken, J. P207 Xu, J. P760 Watt, M. P895 Wilkins, A. P477 Xu, Y. 125 Wattjes, M.P. P324, P759, Williams, A. P246, P673 P766, P767, P848 Williams, M. P513, P533 Yaguchi, H. P711 Watzl, C. P435 Williamson, A.J. P298 Yaldizli, Ö. P316, P809 Waubant, E. P294, P967 Willis, L. P318, P319, Yamaguchi, K. P565, P884 Weaver, J. P963 P774 Yamamura, T. P446 Weber, F. 33 Wilson, E. 138, P873 Yamout, B. P663 Weber, J.R. P892 Winblad, S. P621 Yanagisawa, S. P668 Weber, M. 51, P249, P826 Wingerchuk, D. P429 Yandim Kuscu, D. P178, P370 Weber, T. 113 Winkelmann, J. P682 Yang, L. P478 Weddige, A. P458 Winkler, C. P419 Yang, M. P764 Wegner, C. P251 Winkler, L. P330, P768 Yao, J. P630 Wehus, R. P890 Winter, L. P475 Yarden, J. P552, P972 Weibull, L. 28 Wipfler, P. P401, P448, P892 Yassouridis, A. P910 Weigand, S. P502 Witte, M. 86, 91, P662 Yasui, M. P286 Weill, A. P634 Wodz-Naskiewicz, K. P667 Yazdan Panah, M. P911 Weiner, H. P454 Woelbert, M. P949 Yeh, A. P294 Weiner, J. P817, P852 Wojcik, J. P266 Yeh, E. P318 Weiner, L. P829 Wolf, C. 33 Yeh, E.A. P653 Weinshenker, B. P593 Wolfson, C. 121 Yenson, P. P853 Weinstock-Guttman, B. 82, Wolinski, P. P250 Yeung, M. P456 P265, P294, P318, Wolinsky, J. 79, P476, P872, Yeung, Y. P630 P319, P320, P508, P982, P985 Yildiz, M. P925 P573, P653, P771, Wong, A. P785 Yildiz, S. P370 P772, P773, P774, Wong, H. P471 Yin, M. 114 P776, P797 Woodroofe, N. P537, P969 Yiu, E. P590 Weise, T. P655 Woodworth, J. P478 Yokoyama, K. P568 Weissert, R. P243 Worthington, V. P411 Yonekawa, T. P599, P687 Weizman, A. P479 Woznicova, I. P820 Yong, V. 108, P882 Wekerle, H. 51, 87 Wray, S. P909 Yorkston, K. P539 Weller, M. P685 Wray, W. P665 You, X. P891 Wergeland, S. 16 Wright, A.D. P436 You, X. P207, P229, P418, Wesnes, K.A P463 Wright, D. P400 P810, P866

174 List of Authors

Name Prog. Nr. Name Prog. Nr. Name Prog. Nr.

Young, C. 38, 135, P790, Zayed, N. P339, P747 Ziak, P. P546 P819, P986 Zecca, C. P517, P803 Ziegler, A. P202 Yousef, S. P815 Zeilig, G. P192 Ziegler, K. P391 Yousefzad, A. P725 Zekja, I. P189 Ziemann, U. 10 Yousry, T. P749, P767 Zeman, D. P820 Ziemssen, T. P223, P655, Ytterberg, C. P523 Zeng, W. P887 P730, P918 Yu, J.K. P786 Zephir, H. P167, P390, P466, Zimmer, C. P740 Yuen, T. 107 P592, P605, P607, Zimmermann, H. P954 P867, P899, P980 Zimmermann, J. P277, P666, Zaaraoui, W. P372, P765, Zessack, N. P821, P876 P892 P805 Zettl, U. P268, P419, P839, Zimova, D. P979 Zaffaroni, M. P235, P437, P876, P892 Zipoli, V. P184, P796, P920 P703 Zhang, A. P494, P541, P950 Zipp, F. P275 Zagon, I. P987 Zhang, H. P673 Zivadinov, R. 2, 82, P265, Zahavich, L. P194 Zhang, J. 83, 107 P318, P319, P320, Zajicek, J. P226, P400, Zhang, Y. P557, P561 P321, P413, P573, P847 Zhang, Y. 83, P472 P653, P771, P772, Zak, I. P761 Zhang, Y. P762 P773, P774, P775, Zalc, B. P742 Zhang-Auberson, L. P434, P776, P797, P866 Zamboni, P. 1, P508, P773 P442, P812, P827, Zivkovic, M. P261 Zamboni, R. P508 P830, P843, P844 Zoia, C. P729 Zameer, A. 83, 107, P472 Zhao, J. P665 Zopp, I. P484, P926 Zamvil, S. 51, P710, P826 Zhao, J. P478 Zorzon, M. P800 Zanelli, E. P853a Zhao, Y. 56, P347, Zugna, L. P800 Zanetti, C. P514 P618, P757 Zummo, L. P874 Zapletalova, O. P820 Zhong, K. P323 Zwanenburg, J.J.M. P759 Zastepa, E. P700 Zhu, Y. P904 Zwanikken, C. 38, P451, Zauderer, M. P475 Ziabreva, I. P670 P457, P626, P658, P819 Authors

175 Instructions for Authors

Audiovisual Equipment / Speakers’ Service Centre (SSC) The Speakers’ Service Centre (SSC) is located on level 2 of the congress centre. All lecture rooms will be equipped with a computer and a data projector (beamer) for PowerPoint presentations. Presentations must be handed in via CD-Rom, DVD, USB memory stick or via your own laptop at the SSC before the lecture.

It is essential for the smooth running of the congress that all speakers hand in their PowerPoint presentations at least one hour before the beginning of the session. Speakers will have the opportunity to check their presentations on PCs available in the SSC.

Poster Sessions Posters will be on display in two sessions. Presenters are kindly requested to stand by their poster during the Poster Viewing indicated below. The mounting and removal times are to be strictly adhered to. If the poster has not been removed by the end of the allocated removal time, it will be disposed of by congress staff.

Poster Presentation Presence at Poster Poster Viewing Day Poster Mounting Time Removal Time

Session I Thursday, 15:30–17:00 Wednesday, Thursday, 14 October 13 October 14 October 12:00–14:00 17:00–18:00

Session II Friday, 15:30–17:00 Friday, Saturday, 15 October 15 October 16 October 08:00–09:00 12:00–13:00

176 Instructions for Authors

Poster Session I – Thursday, 14 October 2010 presence of authors required: 15:30–17:00

Topic Nr. Poster Topic Poster Numbers 1 Diagnosis & differential diagnosis 1 P143 – P157 2 MS variants 1 P158 – P172 3 Natural course 1 P173 – P182 4 Epidemiology 1 P183 – P202 5 MS symptoms 1 P203 – P216 6 Clinical assessment tools 1 P217 – P231 7 Economic burden 1 P232 – P236 8 Pathology 1 P237 – P240 9 Experimental models 1 P241 – P254 10 Genetics/transcriptomics 1 P255 – P269 11 Immunology 1 P270 – P288 12 MS and infections 1 P289 – P294 13 Environmental, sex-related and P295 – P305 life-style factors 1 14 Neurobiology 1 P306 – P311 15 Repairing mechanisms 1 P312 – P313 16 Imaging 1 P314 – P359 17 Neurophysiology 1 P360 – P368 18 Neuropsychology and fatigue 1 P369 – P393 19 Immunomodulation 1 P394 – P466 20 Immunosuppression 1 P467 – P471 21 Neuroprotection 1 P472 – P479 22 Long-term treatment monitoring 1 P480 – P496 23 Therapy disease modifying – Others 1 P497 – P508 24 Treatment of specific symptoms 1 P509 – P519 25 Comprehensive care & rehabilitation 1 P520 – P532

26 Quality of life 1 P533 – P540 Instructions for Authors 27 Neuro-Ophthalmology 1 P541 – P550 28 Biomarkers 1 P551 – P576

177 Instructions for Authors

Poster Session II – Friday, 15 October 2010 presence of authors required: 15:30–17:00

Topic Nr. Poster Topic Poster Numbers 29 Diagnosis & differential diagnosis 2 P577 – P591 30 MS variants 2 P592 – P607 31 Natural course 2 P608 – P616 32 Epidemiology 2 P617 – P635 33 MS symptoms 2 P636 – P645 34 Clinical assessment tools 2 P646 – P658 35 Economic burden 2 P659 – P661 36 Pathology 2 P662 – P665 37 Experimental models 2 P666 – P680 38 Genetics/transcriptomics 2 P681 – P694 39 Immunology 2 P695 – P713 40 MS and infections 2 P714 – P719 41 Environmental, sex-related and P720 – P728 life-style factors 2 42 Neurobiology 2 P729 – P733 43 Imaging 2 P734 – P778 44 Neurophysiology 2 P779 – P786 45 Neuropsychology and fatigue 2 P787 – P811 46 Immunomodulation 2 P812 – P873 47 Immunosuppression 2 P874 – P878 48 Neuroprotection 2 P879 – P887 49 Long-term treatment monitoring 2 P888 – P903 50 Therapy disease modifying – Others 2 P904 – P915 51 Treatment of specific symptoms 2 P916 – P927 52 Comprehensive care & rehabilitation 2 P928 – P940 53 Quality of life 2 P941 – P948 54 Neuro-Ophthalmology 2 P949 – P957 55 Biomarkers 2 P958 – P981 56 Late Breaking News P982 – P992

178 Publication and Prizes

Publication All accepted abstracts are published in a supplement to the journal “Multiple Sclerosis” and on CD-ROM. Both items will be available at the meeting and are included in the registration fee. They will be handed out to all participants with the congress documents onsite. In addition to the abstracts, the CD-ROM also includes most of the posters presented during this year’s ECTRIMS meeting. They can be viewed on dedicated terminals in the e-poster area on the ground floor next to the poster area. Starting 13 October 2010 the abstracts will also be available electronically on the congress website www.ectrims.eu/2010.

Prizes Five prizes will be awarded to the best poster presentations (€ 1500, € 1000, and three prizes at € 750). Award winning poster authors will give a short presentation in the Plenary Session on Saturday, 16 October 2010. A further prize of € 500 will be awarded to the best RIMS poster. Two additional prizes of € 1500 each will be awarded to the two best oral presentations given by young investigators (born on or after 1 January 1975). The Multiple Sclerosis International Federation will also award € 1000 to the best presentation of a translational project in the young investigators’ session. Prizes will be awarded in the closing Plenary Session on Saturday, 16 October 2010. Publication and Prizes

179 Registration Information

Congress Registration A congress bag including all documents (Final Programme, Abstract Book, name badge, vouchers, etc.) will be distributed to the registered participants during the following opening hours: Wednesday, 13 October 2010 07:30–19:00 Thursday, 14 October 2010 07:00–18:00 Friday, 15 October 2010 07:45–18:00 Saturday, 16 October 2010 08:15–12:30 The same opening hours will be applied for on-site registrations. Please note that on-site registrants cannot be guaranteed to receive all congress documents.

Registration Fees (in Euro) Until As from 18 August 2010 19 August 2010 Congress delegates ECTRIMS € 450 € 600 RIMS members** € 200 € 300 Physicians in training, researchers and therapists* € 200 € 300 Analyst € 450 € 600 Teaching Courses 1 – 10 € 30 € 40 Accompanying person € 30 € 40

* Physicians in training: colleagues born after 1 January 1975; copy of passport required Therapists: confirmation from head of department required ** RIMS members must provide a receipt of their membership status 2010

The registration fee for participants includes unlimited access to all scientific sessions, the Industrial Exhibition, the Welcome Reception, one congress bag, one copy of the Final Programme, one copy of the Abstract Supplement, lunch (first come, first served) and coffee during the meeting. The fee for accompanying persons includes the Welcome Reception as well as access to the Industrial Exhibition.

Responsibility The participant acknowledges that he/she has no right to lodge damage claims against the organisers should the holding of the congress be hindered or prevented by unexpected political or economic events or generally by force majeure, or should the non- appearance of speakers or other reasons necessitate programme changes. With registration, the participant accepts this proviso.

Confirmation Upon receipt of the correct registration fee, each participant will receive a confirmation of registration. Please bring this confirmation to the Registration Desk at the congress centre as proof of your registration.

180 Registration Information

Cancellation / Refund Policy Refund of registration fees, less 25% administrative charges, can be applied for in writing until 25 August 2010 to the Administrative Secretariat in Basel, Switzerland. After this date no refund will be possible. For any change of names, a fee of € 30 will be charged. On-site changes of name badges due to incorrect submission of names and/or address data will be charged at € 10.

Badges Access to all scientific sessions will only be possible with your personal name badge which you will receive at the Registration Desk at the main entrance of the congress centre in Gothenburg. Please always wear your badge! € 30 will be charged for replacement of a lost badge.

181 Registration Information General Information (in alphabetical order)

Administrative Secretariat ECTRIMS 2010 c/o Congrex Switzerland Ltd. Freie Strasse 90 P.O. Box 4002 Basel / Switzerland Phone +41 61 686 77 11 Fax +41 61 686 77 88 E-mail [email protected] www.ectrims.eu/2010

Badges Access to all scientific sessions will only be possible with your personal name badge which you will receive at the Registration Desk at the main entrance of the congress centre in Gothenburg. Please always wear your badge! € 30 will be charged for replacement of a lost badge.

Cameras and Recordings Cassette recorders, cameras and video cameras are prohibited in lecture halls during all sessions.

Certificates Changes of certificates due to incorrect submission of names and/or address will be charged € 10. Certificates of attendance indicating the CME credits are available as from Friday, 15 October 2010, in the afternoon. They can be printed from self-service stations in the pre-registration area, using the barcode printed on your name badge.

For Italian delegates certificates will be sent after the congress. Italian delegates need to fill out the evaluation form at the Pre-registration Desk in order to receive their CME credits. The CME certificate will be sent after the congress.

Cloakroom A cloakroom is available next to the main entrance on the ground floor to keep your coats and bags.

CME Credits For detailed information please refer to page 10.

Confirmation Upon receipt of the correct registration fee, each participant will receive a confirmation of registration. Please bring this confirmation to the Registration Desk at the congress centre as proof of your registration.

182 General Information (in alphabetical order)

Congress Venue The ECTRIMS 2010 meeting will take place at the Swedish Exhibition & Congress Centre (GCC). The GCC is situated centrally in the heart of the city’s concentrated event area. During the 1970s, the Swedish Exhibition & Congress Centre together with the Swedish Exhibition Centre underwent strong development. In 1984, the tower-shaped Hotel Gothia was built and in 1992 the congress hall was added. Today, the convention centre offers many well-equipped conference rooms including a modern congress hall. The Swedish Exhibition & Congress Centre and the Hotel Gothia Towers – Gothenburg’s tallest hotel – have the ideal size to host the ECTRIMS 2010 meeting. The Swedish Exhibition & Congress Centre Mässans gata 20 402 26 Gothenburg / Sweden www.svenskamassan.se

Currency All official meeting prices are indicated in Euro (€). The official currency in Sweden is the Swedish Krona (SEK) (1 € = 9,43 SEK as per August 2010). All major credit cards are accepted in most hotels, restaurants and shops.

Evaluation After the congress, you will receive an e-mail requesting you to fill in an online survey. Please take a moment to fill in the questionnaire. Your answers will be used to evaluate the scientific content of the programme in order to continuously improve it for future meetings.

Exhibition An industrial exhibition will be organized during the congress. Companies from all over the world will be given ample opportunity to display their latest products, services and technical innovations. The opening hours are as follows:

Wednesday, 13 October 2010 09:30–17:30 Thursday, 14 October 2010 09:30–18:00 Friday, 15 October 2010 09:30–18:00 Saturday, 16 October 2010 09:00–11:00

Gothenburg Gothenburg and Västra Götaland offer an exceptional combination of city life, culture and nature. Gothenburg, the second largest city in Sweden, blends a distinct feeling of cosiness with the pulse of modern urban life. Gothenburg is easily accessible from various international

183 General Information General Information (in alphabetical order) destinations, is a major harbor city with the second largest airport in Sweden and serves as a hub within the Swedish railway network. Gothenburg offers a wide diversity of culture and many places of interest, most of them located in the very heart of the city. Gothenburg is not only home to established venues such as the City Theatre and Folkteatern, the Gothenburg Opera House, the Art Museum and the Concert Hall with the Gothenburg Symphony Orchestra but you will also discover many theatres and cultural events which are free of charge. Gothenburg is known for its fine, locally produced ingredients and top-notch restaurant life. It is also a first-class shopping destination and an ideal venue for meetings, trade fairs and conferences. Gothenburg has a long and successful tradition of trade and industry and some of Scandinavia’s best-known corporations, such as Volvo, SKF, ESAB and Hasselblad have their origins and head offices here. A significant proportion of Sweden’s exports and imports pass through Gothenburg’s port, the largest in Scandinavia.

Hotel Accommodation ECTRIMS 2010 c/o Congrex Travel Ltd. Freie Strasse 90 P.O. Box 4002 Basel / Switzerland Phone +41 61 690 94 11 Fax +41 61 690 94 14 E-mail [email protected] Congrex Travel will be present at a special desk in the congress secretariat during the meeting. Please refer to the hotel counter.

Contact on-site: Phone +46 31 708 82 93 Fax +46 31 708 82 94

Insurance The congress organisers cannot accept liability for personal injuries sustained, or for loss or damage of property belonging to meeting participants or their accompanying persons, neither during, nor as a result of the meeting. Please check the validity of your own insurance.

Internet Corner and W-LAN Internet terminals will be available for all congress participants. They are located on level 1 in the Industrial Exhibition. In addition, the entire congress centre is equipped with free wireless-LAN access.

Language The congress language is English. Simultaneous translation will not be provided.

184 General Information (in alphabetical order)

Lunch Bags & Coffee Breaks Coffee breaks and lunch bags are included in the registration fee. They will be served from Wednesday to Saturday in the industrial exhibition on level 1.

Mobile Phones Kindly be aware that mobile telephones must be switched off during all sessions.

Poster Exhibition For information about the poster exhibition please refer to pages 176–178. Posters can also be viewed electronically during the entire congress at the E-Poster area next to the poster exhibition.

Press Accredited journalists are welcome to cover the ECTRIMS 2010. Upon presentation of your press identification, registration will be free of charge. A fully equipped Press Centre is at your disposal located on level 2. The official ECTRIMS press conference will take place on Wednesday, 13 October 2010 from 13:00–14:00 in the Press Center on level 2.

Registration For detailed information please refer to pages 180–181.

Restaurants One of the many reasons to visit Gothenburg and Western Sweden is definitely the food. Gothenburg is known for its fine, locally produced ingredients and top-notch restaurant life. Four restaurants in Gothenburg have been acknowledged with a star in the Michelin Guide. Since the convention centre is located in central Gothenburg, restaurants in different price ranges and categories are within walking distance of the venue and the hotels. For more information on restaurants please visit www.goteborg.com

Shopping in Gothenburg Gothenburg is a brilliant city for shopping. You can find just about anything within a short walking distance of the centre. There is no shortage of interesting shops right in the heart of the city and if you feel like exploring – or taking a short tram ride – then Järntorget, Linnéstaden, Haga old town, Vasastaden and the main boulevard, Avenyn, offer great shopping possibilities too. Big brand names jostle for space with small specialist shops. Trendy, traditional, cool, essential, exclusive or inexpensive – you’ll find them all. NK and Nordstan are the 2 most well-known indoor shopping malls in the city centre, where you will find everything you need.

185 General Information General Information (in alphabetical order)

Speakers’ Service Centre (SSC) The Speakers’ Service Centre (SSC) is located on level 2 of the congress centre and is connected to all lecture halls. All speakers will be asked to hand in their PowerPoint presentations at the SSC at least 1 hour before the start of their lecture. The Speakers’ Service Centre will already be open on Tuesday, 12 October 2010 from 14:00–18:00.

Tipping Tipping is generally not required in Sweden, since service charges are included in the taxi, hotel and restaurant rates. At restaurants however tipping is appreciated at around 10%, if the guest is satisfied with the service and/or the food.

Tours Desk The tours desk – located next to the congress secretariat – will be available to provide you with detailed information about Gothenburg, booking tour tickets, making restaurant reservations or assisting you in any other way during your stay in Gothenburg.

Contact on-site: Phone +46 31 708 82 95

Gothenburg Transportation Pass From 13–16 October 2010 participants of the 26th ECTRIMS and 15th RIMS can use the entire Gothenburg public transportation system free of charge. Together with your badge you have received a voucher which can be exchanged for a 4-day pass at the “Tours” desk at the secretariat and at the “Local information” desk in the registration area.

Transportation in Gothenburg Please refer to “Travelling to the Swedish Exhibition & Congress Centre” (pages 191–192) for more details.

186 Social Events

Welcome Reception Wednesday, 13 October 2010, 18:45 – 22:15 We are pleased to invite you to the official Welcome Reception of ECTRIMS 2010 that will be held at the Scandinavium, the second largest indoor areana in Sweden. You will enjoy an evening infused with tasteful food, exciting entertainment and an opportunity to mingle with your colleagues. The theme of the evening will be inspired by Sweden, and especially the west coast region. This will be reflected in booth, the food and the entertaining parts of the evening. The entertainment with live band and artists will display the four seasons, which will be shown by Swedish music such as ABBA and beautiful images. The first part of the entertainment will take place from approx. 19:15–19:50. The second part will begin at approx. 20:15 and will end at 20:50. All participants and accompanying persons are invited to attend free of charge. The reception will start at 18:45. You are, however, very welcome to attend as it fits your schedule since there will be entertainment and food served during the whole evening. The Welcome Reception is partially sponsored by the city of Gothenburg and the region of Västra Götaland.

Price: free of charge

187 General Information Social Events

Concert Thursday, 14 October 2010, 19:30–22:00 The Gothenburg Symphony Orchestra was founded in 1905. Wilhelm Stenhammar, the great Swedish composer and conductor of the early 20th century, contributed strongly to the Nordic profile of the orchestra. Several of today’s most sought after conductors work regularly with the orchestra: Kent Nagano, Esa-Pekka Salonen, Vladimir Jurowski and Herbert Blomstedt, amongst others. On Thursday evening the Gothenburg Symphony Orchestra is presenting a selection of Mozart (Maurerische Trauermusik, Symphony no. 25, Requiem) in the Gothenburg Concert Hall. Mozart’s final work, and some would argue his absolute masterpiece, is the Requiem of 1791, which he composed in the same year he died. As a matter of fact, Mozart passed away before he could complete the final movements. This mass for four singers, orchestra and chorus is one of the most touching and powerful pieces of music written for these rich forces. The Maurerische Trauermusik, composed for a fellow free mason, is set in the same mood, while the profound Symphony No. 25 – Mozart’s first great symphony – is the epitome of energy and drama.

Price: Approx. € 33

Gothenburg Symphony Orchestra Photographer: Anna Hult

188 Social Events

Conference Dinner Friday, 15 October 2010, 20:30 The official Conference Dinner will be held at “Kajskjul 8”, situated in a genuine harbour environment directly on the quay. The oldest part of Kajskjul 8 was built in the late 19th century and served as a warehouse for storing spices. In 1994, the building was carefully renovated and transformed into a restaurant, preserving the traditional exterior. Following an aperitif, the vocal ensemble Amanda (www.amanda.nu), a popular and inventive local choir which has toured around the world and is one of Sweden’s most renowned, will offer you an amazing vocal show. The Valdemar band will round-off the evening with its wide repertoire, ranging from rock’n roll to waltz and quickstep. Certainly, an unforgettable night!

Price: € 55 per person Address: Packhusplatsen 11, Gothenburg

Dinner at Kajskjul 8

Transfer buses 20:15 Various transfer buses for Kajskjul 8 will leave from different keypoints and hotels. Bus schedules are available at the “Secretariat” and “Tours” desks on-site.

Make your own way to Kajskjul 8 By public transport: From the Congress Center (Korsvägen stop C): Bus: No 50 Stop Lilla torget; Tram: No 5 Stop Lilla bommen From the Central Station (Centralstationen stop D): Bus: No 50 Stop Lilla torget By foot: Kajskjul 8 is situated in the centre of Göteborg at the harbour, close to the Gotheburg Opera. From the central station, Kajskjul 8 can be reached within a 10 minute walk.

189 General Information Daily Tours

Wednesday, 13 October 2010, 13:00 – 15:30 Thursday, 14 October 2010, 13:00 – 15:30 City Tour of Gothenburg (by bus) Departure/Arrival: Swedish Exhibition & Congress Centre Meeting Time & Point: 12:45 at the Tours Desk Price: € 50 per person Minimum number of participants: 25 persons

Thursday, 14 October 2010, 06:10 – 08:25 Friday, 15 October 2010, 06:10 – 08:25 Fish Auction Departure: Swedish Exhibition & Congress Centre / Elite Park Aveny Hotel Arrival: Swedish Exhibition & Congress Centre Meeting Time & Point: 06:00 at Congress Centre and 06:10 outside Elite Park Aveny Hotel Price: € 85 per person (incl. breakfast) Minimum number of participants: 20 persons

Friday, 15 October 2010, 12:45 – 16:45 Gothenburg Achipelago Tour Departure/Arrival: Swedish Exhibition & Congress Centre Meeting Time & Point: 12:30 at the Tours Desk Price: € 80 per person (incl. coffee, cake, public ferry) Minimum number of participants: 15 persons

Additional tickets for daily tours will be sold on-site at the “Tours” desk. On-site requests for tours are welcome but cannot be guaranteed. Tours are based on a minimum of participants (see details above). The organizers reserve the right to cancel any tour if there are less than the minimum number of persons registered, in which case the ticket fee will be reimbursed in full. Otherwise tickets for tours are non-refundable.

For more information on tours and / or directions to the various meeting points, please contact the “Tours” desk located at the Secretariat at the Swedish Exhibition & Congress Centre (Level 1).

Gothenburg Southern Archipelago

190 Travelling to the Swedish Exhibition & Congress Centre

ECTRIMS delegates will be able to use the public transport system free of charge.

The Swedish Exhibition & Congress Centre The Swedish Exhibition & Congress Centre is located in the city centre within walking distance of most hotels and shopping areas. For tourist information, please refer to the official visiting guide: www.goteborg.com

Free airport shuttle bus On Wednesday, 13 October as well as on Saturday, 16 October a free shuttle service will be in operation between the airport and the Swedish Exhibition & Congress Centre (shuttle bus every 30 minutes).

Airport bus to/from Landvetter airport We recommend using the bus from the airport to the Swedish Exhibition & Congress Centre. During the day, the bus leaves every 15 minutes and takes 20 minutes to its first stop (Korsvägen) which is in front of the convention centre. For timetables please visit www.flygbussarna.com. Price per person: SEK 80 (approx. € 8) one way and SEK 150 (approx. € 15) for a return ticket (can be purchased online). Only credit cards are accepted on board, no cash.

Airport bus to/from Gothenburg city airport (serves Ryanair, Wizz Air and Air Berlin) Departures of the airport coaches are scheduled to coincide with the timetable of all regular flights. Coaches leave the airport for Nils Ericson Terminal 50 minutes after the scheduled flight arrival. For timetables please visit www.flygbussarna.com. The journey takes approx. 30 minutes to the central station (stop Nils Ericssonsterminalen). Price per person: SEK 60 (approx. € 6.50) one way and SEK 110 (approx. € 11.70) for a return ticket. Only credit cards are accepted on board, no cash.

Taxis We recommend Taxi Göteborg, VIP-taxi or Taxi Kurir. All taxi companies have fixed prices, approx. SEK 400 (€ 43) to/from the airports and city centre. We encourage delegates to agree on the fare price with the driver before embarking on their journey. Taxi Göteborg: Tel. +46 31 65 00 00 Taxi Kurir: Tel. +46 31 27 27 27 VIP Taxi: Tel. +46 31 27 16 11

191 General Information Travelling to the Swedish Exhibition & Congress Centre

Arriving by Car Leave the E6 highway at the Mässan/Scandinavium/Liseberg exit. Nearest parking: Focus multi-storey car park, adjacent to the complex.

Arriving by Train From the central station (Drottningtorget), take tram no 4, 13 or 14 to Korsvägen which is located opposite to the Hotel Gothia Towers. From Brunnsparken (next to the central station), take tram no 5. A single journey within Gothenburg costs approx. SEK 25 (€ 2.70).

Gothenburg Transportation Pass From 13–16 October 2010 participants of the 26th ECTRIMS and 15th RIMS can use the entire Gothenburg public transportation system free of charge. Together with your badge you have received a voucher which can be exchanged for a 4-day pass at the “Tours” desk at the secretariat and at the “Local information” desk in the registration area.

Västtrafik is responsible for the public transportation system within Gothenburg and its surrounding areas. A network of trams, buses and ferries makes travel around the city very easy. For more information on routes and timetables see www.vasttrafik.se. A one-way ticket costs approx. SEK 25 (€ 2.70) depending on the purchase method, a 5-journey ticket costs approx. SEK 83 (€ 9). Another option is the “Göteborgspasset” a 1- or 2-day card for SEK 245 (approx. € 27) or SEK 390 (approx. € 43) which allows the use of all public transporta- tion and includes entrance fees to museums, etc. The Gothenburg pass can be purchased in Gothenburg at the tourist information centres in either Kungsportplatsen or Nordstan shopping centre. It can also be purchased from Pressbyrån newsagents and in hotels. How to purchase a ticket There are different procedures to purchase tickets for all types of public transport in Gothenburg. • Single ticket: single tickets can be bought from newsagents such as Pressbyrån, 7-Eleven, etc. • Top up card: if you are planning to use public transportation more frequently you can get a top up card and – top it up with an amount of your choice (SEK 50 (approx. € 5.20) deposit required). The cost for each journey (SEK 16.50 (approx. € 1.70)) will then be deducted from the card by the card reader on board. – top it up with SEK 65 (approx. € 6.70) for unlimited travel within Gothenburg during 24 hours (no deposit required). – top it up with SEK 130 (approx. € 13.40) for unlimited travel within Gothenburg during 72 hours (no deposit required). • Trams: there is a ticket machine available onboard of the trams which only accepts coins. The driver does not accept cash payments. • Buses: on buses only prepaid tickets can be used. • SMS ticket (can only be used with a Swedish mobile phone account!): instructions on how to send SMSs is posted on the tram stop. Costs: approx. SEK 21 (€ 2.20) per one-way ticket. 192 The Swedish Exhibition & Congress Centre – Overview

Footbridge to the Swedish Entrance No. 2, Expo Hall Exhibition Centre

Shopping Centre Car Park Congress Hall

F

G A

B H J K D C

E Goods Reception, Mässans Gata 6

Entrance No. 8, Taxi Stand Congress Hall

Press Centre Airport Bus, Entrance No. 4, Hotel City Trams, Buses Entrance No. 5, Halls A–K The Swedish Exhibition & Congress Centre Main Entrance ECTRIMS 2010

193 General Information The Swedish Exhibition & Congress Centre – Floor Plans

Level 1

to Level 2 Lecture Halls Secretariat Entrance No. 8 Congress Hall Entrance No. 1

Poster Exhibition D

Hall B

to Level 2 A Exhibition @-CornerC Relax Area Main Auditorium

to Level 2

Incontro Eden Bar & Restaurant Restaurant

ption ce Hotel e Entrance No. 2 Expo Hall to Level 2 lobby Hotel r Lecture Halls Teva Pharmaceutical Industries Main Entrance Entrance No. 4 ECTRIMS 2010 Hotel Gothia Towers Registration Cloakroom Registration

Lecture Halls Meeting rooms

Hospitality Suites Industrial & Poster Exhibition

194 The Swedish Exhibition & Congress Centre – Floor Plans

Level 2

Novartis Pharma AG Merck Serono S.A.

Speakers Service Centre (SSC) EMD Serono

Congress Lobby

Reception Entrance No. 1 G4 H2 G2 H Congress Hall G F1 H1 F2

J F3

F F4 Level 3 J2

Stage

Estrad R F5 38 Restaurant & R37 J1 Function Room R3 1 6 R3 R 35 R34 R32 R33 R2 F6

R9 R10 R11 R12 ReceptionReception

R21 R26 R3 R22 R6 Press Centre Entrance No. 2 Expo Hall R4 R5 R23 Press Conference Room Biogen Idec Entrance No. 4 Hotel Gothia Towers Bayer Schering Pharma AG Genzyme

Level 3

Reception R38 R37 R21 Reception R26 R36 R22 R31 R35 R25 R34 R32 R23 R24 R33

Genzyme

Lecture Halls Meeting rooms

Hospitality Suites Industrial & Poster Exhibition

195 General Information List of Exhibitors

305 Almirall, Barcelona / ES 109 Astra Tech AB, Mölndal / SE 201 Bayer Schering Pharma AG, Berlin / DE 205 Biogen Idec, Zug / CH 401 Biogen Idec, Zug / CH 101 competence Network – Multiple Sclerosis, Munich / DE 505 ECTRIMS Congress 2011 303 EDMUS, Lyon / FR 301 ESAOTE, Genoa / IT 501 European Charot Foundation, Molenhoek (Nijmegen) / NL 507 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 317 European MS Platform (EMSP), Bruxelles / BE 509 European Neurological Society (ENS), Basel / CH 115 Genzyme Corporation, Cambridge MA / US 325 Heidelberg Engineering GmbH, Heidelberg / DE 203 Merck Serono SA, Geneva / CH 315 MSBase Registry, Melbourne / AU 307 Multiple Sclerosis International Federation, London / UK 313 Novartis Pharma AG, Basel / CH 321 PBL InterferonSource, Piscataway / US 103 RIMS-Network of MS Centres, Europe 207 Sanofi-aventis, Paris / FR 503 Serono Symposia International Foundation, Rome / IT 323 Synovate Healthcare, London / UK 107 Talecris Biotherapeutics, Frankfurt / DE 209 Teva and Sanofi-aventis 105 Wisepress Ltd, London / UK

196 Exhibition Floor Plan

Catering

to Main @- Auditorium

to Level 2 Catering

201

101 103 313

303 203 301 307 305 105 401 107 205 317 109 206 315321 111 323

113 Secretariat

207 209 325 115 to Level 2

501 503 505 507 509

Entrance Entrance Entrance Entrance Entrance n o i t a m r o f n I l a r e n e

197 G Gothenburg City Map and Hotels

26

3

25

7

16

13 24

37

12

198 Gothenburg City Map and Hotels

17

28

6 34 36 32 4 19 3 9 18 2 D 15 35

1 2

27 11 21 B 33 22 23 30 38 31 5 A 8 C

14

20 29 10

199 General Information Gothenburg City Map and Hotels

List of Hotels Category 1 Elite Plaza 5 2 Avalon 4 3 Clarion 4 4 Eggers 4 5 Elite Park Avenue 4 6 First G 4 7 Göteborg 4 8 Gothia Towers 4 9 Grand Hotel Opera 4 10 Landvetter Airport 4 11 Liseberg Heden 4 12 Novotel 4 13 Quality 11 4 14 Quality Panorama 4 15 Radisson Blu Scandinavia 4 16 Riverton 4 17 Scandic Backadal 4 18 Scandic Crown 4 19 Scandic Europa 4 20 Scandic Mölndal 4 21 Scandic Opalen 4 22 Scandic Plaza Boras 4 23 Scandic Rubinen 4 24 Villan AB 4 25 Best Western Arken 3 26 Fars Hatt 3 27 Flora 3 28 Ibis Göteborg City Centre 3 29 Ibis Göteborg Mölndal 3 30 Lorensberg 3 31 Onyxen 3 32 Örgryte 3 33 Poseidon 3 34 Rica City 3 35 Royal 3 36 Spar Garda 3 37 Spar Majorna 3 38 Vasa 3

A Swedish Exhibition & Congress Centre – Congress Venue B Scandinavium – Welcome Reception C «Konserhuset» – Gothenburg Concert Hall – Concert D Kajskjul 8

200 *Individual needs may vary. That’s why there’s Rebif ®—proven ef‡cacy and a well characterized safety pro‡le in RMS, with options to help meet the needs of patients individually:1-5

Two approved doses allow for tolerability in each individual to be managed over the course of treatment1-2,4-6 Objective adherence data◊ from RebiSmart™ provides for informed decision-making should a sub-optimal response occur∆7-9… …and supports a constructive on-going dialogue to help individual patients adhere to the dosing regimen∆10-13 In addition, new RebiDose™† pre-‡lled pen ensures alternative injection preferences are catered for7,14

◊ Objective data in this context refers to non patient-reported information, based on a pre-planned and automated count that is independent of human interface. ∆ The capacity to know and act upon a patient’s actual adherence necessitates access to the dose-log data in the patient’s RebiSmart™ device for the relevant period, and is subject to the patient having used the RebiSmart™ device as advised. † RebiDose™ approved by the EMA June 2010. Available in ‡rst European countries as of October 2010. Different patients. Different needs.

REBIF®, Solution for injection. Active ingredient: interferon beta-1a. Rx, F. Pharmacotherapeutic group: immunostimulants, interferons, ATC code L03A B07. Pharmaceutical form: Solution for injection. Cartridge - 22 micrograms/0.5 mL, 44 micrograms/0.5 mL, and 8.8 micrograms/0.1 mL + 22 micrograms/0.25 mL. Pre- lled pen – 22 micrograms, 44 micrograms and 8.8 micrograms + 22 micrograms. Pre- lled syringe – 22 micrograms, 44 micrograms, 8.8 micrograms + 22 micrograms. Therapeutic Indications: For the treatment of relapsing multiple sclerosis. In clinical trials, this was characterized by two or more acute exacerbations in the previous two years. Ef cacy not demonstrated in patients with secondary progressive multiple sclerosis without ongoing relapse activity. For information on warnings, special precautions for use, side effects and contraindications see the full summary of product characteristics www.ema.europa.eu. For current prescribing information and price see www.fass.se. Date of revision: August 2010. Contact: Merck AB, 195 87 Stockholm, Tel: +46 (0)8 562 445 00. References:1. PRISMS Study Group. Lancet 1998;352:1498–1504. 2. PRISMS Study Group. Neurology 2001;56;1628–36. 3. Gold R, et al. Eur J Neurol 2005;12:649–656. 4. Giovannoni G, et al. Mult Scler 2009;15:219–28. 5. De Stefano N, et al. Mult Scler 2010;16:888–92. 6. Rebif EMA Summary of Product Characteristics. Available at http://www.emea.europa.eu. 7. RebiSmart™ European Instructions for Use (IFU) 2009. 8. Freedman MS, et al. Can J Neuro Sci 2004;31:157–68. 9. Reynolds MW, et al. Curr Med Res Opin 2010;26:663–74. 10. Zolnierek KBH, et al. Med Care 2009;47:826–34. 11. Bruce JM, et al. Mult Scler 2010;16:112–9. 12. Frohman E et al. The Neurologist 2002;8:227–236 13. Devonshire V, et al. BMC Neurol 2010;10:28. 14. RebiDose Patient Information Lea¤et (PIL) in Europe.

Merck Serono is a division of Merck :(;,330;, :@476:0<4

(SLT[\a\THI 9LZLHYJO PU 4:! 5L^ 0UZPNO[Z 5L^ 7VZZPIPSP[PLZ 5L^ (WWYVHJOLZ

-YPKH`  6J[VILY     ¶   ;OL :^LKPZO ,_OPIP[PVU *VUNYLZZ *LU[YL *VUNYLZZ /HSS

;V SLHYU TVYL WSLHZL ]PZP[ .LUa`TL 4LKPJHS (MMHPYZ H[ IVV[O 

:H[LSSP[L :`TWVZP\T VM [OL ,*;904:  *VUNYLZZ

(SLT[\a\THI PZ UV[ HWWYV]LK PU :^LKLU VY HU` JV\U[Y` MVY [OL [YLH[TLU[ VM 4: HUK ZOV\SK UV[ IL \ZLK PU 4: WH[PLU[Z V\[ZPKL H JVU[YVSSLK JSPUPJHS [YPHS

 .LUa`TL *VYWVYH[PVU (SS YPNO[Z YLZLY]LK 4:<:7